8602662	Chemical	Gene	D006221	6261	True	0	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] Comparison of the segregation of the @GeneTgt$ RYR1 @/GeneTgt$ C1840 T mutation with segregation of the @ChemicalSrc$ caffeine/halothane @/ChemicalSrc$ contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family . BACKGROUND : Malignant hyperthermia ( MH ) is an important cause of anesthesia-induced death . Malignant hyperthermia susceptibility is diagnosed using the in vitro @ChemicalSrc$ caffeine/halothane @/ChemicalSrc$ contracture test ( CHCT ) in fresh muscle biopsy specimens . The CHCT test is highly invasive , expensive , and lacks 100 % specificity . Genetic and biochemical evidence provide strong support for the view that the substitution of cysteine for arginine 614 ( Arg614Cys ) in the human ryanodine receptor gene is one of several mutations that are likely to cause human MH . DNA testing was compared with CHCT as a means of predicting MH susceptibility in a large MH family in which the Arg614Cys mutation was detected . METHODS : A comparison of CHCT and DNA-based diagnosis was conducted in a large Manitoba Mennonite MH kindred identified by an index patient who died at age 45 yr of an MH crisis after general anesthesia . The presence of the Arg614Cys mutation was detected through a combination of polymerase chain reaction and restriction endonuclease digestion . Blood samples for DNA analysis were obtained from 68 family members , including 19 who had undergone muscle biopsies and 1 who had a documented crisis but did not undergo biopsy . Family members were classified as MH-susceptible or MH-normal on the basis of the CHCT . RESULTS : Twenty-two persons were found to be heterozygous for the Arg614Cys mutation . Five of these persons had prior positive CHCT results and one had an MH crisis but did not undergo biopsy . On DNA testing , 44 persons were found to be homozygous for the normal allele . Of these , ten had been classified as MH-normal and five as MH-susceptible on the basis of the CHCT . On reevaluation of the data obtained in our earlier CHCT diagnoses , we found that the condition of the muscle was poor , with no twitch , for three of five individuals homozygous for the normal allele but originally classified as MH-susceptible and for one who was homozygous for the normal allele and originally classified as MH-normal . @ChemicalSrc$ Caffeine/halothane @/ChemicalSrc$ contracture test results for these four persons were considered invalid . The twitch response was good for the two remaining persons who were homozygous for the normal allele but classified as MH- susceptible , because contracture was observed with appropriately low levels of both caffeine and @ChemicalSrc$ halothane @/ChemicalSrc$ . CONCLUSIONS : An absolute correlation between DNA test results and CHCT assignment could not be made in this kindred . Possible explanations for discordance are that the Arg614Cys mutation is not linked to MH , that a second MH mutation is segregating in the family , or that there are errors in the CHCT . Because there is strong evidence supporting the causal nature of the Arg614Cys mutation , the discordant persons are not closely related within the pedigree as they would be if a second MH mutation were segregating , and the CHCT is not 100 % accurate , we propose that the observed discordance between DNA test results and CHCT assignment in this kindred results from two false-positive diagnoses by the CHCT .	1 4 4 1 11 11 11|6 11 11|6 11 11 4 13 4 20 19 18|14 18 18|14 19 20 13 24 24 24 13 30 30 30 29 30 24 1 34 34 37 44 39 37 39 44 44 44 34 47 47 44 34 51 51 53 53 53 53 61 61 56 57|61 61 57|61 61 54 63 61 63 69 69 69 69 61 53 74 74 77 77 77 77 77 77 77 77 77 84 85 82 77 91 87 87 87 91 93 91 96 96 93 115 99 115 101 99 103 99 103 106 103 106 113 113 113 113 113 99 115 96 118 118 115 121 121 118 123 121 125 123 91 128 130 130 130 132 130 135 135 130 137 135 139 137 144 144 144 144 139 146 151 149 149 151 151 144 130 163 163 156 163 158 156 158 158 158 163 163 170 170 170 170 170 170 163 170 175 175 175 171 177 175 179 177 181 179 185 185 185 181 188 188 177 163 191 197 195 195 195 191 197 197 200 200 197 204 204 204 200 204 208 208 204 197 211 216 214 214 211 216 216 220 220 220 216 220 223 220 226 226 223 228 226 223 223 232 230 235 235 232 232 239 239 232 239 216 243 245 245 245 247 245 247 247 252 252 245 255 255 252 245 257 257 260 262 262 257 265 265 262 269 269 269 265 257 275 274 274 271 275 279 279 279 275 275 282 275 285 285 282 282 289 289 282 289 282 294 294 299 299 297 299 299 299 302 302 299 306 306 306 302 299 309 314 314 314 314 314 314 316 314 316 316 320 314 323 323 314 326 326 323 314 329 341 332 332 329 332 338 338 338 338 333 341 341 341 349 344 349 347 347 344 349 341 349 353 353 349 353 359 358 358 359 353 359 364 364 364 360 360 367 359 369 367 369 372 369 375 375 372 379 379 379 375 375 382 375 384 382 341 385|389 389 385|389 389 390 396 394 394 394 390 396 396 396 396 402 402 404 404 404 409 407 409 409 404 412 412 409 416 416 416 412 412 412 421 421 418 404 426 426 426 404 430 429 430 426 433 433 430 433 433|434 433 433|434 404 439 439 443 443 454 447 447 447 443 447 450 447 454 454 454 439 457 457 454 439 460 463 462 460 463 470 467 467 470 470 470 463 472 470 472 480 478 478 478 480 480 470 483 483 480 480 480 488 488 480 488 492 492 489 463 496 496 514 498 496 498 502 502 499 506 506 506 502 514 510 510 514 514 514 514 540 517 517 514 528 518 528 528 528 526 526 526 528 528 514 514 514 532 537 537 537 536 537 514 540 540 540 555 544 544 555 548 548 548 544 548 551 548 554 554 544 540 559 559 559 555 562 562 555 540	Association
8828983	Chemical	Gene	D013390	6261	False	1	What is [PHARMGKB] between @ChemicalSrc$ suxamethonium @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] @GeneTgt$ RYR @/GeneTgt$ mutation G1021A ( Gly341Arg ) is not frequent in Danish and Swedish families with malignant hyperthermia susceptibility . Malignant hyperthermia ( MH ) is a pharmacogenetic disorder . Susceptibility to MH ( MHS ) is presumed to be inherited in an autosomal dominant way . MH crises are triggered by halogenated inhalational anaesthetics and @ChemicalSrc$ suxamethonium @/ChemicalSrc$ , and may be lethal if not treated early and adequately . Until now , eight mutations in the @GeneTgt$ RYR1 @/GeneTgt$ gene have been described as causes of MHS phenotype in various MH families . The mutation @GeneTgt$ RYR1 @/GeneTgt$ G1021A ( Gly341Arg ) has been reported to account for approximately 10 % of Caucasian MHS cases . However , in our study this mutation was discovered in only 1 out of 89 Scandinavian families , indicating that this mutation may be the cause of MHS in only about 1 % of MHS families in those populations . The mutation may have been brought to Scandinavia by an immigrant .	0|4 4 0|4 4 10 6 4 6 10 10 10 15 15 12 12 10 19 19 19 15 10 23 30 25 23 25 30 30 30 30 30 39 34 32 36 34 36 39 39 42 42 39 47 47 47 47 42 39 50 52 52 52 56 56 56 52 56 56|57 56 56|57 52 52 64 64 52 67 67 64 67 68 68 52 74 85 85 77 85 82 82 82|79 82 82|79 77 85 85 85 87 85 90 90 87 94 94 94 87 85 101 101 98|101 101 98|101 107 103 101 103 107 107 107 109 107 113 112 113 109 117 117 117 113 107 128 128 124 124 128 126 128 128 128 131 131 136 134 134 136 136 128 128 128 145 141 145 145 145 145 138 147 145 152 151 151 152 145 155 155 152 158 158 152 128 161 165 165 165 165 165 167 165 170 170 165 165	Association
8952600	Chemical	Gene	D009568	185	True	0	What is [PHARMGKB] between @ChemicalSrc$ nitrendipine @/ChemicalSrc$ and @GeneTgt$ AT1-R @/GeneTgt$ ? [SEP] Influence of the @GeneTgt$ angiotensin II type 1 receptor @/GeneTgt$ gene polymorphism on the effects of perindopril and @ChemicalSrc$ nitrendipine @/ChemicalSrc$ on arterial stiffness in hypertensive individuals . Angiotensin-converting enzyme inhibitors improve arterial stiffness independently of blood pressure reduction . Since we have recently shown that in hypertensive individuals the A1166C polymorphism of the @GeneTgt$ angiotensin II type 1 receptor ( AT1-R @/GeneTgt$ ) is an independent determinant of aortic stiffness , we designed the present study to assess the influence of this polymorphism on the changes of aortic stiffness after chronic treatment with the angiotensin-converting enzyme inhibitor perindopril and the calcium channel blocker @ChemicalSrc$ nitrendipine @/ChemicalSrc$ . Forty perindopril- and 42 @ChemicalSrc$ nitrendipine-treated @/ChemicalSrc$ hypertensive individuals were studied . We evaluated aortic stiffness by measuring the carotid-femoral pulse wave velocity . Carriers of the @GeneTgt$ AT1-RC @/GeneTgt$ allele showed higher baseline values of pulse wave velocity than AA homozygotes ( P & lt ; .05 ) . In the perindopril group , a threefold greater reduction in pulse wave velocity was observed in carriers of the C allele than in AA homozygotes ( -2.85 + /- 0.62 versus -0.94 + /- 0.32 m/s , respectively ; P & lt ; .001 ) , whereas in the @ChemicalSrc$ nitrendipine @/ChemicalSrc$ group , pulse wave velocity decreased only in AA homozygotes and not in @GeneTgt$ AT1-R @/GeneTgt$ C carriers ( -1.38 + /- 0.35 versus + 0.04 + /- 0.60 m/s , respectively ; P & lt ; .01 ) . These results indicate that according to the @GeneTgt$ AT1-R @/GeneTgt$ A1166C genotype , an angiotensin-converting enzyme inhibitor and a calcium channel blocker affect pulse wave velocity in opposite ways . Since some evidence shows that increased pulse wave velocity may enhance cardiovascular risk , it might be useful for physicians to consider the @GeneTgt$ AT1-R @/GeneTgt$ genotype when prescribing an angiotensin-converting enzyme inhibitor or calcium channel blocker to a hypertensive individual .	1 11 11 11|3 11|3 11|3 11|3 11|3 11 11|3 11 1 14 14 1 16 14 16 16|12 16 16|12 22 22 14 25 25 22 1 31 31 32 32 34 32 32 39 39 39 35 32 45 45 45 45 73 67 49 49 67 52 52 67 55 55 52|54|55 52|54|55 52|54|55 52|54|55 52|54|55 52|54|55 52|54|55 52|55 52|54|55 55 67 67 67 45 70 70 67 73 73 73 76 76 73 78 76 80 78 83 83 80 86 86 80 89 89 86 92 92 80 98 98 98 98 98 92 92 104 104 104 104 96|92 92 96|92 73 110 118 110 116 116|112 116 116|112 116 110 118 118 118 122 122 124 122 126 122 131 131 131 131 126 122 139 138 138 135|138 138 135|138 133 139 142 142 139 146 146 146 142 149 149 146 151 149 151 151 151 151 151 139 162 162 162 173 173 167 166 167 173 171 171 171 167 173 173 175 173 179 179 179 175 183 183 183 175 185 175 185 185 185 188 188 185 185 194 185 194 194 185 185 198 198 185 185 185 173 173 210 210 207|210 210 207|210 173 210 214 214 215 173 215 219 219 215 219 226 226 226|221 226 226|221 226 219 228 215 228 228 228 228 228 228 234 238 238 228 238 228 228 228 242 242 242 228 228 173 252 253 253 272 261 255 261 261|257 261 261|257 261 272 261 266 266 266 272 266 271 271 271 266 253 275 275 272 278 278 272 253 284 283 284 298 291 289 289 289 291 291 284 293 291 298 298 298 298 298 300 302 302 298 306 306|303 306 306|303 302 308 302 312 312 312 308 312 315 316 312 320 320 320 308 298	Association
8952600	Chemical	Gene	D020913	185	True	0	What is [PHARMGKB] between @ChemicalSrc$ perindopril @/ChemicalSrc$ and @GeneTgt$ AT1-R @/GeneTgt$ ? [SEP] Influence of the @GeneTgt$ angiotensin II type 1 receptor @/GeneTgt$ gene polymorphism on the effects of @ChemicalSrc$ perindopril @/ChemicalSrc$ and nitrendipine on arterial stiffness in hypertensive individuals . Angiotensin-converting enzyme inhibitors improve arterial stiffness independently of blood pressure reduction . Since we have recently shown that in hypertensive individuals the A1166C polymorphism of the @GeneTgt$ angiotensin II type 1 receptor ( AT1-R @/GeneTgt$ ) is an independent determinant of aortic stiffness , we designed the present study to assess the influence of this polymorphism on the changes of aortic stiffness after chronic treatment with the angiotensin-converting enzyme inhibitor @ChemicalSrc$ perindopril @/ChemicalSrc$ and the calcium channel blocker nitrendipine . Forty @ChemicalSrc$ perindopril- @/ChemicalSrc$ and 42 nitrendipine-treated hypertensive individuals were studied . We evaluated aortic stiffness by measuring the carotid-femoral pulse wave velocity . Carriers of the @GeneTgt$ AT1-RC @/GeneTgt$ allele showed higher baseline values of pulse wave velocity than AA homozygotes ( P & lt ; .05 ) . In the @ChemicalSrc$ perindopril @/ChemicalSrc$ group , a threefold greater reduction in pulse wave velocity was observed in carriers of the C allele than in AA homozygotes ( -2.85 + /- 0.62 versus -0.94 + /- 0.32 m/s , respectively ; P & lt ; .001 ) , whereas in the nitrendipine group , pulse wave velocity decreased only in AA homozygotes and not in @GeneTgt$ AT1-R @/GeneTgt$ C carriers ( -1.38 + /- 0.35 versus + 0.04 + /- 0.60 m/s , respectively ; P & lt ; .01 ) . These results indicate that according to the @GeneTgt$ AT1-R @/GeneTgt$ A1166C genotype , an angiotensin-converting enzyme inhibitor and a calcium channel blocker affect pulse wave velocity in opposite ways . Since some evidence shows that increased pulse wave velocity may enhance cardiovascular risk , it might be useful for physicians to consider the @GeneTgt$ AT1-R @/GeneTgt$ genotype when prescribing an angiotensin-converting enzyme inhibitor or calcium channel blocker to a hypertensive individual .	1 11 11 11|3 11|3 11|3 11|3 11|3 11 11|3 11 1 14 14 1 16 10|14 14 10|14 16 16 22 22 14 25 25 22 1 31 31 32 32 34 32 32 39 39 39 35 32 45 45 45 45 73 67 49 49 67 52 52 67 55 55 52|54|55 52|54|55 52|54|55 52|54|55 52|54|55 52|54|55 52|54|55 52|55 52|54|55 55 67 67 67 45 70 70 67 73 73 73 76 76 73 78 76 80 78 83 83 80 86 86 80 89 89 86 92 92 80 98 98 98 98 98 90|92 92 90|92 92 105 105 105 105 92 73 110 109|118 118 109|118 110 116 116 116 110 118 118 118 122 122 124 122 126 122 131 131 131 131 126 122 139 138 138 135|138 138 135|138 133 139 142 142 139 146 146 146 142 149 149 146 151 149 151 151 151 151 151 139 163 163 160|163 163 160|163 174 174 168 167 168 174 172 172 172 168 174 174 176 174 180 180 180 176 184 184 184 176 186 176 186 186 186 189 189 186 186 195 186 195 195 186 186 199 199 186 186 186 174 174 210 210 210 174 210 214 214 215 174 215 219 219 215 219 226 226 226|221 226 226|221 226 219 228 215 228 228 228 228 228 228 234 238 238 228 238 228 228 228 242 242 242 228 228 174 252 253 253 272 261 255 261 261|257 261 261|257 261 272 261 266 266 266 272 266 271 271 271 266 253 275 275 272 278 278 272 253 284 283 284 298 291 289 289 289 291 291 284 293 291 298 298 298 298 298 300 302 302 298 306 306|303 306 306|303 302 308 302 312 312 312 308 312 315 316 312 320 320 320 308 298	Association
10352931	Chemical	Gene	D006221	6261	False	1	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] A case of discordance between genotype and phenotype in a malignant hyperthermia family . Malignant hyperthermia ( MH ) is an inherited autosomal dominant pharmacogenetic disorder and is the major cause of anaesthesia-induced death . Malignant hyperthermia susceptibility is usually diagnosed by the in vitro contracture test ( IVCT ) performed on fresh muscle biopsies exposed to caffeine and @ChemicalSrc$ halothane @/ChemicalSrc$ , respectively . Around 50 % of affected families are linked to the ryanodine receptor ( @GeneTgt$ RYR1 @/GeneTgt$ ) gene . The human @GeneTgt$ RYR1 @/GeneTgt$ gene maps to chromosome 19q13.1 and encodes a protein that associates as a homotetramer and acts as a calcium-release channel from the sarcoplasmic reticulum . To date , 17 mutations have been identified in the coding region of the @GeneTgt$ RYR1 @/GeneTgt$ gene and appear to be associated to the MH-susceptible phenotype . Here we describe a rare case of discordance between genotype ( characterised by the presence of the Arg614Cys mutation in the @GeneTgt$ RYR1 @/GeneTgt$ gene ) and MH-normal typed phenotype . Although the IVCT remains a very reliable procedure for the assessment of MH status , genetic data can provide in some cases an additional aid to clinical diagnosis .	2 2 4 2 6 4 6 6 13 13 13 13 6 2 16 26 18 16 18 26 26 26 26 26 26 26 26 31 31 31 26 34 34 31 26 38 38 41 41 41 41 47 47 47 44 47 41 49 47 49 47 55 55 55 51 55 58 56 58 59|58 58 59|58 47 41 41 67 68 73 71 71 68 73 73 82 82 82 82 79 82|78 82 82|78 82 73 73 89 89 86|89 89 86|89 90 90 93 93 90 90 90 97 95 99 97 102 102 99 99 99 108 108 108 104 112 112 112 108 90 116 122 122 119 122 122 122 122 126 126 126 122 131 131 131|128 131 131|128 126 122 122 136 136 133 140 140 140 136 122 145 145 145 148 148 145 150 148 152 150 154 148 157 157 154 161 161 161 157 166 166 166|163 166 166|163 161 166 157 171 171 157 145 177 176 177 192 181 180 181 177 184 184 181 187 187 184 192 190 192 192 192 195 195 192 198 198 192 201 201 198 192	Association
10888602	Chemical	Gene	D006221	6261	False	1	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree . Malignant hyperthermia ( MH ) is a pharmacogenetic disorder that predisposes to a sometimes fatal hypermetabolic reaction to halogenated anaesthetics . MH is considered to originate from abnormal regulation of skeletal muscle Ca(2 + ) release . Current diagnosis of MH susceptibility ( MHS ) relies on in vitro contracture testing ( IVCT ) of skeletal muscle . The ryanodine receptor ( @GeneTgt$ RYR1 @/GeneTgt$ ) encoding the major Ca(2 + ) release channel in the skeletal muscle sarcoplasmic reticulum has been shown to be mutated in a number of MH pedigrees . The large Maori pedigree reported here is the largest MHS pedigree investigated to date and comprises five probands who experienced clinical episodes of MH and 130 members diagnosed by the IVCT . Sequencing of the 15 117 bp @GeneTgt$ RYR1 @/GeneTgt$ cDNA in a MHS individual from this pedigree identified a novel C14477 T transition that results in a Thr4826 to Ile substitution in the C-terminal region/transmembrane loop of the skeletal muscle ryanodine receptor . This is the first mutation in the @GeneTgt$ RyR1 @/GeneTgt$ C-terminal region associated solely with MHS . Although linkage analysis showed strong linkage ( max LOD , 11.103 at theta = 0.133 ) between the mutation and MHS in the pedigree using the standardized European IVCT phenotyping protocol , 22 MHS recombinants were observed . The relationship between the IVCT response and genotype was explored and showed that as IVCT diagnostic cut-off points were made increasingly stringent , the number of MHS discordants decreased with complete concordance between the presence or absence of the C14477 T mutation and MHS and MH normal phenotypes , respectively , using a cut-off of 1.2 g tension at 2.0 mM caffeine and 1.8 g tension at 2.0 % @ChemicalSrc$ halothane @/ChemicalSrc$ . Many MHS pedigrees investigated have been excluded from linkage to the @GeneTgt$ RYR1 @/GeneTgt$ gene on the basis of a small number of recombinants ; however , the linkage analysis reported here suggests that other recombinant families excluded from linkage to the @GeneTgt$ RYR1 @/GeneTgt$ gene may actually demonstrate linkage as the number of members tested within the pedigrees increases . The high number of discordants observed using the standardized diagnostic cut-off points is likely to reflect the presence of a second MHS susceptibility locus in the pedigree .	5 5 5 5 5 5 8 5 17 17 17 17 17 15 17 17 5 5 20 27 22 20 22 27 27 27 27 29 27 35 35 33 35 35 29 38 38 35 27 42 42 42 44 42 47 47 44 51 51 51 47 44 44 42 42 57 64 60 60 57 62 60 62 64 69 69 66 69 64 71 69 71 75 75 69 64 91 79 91 81 79|80 79 79|80 81 79 87 87 84 87 79 91 100 97 97 97 97 97 91 100 100 100 103 103 100 106 106 103 109 109 106 100 115 115 115 116 118 116 118 122 122 122 123 118 125 123 123 123 129 127 131 129 133 131 135 133 135 138 135 138 142 142 139 123 160 152 152 148 152 152 152|149 152 152|149 144 156 156 156 144 159 159 156 160 165 165 165 165 160 167 165 170 170 167 173 173 167 178 178 178 178 173 184 184 184 184 184 178 160 191 191 191 191 191 197 197 197|193 197 197|193 197 191 197 201 201 198 191 207 206 207 240 209 207 212 212 209 212 217 216 217 212 217 217 222 222 217 222 222 227 227 222 209 234 234 234 234 234 228 240 238 238 240 240 240 240 243 251 247 247 247 243 247 247 251 251 251 251 261 259 257 259 259 261 261 253 263 261 270 266 270 269 269 266 251 273 273 270 276 276 273 276 276 283 283 283 283 276 283 283 285 288 285 276 273 270 270 270 295 293 299 299 299 295 303 302 303 295 295 307 307 295 311 310 311 307|310 307 307|310 270 317 317 321 317 321 321 321 323 321 328 328 325|328 328 325|328 323 331 331 321 335 335 335 331 337 335 321 346 346 343 343 346 343 344 321 351 350 350 351 346 353 351 358 358 354|358 358 354|358 353 361 361 321 372 365 365 362 367 365 367 371 371 368 361 321 378 378 381 380 378 381 381 387 387 387 387 382 389 381 391 389 393 391 399 399 399 399 399 393 402 402 399 381	Association
11394901	Chemical	Gene	D009538	1548	True	0	What is [PHARMGKB] between @ChemicalSrc$ nicotine @/ChemicalSrc$ and @GeneTgt$ CYP2A6 @/GeneTgt$ ? [SEP] Identification of a single nucleotide polymorphism in the TATA box of the @GeneTgt$ CYP2A6 @/GeneTgt$ gene : impairment of its promoter activity . Human @GeneTgt$ cytochrome P450 2A6 @/GeneTgt$ ( @GeneTgt$ CYP2A6 @/GeneTgt$ ) constitutes the major @ChemicalSrc$ nicotine @/ChemicalSrc$ oxidase , and large interindividual differences are seen in the levels of this enzyme , to a great extent caused by the distribution of several different polymorphic gene variants mainly located in the open reading frame ( ORF ) . In the present study , we report a common polymorphism located in the 5 ' flanking region of @GeneTgt$ CYP2A6 @/GeneTgt$ affecting its expression . DHPLC analysis and complete sequence of the open reading frame of the gene from a Turkish individual revealed a -48 T > G substitution disrupting the TATA box . Using dynamic allele-specific hybridization ( DASH ) , genotyping of this novel variant ( named @GeneTgt$ CYP2A6 @/GeneTgt$ * 9 ) was carried out in 116 Swedish , 132 Turkish , and 102 Chinese subjects , and the allele frequencies were found to be 5.2 , 7.2 , and 15.7 % , respectively . The significance of the polymorphism was investigated by the construction of luciferase reporter plasmids containing 135 or 500 bp of the 5'-upstream region of the gene transfected into human hepatoma B16A2 cells . The constructs carrying the -48 T > G mutation were only expressed at about 50 % of the wild-type alleles . It is concluded that the @GeneTgt$ CYP2A6 @/GeneTgt$ * 9 allele might be one of the most common @GeneTgt$ CYP2A6 @/GeneTgt$ variants in Caucasians that alters the levels of enzyme expression .	1 6 6 6 6 1 10 10 10 6 15 15 12|15 15 12|15 10 1 1 21 21 21 17 1 25 24|25|33 24|25|33 24|25|33 25|33 24|25|33 30 25|26 25 25|26 30 33 38 38 31|38 38 31|38 33 38 38 43 43 45 45 33 48 48 45 51 51 48 45 56 56 56 45 56 60 60 57 66 66 66 66 66 60 68 56 73 73 73 73 68 75 73 75 33 84 84 84 87 87 87 87 90 90 87 90 97 97 97 97 97 91 99 97|98 97 97|98 97 103 101 87 107 123 107 110 107 115 115 115 115 107 118 118 115 122 122 122 118 123 129 126 129 129 129 123 129 133 133 130 123 156 138 138 135 140 138 140 138 156 147 147 147 143 149 147 149 149 149 150 150 153 156 156 156 160 160 156 160 163 160 163 163 168 168 163 168 168 173 173 175 175 156 180 180 180 180 175 180 175 184 175 184 175 175 190 195 193 193 190 195 195 198 198 195 202 202 202 198 202 207 204 204 203 211 211 211 207 214 214 211 214 220 220 220 220 215 195 223 233 223 227 227 230 227 230 224 233 233 233 237 236 237 233 241 241 241 237 233 245 245 245 255 252 252|247 252 252|247 252 252 255 255 255 245 262 262 259 262 258|262 262 258|262 255 264 262 266 264 268 266 271 271 268 245	Association
11526490	Chemical	Gene	D000068877	3815	True	0	What is [PHARMGKB] between @ChemicalSrc$ STI571 @/ChemicalSrc$ and @GeneTgt$ c-KIT @/GeneTgt$ ? [SEP] STI571 inactivation of the gastrointestinal stromal tumor @GeneTgt$ c-KIT @/GeneTgt$ oncoprotein : biological and clinical implications . Mutations in the @GeneTgt$ c-KIT @/GeneTgt$ receptor occur somatically in many sporadic Gastrointestinal Stromal Tumors ( GIST ) , and similar mutations have been identified at the germline level in kindreds with multiple GISTs . These mutations activate the tyrosine kinase activity of @GeneTgt$ c-KIT @/GeneTgt$ and induce constitutive signaling . To investigate the function of activated @GeneTgt$ c-KIT @/GeneTgt$ in GIST , we established a human GIST cell line , GIST882 , which expresses an activating @GeneTgt$ KIT @/GeneTgt$ mutation ( K642E ) in the first part of the cytoplasmic split tyrosine kinase domain . Notably , the K642E substitution is encoded by a homozygous exon 13 missense mutation , and , therefore , GIST882 cells do not express native @GeneTgt$ KIT @/GeneTgt$ . GIST882 @GeneTgt$ c-KIT @/GeneTgt$ protein is constitutively tyrosine phosphorylated , but tyrosine phosphorylation was rapidly and completely abolished after incubating the cells with the selective tyrosine kinase inhibitor @ChemicalSrc$ STI571 @/ChemicalSrc$ . Furthermore , GIST882 cells evidenced decreased proliferation and the onset of apoptotic cell death after prolonged incubation with STI571 . Similar results were obtained after administering @ChemicalSrc$ STI571 @/ChemicalSrc$ to a primary GIST cell culture that expressed a @GeneTgt$ c-KIT @/GeneTgt$ exon 11 juxtamembrane mutation ( K558NP ) . These cell-culture-based studies support an important role for @GeneTgt$ c-KIT @/GeneTgt$ signaling in GIST and suggest therapeutic potential for STI571 in patients afflicted by this chemoresistant tumor .	2 2 10 10 10 10 10 10|7 10 10|7 2 10 15 12 12 2 2 24 23 23 20|23 23 20|23 18 24 24 31 31 31 31 31 24 33 31 33 31 24 38 41 41 41 24 45 45 45 41 47 45 50 50 47 41 54 55 55 59 59 59 55 61 60|59 59 60|59 55 55 66 64 55 70 70 72 70 75 75 72|74 72 72|74 78 72 81 81 70 86 86 86 86 81 86 86 86 91 86 96 96 92|96 96 92|96 91 98 96 98 103 103 103 91 110 110 110 110 110 110 103 81 120 120 118 118 120 120 120 127 127 127 127 127 127 120 127 120 120 137 137 134 137 137 137 120 139 137|138 137 137|138 120 146 143|146 146 143|146 150 150 150 150 150 150 150 154 156 156 150 156 159 156 161 159 163 161 170 170 170 170 170 170 168|161 161 168|161 156 179 179 178 179 179 181 179 181 184 181 188 188 188 184 191 191 179 193 191 179 196 198 198 198 200 198 200 200 200 208 208 208 208 208 200 210 208 217 210|217 217 210|217 217 217 217 210 219 217 219 198 226 226 227 227 230 230 227 234 231|234 234 231|234 230 236 234 227 227 240 238 242 240 244 240 244 249 249 249 245 227	Association
12059893	Chemical	Gene	D006221	6261	True	0	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] Mutation screening in the @GeneTgt$ ryanodine receptor 1 @/GeneTgt$ gene ( @GeneTgt$ RYR1 @/GeneTgt$ ) in patients susceptible to malignant hyperthermia who show definite IVCT results : identification of three novel mutations . BACKGROUND : The ryanodine receptor of the skeletal muscle ( @GeneTgt$ RYR1 @/GeneTgt$ ) seems to be of outstanding importance in the pathogenesis of malignant hyperthermia ( MH ) . It has been shown that point mutations in the @GeneTgt$ RYR1 @/GeneTgt$ gene are strongly associated with the MH phenotype . A correctly determined phenotype is the basic prerequisite for adequate genetic MH screening . In this study we examined only those MH susceptible patients for the presence of potential @GeneTgt$ RYR1 @/GeneTgt$ mutations who showed strong pathological muscle responses in the in vitro contracture test ( IVCT ) . METHODS : A total of 56 MHS index patients who complied with the following IVCT criteria were included in the molecular genetic investigation : Contracture forces & gt ; or = 4 mN at a caffeine concentration of 2.0 mmol/l and & gt ; or = 8 mN at a @ChemicalSrc$ halothane @/ChemicalSrc$ concentration of 0.44 mmol/l . DNA sequences of exons 2 , 6 , 9 , 11 , 12 , 14 , 15 , 17 , 39 , 40 , 45 , 46 , 102 of the @GeneTgt$ RYR1 @/GeneTgt$ gene were analysed by the direct sequencing technique . Furthermore , if an MH mutation was identified in an index patient , all relatives were screened for their family specific @GeneTgt$ RYR1 @/GeneTgt$ defect . RESULTS : In 39 index patients an @GeneTgt$ RYR1 @/GeneTgt$ mutation was detected : Arg163Cys ( n = 2 ) , Asp166Asn ( n = 1 ) , Gly341Arg ( n = 2 ) , Arg401His ( n = 2 ) , Arg614Cys ( n = 12 ) , Asp2129Glu ( n = 1),Vol2168Met ( n = 1 ) , Thr2206Met ( n = 9 ) , Ala2428Thr ( n = 1 ) , Gly2434Arg ( n = 2 ) , Arg2435His ( n = 1 ) , Arg2452Trp ( n = 1 ) , Arg2454His ( n = 4 ) . Three new @GeneTgt$ RYR1 @/GeneTgt$ mutations were identified . We found a potential MH mutation in a further 130 relatives of the 39 index patients . Thirty-seven individuals were classified as MHS exclusively by molecular genetic techniques and did not have to undergo the IVCT . CONCLUSIONS : The ascertained high rate of successful MH mutation screening ( 69.64 % ) is obviously associated with the more clearly defined MHS diagnosis in the IVCT . According to the EMHG guidelines for the molecular genetic detection of MH susceptibility , a positive MH disposition could be determined in numerous persons by a less invasive technique .	2 2 9 9 9|4 9|4 9|4 9 9|4 2 11 9|7 9 9|7 11 15 9 15 19 19 16 21 19 24 24 21 2 2 30 30 30 26 2 34 34 38 38 47 42 42 42 38 44 42|43 42 42|43 44 34 52 52 52 52 47 55 55 52 58 58 55 60 58 60 47 67 67 67 67 78 70 78 75 75 72|75 75 72|75 70 78 78 67 82 82 82 78 67 88 87 88 92 92 92 92 92 97 97 97 97 92 92 101 101 103 103 103 108 108 108 108 103 111 111 108 116 116 116|113 116 116|113 111 118 116 122 122 122 118 128 128 128 125 128 122 130 128 130 103 151 151 137 151 142 142 142 142 137 144 142 149 149 149 149 144 151 151 156 156 156 156 151 151 159 151 159 159 159 159 159 166 164 170 170 170 164 173 173 170 173 173 173 173 173 159 181 179 186 186 183|186 186 183|186 179 189 189 186 151 192 226 194 192 194 194 194 194 194 194 194 194 194 194 194 194 194 194 194 209 209 211 194 194 194 194 194 194 194 224 224 224|220 224 224|220 194 226 226 231 231 231 231 226 226 251 251 242 240 240 242 242 251 246 246 246 242 251 249 251 251 251 258 254 255 258 258|255 258 258|255 251 251 261 261 266 266 266 272 270 270|267 270 270|267 272 272 261 261 261 276 274 276 277 277 276 276 283 281 283 284 284 283 283 290 288 290 291 290 283 283 297 295 297 298 298 297 297 304 302 304 305 304 295 274 311 312 274 312 315 312 315 316 315 274 274 322 320 322 323 322 274 274 329 327 329 330 329 274 274 337 337 334 337 337 274 274 343 341 343 344 343 274 274 350 348 350 351 350 274 274 357 355 357 358 357 261 367 367 364|367 367 364|367 369 369 369 369 373 373 377 377 377 373 382 382 382 382 377 387 387 387 387 382 373 390 392 392 392 394 392 392 399 399 399 392 392 403 403 392 405 403 407 405 392 409 409 414 414 414 426 419 419 419 419 414 422 422 414 422 426 426 409 433 433 430 431 433 433 426 436 436 433 409 442 438 442 442 458 447 447 447 447 442 450 450 447 458 455 455 455 458 458 458 458 461 461 458 466 466 465 466 458 458	Association
12185559	Chemical	Gene	C035349	7364	False	2	What is [PHARMGKB] between @ChemicalSrc$ M6G @/ChemicalSrc$ and @GeneTgt$ UGT2B7 @/GeneTgt$ ? [SEP] Morphine glucuronide-to-morphine plasma ratios are unaffected by the @GeneTgt$ UGT2B7 @/GeneTgt$ H268Y and UGT1A1 * 28 polymorphisms in cancer patients on chronic morphine therapy . OBJECTIVE : @GeneTgt$ UDP-glucuronosyltransferase ( UGT ) 2B7 @/GeneTgt$ is the major UGT isoform responsible for the 3- and 6-glucuronidation of morphine in humans . Studies in rats have indicated that UGT1A1 may also contribute to the formation of morphine 3-glucuronide ( M3 G ) . Our objective was to investigate whether the @GeneTgt$ UGT2B7 @/GeneTgt$ H268Y and UGT1A1 * 28 polymorphisms contribute to the variability in morphine glucuronide-to-morphine plasma ratios among cancer patients undergoing analgesic therapy with morphine . METHODS : Seventy patients with normal hepatic and renal function using slow-release morphine to relieve cancer pain were included . @GeneTgt$ UGT2B7 @/GeneTgt$ genotyping was performed using restriction enzyme analysis of polymerase chain reaction (PCR)-amplified DNA fragments . Wild-type and variant alleles of the UGT1A1 gene were identified using sizing of PCR-amplified fragments . @ChemicalSrc$ Morphine 6-glucuronide @/ChemicalSrc$ @ChemicalSrc$ (M6G)/morphine @/ChemicalSrc$ , M3G/morphine , and M3G/M6 G plasma ratios were compared between genotypes . RESULTS : The M3G/morphine , M6G/morphine , and M3G/M6 G plasma ratios varied 16- , 42- , and sevenfold , respectively , among individuals . No statistically significant differences in plasma ratios were found between individuals possessing @GeneTgt$ UGT2B7 @/GeneTgt$ H/H ( n=20 ) , H/Y ( n=30 ) , or Y/Y ( n=20 ) genotypes . Five patients were homozygous for the UGT1A1 TA(7 ) allele , which is associated with reduced UGT1A1 gene expression . However , the mean M3G/M6 G and M3G/morphine plasma ratios in TA(7 ) homozygous subjects did not differ significantly from those of heterozygous or homozygous wild-type ( TA(6 ) ) individuals . CONCLUSION : The @GeneTgt$ UGT2B7 @/GeneTgt$ H268Y polymorphism can not account for the considerable variation in glucuronide-to-morphine ratios in cancer patients . Moreover , the contribution of UGT1A1 to the formation of M3 G appears to be of minor biological significance , at least in a @GeneTgt$ UGT2B7 @/GeneTgt$ background .	2 4 4 6 6 6 11 11 8|11 11 8|11 16 11 11 13 16 6 19 19 16 23 23 23 19 6 26 26 27|28|38 27|28|38 27|28|38 27|28|38 27|28|38 28|38 27|28|38 38 38 38 38 26 38 42 42 39 42 42 46 42 48 42 38 55 53 51 55 55 60 60 60 60 55 63 63 60 66 66 63 69 69 66 69 55 73 74 74 76 74 87 81 81|78 81 81|78 86 81 81 81 86 87 76 90 90 87 95 95 95 95 90 98 98 95 98 101 99 103 101 74 124 124 109 124 112 112 109 112 112 112 109 118 116 120 116 122 120 124 124 124 125|128 128 125|128 130 130 130 130 134 134 131 138 138 138 141 141 141 134 130 147 144 144 153 151 151 151 147 153 153 153 154 158 158 155 153 159|160|163 159|160|163 160|163 159|160|163 160|174 174 160|174 163 163 163 163 163 171 172 174 174 174 176 174 174 180 180 183 192 183 183 183 183 183 190 191 183 180 192 193 193 192 192 192 192 192 192 203 192 192 208 207 208 213 211 211 208 213 213 215 213 215 216|219 219 216|219 234 221 219 221 219 219 226 224 226 219 219 219 232 230 234 216 213 238 240 240 240 246 246 246 246 246 240 246 250 250 246 255 255 255 255 250 240 274 274 260 274 262 260 262 262 266 262 271 271 271 271 266 274 274 274 274 277 274 279 287 279 279 279 284 282 284 284 277 274 289 289 295 291|295 295 291|295 295 298 298 298 289 302 302 302 298 305 305 302 308 308 305 289 323 323 314 323 316 314 319 319 314 322 322 319 323 329 329 329 329 329 323 323 337 331 337 337 334|337 337 334|337 323 323	Association
12208804	Chemical	Gene	D020117	6331	False	1	What is [PHARMGKB] between @ChemicalSrc$ cisapride @/ChemicalSrc$ and @GeneTgt$ SCN5A @/GeneTgt$ ? [SEP] Drug-induced long-QT syndrome associated with a subclinical @GeneTgt$ SCN5A @/GeneTgt$ mutation . BACKGROUND : Subclinical mutations in genes associated with the congenital long-QT syndromes ( LQTS ) have been suggested as a risk factor for drug-induced LQTS and accompanying life-threatening arrhythmias . Recent studies have identified genetic variants of the cardiac K+ channel genes predisposing affected individuals to acquired LQTS . We have identified a novel Na+ channel mutation in an individual who exhibited drug-induced LQTS . METHODS AND RESULTS : An elderly Japanese woman with documented QT prolongation and torsade de pointes during treatment with the prokinetic drug @ChemicalSrc$ cisapride @/ChemicalSrc$ underwent mutational analysis of LQTS-related genes . A novel missense mutation ( L1825P ) was identified within the C-terminus region of the cardiac Na+ channel ( @GeneTgt$ SCN5A @/GeneTgt$ ) . The L1825P channel heterologously expressed in tsA-201 cells showed Na+ current with slow decay and a prominent tetrodotoxin-sensitive noninactivating component , similar to the gain-of-function phenotype most commonly observed for @GeneTgt$ SCN5A-associated @/GeneTgt$ congenital LQTS ( LQT3 ) . In addition , L1825P exhibited loss of function Na+ channel features characteristic of Brugada syndrome . Peak Na+ current density observed in cells expressing L1825P was significantly diminished , and the voltage dependence of activation and inactivation was shifted toward more positive and negative potentials , respectively . CONCLUSIONS : This study demonstrates that subclinical mutations in the LQTS-related gene @GeneTgt$ SCN5A @/GeneTgt$ may predispose certain individuals to drug-induced cardiac arrhythmias .	3 3 3 3 10 10 10 10|7 10 10|7 4 3 13 13 16 30 18 16 18 24 24 24 24 19 26 24 26 30 30 13 34 34 34 30 37 37 34 30 30 41 39 30 44 46 46 46 48 46 54 54 54 54 54 48 54 46 56 59 56 59 46 64 64 64 69 69 69 69 64 72 72 69 74 72 76 74 64 102 78 78 102 85 85 85 102 89 89 89 85 89 89 93 89 95 89 100 100 100 100 95|99 95 95|99 102 104 102 107 107 104 102 113 113 113 118 115 113 115 118 118 122 122 122 118 127 127 127 127 122 129 127|128 127 127|128 129 118 136 136 142 138 136 141 141 138 142 142 143 147 147 144 147 153 153 153 153 147 153 153 159 159 159 155 161 162 159 167 167|163 167 167|163 167 162 169 167 169 142 174 177 177 177 177 177 183 183 183 183 178 183 187 187 184 177 192 192 192 200 192 195 193 195 196 200 200 200 200 200 205 205 211 207 205 207 207 211 200 214 214 211 214 214 214 217 211 211 221 221 224 225 221 236 228 236 233 233 233 233 228|232 228 228|232 236 225 238 236 242 242 242 236 221	Association
12563174	Chemical	Gene	D013726	154	True	0	What is [PHARMGKB] between @ChemicalSrc$ terbutaline @/ChemicalSrc$ and @GeneTgt$ beta2AR @/GeneTgt$ ? [SEP] The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo . Studies performed have shown that the Arg16Gly allele in beta-adrenoceptors ( @GeneTgt$ beta2AR @/GeneTgt$ ) enhances susceptibility to agonist-induced down-regulation , while the Gln27Glu polymorphism diminishes it . In this study , we tested whether similar phenotypes occur in vivo . We assessed 32 volunteers ( mean age 25 + /- 2 years ) with different genotypes ( group A : wild-type @GeneTgt$ beta2AR @/GeneTgt$ , n = 16 ; group B : homozygous Glu27 , n = 10 ; group C : homozygous Gly16 , n = 6 ) for the effect of 2 weeks treatment with 3 x 5 mg/day oral @ChemicalSrc$ terbutaline @/ChemicalSrc$ on @ChemicalSrc$ terbutaline @/ChemicalSrc$ infusion-induced increases in heart rate and contractility ( i.e. shortening of heart rate-corrected duration of electromechanical systole , QS2c ) . At baseline , @ChemicalSrc$ terbutaline @/ChemicalSrc$ infusion increased heart rate and contractility similarly among subjects in the three groups . Treatment with oral @ChemicalSrc$ terbutaline @/ChemicalSrc$ for 14 days reduced the ability of intravenous ( i.v . ) @ChemicalSrc$ terbutaline @/ChemicalSrc$ to increase heart rate and contractility . The extent of this reduction was similar but the time course of desensitization differed among the three groups . While in groups A and C @ChemicalSrc$ terbutaline @/ChemicalSrc$ infusion-induced increases in heart rate and contractility were reduced within 24 h after oral ingestion of @ChemicalSrc$ terbutaline @/ChemicalSrc$ , a significant effect on response to @ChemicalSrc$ terbutaline @/ChemicalSrc$ infusion was not evident for the first 3 days of @ChemicalSrc$ terbutaline @/ChemicalSrc$ treatment in group B. The Arg16Gly and the Gln27Glu variants of the @GeneTgt$ beta2AR @/GeneTgt$ do not alter the extent of agonist-induced @GeneTgt$ beta2AR @/GeneTgt$ desensitization in vivo but Glu27 homozygotes develop desensitization more slowly . This result may have implications for cardiac side-effects in patients who are Glu27 homozygotes and who receive @GeneTgt$ beta2AR @/GeneTgt$ agonist therapy .	4 4 4 5 5 7 5 9 7 13 13 13 9 15 5 5 20 17 20 20 31 24 24 31 26 24 28 26|27 26 26|27 28 20 31 35 35 32 31 41 40 40 41 31 41 20 47 47 50 50 50 50 54 53 54 50 56 54 50 59 59 61 59 64 64 61 64 64 69 69 64 69 73 73 59 76 76 79 79 79 73|78 73 73|78 83 83 59 83 87 87 83 90 90 87 93 93 87 93 93 97 93 100 100 97 103 103 93 103 103 108 108 83 112 111 112 108 119 119 114 114 114 119 117|112 112 117|112 125 124|119 124 124|119 125 108 128 128 125 128 128 133 133 83 137 136 137 133 140 140 137 140 140 133 59 149 154 154 150|153 153 150|153 154 154 156 154 156 156 154 161 154 165 165 165 161 154 176 171 171 168|170 168 168|170 175 175 168 176 178 176 180 185 182 185 182 185 183|178 178 183|178 188 178 190 188 190 190 176 197 202 200 200 197 202 202 202 206 206 209 208 206 202 213 213 213 209 202 224 217 215 217 218 223 223|220 223 223|220 218 231 227 227 224 227 227 231 231 234 234 231 237 237 231 239 237 237 237 239 244 244 239 246 244 250 250|245 250 250|245 246 253 253 231 258 258 258 258 253 262 262|256 262 262|256 258 267 267 267 267 262 267 271 271 267 274 274 271|269 271 271|269 278 278 231 280 278 285 285 285|277 285 285|277 280 287 278 278 290 291 278 291 294 291 231 303 305 305 305 305 309 309 306 311 309 315 315 315 311 305 318 305 318|322 322 318|322 322 318 305	Association
12576843	Chemical	Gene	D000068677	2784	True	0	What is [PHARMGKB] between @ChemicalSrc$ sildenafil @/ChemicalSrc$ and @GeneTgt$ GNB3 @/GeneTgt$ ? [SEP] @ChemicalSrc$ Sildenafil @/ChemicalSrc$ response is influenced by the @GeneTgt$ G protein beta 3 @/GeneTgt$ subunit @GeneTgt$ GNB3 @/GeneTgt$ C825 T polymorphism : a pilot study . PURPOSE : @ChemicalSrc$ Sildenafil @/ChemicalSrc$ is the oral phosphodiesterase-5 inhibitor that revolutionized treatment for erectile dysfunction . We investigated a potential association of the @GeneTgt$ G protein beta 3 @/GeneTgt$ subunit ( @GeneTgt$ GNB3 @/GeneTgt$ ) C825 T polymorphism , a determinant of intracellular signal transduction , with the drug response to @ChemicalSrc$ sildenafil @/ChemicalSrc$ in patients with erectile dysfunction . MATERIALS AND METHODS : In 113 men with erectile dysfunction and 111 healthy male controls genotype status of the @GeneTgt$ GNB3 @/GeneTgt$ C825 T polymorphism was determined by polymerase chain reaction and restriction analysis . Patients with erectile dysfunction received @ChemicalSrc$ sildenafil @/ChemicalSrc$ at a dose of 25 to 100 mg . according to the individual erectile response . Drug response was measured by interviewing the patient according to the erection scale of 0 to 5 . RESULTS : The @GeneTgt$ GNB3 @/GeneTgt$ genotype distribution of patients with erectile dysfunction exactly matched that of healthy controls . Analysis of the response to @ChemicalSrc$ sildenafil @/ChemicalSrc$ revealed a significant association of C825 T allele status with the erectile response to @ChemicalSrc$ sildenafil @/ChemicalSrc$ . In the group with TT genotype we observed a 90.9 % response but only a 50.9 % and 48.9 % response in patients with the CC and TC genotype , respectively . The odds ratio for a positive erectile response was 10.0 ( 95 % CI 1.2 to 81.1 ) for patients with the TT versus the TC/CC genotype ( p = 0.01 ) . CONCLUSIONS : The response to @ChemicalSrc$ sildenafil @/ChemicalSrc$ is significantly associated with @GeneTgt$ GNB3 @/GeneTgt$ C825 T genotype status in patients with erectile dysfunction .	0|3 3 0|3 5 5 5 18 18 18|6 18|6 18|6 18|6 18 18|6 18 8|18 18 8|18 18 18 5 5 22 22 5 5 35 35 35|28 35 35|28 35 35 35 35 35 37 35 37 41 41 38 35 45 45 48 48 45 63 63 63|50 63|50 63|50 63|50 63 63|50 63 58 53|63 63 53|63 63 63 63 48 63 66 63 70 70 70 66 63 75 75 75 48 77 75|71 75 75|71 80 77 83 83 80 45 113 88 88 88 94 94 102 97 97 94 97 101 101 97 88 104 102 111 111 111|106 111 111|106 111 111 104 113 113 117 117 117 113 117 120 117 113 127 126 126 123 127 127 127 127 132 132 127 137 136 136 137 132 127 145 140 145 145 145 145 145 148 150 150 150 152 150 154 152 159 155 159 159 152 161 159 163 161 150 165 165 171 167|171 171 167|171 171 178 173 171 176 176 173 178 165 178 182 182 179 165 192 188 188 185 190 188|189 188 188|189 192 195 195 192 200 200 199 200 195 204 204 204 195 206 204 204 204 192 213 213 218 216 216 213 218 218 222 221 222 218 218 227 227 227 218 227 230 231 227 233 231 236 236 233 236 236 236 227 227 218 245 245 256 250 250 250 250 245 256 256 255 255 256 256 259 257 256 259 262 256 265 265 262 269 269 269 262 273 273 271 269 273 256 276 276 279 285 281 279|280 279 279|280 285 285 276 292 292|285 292 292|285 292 292 292 285 294 292 297 297 294 276	Association
12883402	Chemical	Gene	D006221	6261	True	0	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] Detection of a novel @GeneTgt$ ryanodine receptor subtype 1 @/GeneTgt$ mutation ( R328W ) in a malignant hyperthermia family by sequencing of a leukocyte transcript . BACKGROUND : To determine whether malignant hyperthermia ( MH ) susceptibility in a Canadian pedigree is associated with a mutation in the @GeneTgt$ ryanodine receptor subtype 1 @/GeneTgt$ ( @GeneTgt$ RYR1 @/GeneTgt$ ) gene , the complete @GeneTgt$ RYR1 @/GeneTgt$ transcript obtained from the leukocytes of one MH-susceptible family member was sequenced , using a newly developed protocol . METHODS : RNA was extracted from leukocytes and converted into complementary DNA . Overlapping fragments of @GeneTgt$ RYR1 @/GeneTgt$ complementary DNA were amplified by the polymerase chain reaction and used for double-strand sequencing to find a single mutation likely to be causal of MH susceptibility . Inheritance of the mutation in the family was studied by restriction endonuclease analysis and/or sequencing of genomic DNA and compared to available caffeine @ChemicalSrc$ halothane @/ChemicalSrc$ contracture test data . The mutation was introduced into rabbit @GeneTgt$ RYR1 @/GeneTgt$ complementary DNA , the complementary DNA was expressed in human embryonic kidney line 293 cells , and Ca2 + release by the mutant Ca2 + release channel was measured following the addition of caffeine and @ChemicalSrc$ halothane @/ChemicalSrc$ . RESULTS : A novel arginine 328 to tryptophan mutation in @GeneTgt$ RYR1 @/GeneTgt$ was detected by direct sequencing of the @GeneTgt$ RYR1 @/GeneTgt$ transcript from leukocytes of one MH-susceptible individual . A causal role for this mutation in MH is indicated by cosegregation of the mutation with the MH-susceptible phenotype within the family and by the demonstration that the mutant channel has increased sensitivity to both caffeine and @ChemicalSrc$ halothane @/ChemicalSrc$ . CONCLUSIONS : The feasibility of using complete @GeneTgt$ RYR1 @/GeneTgt$ transcripts from leukocytes for sequence analysis offers an efficient and noninvasive method for scanning @GeneTgt$ RYR1 @/GeneTgt$ for novel mutations .	1 10 10 10 10|4 10|4 10|4 10|4 10 10|4 1 12 10 12 18 18 18 18 10 20 1 24 24 24 20 1 27 30 30 27 43 37 37 35 33 35 43 41 41 41 37 43 30 46 46 43 58 58 58|48|49 58|48|49 58|48|49 58|48|49 58|49 58|48|49 58 50|58 58 50|58 58 46 58 64 64 64|56 64 64|56 75 64 68 68 65 73 73 73 73 68 75 30 75 75 81 80 81 77 27 90 90 90 90 90 92 90 90 90 97 97 94 90 100 107 105 101|105 105 101|105 105 100 107 107 112 112 112 112 107 107 107 117 117 114 119 114 122 122 119 122 126 126 123 129 129 126 107 140 135 135 132 138 138 135 140 140 144 144 144 140 144 144 149 149 146 140 140 159 159 159 157|154 157 157|154 159 159 151 140 163 165 165 165 171 171 171|167 171 171|167 171 165 177 175 175 177 177 165 182 182 182 182 184 182 177 184 177 177 177 177 193 193 193 189 177 196 198 198 177 201 201 198 203 201 203 203 203 203 177 210 210 214 214 223 214 218 218 214 220 218|219 218 218|219 223 210 226 226 223 231 231 227|231 231 227|231 226 233 231 237 237 237 233 210 243 243 250 246 246 243 248 246 250 250 252 250 255 255 252 259 259 259 255 262 262 259 252 266 266 252 272 270 270 272 272 266 272 276 276 273 276 276|277 276 276|277 250 282 282 285 297 287 285 291 291|288 291 291|288 287 293 291 296 296 287 282 302 302 299 299 297 305 305 302|303 302 302|303 309 309 302 282	Association
12914549	Chemical	Gene	D020112	5243	False	1	What is [PHARMGKB] between @ChemicalSrc$ Rh123 @/ChemicalSrc$ and @GeneTgt$ Pgp @/GeneTgt$ ? [SEP] @GeneTgt$ MDR1 @/GeneTgt$ polymorphisms G2677 T in exon 21 and C3435 T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes . @GeneTgt$ P-glycoprotein @/GeneTgt$ ( @GeneTgt$ Pgp @/GeneTgt$ ) is a member of the ABC-transporter family , and in humans , is encoded by the @GeneTgt$ MDR1 @/GeneTgt$ gene . Recently , several single-nucleotide polymorphisms in the @GeneTgt$ MDR1 @/GeneTgt$ gene were identified . The aim of the present study was to evaluate the effect of the @GeneTgt$ MDR1 @/GeneTgt$ genetic polymorphisms G2677 T and C3435 T on @GeneTgt$ Pgp @/GeneTgt$ activity in CD56 + and CD4 + peripheral blood cells . Using flow cytometry , @ChemicalSrc$ rhodamine 123 @/ChemicalSrc$ ( @ChemicalSrc$ Rh123 @/ChemicalSrc$ ) efflux was determined in 46 male healthy volunteers . Median Rh123 fluorescence in control sample , after baseline dye uptake , was set as 100 % . @ChemicalSrc$ Rh123 @/ChemicalSrc$ fluorescence in efflux samples , exposed to different efflux periods , was used to calculate the percentage of @ChemicalSrc$ Rh123 @/ChemicalSrc$ retained in the cells in comparison with control . There was no significant difference in Rh123 efflux in CD56 + cells after 5 , 10 , 15 , and 30 min efflux between individuals with different @GeneTgt$ MDR1 @/GeneTgt$ genotypes . Also , in CD4 + cells after 15 , 30 , 60 , and 90 min , Rh123 efflux did not reveal statistically different results for the three genotypes at 2677 and 3435 . Rh123 efflux was not enhanced by a 10-day rifampin administration , as determined in 15 individuals before and after rifampin treatment . In conclusion , we found no impact of the @GeneTgt$ MDR1 @/GeneTgt$ G2677 T and C3435 T polymorphisms on @GeneTgt$ Pgp @/GeneTgt$ activity in CD56 + and CD4 + peripheral blood lymphocytes .	0|5 5 0|5 5 5 15 7 5 7 7 7 7 13 11 13 15 17 15 20 20 17 24 24 24 17 15 26|35 35 26|35 30 27|28 27 27|28 30 35 35 46 39 39 39 35 35 35 43 35 35 46 46 51 51 51|46 51 51|46 46 46 67 67 60 60 67 65 65 65|62 65 65|62 60 67 67 67 71 76 75 75 75 71 76 78 76 80 78 87 87 85|82 85 85|82 87 87 80 87 88 88 88 95 95|91 95 95|91 80 97 95 97 97 97 97 104 104 97 76 121 110 108 110 116|111|119 116|111|119 116|119 116|111|119 116 112|113 112 112|113 116 108 121 121 126 126 126 126 121 121 132 132 143 135 135 132 132 140 139 140 132 132 143 143 146 146 143 143 147|150 150 147|150 162 153 153 150 153 153 159 159 159 155 153 162 162 164 162 166 164 168 166 166 166 166 173 173 170 175 170 177 175 162 182 182 185 185 182 188 188 185 190 188 190 190 203 203 194 194 198 194 194 194 194 203 185 205 203 210 210 207|210 210 207|210 205 182 234 234 216 234 216 216 220 228 220 220 222 222 220 220 220 216 234 231 234 234 234 234 236 237 234 241 241 241 237 243 241 243 243 234 248 251 251 251 251 256 256 256 256 251 251 259 251 262 262 259 267 263 263 263 259 251 270 273 273 273 273 275 273 280 280 277|280 280 277|280 275 280 281 281 285 281 289 285|289 289 285|289 275 291 289 291 291 291 291 298 298 291 273	Association
14586389	Chemical	Gene	D008139	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ loperamide @/ChemicalSrc$ and @GeneTgt$ MDR1 @/GeneTgt$ ? [SEP] No effect of @GeneTgt$ MDR1 @/GeneTgt$ C3435 T variant on @ChemicalSrc$ loperamide @/ChemicalSrc$ disposition and central nervous system effects . BACKGROUND : The @GeneTgt$ MDR1 @/GeneTgt$ gene encodes the efflux transporter @GeneTgt$ P-glycoprotein @/GeneTgt$ , which is highly expressed in the small intestine and in the blood-brain barrier . A major function of @GeneTgt$ P-glycoprotein @/GeneTgt$ is to limit the absorption and central nervous system exposure of numerous xenobiotics . A genetic polymorphism in the @GeneTgt$ MDR1 @/GeneTgt$ gene ( C3435 T ) has been associated with changes in the intestinal expression level and function of @GeneTgt$ P-glycoprotein @/GeneTgt$ . The aim of this study was to investigate the effect of this polymorphism on disposition and brain entry of the @GeneTgt$ P-glycoprotein @/GeneTgt$ substrate @ChemicalSrc$ loperamide @/ChemicalSrc$ . METHODS : Healthy white volunteers were genotyped for the @GeneTgt$ MDR1 @/GeneTgt$ C3435 T polymorphism , and a 16-mg oral dose of @ChemicalSrc$ loperamide @/ChemicalSrc$ was administered to 8 subjects with the 3435TT genotype and 8 subjects with the 3435CC genotype . Plasma levels of @ChemicalSrc$ loperamide @/ChemicalSrc$ were determined by liquid chromatography-tandem mass spectrometry . @ChemicalSrc$ Loperamide-induced @/ChemicalSrc$ respiratory depression was detected as the ventilatory response to carbon dioxide and was used as a measure of central nervous system side effects . RESULTS : We found no significant difference in @ChemicalSrc$ loperamide @/ChemicalSrc$ pharmacokinetics between individuals homozygous for the C and the T alleles in position 3435 of @GeneTgt$ MDR1 @/GeneTgt$ , as follows : peak plasma drug concentration , 3164 + /- 1053 pg/mL and 3021 + /- 984 pg/mL ; area under the concentration-time curve from 0 to 8 hours , 14414 + /- 4756 pg . h/mL and 14923 + /- 6466 pg . h/mL ; and time to peak plasma drug concentration , 3.9 + /- 1.4 hours and 3.9 + /- 2.6 hours for the @GeneTgt$ MDR1 @/GeneTgt$ 3435CC and 3435TT genotypes , respectively ( P & gt;.05 , for all parameters ) . Hypercapnic ventilatory response changed only minimally after ingestion of @ChemicalSrc$ loperamide @/ChemicalSrc$ ( the coefficient of variation during the 0- to 8-hour period was 21 % + /- 14 % for the sample population ) , and there was no @GeneTgt$ MDR1 @/GeneTgt$ 3435 genotype-related effect on respiratory response . Carriers of the 2 major @GeneTgt$ MDR1 @/GeneTgt$ haplotypes , @GeneTgt$ MDR1 @/GeneTgt$ * 1 and @GeneTgt$ MDR1 @/GeneTgt$ * 13 , did not differ in their response to @ChemicalSrc$ loperamide @/ChemicalSrc$ . CONCLUSION : There was no association between the @GeneTgt$ MDR1 @/GeneTgt$ C3435 T variation and plasma levels or central nervous system effects of the @GeneTgt$ P-glycoprotein @/GeneTgt$ substrate @ChemicalSrc$ loperamide @/ChemicalSrc$ in a white study population . The @GeneTgt$ MDR1 @/GeneTgt$ haplotype structure was quite variable and supports the use of haplotypes instead of single nucleotide polymorphisms in determining clinical consequences of genetic variation .	2 2 8 8|3 8 8|3 8 8 2 12 8|12 12 8|12 2 12 17 17 17 12 2 27 21 26 23|26 26 23|26 27 27 31 31 31 29|27 27 29|27 31 37 37 37 31 41 41 41 37 41 46 46 46 41 27 52 52 58 54 52|53 52 52|53 58 58 58 60 58 60 65 65 65 60 68 68 60 58 73 73 85 78 78 78|75 78 78|75 73 81 81 78 81 85 85 85 87 85 92 92 92 92 87 92 92 96 94 94 94 85 102 106 105 105 102 106 108 106 110 108 113 113 110 115 110 115 118 115 124 124 120|123 123 120|123 124 122|115 115 122|115 106 135 135 133 133 135 135 135 142 142 137|142 142 137|142 142 142 135 135 135 148 148 148 153 150 148 148 148 153 135 156 156 153 160 160 160 156 160 163 160 167 167 167 153 135 172 177 174 172|173 172 172|173 177 177 182 182 182 182 177 177 184|188 188 184|188 188 190 190 190 194 194 194 190 197 197 194 190 200 190 203 203 200 209 209 209 209 209 203 190 212 212 215 212 218 218 215 222 219|222 222 219|222 218 224 222 224 228 228 225 224 232 232 224 234 232 234 237 235|234 234 235|234 215 241 215 241 246 246 246 241 246 246 246 215 252 215 252 252 254 258 258 252 258 252 264 264 264 260 269 268 268 269 264 269 275 271 271 275 252 212 279 279 279 281 285 285 279 285 287 287 287 287 292 290 295 295 292 295 301 297 297 301 287 301 301 287 287 307 287 315 315 315|309 315 315|309 310 310 310 307 307 319 319 307 319 319 319 325 325 319 307 287 331 331 332 332 334 332 336 332 338 336|337 336 336|337 342 342 353 344 342 350 350 349 347 350 342 353 353 332 353 353 357 353 361 361 361 357 357 357 353 366 353 372 372|366 372 372|366 372 372 366 375 375 372 366 400 386 386 386 386 386|383 386 386|383 379 386 386 386 386 388 388 388 388|390 388 388|390 393 393 386 400 400 400 403 403 400 405 400|401 400 400|401 400 412 415 415 412 417 415 424 424 419|424 424 419|424 424 424 417 424 427 424 424 432 432 432 424 438 438 437|433 437 437|433 438 435|424 424 435|424 444 444 444 444 424 412 453 449|453 453 449|453 453 456 456 456 456 456 456 460 458 462 460 467 463 467 467 460 469 458 471 469 474 474 471 456	Association
14625131	Chemical	Gene	D019821	3953	True	0	What is [PHARMGKB] between @ChemicalSrc$ simvastatin @/ChemicalSrc$ and @GeneTgt$ Ob-R @/GeneTgt$ ? [SEP] @GeneTgt$ Leptin receptor @/GeneTgt$ polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by @ChemicalSrc$ simvastatin @/ChemicalSrc$ in Japanese men . OBJECTIVE : To investigate whether @GeneTgt$ leptin receptor @/GeneTgt$ ( @GeneTgt$ Ob-R @/GeneTgt$ ) Arg223Gln polymorphism influences serum lipid levels and whether this polymorphism affects the efficiency of the cholesterol lowering HMG-CoA reductase inhibitor , @ChemicalSrc$ simvastatin @/ChemicalSrc$ [ Clin . Cardiol . 16 ( 1993 ) 317 ] . DESIGN : Case-control association study . SUBJECTS : We studied 201 Japanese men without medical care , and 78 Japanese who took @ChemicalSrc$ simvastatin @/ChemicalSrc$ . METHODS : Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism ( PCR-RFLP ) . Serum lipid and leptin levels were determined . RESULTS : Subjects with the Arg/Arg homozygotes had significantly higher serum total cholesterol ( TC ) and low density lipoprotein cholesterol ( LDL-C ) levels than those with the Arg/Gln heterozygotes and Gln/Gln homozygotes ( TC : Arg/Arg : 213+/-3 , Arg/Gln : 196+/-6 , Gln/Gln : 184+/-5 , P=0.004 for comparison among three genotypes , P=0.008 for difference between Arg/Arg and Arg/Gln , and P=0.025 for difference between Arg/Arg and Gln/Gln , LDL-C : Arg/Arg : 127+/-3 , Arg/Gln : 112+/-6 , Gln/Gln : 114+/-8 , P=0.027 ) for comparison among three genotypes and P=0.011 for difference between Arg/Arg and Arg/Gln . Subjects with the Arg/Arg homozygotes had significantly lower serum high density lipoprotein cholesterol ( HDL-C ) levels than those with the Arg/Gln heterozygotes and Gln/Gln homozygotes ( Arg/Arg : 55+/-1 , Arg/Gln : 62+/-3 , Gln/Gln : 57+/-7 , P=0.046 ) for comparison among three genotypes and P=0.013 for difference between Arg/Arg and Arg/Gln . In addition , in 78 patients with hypercholesterolemia who took 5 mg @ChemicalSrc$ simvastatin @/ChemicalSrc$ , the TC lowering effect by @ChemicalSrc$ simvastatin @/ChemicalSrc$ in subjects with the Arg/Arg homozygotes was significantly lower than in those with the Arg/Gln heterozygotes and Gln/Gln homozygotes ( the reduction in serum TC levels ; 62+/-4 vs. 79+/-6 , P=0.044 ) . CONCLUSIONS : We demonstrate that @GeneTgt$ Ob-R @/GeneTgt$ Arg223Gln polymorphism in Japanese men is associated with significant elevation of serum TC and LDL-C levels . Our data also show that the Arg/Arg homozygotes tend to show lowered level of serum HDL-C. Furthermore , this polymorphism tends to show an attenuated response to an HMG-CoA reductase inhibitor in terms of the cholesterol lowering effect . These results suggest that the @GeneTgt$ Ob-R @/GeneTgt$ gene may serve as a novel modifier gene for hypercholesterolemia in Japanese men .	0|4 0|4 4 0|4 6 6 6 10 10 10 6 10 10 16 16 16 12 18 12|15 12 12|15 22 22 18 6 26 26 29 26 40 30|39|31 30|39|31 39|31 30|39|31 39 39|32 39 39|32 39 39 40 29 43 43 40 40 48 47 48 40 50 48 53 53 50 48 57 57 54 57 62|55 62 62|55 62 64 64 57 68 68 68 64 68 68 64 26 76 76 80 80 76 76 82 85 85 82 88 88 85 91 91 85 85 85 95 85 97 95 97 97 97 82 106 106 106 106 106 113 113 113 113 113 113 106 115 113 115 106 119 124 119 119 119 124 124 124 133 126 133 132 132 132 128 133 135 138 138 138 150 140 138 140 138 146 146 146 138 148 146 148 133 152 150 156 156 156 152 156 159 156 161 159 161 161 165 173 173 173 173 173 169 173 173 163 173 173 177 173 180 180 177 161 161 184 182 186 184 186 186 161 161 161 193 133 195 193 195 195 199 195 199 203 203 195 213 204 205 213 207 207 209 207 207 195 195 216 133 219 219 216 219 219 223 133 225 223 225 225 133 234 233 233 233 229 236 236 236 241 241 241 241 245 243 241 243 236 247 245 251 251 251 247 251 254 251 258 258 258 254 260 258 260 260 262 258 264 258 268 258 268 271 236 274 274 271 274 274 278 271 280 278 280 280 236 285 314 314 289 289 314 291 289 293 289 295 296 293|295 293 293|295 296 300 296 289 301 304 301|302 301 301|302 307 304 311 311 311 307 314 314 314 317 317 314 321 321 321 317 321 324 321 327 327 314 331 331 331 327 327 337 333 333 333 327 327 314 342 342 345 342 355 350|346 350 350|346 350 355 353 353 350 355 345 358 358 355 361 361 358 361 361 361 342 368 370 370 370 375 374 374 375 370 377 375 379 377 382 382 379 387 387 386 387 370 389 387 392 392 389 397 397 397 397 392 399 392 404 404 404 404 399 370 407 408 408 415 413 413|410 413 413|410 415 415 408 420 420 420 420 415 422 420 425 425 422 408	Association
14641996	Chemical	Gene	D006221	6261	True	0	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RyR1 @/GeneTgt$ ? [SEP] Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala . Malignant hyperthermia ( MH ) is caused by increased calcium release from sarcoplasmic reticulum , triggered by volatile anesthetics or depolarizing muscle relaxants . Numerous mutations associated with MH have been detected in the skeletal muscle type ryanodine receptor gene ( @GeneTgt$ RyR1 @/GeneTgt$ ) , but so far facilitated calcium release has only been demonstrated for a few of them . This is a prerequisite for confirming the causative role of an @GeneTgt$ RyR1 @/GeneTgt$ mutation for MH . Calcium release from sarcoplasmic reticulum induced by 4-chloro-m-cresol ( 4CmC ) , caffeine , and @ChemicalSrc$ halothane @/ChemicalSrc$ was determined in human myotubes by calcium imaging . The @GeneTgt$ RyR1 @/GeneTgt$ Ile2182Phe mutation and the @GeneTgt$ RyR1 @/GeneTgt$ Gly2375Ala mutation have been identified in individuals susceptible to MH . In myotubes of individuals carrying the @GeneTgt$ RyR1 @/GeneTgt$ Ile2182Phe or the @GeneTgt$ RyR1 @/GeneTgt$ Gly2375Ala mutation , the EC(50 ) for caffeine and @ChemicalSrc$ halothane @/ChemicalSrc$ was reduced ; in the Ile2182Phe myotubes , the EC(50 ) for 4CmC was also reduced , all consistent with facilitated calcium release from the sarcoplasmic reticulum . From these data we conclude that both mutations are pathogenic for MH .	2 7 5 5 2 7 7 10 10 7 10 13 11 20 20 20 20 20 20 13 20 21 21 7 26 31 28 26 28 31 31 35 35 35 31 38 38 35 35 35 43 43 40 43 47 47 43 31 50 56 50 53 51 56 56 56 64 64 64 64 64 64 64 56 66 64|65 64 64|65 66 64 56 72 73 56 75 73 79 79 79 56 82 82 79 84 82 56 90 90 90 90 92 90 95 95 92 100 100 97|100 100 97|100 95 102 100 90 106 123 109 109 106 109 112 110 114 112 114 112 112 112 112 112|119 112 112|119 123 123 126 126 123 129 129 123 123 136 132|136 136 132|136 136 145 136 142 142|137 142 142|137 142 136 145 145 145 147 145 147 150 148 145 155 171 157 155 157 162 162|159 162 162|159 158 162 168 163|168 168 163|168 168 162 171 171 179 171 174 171 174 173|174 174 173|174 179 179 179 184 184 184 193 184 187 184 187 190 184 193 193 179 196 196 193 200 200 200 196 204 204 204 200 193 211 211 213 213 213 218 216 218 218 213 220 218 213	Association
14975928	Chemical	Gene	D020117	3757	True	0	What is [PHARMGKB] between @ChemicalSrc$ cisapride @/ChemicalSrc$ and @GeneTgt$ HERG @/GeneTgt$ ? [SEP] Molecular and functional characterization of common polymorphisms in @GeneTgt$ HERG @/GeneTgt$ ( @GeneTgt$ KCNH2 @/GeneTgt$ ) potassium channels . Long QT syndrome ( LQTS ) is a cardiac repolarization disorder that can lead to arrhythmias and sudden death . Chromosome 7-linked inherited LQTS ( LQT2 ) is caused by mutations in human ether-a-go-go-related gene ( @GeneTgt$ HERG @/GeneTgt$ ; @GeneTgt$ KCNH2 @/GeneTgt$ ) , whereas drug-induced LQTS is caused primarily by @GeneTgt$ HERG @/GeneTgt$ channel block . Many common polymorphisms are functionally silent and have been traditionally regarded as benign and without physiological consequence . However , the identification of common nonsynonymous single nucleotide polymorphisms ( nSNPs ; i.e. , amino-acid coding variants ) with functional phenotypes in the SCN5A Na(+ ) channel and MiRP1 K(+ ) channel beta-subunit have challenged this viewpoint . In this report , we test the hypothesis that common missense @GeneTgt$ HERG @/GeneTgt$ polymorphisms alter channel physiology . Comprehensive mutational analysis of @GeneTgt$ HERG @/GeneTgt$ was performed on genomic DNA derived from a population-based cohort of sudden infant death syndrome and two reference allele cohorts derived from 100 African American and 100 Caucasian individuals . Amino acid-encoding variants were considered common polymorphisms if they were present in at least two of the three study cohorts with an allelic frequency & gt;0.5 % . Four nSNPs were identified : K897 T , P967L , R1047L , and Q1068R . Wild-type ( WT ) and polymorphic channels were heterologously expressed in human embryonic kidney cells , and biochemical and voltage-clamp techniques were used to characterize their functional properties . All channel types were processed similarly , but several electrophysiological differences were identified : 1 ) K897 T current density was lower than the other polymorphic channels ; 2 ) K897 T channels activated at more negative potentials than WT and R1047L ; 3 ) K897 T and Q1068R channels inactivated and recovered from inactivation faster than WT , P967L , and R1047L channels ; and 4 ) K897 T channels showed subtle differences compared with WT channels when stimulated with an action potential waveform . In contrast to K897 T and Q1068R channels , P967L and R1047L channels were electrophysiologically indistinguishable from WT channels . All @GeneTgt$ HERG @/GeneTgt$ channels had similar sensitivity to block by @ChemicalSrc$ cisapride @/ChemicalSrc$ . Therefore , some @GeneTgt$ HERG @/GeneTgt$ polymorphic channels are electrophysiologically different from WT channels .	1 1 1 1 7 7 1 16 8|16 16 8|16 16 16|10 16 16|10 16 16 1 1 22 22 30 24 22 24 30 30 30 30 30 33 33 30 35 33 35 38 35 30 41 43 43 48 45 43 45 48 48 50 48 54 54 54 50 56 55|54 54 55|54 56 56|57 56 56|57 56 48 67 65 67 67 48 67 73 73|67 73 73|67 73 67 48 80 80 83 83 83 83 83 88 88 88 83 90 88 90 94 94 90 83 131 131 99 131 105 105 105 105 105 99 107 105 107 113 113 113 113 107 113 117 117 113 123 123 123 120 123 117 123 126 129 129 129 123 131 131 133 131 131 137 137 140 140 140 140 142 140 149 148 148 145|148 148 145|148 149 142 151 149 140 156 156 161 158 156|157 156 156|157 161 161 164 164 161 164 169 169 169 165 174 174 174 174 169 169 179 179 179 169 179 184 184 184 188 184 184 188 180 161 193 193 195 195 195 197 195 201 201 201 195 204 204 205 201 210 210 210 210 205 214 214 214 210 214 217 214 195 220 222 222 222 222 225 222 225 225 227 227 227 225 225 222 256 236 234 236 234 234 243 243 243 234 248 248 248 248 243 248 243 243 251 251 234 256 256 258 256 261 261 258 256 265 265 267 267 267 267 267 267 272 273 275 275 267 275 284 277 282 282 282 284 284 275 289 289 289 289 284 284 295 291 295 295 296 284 300 299 300 296 302 300 302 302 284 309 309 309 313 309 309 313 284 313 313 317 315 284 320 318 320 320 322 320 320 320 284 284 334 329 333 333 334 284 336 334 340 340 340 334 342 334 347 347 347 347 342 267 350 353 353 353 364 353 353 364 356 356 358 358 356 364 364 364 367 367 364 364 372 369|372 372 369|372 373 373 375 373 377 375 379 377 377 377 373 393 393 390 386|389 389 386|389 390 393 393 393 393 396 396 393 393	Association
15044558	Chemical	Gene	D010076	7366	True	0	What is [PHARMGKB] between @ChemicalSrc$ oxazepam @/ChemicalSrc$ and @GeneTgt$ UGT2B15 @/GeneTgt$ ? [SEP] @GeneTgt$ UDP-glucuronosyltransferase ( UGT ) 2B15 @/GeneTgt$ pharmacogenetics : @GeneTgt$ UGT2B15 @/GeneTgt$ D85Y genotype and gender are major determinants of @ChemicalSrc$ oxazepam @/ChemicalSrc$ glucuronidation by human liver . @ChemicalSrc$ Oxazepam @/ChemicalSrc$ is a commonly used 1,4-benzodiazepine anxiolytic drug that is polymorphically metabolized in humans . However , the molecular basis for this phenomenon is currently unknown . We have previously shown that S-oxazepam glucuronide , the major @ChemicalSrc$ oxazepam @/ChemicalSrc$ metabolite , is selectively formed by @GeneTgt$ UDP-glucuronosyltransferase ( UGT ) 2B15 @/GeneTgt$ , whereas the minor R-oxazepam glucuronide is produced by multiple UGTs other than @GeneTgt$ UGT2B15 @/GeneTgt$ . Phenotype-genotype studies were conducted using microsomes and DNA prepared from the same set of 54 human livers . Sequencing of the @GeneTgt$ UGT2B15 @/GeneTgt$ gene revealed three nonsynonymous polymorphisms , D85Y , T352I , and K523 T , with variant allele frequencies of 0.56 , 0.02 , and 0.40 , respectively . D85Y genotype showed a significant effect ( p = 0.012 ) on @ChemicalSrc$ S-oxazepam @/ChemicalSrc$ glucuronidation with lower median activities in 85Y/Y livers ( 49 pmol/min/mg protein ) compared with 85D/D livers ( 131 pmol/min/mg ) , whereas 85D/Y livers were intermediate in activity ( 65 pmol/min/mg ) . There was also a significant trend ( p = 0.049 ) for higher @ChemicalSrc$ S-oxazepam @/ChemicalSrc$ activities in the two 352T/I livers ( 135 and 210 pmol/min/mg ) compared with the remaining 352T/T livers ( median , 64 pmol/min/mg ) . Conversely , K523 T genotype had no apparent effect on @ChemicalSrc$ oxazepam @/ChemicalSrc$ glucuronidation ( p & gt ; 0.05 ) . Donor gender also significantly influenced @ChemicalSrc$ S-oxazepam @/ChemicalSrc$ glucuronidation with higher median activities in male ( 65 pmol/min/mg ) compared with female ( 39 pmol/min/ mg ) livers ( p = 0.042 ) . @ChemicalSrc$ R-Oxazepam @/ChemicalSrc$ glucuronidation was not affected by either genotype or gender ( p & gt ; 0.05 ) . In conclusion , gender and D85Y genotype are identified as major determinants of @ChemicalSrc$ S-oxazepam @/ChemicalSrc$ glucuronidation by human liver and may explain in part polymorphic @ChemicalSrc$ oxazepam @/ChemicalSrc$ glucuronidation by human subjects .	0|1|7 0|1|7 0|1|7 0|1|7 0|1|7 1|7 0|1|7 7 7 3|12 12 3|12 12 17 12 12 17 17 7 21 12|21 21 12|21 17 24 24 17 17 28|37 37 28|37 37 37 34 37 37 37 37 41 41 41 37 43 41 37 56 56 50 50 56 53 53 50 56 56 56 56 61 61 61 61 74 64 74 74 70 70 67|70 70 67|70 74 70 74 74 61 76 74|76 74|76 74|76 74|76 74|76 74|76 74|76 74 89 87 87 87 89 89 74 92 92 89 92 93 92|88 92 92|88 61 102 104 104 104 104 105 106 106 106 113 113 113 109 117 117 117 113 104 125 124 124 121|124 124 121|124 119 125 128 128 125 128 128 130 130 130 130 136 130 128 141 141 141 128 143 141 143 143 143 143 143 148 125 125 154 155 155 158 158 155 161 161 158 161 161 167 164|167 167 164|167 158 171 171 171 167 174 174 171 178 178 178 174 178 155 183 183 180 186 186 183 186 155 193 191 193 193 155 195 193 198 198 195 198 155 203 203 203 207 207 203 210 210 207 210 210 217 217 217|214 217 217|214 210 222 222 222 222 217 227 227 224 224 222 227 203 234 234 234 234 229 239 239 239 239 234 239 203 248 248 247 247 248 248 251 251 248 255 252|255 255 252|255 251 257 255 257 257 261 257 261 248 266 269 269 269 269 272|269 272 272|269 269 276 276 276 272 278 276 281 281 278 281 291 285 291 289 289 289 285 289 269 294 294 291 294 294 269 298|301 301 298|301 304 304 304 304 307 307 304 307 307 311 307 311 311 315 311 315 304 320 327 327 327 322 322 322 327 327 330 330 327 334 334|331 334 334|331 330 337 337 330 327 340 327 346 341 346 342|346 346 342|346 340 349 349 346 327	Association
15210166	Chemical	Gene	D006221	6261	False	1	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RyR1 @/GeneTgt$ ? [SEP] Functional characterization of malignant hyperthermia-associated @GeneTgt$ RyR1 @/GeneTgt$ mutations in exon 44 , using the human myotube model . Malignant hyperthermia ( MH ) is a pharmacogenetic disorder with an autosomal dominant inheritance . During exposure to triggering agents as volatile anaesthetics , affected individuals may develop a potentially fatal hypermetabolic syndrome caused by excessive calcium release from the sarcoplasmic reticulum in skeletal muscle . More than 60 MH associated mutations were found in the gene of @GeneTgt$ skeletal muscle ryanodine receptor @/GeneTgt$ ( @GeneTgt$ RyR1 @/GeneTgt$ ) , but only some of them have been functionally characterized . Primary human myotubes were cultured from carriers of @GeneTgt$ RyR1 @/GeneTgt$ mutations in exon 44 ( Ala2350Thr , Arg2355Trp , Gly2375Ala ) and from MH non-susceptible individuals . Investigation of calcium homeostasis with the calcium sensitive probe Fura 2 showed a higher sensitivity to the ryanodine receptor agonists 4-chloro-m-cresol , caffeine and @ChemicalSrc$ halothane @/ChemicalSrc$ for the myotubes derived from the mutation carriers as compared to those of the control group . The presence of @GeneTgt$ RyR1 @/GeneTgt$ mutations with impact on calcium homeostasis emphasizes the functional significance of exon 44 .	2 2 8 8 8 8|5 8 8|5 2 10 8 10 2 2 17 17 17 13 2 21 28 23 21 23 28 28 28 28 33 33 33 33 28 28 36 47 39 39 36 42 42 36 42 45 47 47 47 52 50 52 52 47 52 57 57 57 53 61 61 61 57 64 64 57 47 68 68 71 70 71 73 73 73 76 76 73 78 76|77|78 76|77|78 76|77|78 76|77|78 76|78 76|77|78 84 78|79 78 78|79 84 73 73 90 96 92 90 96 96 96 73 96 102 102 104 104 104 106 104 110 107|110 110 107|110 106 112 110 112 115 112 115 115 115 115 115 112 125 124 125 112 104 139 131 131 128 136 136 135 136 137 128 137 139 142 142 139 147 147 147 147 142 147 148 148 148 151|148 148 151|148 156 156 142 156 161 161 161 157 163 139 165 163 169 169 169 165 139 173 183 177 174|177 177 174|177 173 179 173 182 182 179 183 186 186 183 188 186 188 183	Association
15522280	Chemical	Gene	C063533	3757	True	0	What is [PHARMGKB] between @ChemicalSrc$ dofetilide @/ChemicalSrc$ and @GeneTgt$ KCNH2 @/GeneTgt$ ? [SEP] Role of a @GeneTgt$ KCNH2 @/GeneTgt$ polymorphism ( R1047 L ) in @ChemicalSrc$ dofetilide-induced @/ChemicalSrc$ Torsades de Pointes . Various drugs are reported to prolong the QT-interval on the surface ECG , thereby increasing the risk of developing a potentially fatal arrhythmia known as Torsades de Pointes ( TdP ) . TdP case reports for these drugs have often been associated with risk factors such as overdosing , concomitant drugs and/or existing pathophysiological conditions . A few cases appear to be devoid of these factors . To determine what role genetic variation in the hERG gene plays in drug-induced arrhythmias , we screened DNA samples collected from 105 atrial-fibrillation patients treated with @ChemicalSrc$ dofetilide @/ChemicalSrc$ for polymorphisms , seven of whom developed TdP. An uncommon missense change , R1047L , was identified in two of seven patients who experienced TdP as compared with five of 98 individuals who were free of TdP. Included in the affected individuals was the only subject homozygous for this SNP . Cellular electrophysiological studies revealed a 10-mV positive shift in the steady-state activation curve of the 1047L hERG channel stably expressed in HEK-293 cells as compared with the wild-type ( WT ) channel . The activation and inactivation kinetics of the 1047L current were significantly slower than the WT ( P & lt ; 0.05 ) at given membrane potentials . A computer simulation using a rabbit ventricular myocyte model indicated that same extent of changes in the I(Kr ) channel may result in an approximately 15 % prolongation in the action potential duration . Our study suggests that 1047L leads to a functional impairment of the hERG channel , which may contribute to the higher incidence of TdP in 1047L carriers when challenged with a channel blocker .	1 6 6 3|6 6 3|6 1 9 9 6 9 16 16|10 16 16|10 16 16 6 1 21 23 23 23 25 23 27 25 30 30 31 27 25 34 23 36 34 38 36 42 41 42 38 42 47 47 47 43 49 47 49 23 53 54 61 57 57 54 61 61 61 61 64 64 61 67 65 64 67 70 67 70 74 74 70 61 78 78 79 79 82 82 79 85 85 82 79 88 103 90 88 92 97 96 96 96 92 88 100 100 97 103 103 103 105 103 105 110 110 110 106 110 113 111|112 111 111|112 116 113 121 121 120 118 103 126 126 126 126 131 126 126 126 131 121 133 131 136 136 133 138 136 138 141 138 143 141 146 146 143 149 149 146 151 149 151 156 156 156 152 161 161 160 161 131 164 164 161 103 169 169 170 170 174 174 174 170 179 179 179 179 174 184 184 184 184 179 186 184 189 189 186 191 186 198 198 198 196 198 198 191 170 201 211 201 201 201 208 208 208 201 211 211 211 214 214 211 216 214 216 216 216 216 216 225 225 225 211 211 229 229 236 229 235 235 235 235 230 236 248 239 248 241 239 246 246 246 246 241 248 236 254 254 252 253 254 248 259 259 259 259 254 236 262 263 263 266 266 263 270 270 270 266 274 274 274 270 274 278 278 274 282 282 282 278 284 282 287 287 282 289 278 293 293 293 289 263	Association
15542732	Chemical	Gene	D008694	4988	True	0	What is [PHARMGKB] between @ChemicalSrc$ methamphetamine @/ChemicalSrc$ and @GeneTgt$ OPRM @/GeneTgt$ ? [SEP] Gene polymorphisms of the mu opioid receptor in @ChemicalSrc$ methamphetamine @/ChemicalSrc$ abusers . In drug addiction , the opioid system is thought to mediate motivational effects through dopamine-independent mechanisms . We have investigated associations of the mu-opioid receptor gene ( @GeneTgt$ OPRM @/GeneTgt$ ) variations with @ChemicalSrc$ methamphetamine @/ChemicalSrc$ ( MAP ) dependence/psychosis . The allelic frequency of A118 G ( Asn40Asp ) in exon 1 of ORPM was 45.3 % in our control subjects , but only 7.5 - 25.8 % in the Caucasian or African-American population of previous studies . We have identified several novel polymorphisms in intron 1 and the 5 ' untranslated region ( 5'UTR ) of @GeneTgt$ OPRM @/GeneTgt$ . Polymorphisms in the functionally relevant 5 ' regulatory region of @GeneTgt$ OPRM @/GeneTgt$ were different in our Japanese population from Caucasian or African-American populations . No significant differences between controls and MAP abusers were found in either genotype or allele frequency at any single nucleotide polymorphism ( SNP ) or (AC)n dinucleotide repeat in intron 1 . A subdivision of our MAP group revealed that A118 G of @GeneTgt$ OPRM @/GeneTgt$ shows a significant association with MAP psychosis having latency less than three years . Further analysis should be capable of identifying associations between the @GeneTgt$ OPRM @/GeneTgt$ variations and MAP dependence/psychosis .	2 2 7 7 7 7 2 11 8|11 11 8|11 2 2 16 16 22 22 20 20 22 22 22 24 22 26 24 29 29 24 22 33 33 33 33 39 39 39 39 44 41 39|40 39 39|40 41 34 51 51|44 51 51|44 51 51 51 44 33 57 57 71 60 60 57 62 60 62 65 60 65 68 65 71 71 71 75 75 75 71 71 71 82 82 81 79 71 88 88 88 85 85 82 91 91 88 71 95 95 95 98 98 95 100 98 100 98 107 107 107 107 98 109 107 109 112 111|107 107 111|107 95 129 124 124 120 124 124 124 124 116 126 124|125 124 124|125 129 129 133 133 133 129 135 138 135 135 133 129 143 143 150 145 143 145 148 145 150 150 153 153 150 153 156 153 161 161 161 161 153 163 161 163 161 168 168 161 170 168 170 150 174 179 178 178 178 174 179 186 182 186 184 182|183 182 182|183 179 189 189 186 192 192 189 186 193 197 197 198 186 179 202 205 205 205 205 207 205 207 213 213 210|213 213 210|213 208 213 216 213 205	Association
15860653	Chemical	Gene	D009853	196	False	1	What is [PHARMGKB] between @ChemicalSrc$ omeprazole @/ChemicalSrc$ and @GeneTgt$ AhR @/GeneTgt$ ? [SEP] Functional analysis of six human @GeneTgt$ aryl hydrocarbon receptor @/GeneTgt$ variants in a Japanese population . @GeneTgt$ Aryl hydrocarbon receptor @/GeneTgt$ ( @GeneTgt$ AhR @/GeneTgt$ ) is an important transcriptional regulator involved in the induction of CYP1A1 , CYP1A2 , CYP1B1 , UGT1A1 , and UGT1A6 . In this study , functional properties of four novel naturally occurring human @GeneTgt$ AhR @/GeneTgt$ variants ( K401R , N487D , I514 T , and K17T/R554 K ) were examined along with the single variants K17 T and R554 K . The luciferase reporter assay using the CYP1A1 promoter reporter in HeLa cells treated with beta-naphthoflavone or 3-methylcholanthrene , which are known as typical agonists for @GeneTgt$ AhR @/GeneTgt$ , showed that reporter activities of the K401R and N487D variants were reduced to 40 to 58 % of those of wild-type ( WT ) but not of the other variants . Similarly , the K401R and N487D variants also reduced the @ChemicalSrc$ omeprazole-induced @/ChemicalSrc$ reporter activities to approximately 56 and 74 % of those of the WT , respectively . The reduced activities of the two variants were probably caused by the reduced protein expression levels , since the protein levels of the K401R and N487D variants were approximately 52 and 47 % of the WT , respectively , without any changes in their mRNA levels . The reduced protein levels were recovered by treatment with a proteasome inhibitor MG132 [ N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal ] , suggesting that the reduced protein levels were caused by the accelerated proteasomal degradation by a proteasome . Together , the current data demonstrate that the K401R and N487D variants reduce their apparent transcriptional activities , both ligand-induced and @ChemicalSrc$ omeprazole-induced @/ChemicalSrc$ activation , probably through reduced protein expression . Thus , these two variants may influence drug metabolism through reduced induction of CYP1A1 and other target enzymes .	2 2 10 10 10 10|5 10|5 10|5 10 10|5 2 14 14 14 10 2 16|17|29 16|17|29 16|17|29 17|29 16|17|29 22 17|18 17 17|18 22 29 29 29 29 29 29 33 33 30 35 33 35 35 35 35 35 35 35 35 35 29 50 50 76 76 53 76 62 62 62 58 56 62 59|62 62 59|62 53 64 62 64 64 66 69 66 64 64 64 64 64 76 76 76 81 81 81 76 83 81 83 86 83 76 92 92 92 117 92 97 97 97 93 100 100 97 100 103 101 103 103 103 109 109 103 112 112 109 114 112|113 112 112|113 117 117 128 120 128 126 126 122 123 123 120 128 117 133 132 132 133 128 135 133 137 135 139 137 139 137 146 146 146 146 137 117 157 157 155 155 152 152 157 157 157 162 158|162 162 158|162 162 157 165 165 168 165 165 157 170 168 173 173 170 168 168 157 180 180 187 184 184 184 180 187 187 187 193 193 193 193 193 187 187 210 198 198 210 204 204 200 201 201 198 210 207 210 207 207 187 213 213 210 210 210 210 219 219 210 223 223 223 219 187 228 228 228 230 230 230 232 230 237 237 237 237 232 239 237 239 239 230 230 250 248 248 248 250 250 243 255 255 255 255 250 258 258 255 230 265 265 264 264 265 265 272 271 271 268 268 272 265 276 276 276 272 276 279 272 279 279|280 279 279|280 279 272 272 289 289 289 272 265 298 298 296 296 298 298 298 300 298 303 303 298 305 303 305 309 309 305 298	Association
16081343	Chemical	Gene	C044946	4524	True	0	What is [PHARMGKB] between @ChemicalSrc$ benazepril @/ChemicalSrc$ and @GeneTgt$ MTHFR @/GeneTgt$ ? [SEP] A common haplotype on @GeneTgt$ methylenetetrahydrofolate reductase @/GeneTgt$ gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients -- a family-based association study . Our recent study indicated that @GeneTgt$ MTHFR @/GeneTgt$ C677 T polymorphism may involve in genetic control of blood pressure response to treatment by @ChemicalSrc$ benazepril @/ChemicalSrc$ , an ACE inhibitor . Currently , we proposed to further investigate whether short-term blood pressure response to @ChemicalSrc$ benazepril @/ChemicalSrc$ , was modulated by haplotypes re-constructed from both C677 T and A1298C polymorphisms in @GeneTgt$ MTHFR @/GeneTgt$ gene . A total of 410 hypertensive patients recruited from 344 nuclear families were treated orally with @ChemicalSrc$ benazepril @/ChemicalSrc$ at a daily dosage of 10 mg for 15 consecutive days . Blood pressures were measured at baseline and on the 16th day of treatment . In addition , 689 family members of these patients were also genotyped . Among these patients , the frequency of @GeneTgt$ MTHFR @/GeneTgt$ A1298C AA , AC and CC genotypes was 74.4 % , 23.9 % , and 1.7 % , respectively . The frequency of @GeneTgt$ MTHFR @/GeneTgt$ C677 T CC , CT and TT genotypes was 23.7 % , 51.2 % , and 25.1 % , respectively . Only three haplotypes , 677T-1298A ( 50.8 % ) , 677C-1298A ( 35.7 % ) , and 677C-1298C ( 13.5 % ) were re-constructed . Multivariate regression models with generalized estimating equation ( GEE ) correction detected that the individuals carrying one copy of haplotype 677C-1298C had significantly lower diastolic and systolic blood pressure response ( DeltaDBP and DeltaSBP ) to @ChemicalSrc$ benazepril @/ChemicalSrc$ treatment ( p= 0.003 and p = 0.043 , respectively ) , in comparison to those without haplotype 677C-1298C . The results of family-based association test further confirmed that haplotype 677C-1298C was more frequently transmitted in subjects with either lower residual of DeltaDBP or DeltaSBP . For residual of DeltaDBP , the p-values are 0.007 in an additive model and 0.005 in a dominant model . For residual of DeltaSBP , the p-values are 0.009 in an additive model and 0.006 in a dominant model . Our findings suggest that @GeneTgt$ MTHFR @/GeneTgt$ 677C-1298C haplotype modulate blood pressure responsiveness to shortterm treatment of ACE inhibitor in Chinese essential hypertensive patients .	3 3 9 8 8|4 8|4 8 8|4 3 9 11 9 15 15 15 11 18 18 11 22 22 22 11 22 27 27 27 22 9 32 32 33 33 41 39|34 39 39|34 39 39 41 41 33 44 44 41 48 48 48 44 50 48 52 50 50 50 52 57 57 52 33 64 64 64 64 67 67 64 78 72 72 72 78 74 72|73 72 72|73 72 78 67 80 78 80 85 85 85 81 85 85 85 92 92|88 92 92|88 81 64 97 108 101 101 101 97 101 106 106 106 102 108 108 108 111 108|110 108 108|110 116 116 116 108 119 119 116 123 123 123 108 108 127 129 129 129 131 129 131 136 136 136 131 138 136 129 141 151 151 145 145 151 148 148 145 151 151 151 151 155 155 171 171 158 171 163 163|159 163 163|159 163 158 163 163 163 163 163 171 171 171 171 174 171 174 174 178 174 178 171 171 184 198 190 190|185 190 190|185 190 190 184 190 190 192 192 184 198 198 198 198 201 198 201 201 205 201 205 198 198 211 212 233 212 212 217 217 214 217 212 212 223 223 220 223 212 212 212 230 230 212 230 233 233 233 237 237 246 241 241 241 245 243 241 243 246 246 256 249 256 249 252 250 254 252 254 246 258 264 264 259 259 264 264 256 266 264 266 266 266 273 270|273 273 270|273 256 275 273 275 275 279 275 279 279 279 279 275 286 256 288 286 290 288 290 246 295 301 299 299 299 295 301 301 308 308 303 308 307 308 301 310 308 314 313 314 308 316 314 316 316 301 321 328 323 321 328 326 328 328 328 332 332 332 328 328 328 338 338 338 328 328 341 348 343 341 348 346 348 348 348 352 352 352 348 348 348 358 358 358 348 348 361 362 362 368 363|366 366 363|366 367 368 362 371 371 368 374 374 371 377 377 374 382 382 382 382 374 362	Association
16302021	Chemical	Gene	D005473	3356	False	1	What is [PHARMGKB] between @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and @GeneTgt$ serotonin 2A receptor @/GeneTgt$ ? [SEP] Response to @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and serotonin 1A receptor ( C-1019 G ) polymorphism in Taiwan Chinese major depressive disorder . Serotonin systems appear to play a key role in the pathogenesis of major depression and the therapeutic mechanisms of antidepressants . The firing rate of dorsal raphe serotonergic neurons is controlled by somatodendritic 5-hydroxytryptamine 1A ( HTR1A ) autoreceptors , and desensitization of these receptors is implicated in the antidepressant mechanism of selective serotonin reuptake inhibitors . We tested whether a functional polymorphism ( C-1019 G ) in the promoter region of the HTR1A gene and serotonin-related genetic variants are related to @ChemicalSrc$ fluoxetine @/ChemicalSrc$ antidepressant effect . We genotyped the HTR1A C-1019 G polymorphism as well as polymorphisms in the serotonin transporter gene-linked polymorphic region ( SERTPR ) , variable-number tandem-repeat polymorphisms in intron 2 ( STin2 ) of the serotonin transporter gene , @GeneTgt$ serotonin 2A receptor @/GeneTgt$ ( T102C ) , tryptophan hydroxylase ( A218C ) , and G-protein beta3 subunit ( C825 T ) in 224 Chinese patients from southern Taiwan with major depression , who accepted 4-week fluoxetine treatment and therapeutic evaluation . Our results demonstrated that the HTR1A -1019C/C carriers ( P=0.009 ) and SERTPR l/l carriers ( P&lt;0.001 ) showed a better response to @ChemicalSrc$ fluoxetine @/ChemicalSrc$ , while other polymorphisms were not associated with @ChemicalSrc$ fluoxetine @/ChemicalSrc$ therapeutic response . The major limitation of this study is the lack of a placebo control . Future prospective study with placebo control may help to predict and individualize antidepressant treatment .	1 3 2|13 13 2|13 3 8 8 13 13 13 13 13 1 19 19 19 19 19 13 1 23 24 24 26 24 29 29 26 32 32 26 35 35 32 32 39 39 32 41 39 24 45 45 52 50 50 50 50 45 52 52 60 60 60 60 58 60 58 52 60 60 68 66 66 63 68 52 72 72 72 68 77 77 77 77 72 68 80 80 102 84 84 102 87 87 84 87 92 92 92 84 96 96 96 92 96 100 100 84 102 80 107 103|107 107 103|107 107 102 80 111 111 116 116 116 116 111 116 117 117 116 127 127 125 125 127 127 120 129 127 129 127 134 134 120 136 134 136 139 136 139 145 145 145 145 136 145 145|146|147 145|146|147 145|146|147 145|147 145|146|147 152 147 152 145 156 145 158 156 158 145 136 164 164 136 167 167 164 167 172 172 172 136 175 175 172 178 178 172 178 181 178 184 184 181 184 187 184 111 191 192 192 208 197 197 197 208 199 197 199 197 204 204 197 206 204 206 192 211 211 208 213 211|212 211 211|212 208 221 218 221 221 221 208 226 221|225 225 221|225 226 221 192 232 232 238 235 235 232 238 238 238 242 242 242 238 238 246 246 251 249 249 246 251 251 253 251 253 253 257 255 251	Association
16330681	Chemical	Gene	D004317	4689	False	1	What is [PHARMGKB] between @ChemicalSrc$ doxorubicin @/ChemicalSrc$ and @GeneTgt$ NCF4 @/GeneTgt$ ? [SEP] NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with @ChemicalSrc$ doxorubicin-induced @/ChemicalSrc$ cardiotoxicity . BACKGROUND : A significant number of patients treated with anthracyclines develop cardiotoxicity ( anthracycline-induced cardiotoxicity [ ACT ] ) , mainly presenting as arrhythmias ( acute ACT ) or congestive heart failure ( chronic ACT ) . There are no data on pharmacogenomic predictors of ACT . METHODS AND RESULTS : We genotyped participants of the German non-Hodgkin lymphoma study ( NHL-B ) who were followed up for the development of heart failure for a median of & gt;3 years . Single-nucleotide polymorphisms ( SNPs ) were selected from 82 genes with conceivable relevance to ACT . Of 1697 patients , 55 developed acute and 54 developed chronic ACT ( cumulative incidence of either form , 3.2 % ) . We detected 5 significant associations with polymorphisms of the NAD(P)H oxidase and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporters . Chronic ACT was associated with a variant of the NAD(P)H oxidase subunit @GeneTgt$ NCF4 @/GeneTgt$ ( rs1883112 , -212A--&gt;G ; symbols with right-pointing arrows , as edited ? ' odds ratio [ OR ] , 2.5 ; 95 % CI , 1.3 to 5.0 ) . Acute ACT was associated with the His72Tyr polymorphism in the p22phox subunit ( rs4673 ; OR , 2.0 ; 95 % CI , 1.0 to 3.9 ) and with the variant 7508T--&gt;A ( rs13058338 ; OR , 2.6 ; 95 % CI , 1.3 to 5.1 ) of the RAC2 subunit of the same enzyme . In agreement with these results , mice deficient in NAD(P)H oxidase activity , unlike wild-type mice , were resistant to chronic @ChemicalSrc$ doxorubicin @/ChemicalSrc$ treatment . In addition , acute ACT was associated with the Gly671Val variant of the @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporter multidrug resistance protein 1 ( MRP1 ) ( OR , 3.6 ; 95 % CI , 1.6 to 8.4 ) and with the Val1188Glu-Cys1515Tyr ( rs8187694-rs8187710 ) haplotype of the functionally similar MRP2 ( OR , 2.3 ; 95 % CI , 1.0 to 5.4 ) . Polymorphisms in adrenergic receptors previously demonstrated to be predictive of heart failure were not associated with ACT . CONCLUSIONS : Genetic variants in @ChemicalSrc$ doxorubicin @/ChemicalSrc$ transport and free radical metabolism may modulate the individual risk to develop ACT .	2 10 2 2 8 8 8 10 10 10 14 11|14 14 11|14 10 10 17 17 21 21 27 23 21 23 26 24 17 27 31 31 28 33 31 33 31 28 38 28 40 38 43 43 40 43 40 48 48 40 51 51 48 51 17 55 55 57 55 60 60 57 62 60 55 69 64 64 69 69 69 69 76 76 76 76 76 70 78 76 78 82 82 70 82 86 86 82 89 89 86 92 92 86 96 93 93 92 69 99 104 101 99 101 104 104 107 107 104 110 110 104 112 110 104 116 116 119 119 119 119 119 120 120 119 125 123 128 128 125 131 131 128 131 134 131 128 119 138 138 141 141 138 143 141 147 147 147 143 147 147|148 147 147|148 152 147 138 156 158 158 158 161 161 158 167 166 166 166 167 166|161 161 166|161 170 167 170 158 158 158 177 177 174 174 180 158 158 184 184 158 184 184 186 184 184 189 192 193 184 193 197 197 193 184 158 202 204 204 204 208 208 208 204 212 212 212 208 214 212 214 214 214 214 214 221 222 204 222 226 226 222 222 204 232 232 232 204 234 232 234 234 234 234 234 241 242 204 242 246 246 242 246 251 251 251 246 255 255 255 251 204 258 275 261 261 258 275 275 263 268 268 268 264 263 272 272 263 263 275 275 280 280 280|277 280 280|277 275 275 284 289 289 287 289 289 289 293 293 293 289 305 305 295|305 305 295|305 305 305 305 305 305 302 305 293 305 305 310 310 314 310 313 314 289 314 318 318 314 314 289 327 327 322 325 327 327 289 332 332 331 332 327 334 332 336 334 336 339 340 327 344 344 344 340 344 289 353 351 351 348 353 353 356 356 353 359 359 356 362 362 353 364 362 353 366 366 369 379 373 373|370 373 373|370 369 373 377 377 373 379 366 382 382 379 384 382 384 379	Association
16330681	Chemical	Gene	D004317	1535	False	1	What is [PHARMGKB] between @ChemicalSrc$ doxorubicin @/ChemicalSrc$ and @GeneTgt$ p22phox @/GeneTgt$ ? [SEP] NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with @ChemicalSrc$ doxorubicin-induced @/ChemicalSrc$ cardiotoxicity . BACKGROUND : A significant number of patients treated with anthracyclines develop cardiotoxicity ( anthracycline-induced cardiotoxicity [ ACT ] ) , mainly presenting as arrhythmias ( acute ACT ) or congestive heart failure ( chronic ACT ) . There are no data on pharmacogenomic predictors of ACT . METHODS AND RESULTS : We genotyped participants of the German non-Hodgkin lymphoma study ( NHL-B ) who were followed up for the development of heart failure for a median of & gt;3 years . Single-nucleotide polymorphisms ( SNPs ) were selected from 82 genes with conceivable relevance to ACT . Of 1697 patients , 55 developed acute and 54 developed chronic ACT ( cumulative incidence of either form , 3.2 % ) . We detected 5 significant associations with polymorphisms of the NAD(P)H oxidase and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporters . Chronic ACT was associated with a variant of the NAD(P)H oxidase subunit NCF4 ( rs1883112 , -212A--&gt;G ; symbols with right-pointing arrows , as edited ? ' odds ratio [ OR ] , 2.5 ; 95 % CI , 1.3 to 5.0 ) . Acute ACT was associated with the His72Tyr polymorphism in the @GeneTgt$ p22phox @/GeneTgt$ subunit ( rs4673 ; OR , 2.0 ; 95 % CI , 1.0 to 3.9 ) and with the variant 7508T--&gt;A ( rs13058338 ; OR , 2.6 ; 95 % CI , 1.3 to 5.1 ) of the RAC2 subunit of the same enzyme . In agreement with these results , mice deficient in NAD(P)H oxidase activity , unlike wild-type mice , were resistant to chronic @ChemicalSrc$ doxorubicin @/ChemicalSrc$ treatment . In addition , acute ACT was associated with the Gly671Val variant of the @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporter multidrug resistance protein 1 ( MRP1 ) ( OR , 3.6 ; 95 % CI , 1.6 to 8.4 ) and with the Val1188Glu-Cys1515Tyr ( rs8187694-rs8187710 ) haplotype of the functionally similar MRP2 ( OR , 2.3 ; 95 % CI , 1.0 to 5.4 ) . Polymorphisms in adrenergic receptors previously demonstrated to be predictive of heart failure were not associated with ACT . CONCLUSIONS : Genetic variants in @ChemicalSrc$ doxorubicin @/ChemicalSrc$ transport and free radical metabolism may modulate the individual risk to develop ACT .	2 10 2 2 8 8 8 10 10 10 14 11|14 14 11|14 10 10 17 17 21 21 27 23 21 23 26 24 17 27 31 31 28 33 31 33 31 28 38 28 40 38 43 43 40 43 40 48 48 40 51 51 48 51 17 55 55 57 55 60 60 57 62 60 55 69 64 64 69 69 69 69 76 76 76 76 76 70 78 76 78 82 82 70 82 86 86 82 89 89 86 92 92 86 96 93 93 92 69 99 104 101 99 101 104 104 107 107 104 110 110 104 112 110 104 116 116 119 119 119 119 119 120 120 119 125 123 128 128 125 131 131 128 131 134 131 128 119 138 138 141 141 138 143 141 147 147 147 143 147 147|148 147 147|148 152 147 138 156 158 158 158 161 161 158 167 166 166 166 167 161 169 167 169 158 158 158 176 176 173 173 179 158 158 183 183 158 183 183 185 183 183 188 191 192 183 192 196 196 192 183 158 200 202 202 202 206 206 206 202 211 211 208|211 211 208|211 206 213 211 213 213 213 213 213 220 221 202 221 225 225 221 221 202 231 231 231 202 233 231 233 233 233 233 233 240 241 202 241 245 245 241 245 250 250 250 245 254 254 254 250 202 258 275 261 261 258 275 275 263 268 268 268 264 263 272 272 263 263 275 275 280 280 280|277 280 280|277 275 275 284 289 289 287 289 289 289 293 293 293 289 305 305 295|305 305 295|305 305 305 305 305 305 302 305 293 305 305 310 310 314 310 313 314 289 314 318 318 314 314 289 327 327 322 325 327 327 289 332 332 331 332 327 334 332 336 334 336 339 340 327 344 344 344 340 344 289 353 351 351 348 353 353 356 356 353 359 359 356 362 362 353 364 362 353 366 366 369 379 373 373|370 373 373|370 369 373 377 377 373 379 366 382 382 379 384 382 384 379	Association
16330681	Chemical	Gene	D004317	5880	False	1	What is [PHARMGKB] between @ChemicalSrc$ doxorubicin @/ChemicalSrc$ and @GeneTgt$ RAC2 @/GeneTgt$ ? [SEP] NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with @ChemicalSrc$ doxorubicin-induced @/ChemicalSrc$ cardiotoxicity . BACKGROUND : A significant number of patients treated with anthracyclines develop cardiotoxicity ( anthracycline-induced cardiotoxicity [ ACT ] ) , mainly presenting as arrhythmias ( acute ACT ) or congestive heart failure ( chronic ACT ) . There are no data on pharmacogenomic predictors of ACT . METHODS AND RESULTS : We genotyped participants of the German non-Hodgkin lymphoma study ( NHL-B ) who were followed up for the development of heart failure for a median of & gt;3 years . Single-nucleotide polymorphisms ( SNPs ) were selected from 82 genes with conceivable relevance to ACT . Of 1697 patients , 55 developed acute and 54 developed chronic ACT ( cumulative incidence of either form , 3.2 % ) . We detected 5 significant associations with polymorphisms of the NAD(P)H oxidase and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporters . Chronic ACT was associated with a variant of the NAD(P)H oxidase subunit NCF4 ( rs1883112 , -212A--&gt;G ; symbols with right-pointing arrows , as edited ? ' odds ratio [ OR ] , 2.5 ; 95 % CI , 1.3 to 5.0 ) . Acute ACT was associated with the His72Tyr polymorphism in the p22phox subunit ( rs4673 ; OR , 2.0 ; 95 % CI , 1.0 to 3.9 ) and with the variant 7508T--&gt;A ( rs13058338 ; OR , 2.6 ; 95 % CI , 1.3 to 5.1 ) of the @GeneTgt$ RAC2 @/GeneTgt$ subunit of the same enzyme . In agreement with these results , mice deficient in NAD(P)H oxidase activity , unlike wild-type mice , were resistant to chronic @ChemicalSrc$ doxorubicin @/ChemicalSrc$ treatment . In addition , acute ACT was associated with the Gly671Val variant of the @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporter multidrug resistance protein 1 ( MRP1 ) ( OR , 3.6 ; 95 % CI , 1.6 to 8.4 ) and with the Val1188Glu-Cys1515Tyr ( rs8187694-rs8187710 ) haplotype of the functionally similar MRP2 ( OR , 2.3 ; 95 % CI , 1.0 to 5.4 ) . Polymorphisms in adrenergic receptors previously demonstrated to be predictive of heart failure were not associated with ACT . CONCLUSIONS : Genetic variants in @ChemicalSrc$ doxorubicin @/ChemicalSrc$ transport and free radical metabolism may modulate the individual risk to develop ACT .	2 10 2 2 8 8 8 10 10 10 14 11|14 14 11|14 10 10 17 17 21 21 27 23 21 23 26 24 17 27 31 31 28 33 31 33 31 28 38 28 40 38 43 43 40 43 40 48 48 40 51 51 48 51 17 55 55 57 55 60 60 57 62 60 55 69 64 64 69 69 69 69 76 76 76 76 76 70 78 76 78 82 82 70 82 86 86 82 89 89 86 92 92 86 96 93 93 92 69 99 104 101 99 101 104 104 107 107 104 110 110 104 112 110 104 116 116 119 119 119 119 119 120 120 119 125 123 128 128 125 131 131 128 131 134 131 128 119 138 138 141 141 138 143 141 147 147 147 143 147 147|148 147 147|148 152 147 138 156 158 158 158 161 161 158 167 166 166 166 167 161 169 167 169 158 158 158 176 176 173 173 179 158 158 183 183 158 183 183 185 183 183 188 191 192 183 192 196 196 192 183 158 200 202 202 202 206 206 206 202 210 210 210 206 212 210 212 212 212 212 212 219 220 202 220 224 224 220 220 202 230 230 230 202 232 230 232 232 232 232 232 239 240 202 240 244 244 240 244 250 250 247|250 250 247|250 244 254 254 254 250 202 258 275 261 261 258 275 275 263 268 268 268 264 263 272 272 263 263 275 275 280 280 280|277 280 280|277 275 275 284 289 289 287 289 289 289 293 293 293 289 305 305 295|305 305 295|305 305 305 305 305 305 302 305 293 305 305 310 310 314 310 313 314 289 314 318 318 314 314 289 327 327 322 325 327 327 289 332 332 331 332 327 334 332 336 334 336 339 340 327 344 344 344 340 344 289 353 351 351 348 353 353 356 356 353 359 359 356 362 362 353 364 362 353 366 366 369 379 373 373|370 373 373|370 369 373 377 377 373 379 366 382 382 379 384 382 384 379	Association
16330681	Chemical	Gene	D004317	4363	True	0	What is [PHARMGKB] between @ChemicalSrc$ doxorubicin @/ChemicalSrc$ and @GeneTgt$ MRP1 @/GeneTgt$ ? [SEP] NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with @ChemicalSrc$ doxorubicin-induced @/ChemicalSrc$ cardiotoxicity . BACKGROUND : A significant number of patients treated with anthracyclines develop cardiotoxicity ( anthracycline-induced cardiotoxicity [ ACT ] ) , mainly presenting as arrhythmias ( acute ACT ) or congestive heart failure ( chronic ACT ) . There are no data on pharmacogenomic predictors of ACT . METHODS AND RESULTS : We genotyped participants of the German non-Hodgkin lymphoma study ( NHL-B ) who were followed up for the development of heart failure for a median of & gt;3 years . Single-nucleotide polymorphisms ( SNPs ) were selected from 82 genes with conceivable relevance to ACT . Of 1697 patients , 55 developed acute and 54 developed chronic ACT ( cumulative incidence of either form , 3.2 % ) . We detected 5 significant associations with polymorphisms of the NAD(P)H oxidase and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporters . Chronic ACT was associated with a variant of the NAD(P)H oxidase subunit NCF4 ( rs1883112 , -212A--&gt;G ; symbols with right-pointing arrows , as edited ? ' odds ratio [ OR ] , 2.5 ; 95 % CI , 1.3 to 5.0 ) . Acute ACT was associated with the His72Tyr polymorphism in the p22phox subunit ( rs4673 ; OR , 2.0 ; 95 % CI , 1.0 to 3.9 ) and with the variant 7508T--&gt;A ( rs13058338 ; OR , 2.6 ; 95 % CI , 1.3 to 5.1 ) of the RAC2 subunit of the same enzyme . In agreement with these results , mice deficient in NAD(P)H oxidase activity , unlike wild-type mice , were resistant to chronic @ChemicalSrc$ doxorubicin @/ChemicalSrc$ treatment . In addition , acute ACT was associated with the Gly671Val variant of the @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporter multidrug resistance protein 1 ( @GeneTgt$ MRP1 @/GeneTgt$ ) ( OR , 3.6 ; 95 % CI , 1.6 to 8.4 ) and with the Val1188Glu-Cys1515Tyr ( rs8187694-rs8187710 ) haplotype of the functionally similar MRP2 ( OR , 2.3 ; 95 % CI , 1.0 to 5.4 ) . Polymorphisms in adrenergic receptors previously demonstrated to be predictive of heart failure were not associated with ACT . CONCLUSIONS : Genetic variants in @ChemicalSrc$ doxorubicin @/ChemicalSrc$ transport and free radical metabolism may modulate the individual risk to develop ACT .	2 10 2 2 8 8 8 10 10 10 14 11|14 14 11|14 10 10 17 17 21 21 27 23 21 23 26 24 17 27 31 31 28 33 31 33 31 28 38 28 40 38 43 43 40 43 40 48 48 40 51 51 48 51 17 55 55 57 55 60 60 57 62 60 55 69 64 64 69 69 69 69 76 76 76 76 76 70 78 76 78 82 82 70 82 86 86 82 89 89 86 92 92 86 96 93 93 92 69 99 104 101 99 101 104 104 107 107 104 110 110 104 112 110 104 116 116 119 119 119 119 119 120 120 119 125 123 128 128 125 131 131 128 131 134 131 128 119 138 138 141 141 138 143 141 147 147 147 143 147 147|148 147 147|148 152 147 138 156 158 158 158 161 161 158 167 166 166 166 167 161 169 167 169 158 158 158 176 176 173 173 179 158 158 183 183 158 183 183 185 183 183 188 191 192 183 192 196 196 192 183 158 200 202 202 202 206 206 206 202 210 210 210 206 212 210 212 212 212 212 212 219 220 202 220 224 224 220 220 202 230 230 230 202 232 230 232 232 232 232 232 239 240 202 240 244 244 240 244 249 249 249 244 253 253 253 249 202 256 273 259 259 256 273 273 261 266 266 266 262 261 270 270 261 261 273 273 278 278 278|275 278 278|275 273 273 282 287 287 285 287 287 287 291 291 291 287 303 303 293|303 303 293|303 303 303 303 303 303 300 303 291|301 291 291|301 303 303 309 309 313 309 312 313 287 313 317 317 313 313 287 326 326 321 324 326 326 287 331 331 330 331 326 333 331 335 333 335 338 339 326 343 343 343 339 343 287 353 351 351 348 353 353 356 356 353 359 359 356 362 362 353 364 362 353 366 366 369 379 373 373|370 373 373|370 369 373 377 377 373 379 366 382 382 379 384 382 384 379	Association
16330681	Chemical	Gene	D004317	1244	True	0	What is [PHARMGKB] between @ChemicalSrc$ doxorubicin @/ChemicalSrc$ and @GeneTgt$ MRP2 @/GeneTgt$ ? [SEP] NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with @ChemicalSrc$ doxorubicin-induced @/ChemicalSrc$ cardiotoxicity . BACKGROUND : A significant number of patients treated with anthracyclines develop cardiotoxicity ( anthracycline-induced cardiotoxicity [ ACT ] ) , mainly presenting as arrhythmias ( acute ACT ) or congestive heart failure ( chronic ACT ) . There are no data on pharmacogenomic predictors of ACT . METHODS AND RESULTS : We genotyped participants of the German non-Hodgkin lymphoma study ( NHL-B ) who were followed up for the development of heart failure for a median of & gt;3 years . Single-nucleotide polymorphisms ( SNPs ) were selected from 82 genes with conceivable relevance to ACT . Of 1697 patients , 55 developed acute and 54 developed chronic ACT ( cumulative incidence of either form , 3.2 % ) . We detected 5 significant associations with polymorphisms of the NAD(P)H oxidase and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporters . Chronic ACT was associated with a variant of the NAD(P)H oxidase subunit NCF4 ( rs1883112 , -212A--&gt;G ; symbols with right-pointing arrows , as edited ? ' odds ratio [ OR ] , 2.5 ; 95 % CI , 1.3 to 5.0 ) . Acute ACT was associated with the His72Tyr polymorphism in the p22phox subunit ( rs4673 ; OR , 2.0 ; 95 % CI , 1.0 to 3.9 ) and with the variant 7508T--&gt;A ( rs13058338 ; OR , 2.6 ; 95 % CI , 1.3 to 5.1 ) of the RAC2 subunit of the same enzyme . In agreement with these results , mice deficient in NAD(P)H oxidase activity , unlike wild-type mice , were resistant to chronic @ChemicalSrc$ doxorubicin @/ChemicalSrc$ treatment . In addition , acute ACT was associated with the Gly671Val variant of the @ChemicalSrc$ doxorubicin @/ChemicalSrc$ efflux transporter multidrug resistance protein 1 ( MRP1 ) ( OR , 3.6 ; 95 % CI , 1.6 to 8.4 ) and with the Val1188Glu-Cys1515Tyr ( rs8187694-rs8187710 ) haplotype of the functionally similar @GeneTgt$ MRP2 @/GeneTgt$ ( OR , 2.3 ; 95 % CI , 1.0 to 5.4 ) . Polymorphisms in adrenergic receptors previously demonstrated to be predictive of heart failure were not associated with ACT . CONCLUSIONS : Genetic variants in @ChemicalSrc$ doxorubicin @/ChemicalSrc$ transport and free radical metabolism may modulate the individual risk to develop ACT .	2 10 2 2 8 8 8 10 10 10 14 11|14 14 11|14 10 10 17 17 21 21 27 23 21 23 26 24 17 27 31 31 28 33 31 33 31 28 38 28 40 38 43 43 40 43 40 48 48 40 51 51 48 51 17 55 55 57 55 60 60 57 62 60 55 69 64 64 69 69 69 69 76 76 76 76 76 70 78 76 78 82 82 70 82 86 86 82 89 89 86 92 92 86 96 93 93 92 69 99 104 101 99 101 104 104 107 107 104 110 110 104 112 110 104 116 116 119 119 119 119 119 120 120 119 125 123 128 128 125 131 131 128 131 134 131 128 119 138 138 141 141 138 143 141 147 147 147 143 147 147|148 147 147|148 152 147 138 156 158 158 158 161 161 158 167 166 166 166 167 161 169 167 169 158 158 158 176 176 173 173 179 158 158 183 183 158 183 183 185 183 183 188 191 192 183 192 196 196 192 183 158 200 202 202 202 206 206 206 202 210 210 210 206 212 210 212 212 212 212 212 219 220 202 220 224 224 220 220 202 230 230 230 202 232 230 232 232 232 232 232 239 240 202 240 244 244 240 244 249 249 249 244 253 253 253 249 202 256 273 259 259 256 273 273 261 266 266 266 262 261 270 270 261 261 273 273 278 278 278|275 278 278|275 273 273 282 287 287 285 287 287 287 291 291 291 287 303 303 293|303 303 293|303 303 303 303 303 303 300 303 291 303 303 308 308 312 308 311 312 287 312 316 316 312 312 287 325 325 320 323 325 325 287 330 330 329 330 328|325 325 328|325 333 330 335 333 335 338 339 325 343 343 343 339 343 287 353 351 351 348 353 353 356 356 353 359 359 356 362 362 353 364 362 353 366 366 369 379 373 373|370 373 373|370 369 373 377 377 373 379 366 382 382 379 384 382 384 379	Association
16607077	Chemical	Gene	D011345	3569	True	0	What is [PHARMGKB] between @ChemicalSrc$ fenofibrate @/ChemicalSrc$ and @GeneTgt$ IL-6 @/GeneTgt$ ? [SEP] @GeneTgt$ Interleukin-6 @/GeneTgt$ -174 G/C promoter polymorphism and effects of @ChemicalSrc$ fenofibrate @/ChemicalSrc$ and simvastatin on inflammatory markers in hypercholesterolemic patients . To evaluate whether the @GeneTgt$ interleukin-6 @/GeneTgt$ ( @GeneTgt$ IL-6 @/GeneTgt$ ) -174 G/C polymorphism might alter the effects of micronized @ChemicalSrc$ fenofibrate @/ChemicalSrc$ or simvastatin therapy on inflammatory markers , we measured @GeneTgt$ IL-6 @/GeneTgt$ , C-reactive protein , CD40 ligand , adhesion molecules , P-selectin and monocyte chemoattractant protein-1 in hypercholesterolemic patients both before and after a 30-day treatment . Serum @GeneTgt$ IL-6 @/GeneTgt$ levels were significantly higher in patients with the GC or CC genotypes ( P=0.04 ) . The presence of the C allele was associated with greater absolute reduction of @GeneTgt$ IL-6 @/GeneTgt$ levels ( P=0.04 ) following @ChemicalSrc$ fenofibrate @/ChemicalSrc$ treatment . There was no significant association between the -174 G/C @GeneTgt$ IL-6 @/GeneTgt$ polymorphism and the effects of simvastatin treatment . A relationship between the -174 G/C @GeneTgt$ IL-6 @/GeneTgt$ polymorphism and the anti-inflammatory action of @ChemicalSrc$ fenofibrate @/ChemicalSrc$ reported might be useful in the optimization of the treatment regimen in patients receiving this class of drugs .	0|6 6 0|6 6 6 6 6 6 6 10 8 8 8 10 10 16 16 8 19 19 16 6 24 24 37 35 26|35 35 26|35 30 27|28 27 27|28 30 35 35 37 37 24 39 37 42 42 39 39 39 42 46 42 49 49 39 52 52 24 49|52 52 49|52 53 57 53 57 60 53 53 63 53 53 53 53 69 69 53 72 72 52 74 79 74 79 79 79 52 52 88 85|88 88 85|88 91 91 91 91 93 91 96 96 93 96 96 96 101 96 101 91 106 112 110 110 110 106 112 112 116 116 116 112 120 120|117 120 120|117 116 122 120 122 127 123|127 127 123|127 116 112 132 132 135 135 132 142 142 142 142 139|142 142 139|142 135 142 145 142 148 148 145 132 152 170 159 159 159 159 159|156 159 159|156 152 159 163 163 159 165 163 163 163 152 170 170 170 173 173 170 177 177 177 173 179 177 179 182 180 184 182 170	Association
16842817	Chemical	Gene	D011802	3757	True	0	What is [PHARMGKB] between @ChemicalSrc$ quinidine @/ChemicalSrc$ and @GeneTgt$ SQT1 @/GeneTgt$ ? [SEP] Disopyramide is an effective inhibitor of mutant @GeneTgt$ HERG @/GeneTgt$ K+ channels involved in variant 1 short QT syndrome . The recently identified idiopathic short QT syndrome ( SQTS ) is associated with an increased risk of arrhythmia and sudden death . The use of implantable cardioverter defibrillators helps to protect SQTS patients from ventricular fibrillation ; however , pharmacological treatments to normalise the QT interval are limited : thus far only @ChemicalSrc$ quinidine @/ChemicalSrc$ has been found to be effective in a subset of patients , with the @GeneTgt$ SQT1 @/GeneTgt$ variant . @GeneTgt$ SQT1 @/GeneTgt$ is associated with an amino acid substitution ( N588 K ) in the @GeneTgt$ KCNH2-encoded @/GeneTgt$ @GeneTgt$ HERG @/GeneTgt$ K(+ ) channel that reduces @GeneTgt$ HERG @/GeneTgt$ current ( @GeneTgt$ I(HERG @/GeneTgt$ ) ) inactivation and sensitivity to drug block . We demonstrate here that the @GeneTgt$ N588K-HERG @/GeneTgt$ mutation only slightly attenuates @GeneTgt$ I(HERG @/GeneTgt$ ) blockade by the Class Ia antiarrhythmic drug disopyramide ( 1.5-fold elevation of IC(50 ) ) , compared to @ChemicalSrc$ quinidine @/ChemicalSrc$ ( 3.5-fold elevation of IC(50 ) ) and the Class III antiarrhythmic drug E-4031 ( 11.5-fold elevation of IC(50 ) ) . Thus , of the drugs studied to date , disopyramide is the one least affected by the @GeneTgt$ SQT1 @/GeneTgt$ @GeneTgt$ HERG @/GeneTgt$ mutation . Disopyramide is associated with QT prolongation in normal use and our findings provide a rational basis for its evaluation as a treatment for @GeneTgt$ SQT1 @/GeneTgt$ .	5 5 5 5 5 11 11 11|7 11 11|7 11 5 11 18 18 18 18 18 12 5 27 23 27 27 27 27 32 29 27 29 32 32 36 36 36 32 38 36 38 41 38 32 44 49 48 48 48 44 49 51 49 53 51 56 56 51 49 68 68 61 68 63 61 66 66 63 68 49 68 71 72 77 77|72 77 77|72 77 77 49 80 80 77 83 83 80 85 83 80 91 91 91|87 91 91|87 80 49 94|98 98 94|98 98 98 103 103 103 103 98 106 106 103 106 116 116 108|116 116 108|116 114|109 114 114|109 116 116 103 118 116 121|115 121 121|115 127 123 118|121 121 118|121 123 121 118 127 127 132 132 127 98 140 140 140 149 146 146|143 146 146|143 149 148 149 140 148|149 149 148|149 149 149 160 160 160 160 160 160 153 163 163 149 165 163 165 163 149 140 171 168|169 169 168|169 175 175 171 177 175 177 175 171 186 186 186 186 186 171 189 189 186 191 189 191 189 140 210 210 202 202 210 202 205 203 210 210 210 210 211 212 212 219 219 214|219 219 214|219 215|219 219 215|219 212 212 225 225 225 228 228 225 231 231 228 228 234 235 225 238 238 235 241 241 238 244 244 241 246 244|245 244 244|245 225	Association
16842817	Chemical	Gene	D004206	3757	True	0	What is [PHARMGKB] between @ChemicalSrc$ Disopyramide @/ChemicalSrc$ and @GeneTgt$ SQT1 @/GeneTgt$ ? [SEP] @ChemicalSrc$ Disopyramide @/ChemicalSrc$ is an effective inhibitor of mutant @GeneTgt$ HERG @/GeneTgt$ K+ channels involved in variant 1 short QT syndrome . The recently identified idiopathic short QT syndrome ( SQTS ) is associated with an increased risk of arrhythmia and sudden death . The use of implantable cardioverter defibrillators helps to protect SQTS patients from ventricular fibrillation ; however , pharmacological treatments to normalise the QT interval are limited : thus far only quinidine has been found to be effective in a subset of patients , with the @GeneTgt$ SQT1 @/GeneTgt$ variant . @GeneTgt$ SQT1 @/GeneTgt$ is associated with an amino acid substitution ( N588 K ) in the @GeneTgt$ KCNH2-encoded @/GeneTgt$ @GeneTgt$ HERG @/GeneTgt$ K(+ ) channel that reduces @GeneTgt$ HERG @/GeneTgt$ current ( @GeneTgt$ I(HERG @/GeneTgt$ ) ) inactivation and sensitivity to drug block . We demonstrate here that the @GeneTgt$ N588K-HERG @/GeneTgt$ mutation only slightly attenuates @GeneTgt$ I(HERG @/GeneTgt$ ) blockade by the Class Ia antiarrhythmic drug @ChemicalSrc$ disopyramide @/ChemicalSrc$ ( 1.5-fold elevation of IC(50 ) ) , compared to quinidine ( 3.5-fold elevation of IC(50 ) ) and the Class III antiarrhythmic drug E-4031 ( 11.5-fold elevation of IC(50 ) ) . Thus , of the drugs studied to date , @ChemicalSrc$ disopyramide @/ChemicalSrc$ is the one least affected by the @GeneTgt$ SQT1 @/GeneTgt$ @GeneTgt$ HERG @/GeneTgt$ mutation . @ChemicalSrc$ Disopyramide @/ChemicalSrc$ is associated with QT prolongation in normal use and our findings provide a rational basis for its evaluation as a treatment for @GeneTgt$ SQT1 @/GeneTgt$ .	0|6 6 0|6 6 6 6 6 12 12 12|7 12 12|7 12 6 12 19 19 19 19 19 13 6 29 25 29 29 29 29 34 31 29 31 34 34 38 38 38 34 40 38 40 43 40 34 46 51 50 50 50 46 51 53 51 55 53 58 58 53 51 70 70 63 70 65 63 68 68 65 70 51 70 73 74 78 78 78 78 51 81 81 78 84 84 81 86 84 81 92 92 92|89 92 92|89 81 51 94|98 98 94|98 98 98 103 103 103 103 98 106 106 103 106 116 116 108|116 116 108|116 114|109 114 114|109 116 116 103 118 116 121|115 121 121|115 127 123 118|121 121 118|121 123 121 118 127 127 132 132 127 98 140 140 140 149 146 146|143 146 146|143 149 148 149 140 148|149 149 148|149 149 149 160 160 160 160 160 160 157|153 153 157|153 164 164 149 166 164 166 164 149 140 172 170 175 175 172 177 175 177 175 172 186 186 186 186 186 172 189 189 186 191 189 191 189 140 211 211 202 202 211 202 205 203 211 206|211 211 206|211 211 211 212 213 213 220 220 214|220 220 214|220 215|220 220 215|220 213 213 224|228 228 224|228 228 228 231 231 228 234 234 231 231 237 238 228 241 241 238 244 244 241 247 247 244 249 247 247 247 228	Association
17085664	Chemical	Gene	D000077156	1956	True	0	What is [PHARMGKB] between @ChemicalSrc$ gefitinib @/ChemicalSrc$ and @GeneTgt$ EGFR @/GeneTgt$ ? [SEP] Novel D761Y and common secondary T790 M mutations in @GeneTgt$ epidermal growth factor receptor-mutant @/GeneTgt$ lung adenocarcinomas with acquired resistance to kinase inhibitors . PURPOSE : In patients whose lung adenocarcinomas harbor @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ ( @GeneTgt$ EGFR @/GeneTgt$ ) tyrosine kinase domain mutations , acquired resistance to the tyrosine kinase inhibitors ( TKI ) @ChemicalSrc$ gefitinib @/ChemicalSrc$ ( Iressa ) and erlotinib ( Tarceva ) has been associated with a second-site @GeneTgt$ EGFR @/GeneTgt$ mutation , which leads to substitution of methionine for threonine at position 790 ( T790 M ) . We aimed to elucidate the frequency and nature of secondary @GeneTgt$ EGFR @/GeneTgt$ mutations in patients with acquired resistance to TKI monotherapy . EXPERIMENTAL DESIGN : Tumor cells from patients with acquired resistance were examined for secondary @GeneTgt$ EGFR @/GeneTgt$ kinase domain mutations by molecular analyses . RESULTS : Eight of 16 patients ( 50 % observed rate ; 95 % confidence interval , 25 - 75 % ) had tumor cells with second-site @GeneTgt$ EGFR @/GeneTgt$ mutations . Seven mutations were T790 M and one was a novel D761Y mutation found in a brain metastasis . When combined with a drug-sensitive L858R mutation , the D761Y mutation modestly reduced the sensitivity of mutant @GeneTgt$ EGFR @/GeneTgt$ to TKIs in both surrogate kinase and cell viability assays . In an autopsy case , the T790 M mutation was found in multiple visceral metastases but not in a brain lesion . CONCLUSIONS : The T790 M mutation is common in patients with acquired resistance . The limited spectrum of TKI-resistant mutations in @GeneTgt$ EGFR @/GeneTgt$ , which binds to erlotinib in the active conformation , contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib , which binds to ABL and KIT , respectively , in closed conformations . Collectively , our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anatomic site and mode of binding to the kinase target .	2 2 2 8 8 8 8 2 16 16|9 16|9 16|9 16|9 16 16|9 16 2 19 19 2 22 22 19 2 25 25 28 32 31 31 32 25 32|33|45 32|33|45 32|33|45 32|33|45 33|45 32|33|45 39 33|34 33 33|34 39 45 45 45 32 32 32 69 53 53 53 53 57 55 57 55 48|51 48 48|51 60 57 60 57 57 65 63 65 69 69 47 75 75 75 66|75 75 66|75 69 75 78 75 80 78 82 80 84 80 86 80 86 90 90 86 90 25 98 98 100 98 102 100 102 102 109 109 106|109 109 106|109 102 111 102 114 114 111 117 117 114 98 121 121 131 124 131 126 124 129 129 126 131 121 138 138 138|133 138 138|133 138 138 131 141 141 131 131 166 144 148 148 149 144 154 152 154 154 149 154 159 159 159 166 159 163 163 164 159 159 166 168 166 173 173 170|173 173 170|173 166 166 177 180 180 180 180 180 180 187 187 187 187 180 187 192 192 192 188 180 195 206 200 200 200 200 195 206 204 204 206 206 206 208 206 211 211 210|208 208 210|208 214 208 218 218 218 208 218 218 222 218 206 228 228 228 235 235 233 233 233 235 235 235 239 239 239 235 239 245 245 245 245 239 235 247 247 252 252 252 254 254 247 256 254 259 259 256 247 263 263 280 266 266 263 268 266|267 266 266|267 268 272 268 274 272 278 278 278 272 263 280 284 284 284 280 287 287 284 287 291 291 288 293 291 293 296 293 298 296 298 298 293 280 280 306 306 280 280 313 313 312 313 313 326 316 326 316 316 323 323 323 323 316 326 326 313 330 330 330 326 330 330 334 330 338 338 338 334 313	Association
17192902	Chemical	Gene	D000077156	1956	True	0	What is [PHARMGKB] between @ChemicalSrc$ gefitinib @/ChemicalSrc$ and @GeneTgt$ EGFR @/GeneTgt$ ? [SEP] The impact of @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ gene status on @ChemicalSrc$ gefitinib-treated @/ChemicalSrc$ Japanese patients with non-small-cell lung cancer . We investigated the relationships between genetic factors and clinical outcome in Japanese non-small-cell lung cancer ( NSCLC ) patients treated with @ChemicalSrc$ gefitinib @/ChemicalSrc$ . Ninety-eight NSCLC patients who had been treated with @ChemicalSrc$ gefitinib @/ChemicalSrc$ , were screened for mutations in @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ ( @GeneTgt$ EGFR @/GeneTgt$ ) exons 18 - 21 , KRAS exon2 , and polymorphisms including the CA simple sequence repeat in intron1 ( CA-SSR1 ) and single nucleotide polymorphisms in the promoter region ( -216G/T and -191C/A ) , using a PCR-based assay and direct sequencing . The @GeneTgt$ EGFR @/GeneTgt$ copy number status was also evaluated using a fluorescence in situ hybridization assay . @GeneTgt$ EGFR @/GeneTgt$ and KRAS mutations were found in 38 ( 38.8 % ) and 8 ( 8.2 % ) of the 98 patients , respectively . A high @GeneTgt$ EGFR @/GeneTgt$ copy number status was identified in 31 ( 41.3 % ) of the 75 assessable patients . Drug-sensitive @GeneTgt$ EGFR @/GeneTgt$ mutations limited to exon19 deletions and L858R were independent predictive factors of a stronger sensitivity to @ChemicalSrc$ gefitinib @/ChemicalSrc$ ( p = 0.0002 ) , the overall survival ( OS ) ( p = 0.0036 ) , and prolonged progression-free survival ( PFS ) ( p & lt ; 0.0001 ) . The @GeneTgt$ EGFR @/GeneTgt$ copy number status was not related to a sensitivity to @ChemicalSrc$ gefitinib @/ChemicalSrc$ and prolonged OS and PFS . Regarding polymorphisms , patients with a short CA-SSR1 showed a prolonged OS as compared with those with a long length in patients with a drug-sensitive @GeneTgt$ EGFR @/GeneTgt$ mutation , although this difference was not significant ( p = 0.13 ) . Thus , drug-sensitive @GeneTgt$ EGFR @/GeneTgt$ mutations predict a favorable clinical outcome and a high @GeneTgt$ EGFR @/GeneTgt$ copy number may not be related to clinical benefits in @ChemicalSrc$ gefitinib-treated @/ChemicalSrc$ Japanese patients with NSCLC . Our findings also suggest that the CA-SSR1 length may influence the clinical outcome in patients with a drug-sensitive @GeneTgt$ EGFR @/GeneTgt$ mutation .	2 2 10 10|3 10|3 10|3 10|3 10 10|3 10 2 15 15|7 15 15|7 15 10 19 19 19 15 2 24 24 26 24 29 29 26 29 32 29 41 41 41 37 41 39 41 41 32 41 44 42|43 42 42|43 24 50 50 60 54 54 54 50 56 55|54 54 55|54 50 60 60 62 60 64 64|73|62 64|73|62 64|73|62 64|73|62 64|73 64|73|62 70 64|73 73 64|73 73 62 79 76 74 76 79 62 79 62 62 88 88 88 88 88 82 92 92 92 88 92 88 97 97 88 101 101 101 97 103 101 103 103 103 60 60 111 111 108 111 114 111 60 124 119|124 124 119|124 124 124 127 127 127 127 127 134 134 134 131 134 128 127 136|143 143 136|143 137 137 137 143 143 145 143 148 148 145 148 145 145 154 154 151 154 159 159 159 145 143 143 143 170 170 165|170 170 165|170 170 170 172 172 172 174 172 177 177 174 177 183 183 183 183 174 172 189 186|189 189 186|189 190 190 193 193 190 193 193 199 199 199 190 203 203 203 199 205 203 203 203 209 209 199 209 209 199 215 215 199 217 215 217 221 221 215 221 221 199 190 228 228 190 230 228 230 233 230 233 233 237 233 237 190 247 242|247 247 242|247 247 247 250 250 250 250 253 253 250 255 253 253 253 253 259 253 259 259 250 266 273 273 273 272 272 272 268 273 276 276 273 278 273 280 278 284 284 284 280 286 284 292 292 292 289|292 292 289|292 286 273 299 296 299 299 299 273 302 302 299 302 302 273 313 313 312 309|312 312 309|312 313 313 317 317 317 313 317 324 324 324|319 324 324|319 324 317 328 328 328 313 331 331 328 336 330|336 336 330|336 336 331 338 336 313 344 346 346 346 352 350 350 352 352 346 355 355 352 357 355 363 363 363 360|363 363 360|363 357 346	Association
17324111	Chemical	Gene	D061466	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ lopinavir @/ChemicalSrc$ and @GeneTgt$ MDR1 @/GeneTgt$ ? [SEP] @GeneTgt$ Multidrug resistance 1 @/GeneTgt$ polymorphisms and trough concentrations of atazanavir and @ChemicalSrc$ lopinavir @/ChemicalSrc$ in patients with HIV . INTRODUCTION : HIV-infected patients receiving protease inhibitors may benefit from therapeutic drug monitoring-assisted dose adjustment to achieve target plasma concentrations . However , efflux pumps such as permeability-glycoprotein , which is encoded by the @GeneTgt$ multidrug resistance (MDR)1 @/GeneTgt$ gene , may decrease intracellular drug concentrations , thus reducing the amount of drug at the site of action . Plasma concentrations of protease inhibitors and CD4 cell count response have been associated with the T allele at the @GeneTgt$ MDR1 @/GeneTgt$ C3435 T locus . We examined @GeneTgt$ MDR1 @/GeneTgt$ single nucleotide polymorphisms in a cohort of patients in whom therapeutic drug monitoring is ongoing through a research protocol . METHODS : In a multicenter study , genotypic analyses at two @GeneTgt$ MDR1 @/GeneTgt$ loci , C3435 T and G2677 T , were performed by a real-time polymerase chain reaction method using DNA from 103 patients categorized as substance users or nonusers on atazanavir or @ChemicalSrc$ lopinavir @/ChemicalSrc$ as the primary antiretrovirals . Allelic frequencies were determined as a function of racial/ethnic background , substance use status and trough concentrations of atazanavir and @ChemicalSrc$ lopinavir @/ChemicalSrc$ . RESULTS : The C/T and G/T alleles at the @GeneTgt$ MDR1 @/GeneTgt$ C3435 T and G2677 T loci were equally frequent in the Caucasian population , but the wild-type alleles were more prevalent in the African-American population ( 59 % homozygous [ CC ] and 32 % heterozygous [ CT ] for C3435 T ; 80 % homozygous [ GG ] and 16 % heterozygous [ GT ] for G2677 T ) . The frequencies in the Hispanic population were 46 % CC and 38 % CT for C3435 T , and 58 % GG and 38 % GT for G2677 T . No significant differences were seen in allele frequencies for @GeneTgt$ MDR1 @/GeneTgt$ polymorphisms in substance user versus nonuser groups . Trough plasma concentrations of atazanavir or @ChemicalSrc$ lopinavir @/ChemicalSrc$ were not correlated with the variant T allele . CONCLUSIONS : These data confirm the higher prevalence of wild-type alleles of the @GeneTgt$ MDR1 @/GeneTgt$ gene in African-Americans and the linkage disequilibrium between C3435 T and G2677 T loci . The T allele at the @GeneTgt$ MDR1 @/GeneTgt$ C3435 T and G2677 T loci was not associated with higher atazanavir or @ChemicalSrc$ lopinavir @/ChemicalSrc$ trough concentrations .	0|5 0|5 0|5 5 0|5 5 5 8 5 10 8 10 8|10 10 8|10 15 8 17 15 5 29 29 24 29 24 27 25 29 29 35 35 35 35 35 29 37 29 40 40 37 29 45 45 45 45 48 46 45 48 52 52 45 59 59 59|54 59|54 59|54 59 59|54 52 45 62 45 65 65 62 45 68 45 70 68 72 70 75 75 70 77 75 45 81 92 84 84 81 84 89 89 89 84 92 92 92 96 96 96 92 103 103 103|98 103 103|98 103 103 96 92 107 107 107|112 112 107|112 112 112 107 115 115 107 117 115 119 124 122 122 119 124 117 128 128 128 124 107 153 153 136 136 136 153 153 139 153 144 144 141|144 144 141|144 139 144 147 144 144 150 144 139 153 153 160 160 160 160 160 160 153 160 161 165 165 162 165 169 169 166 169 169 173 171 173 173 173 173 180 180 180 166 153 185 187 187 187 190 190 187 193 193 190 193 196 197 193 197 200 197 202 200 202 202|203 202 202|203 187 208 208 214 214 211 211 227 220 220 216|220 220 216|220 220 214 220 220 224 220 227 227 208 231 231 231 227 227 227 236 236 239 239 239 227 243 243 243 239 249 246 249 249 249 243 249 239 253 254 239 256 254 256 260 260 239 208 263 264 266 266 208 266 266 270 271 266 273 271 273 277 277 271 266 208 282 290 286 286 286 282 290 290 290 290 290 293 294 290 297 297 294 294 294 301 302 294 294 306 306 294 309 309 306 290 313 313 315 315 315 318 318 315 322 319|322 322 319|322 318 325 325 322 325 328 325 315 333 333 341 335 333 335 335|336 335 335|336 341 341 341 346 346 346 346 341 341 349 349 352 353 349 356 356 353 359 359 356 364 364 364|361 364 364|361 359 366 356 366 370 370 366 373 373 370 373 373 377 373 349 382 382 395 388 388 388|384 388 388|384 388 382 388 388 392 395 395 395 395 398 398 395 398 398 398 398 403 398 395	Association
17394430	Chemical	Gene	D000077205	4023	True	0	What is [PHARMGKB] between @ChemicalSrc$ pioglitazone @/ChemicalSrc$ and @GeneTgt$ LPL @/GeneTgt$ ? [SEP] Response to @ChemicalSrc$ pioglitazone @/ChemicalSrc$ treatment is associated with the @GeneTgt$ lipoprotein lipase @/GeneTgt$ S447X variant in subjects with type 2 diabetes mellitus . To investigate the influence of the S447X variant in @GeneTgt$ lipoprotein lipase @/GeneTgt$ ( @GeneTgt$ LPL @/GeneTgt$ ) gene on the response rate to therapy with the thiazolidinedione @ChemicalSrc$ pioglitazone @/ChemicalSrc$ . A total of 113 diabetic patients were treated with @ChemicalSrc$ pioglitazone @/ChemicalSrc$ 30 mg for 10 weeks . Response to the @ChemicalSrc$ pioglitazone @/ChemicalSrc$ treatment was defined by either a & gt;10 % relative reduction in fasting blood glucose ( FBG ) or a more than 1 % decrease in glycosylated haemoglobin ( HbA1c ) values after 10 weeks of @ChemicalSrc$ pioglitazone @/ChemicalSrc$ treatment . The genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism method . Using the criteria & gt;10 % relative reduction in FBG after 10 weeks of pioglitaone treatment , responder frequency to @ChemicalSrc$ pioglitazone @/ChemicalSrc$ treatment in S447S genotype group is significantly higher than S447X genotype group . Meanwhile , the S447X genotype conferred a statistically significant 0.538-fold reduction in response rate to @ChemicalSrc$ pioglitazone @/ChemicalSrc$ treatment relative to the S447S genotype . Moreover , @ChemicalSrc$ pioglitazone @/ChemicalSrc$ treatment has significantly beneficial effects on serum lipid profile and blood pressure in S447S genotype carriers . The S447X variant in @GeneTgt$ LPL @/GeneTgt$ gene may be a cause for therapy modification by @ChemicalSrc$ pioglitazone @/ChemicalSrc$ .	7 5 2|5 5 2|5 1 7 7 14 14 8|14 8|14 14 8|14 14 7 16 14 21 21 21 21 16 7 26 26 28 26 32 32 32 28 41 33|34|41 33|34|41 41|34 33|34|41 38 41|35 41 41|35 41 32 45 45 45 28 47 28 51 51 51 47 47 47 26 58 64 62 62 62 58 64 64 66 64|65 64 64|65 69 66 72 72 64 64 82 80 80 77|80 80 77|80 75 82 82 90 85 90 85 85 85 90 82 94 94 94 90 96 94 96 94 102 102 100 103 104 90 111 111 111 109 111 111 104 114 114 90 118 114|118 118 114|118 114 82 123 125 125 125 133 129 129 133 133 133 133 125 125 164 137 135 137 137 137 142 137 144 137 147 147 135 150 150 147 150 153 150 157 154|157 157 154|157 153 161 161 161 157 164 164 164 168 168 168 164 164 176 176 175 175 176 176 181 179 181 181 176 184 184 181 188 188|185 188 188|185 181 176 193 193 193 189 176 201 201 197|200 200 197|200 201 201 203 204 201 208 208 208 201 208 211 208 215 215 215 208 201 220 220 228 224 221|224 224 221|224 220 228 228 228 228 231 231 228 233 231 231 231 228	Association
17460608	Chemical	Gene	D000077786	6559	True	0	What is [PHARMGKB] between @ChemicalSrc$ torsemide @/ChemicalSrc$ and @GeneTgt$ NCC @/GeneTgt$ ? [SEP] Genetic variation in the renal sodium transporters NKCC2 , @GeneTgt$ NCC @/GeneTgt$ , and ENaC in relation to the effects of loop diuretic drugs . There is little data on genetic predictors of loop diuretic efficacy in humans . Therefore , we investigated the diuretic effects of single oral doses of bumetanide , frusemide , and @ChemicalSrc$ torsemide @/ChemicalSrc$ in a crossover study in 97 healthy Caucasians in relation to genetic variation in the renal sodium transporters NKCC2 ( coded by SLC12A1 ) , @GeneTgt$ NCC @/GeneTgt$ ( @GeneTgt$ SLC12A3 @/GeneTgt$ ) , and ENaC ( three subunits coded by SCNN1A , SCNN1B , and SCNN1 G ) . The @GeneTgt$ NCC @/GeneTgt$ alanine 264 allele ( Gly264Ala ) and the most frequent SCNN1B haplotype were associated with stronger diuresis , indicating lower reabsorbing function of these alleles . The variant alleles of the tightly coupled polymorphisms rs5723 ( Leu649Leu ) and rs5729 in SCNN1 G were associated with weaker diuresis , indicating higher activity . Extended haplotype homozygosity implied evolutionary selection of the @GeneTgt$ NCC @/GeneTgt$ alanine 264 allele . In conclusion , acute diuretic effects of loop diuretics were affected by genetic variation in sodium transporters that , in the nephron , are located distally from NKCC2 .	2 2 7 7 7 7 2 7 8 8|9 8 8|9 8 8 8 16 2 19 19 16 23 23 23 19 2 27 27 29 27 32 32 29 36 36 36 32 38 36 27 43 43 43 43 46 46 43 50 50 50 46 52 50 52 52 52 52 56|52 52 56|52 62 62 62 46 66 66 66 62 68 43 71 71 68 76 76 76 76 77 71 79 43 81 79 79 43 95|82 95 95|82 87 84 84 84 87 84 84 84 95 95 43 95 98 96 98 98 98 98 104 98 95 43 115 110|115 115 110|115 115 115 126 117 115 117 115 124 122 124 124 126 126 126 129 129 126 126 126 134 134 131 137 137 134 126 142 142 158 147 147 146 147 142 147 150 147 150 147 147 156 156 147 158 158 161 161 158 158 158 165 163 158 169 169 170 170 172 170 179 179 174|179 179 174|179 179 179 172 170 183 192 192 187 187 192 190 190 187 192 192 195 195 192 198 198 195 206 206 203 203 206 206 206 198 209 209 206 192	Association
17460608	Chemical	Gene	D002034	6559	True	0	What is [PHARMGKB] between @ChemicalSrc$ bumetanide @/ChemicalSrc$ and @GeneTgt$ NCC @/GeneTgt$ ? [SEP] Genetic variation in the renal sodium transporters NKCC2 , @GeneTgt$ NCC @/GeneTgt$ , and ENaC in relation to the effects of loop diuretic drugs . There is little data on genetic predictors of loop diuretic efficacy in humans . Therefore , we investigated the diuretic effects of single oral doses of @ChemicalSrc$ bumetanide @/ChemicalSrc$ , frusemide , and torsemide in a crossover study in 97 healthy Caucasians in relation to genetic variation in the renal sodium transporters NKCC2 ( coded by SLC12A1 ) , @GeneTgt$ NCC @/GeneTgt$ ( @GeneTgt$ SLC12A3 @/GeneTgt$ ) , and ENaC ( three subunits coded by SCNN1A , SCNN1B , and SCNN1 G ) . The @GeneTgt$ NCC @/GeneTgt$ alanine 264 allele ( Gly264Ala ) and the most frequent SCNN1B haplotype were associated with stronger diuresis , indicating lower reabsorbing function of these alleles . The variant alleles of the tightly coupled polymorphisms rs5723 ( Leu649Leu ) and rs5729 in SCNN1 G were associated with weaker diuresis , indicating higher activity . Extended haplotype homozygosity implied evolutionary selection of the @GeneTgt$ NCC @/GeneTgt$ alanine 264 allele . In conclusion , acute diuretic effects of loop diuretics were affected by genetic variation in sodium transporters that , in the nephron , are located distally from NKCC2 .	2 2 7 7 7 7 2 7 8 8|9 8 8|9 8 8 8 16 2 19 19 16 23 23 23 19 2 27 27 29 27 32 32 29 36 36 36 32 38 36 27 43 43 43 43 46 46 43 50 50 50 46 52 50|51 50 50|51 52 52 52 52 52 62 62 62 46 66 66 66 62 68 43 71 71 68 76 76 76 76 77 71 79 43 81 79 79 43 95|82 95 95|82 87 84 84 84 87 84 84 84 95 95 43 95 98 96 98 98 98 98 104 98 95 43 115 110|115 115 110|115 115 115 126 117 115 117 115 124 122 124 124 126 126 126 129 129 126 126 126 134 134 131 137 137 134 126 142 142 158 147 147 146 147 142 147 150 147 150 147 147 156 156 147 158 158 161 161 158 158 158 165 163 158 169 169 170 170 172 170 179 179 174|179 179 174|179 179 179 172 170 183 192 192 187 187 192 190 190 187 192 192 195 195 192 198 198 195 206 206 203 203 206 206 206 198 209 209 206 192	Association
17460608	Chemical	Gene	D005665	6559	True	0	What is [PHARMGKB] between @ChemicalSrc$ frusemide @/ChemicalSrc$ and @GeneTgt$ NCC @/GeneTgt$ ? [SEP] Genetic variation in the renal sodium transporters NKCC2 , @GeneTgt$ NCC @/GeneTgt$ , and ENaC in relation to the effects of loop diuretic drugs . There is little data on genetic predictors of loop diuretic efficacy in humans . Therefore , we investigated the diuretic effects of single oral doses of bumetanide , @ChemicalSrc$ frusemide @/ChemicalSrc$ , and torsemide in a crossover study in 97 healthy Caucasians in relation to genetic variation in the renal sodium transporters NKCC2 ( coded by SLC12A1 ) , @GeneTgt$ NCC @/GeneTgt$ ( @GeneTgt$ SLC12A3 @/GeneTgt$ ) , and ENaC ( three subunits coded by SCNN1A , SCNN1B , and SCNN1 G ) . The @GeneTgt$ NCC @/GeneTgt$ alanine 264 allele ( Gly264Ala ) and the most frequent SCNN1B haplotype were associated with stronger diuresis , indicating lower reabsorbing function of these alleles . The variant alleles of the tightly coupled polymorphisms rs5723 ( Leu649Leu ) and rs5729 in SCNN1 G were associated with weaker diuresis , indicating higher activity . Extended haplotype homozygosity implied evolutionary selection of the @GeneTgt$ NCC @/GeneTgt$ alanine 264 allele . In conclusion , acute diuretic effects of loop diuretics were affected by genetic variation in sodium transporters that , in the nephron , are located distally from NKCC2 .	2 2 7 7 7 7 2 7 8 8|9 8 8|9 8 8 8 16 2 19 19 16 23 23 23 19 2 27 27 29 27 32 32 29 36 36 36 32 38 36 27 43 43 43 43 46 46 43 50 50 50 46 52 50 52 52|53 52 52|53 52 52 52 62 62 62 46 66 66 66 62 68 43 71 71 68 76 76 76 76 77 71 79 43 81 79 79 43 95|82 95 95|82 87 84 84 84 87 84 84 84 95 95 43 95 98 96 98 98 98 98 104 98 95 43 115 110|115 115 110|115 115 115 126 117 115 117 115 124 122 124 124 126 126 126 129 129 126 126 126 134 134 131 137 137 134 126 142 142 158 147 147 146 147 142 147 150 147 150 147 147 156 156 147 158 158 161 161 158 158 158 165 163 158 169 169 170 170 172 170 179 179 174|179 179 174|179 179 179 172 170 183 192 192 187 187 192 190 190 187 192 192 195 195 192 198 198 195 206 206 203 203 206 206 206 198 209 209 206 192	Association
17467808	Chemical	Gene	D015283	1395	True	0	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ CRHR2 @/GeneTgt$ ? [SEP] Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment . BACKGROUND : Dysregulation of the hypothalamic-pituitary-adrenal ( HPA ) axis has been observed in major depression . Normalization of HPA axis has been suggested to play a role in the mechanisms of action of antidepressants . Our aim was to investigate the influence of genetic variants in CRHR1 , @GeneTgt$ CRHR2 @/GeneTgt$ , CRH-BP and FKBP5 genes on both the vulnerability for depression and the response to antidepressant treatment . METHODS : The sample consisted of 159 depressive outpatients and 96 healthy controls of Spanish origin . Patients were assessed for clinical features including , among others , age of onset , seasonality or suicidal behavior . The episode was treated with @ChemicalSrc$ citalopram @/ChemicalSrc$ and followed along 12 weeks . Severity of symptoms was evaluated at the inclusion and then monthly along the follow-up using a 21-item Hamilton Depression Rating Score ( HDRS ) . SNPs were assayed using Applied Biosystems SNaP-Shot and TaqMan technology . RESULTS : rs110402 , in CRHR1 gene , was associated with an increased risk to present a seasonal pattern and an early age of onset of the first depressive episode . Allele G carriers of rs2270007 of @GeneTgt$ CRHR2 @/GeneTgt$ gene , showed a worse overall response to @ChemicalSrc$ citalopram @/ChemicalSrc$ along time of follow-up ( Genotype effect F=7.45 , P=0.007 ) . G allele carriers showed 2.93 increased risk ( 95 % CI [ 1.24 - 6.90 ] ) for non-responding at 4th week to @ChemicalSrc$ citalopram @/ChemicalSrc$ treatment ( chi(2)=7.59 , df=1 , P=0.006 ) . LIMITATIONS : On the light of the moderate sample size , associations based on the mentioned polymorphisms need to be considered with caution and require further replication studies in other samples . CONCLUSIONS : Variability at genes encoding proteins with a pivotal role in HPA axis regulation seems to influence i ) the expression of severity variables of the depressive spectrum including early age of onset or a seasonal pattern and ii ) the interindividual variation in clinical response to SSRI antidepressants .	2 2 5 5 2 8 8 5 8 11 8 14 14 11 2 16 16 28 25 25 25 23 21 23 18 28 28 16 31 31 28 28 39 36 36 33 39 39 39 41 39 43 41 46 46 43 48 46 50 48 39 53 56 56 56 56 58 56 61 61 58 63 61 63 63|64 63 63|64 63 63 63 63 63 75 75 75 58 77 75 75 80 75 83 83 80 56 90 90 89 90 90 94 94 94 90 94 98 98 94 101 101 98 90 105 105 105 108 108 105 112 109 112 108 112 112 116 114 112 121 118 118 112 105 124 126 126 126 128 126|127 126 126|127 126 126 134 134 131 126 141 139 137 141 141 144 144 141 141 147 141 150 150 147 150 157 157 155 157 157 151 159 157 159 141 164 164 164 164 167 165 165 168 168 165 164 173 173 182 175 179 179 175 175 182 173 186 186 186 182 188 186 191 191 188 191 195 195 191 197 195 202 202 202 202 197 182 206 206 214 208 206 212 212|209 212 212|209 208 206 214 218 218 216 214 220 218 218 218 223 218 225 223 229 229 229 225 231 229 229 214 238 238 239 239 242 242 239 246 245 246 242 250 250 250 246 250 250 254 246 257 257 254 261 261|258 261 261|258 246 263 261 263 263 267 263 263 239 271 288 275 275 288 280 280 280 280 275 288 288 282 287 287 287 283 271 291 291 288 293 291 288 288 298 298 295 301 301 298 271 303 303 318 307 305 307 308 313 313 313 308 317 317 317 313 303 320 318 324 321 324 320 327 327 324 331 331 331 327 334 334 331 336 334 334 340 340 334 334 346 342 346 346 324 349 349 346 352 352 349 318	Association
17710899	Chemical	Gene	D013390	6261	False	2	What is [PHARMGKB] between @ChemicalSrc$ succinylcholine @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families . Malignant hyperthermia is an autosomal dominant myopathy triggered by volatile anesthetics or @ChemicalSrc$ succinylcholine @/ChemicalSrc$ in susceptible persons . While in vitro contracture testing ( IVCT ) is the gold standard to establish malignant hyperthermia ( MH ) susceptibility , genetic analysis is increasingly used to diagnose this condition . This work aimed to determine the frequency and distribution of ryanodine receptor ( @GeneTgt$ RYR1 @/GeneTgt$ ) mutations in the Belgian MH-population as investigated by IVCT in our centre , as well as the discordance rates between the 2 techniques . Sequence analysis of 16 RYRI-exons in 29 selected families resulted in the detection of 10 mutations ( 4 Gly341Arg , 2 Arg614Leu , and 1 Cys35Arg , Arg614Cys , Arg2163Cys and Arg2435His ) . Discordance between IVCT and mutation analysis was observed in only 6 out of 96 individuals from 4 different families . No mutation-positive/ IVCT-negative diagnosis was found . Genetic evaluation of @GeneTgt$ RYR1-mutations @/GeneTgt$ can secure a diagnosis and aid in genetic counselling of individual family members but only in those families in which significant clinical information is present , as well as phenotyping by IVCT has been realized .	3 3 3 5 3 8 8 5 11 11 5 3 14 19 19 19 19 19 19 19 23 23 20 23 23|24 23 23|24 29 29 23 19 43 36 33 36 43 38 36 38 43 43 43 57 45 43 51 51 49 47 49 45 57 54 57 57 57 57 59 57 61 59 57 64 64 64 67 65 69 67 69 69 79 79 79 76 74|75 74 74|75 76 69 83 83 83 69 85 67 87 85 90 90 85 85 67 92 92 97 97 67 101 101 101 97 65 105 113 108 108 105 112 112 112 108 113 116 116 113 119 119 116 122 122 119 125 125 122 122 122 129 122 131 122 122 122 133 133 122 113 145 140 138 140 143 140 145 145 148 148 152 151 151 152 145 156 156 156 152 145 161 161 161 163 163 163 163 166 171 168 166|167 166 166|167 171 171 173 171 173 173 178 178 173 182 182 182 178 171 187 187 187 171 189 194 192 192 194 194 187 194 194 196 196 194 201 199 204 204 171 171	Association
17914325	Chemical	Gene	D017374	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ paroxetine @/ChemicalSrc$ and @GeneTgt$ MDR1 @/GeneTgt$ ? [SEP] Pharmacogenetics in modern psychiatry . There is no unique scientific agreement about genetic variations that could beyond any doubt predict phenotype of the response to pharmacotherapy . The knowledge about the predictors for therapy and serious adverse effects could be very useful in clinical practice . It is obvious that the combination of variation in metabolizing enzymes , transporter proteins and drug targets fully explains heterogeneity in response to psychiatric treatment . We assume that genetic polymorphisms of serotoninergic transporter and @GeneTgt$ MDR1 @/GeneTgt$ could be important in prediction of therapeutic response in patients with major depression treated with @ChemicalSrc$ paroxetine @/ChemicalSrc$ . Our results show that SERTPR-LL genotype might predispose significantly better @ChemicalSrc$ paroxetine @/ChemicalSrc$ treatment response compared to SS genotype in MDD patients and that variants G2677 T and C3435 T are not associated with therapeutic response to @ChemicalSrc$ paroxetine @/ChemicalSrc$ in patients with major depressive disorder .	1 4 4 1 1 7 7 11 11 11 7 14 14 11 20 20 19 19 20 14 20 24 24 21 26 24 7 29 42 32 32 29 34 32 34 34 36 34 42 42 42 42 45 45 42 42 48 48 48 65 52 65 54 52 57 57 54 57 60 57 60 63 60 65 49 65 68 66 71 71 68 48 74 74 86 77 86 80 80 77 80 80|81 80 80|81 86 86 74 88 86 91 91 88 93 91 96 96 93 96 99 97 97 97 74 105 106 106 111 109 111 111 106 113 117 113|117 117 113|117 117 111 121 121 121 111 124 124 121 111 135 135 127 128 129 129 129 135 135 111 138 138 135 140 138 138 138 143 140 147 147 147 143 106	Association
18004207	Chemical	Gene	D009270	4988	True	0	What is [PHARMGKB] between @ChemicalSrc$ naloxone @/ChemicalSrc$ and @GeneTgt$ OPRM1 @/GeneTgt$ ? [SEP] Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene ( @GeneTgt$ OPRM1 @/GeneTgt$ ) on HPA-axis activation . BACKGROUND : Studies in European Americans ( EAs ) have shown that the hypothalamic-pituitary-adrenal (HPA)-axis activation by the opioid blockade is moderated by the single nucleotide polymorphism ( SNP ) A118 G ( Asn40Asp ) at the mu-opioid receptor locus ( @GeneTgt$ OPRM1 @/GeneTgt$ ) . We examined the effect of this , and of five intronic @GeneTgt$ OPRM1 @/GeneTgt$ SNPs , on adrenocorticotropic hormone and cortisol concentrations , following the placebo-controlled administration of @ChemicalSrc$ naloxone @/ChemicalSrc$ to healthy individuals who were of EA or Asian ancestry . METHODS : We used a balanced , within-participant design with two test sessions to examine the hormonal responses to intravenous @ChemicalSrc$ naloxone @/ChemicalSrc$ ( an opioid antagonist ) ( 125 microg/kg ) or placebo in 29 healthy participants ( 62 % men , 59 % of Asian ancestry ) . DNA isolated from whole blood was PCR amplified and genotyped using a fluorogenic 5 nuclease assay ( TaqMan ) method . RESULTS : Consistent with earlier reports , participants with one or two Asp40 alleles ( n=16 ) had a significantly greater cortisol response to @ChemicalSrc$ naloxone @/ChemicalSrc$ than Asn40 homozygotes , but the effect was limited to EAs . Asians with the Asp40 allele did not show a greater increase in cortisol response compared with Asn40 homozygotes . None of the intronic SNPs was associated with cortisol response either directly or via an interaction effect with Asn40Asp . CONCLUSIONS : Effects of the Asn40Asp polymorphism at @GeneTgt$ OPRM1 @/GeneTgt$ on HPA-axis activation seem to be population-specific . The association between the Asn40Asp and the HPA-axis response to @ChemicalSrc$ naloxone @/ChemicalSrc$ can not , therefore , be explained with reference only to the amino acid substitution encoded by that polymorphism . Further research to understand the basis for the observed association is warranted .	2 2 6 6 6 2 11 11 11 11 2 13 11|12 11 11|12 13 18 18 2 2 21 21 31 26 26 23 28 26 28 31 21 42 36 36 36 42 40 40 40 36 42 31 47 47 47 47 42 49 52 49 52 47 54 52 54 60 60 60 60 47 62 60|61 60 60|61 62 31 68 68 70 68 72 70 70 70 80 80 80 77|80 80 77|80 70 80 84 84 70 84 84 84 68 92 92 92 68 94 92 92 92 98 98 92 102 102 102 98 102 105 102 68 112 112 112 112 117 117 114 114 112 121 121 121 117 123 112 126 126 123 129 129 126|128 126 126|128 134 134 134 129 134 138 138 134 138 129 129 145 145 145 141 149 148 149 123 149 152 149 155 155 152 149 112 166 159 163 163 160 166 166 166 166 166 168 178 178 174 174 178 176 174 176 169 166 197 180 180 185 185 182 197 197 189 187 189 189 193 189 195 187 195 197 202 200 202 202 197 204 203|202 202 203|202 208 208 197 197 197 212 214 214 197 216 214 214 226 223 223 223 219 226 226 226 229 229 226 232 232 229 226 236 236 233 226 244 242 242 242 238 244 244 247 247 244 254 254 249 254 254 254 244 256 254 244 258 258 271 264 264 264 260 266 265|264 264 265|264 270 270 260 258 274 274 271 271 278 295 281 281 278 281 285 285 281 287 285|286 285 285|286 295 295 295 295 295 295 295 297 295 303 303 303 303 303 295 303 307 307 304 295 311 321 313 311 315 313 319 319 319 315 321 321 321	Association
18025780	Chemical	Gene	D007501	3077	True	0	What is [PHARMGKB] between @ChemicalSrc$ iron @/ChemicalSrc$ and @GeneTgt$ HFE @/GeneTgt$ ? [SEP] @GeneTgt$ HFE @/GeneTgt$ genotype influences erythropoiesis support requirement in hemodialysis patients : a prospective study . BACKGROUND/AIMS : @GeneTgt$ HFE @/GeneTgt$ protein controls @ChemicalSrc$ iron @/ChemicalSrc$ absorption and cycling , and @GeneTgt$ HFE @/GeneTgt$ mutations influence @ChemicalSrc$ iron @/ChemicalSrc$ status . The aim was to evaluate the effect of the @GeneTgt$ HFE @/GeneTgt$ genotype on the need for @ChemicalSrc$ iron @/ChemicalSrc$ and erythropoietin in Italian hemodialysis patients . METHODS : Ninety-six prevalent patients were evaluated at the time of enrolment and prospectively followed for 3 years . Patients were given r-HuEPO and Fe3 + -gluconate according to guidelines . The @GeneTgt$ HFE @/GeneTgt$ genotype was determined by restriction analysis . RESULTS : Three patients ( 3 % ) carried the C282Y mutation , 4 ( 4 % ) were homozygous and 18 ( 19 % ) heterozygous for the H63D mutation , and 71 ( 74 % ) were negative for both . At enrolment , subjects positive for @GeneTgt$ HFE @/GeneTgt$ mutations had higher @ChemicalSrc$ iron @/ChemicalSrc$ stores ( ferritin 617 + /- 663 vs. 423 + /- 386 ng/ml , p = 0.05 ) , were receiving less @ChemicalSrc$ iron @/ChemicalSrc$ ( 82.5 + /- 66 vs. 110 + /- 154 mg/month , p = 0.05 ) and a lower r-HuEPO dosage ( 98 + /- 83 vs. 142 + /- 138 U/kg/week , p = 0.03 ) . Consistently during the study period , patients positive for @GeneTgt$ HFE @/GeneTgt$ mutations received a lower amount of r-HuEPO ( 94.5 + /- 63 vs. 186 + /- 344 U/kg/week , p = 0.01 ) and @ChemicalSrc$ iron @/ChemicalSrc$ ( 97 + /- 63 vs. 121 + /- 68 mg/month , p = 0.07 ) . Upon Cox regression analysis , after adjustment for confounding variables , the presence of @GeneTgt$ HFE @/GeneTgt$ mutations was associated with a reduced risk of death ( HR 0.6 , 95 % CI 0.34 - 1.03 , p = 0.06 ) . CONCLUSION : @GeneTgt$ HFE @/GeneTgt$ mutations reduce the amount of r-HuEPO and @ChemicalSrc$ iron @/ChemicalSrc$ necessary to support erythropoiesis in hemodialysis .	0|3 3 0|3 4 4 6 7 4 10 10 7 4 14 14 4 4 22 22 18|21 21 18|21 22 22 25|21 25 25|21 22 25 25 25 25 32|27 32 32|27 33 22 36|30 36 36|30 33 22 43 46 46 46 46 48 46 53 53 50|53 53 50|53 48 56 56 48 58 56 56 56 58 58 65 65 65 58 46 75 75 73 73 75 75 75 78 78 75 80 78 75 83 75 86 86 83 75 90 90 90 90 91 91 91 91 98 96 90 90 103 100|103 103 100|103 105 105 105 108 108 105 105 130 111 114 119 117 117 114 117 111 122 122 119 122 127 127 127 119 127 130 130 130 130 135 135 137 135 130 141 141 141 137 130 130 150 147 147 144 147 150 130 152 150 150 155 158 158 158 158 162 162|159 162 162|159 158 158 167 163|167 167 163|167 163 169 167 169 169 169 169 173 173 169 169 179 169 182 182 169 182 182 169 187 163 189 186|187 187 186|187 192 189 192 192 192 195 195 192 201 201 192 204 204 201 204 204 201 211 211 211 192 213 211 213 213 213 216 216 213 213 222 213 225 225 213 225 213 158 244 236 236 236 244 244 244 238 243 240|243 243 240|243 239 244 247 247 244 249 247 251 249 251 251 251 254 254 251 251 260 251 263 263 244 263 264 263 263|265 263 263|265 270 279 270 270 270 273 273 270 270 279 263 282 282 279 282 282 244 291 291 291 306 306 294 306 297 297 294 306 300 306 304 304|301 304 304|301 300 306 306 310 310 310 306 312 310 314 312 314 314 318 314 318 318 320 318 325 325 314 325 314 306 330 335 331|334 334 331|334 335 330 337 335 339 337 339 339 339 339 339 345 337 345 348 345 335	Association
18398146	Chemical	Gene	D001761	642	True	0	What is [PHARMGKB] between @ChemicalSrc$ bleomycin @/ChemicalSrc$ and @GeneTgt$ BLMH @/GeneTgt$ ? [SEP] Variation in @GeneTgt$ bleomycin hydrolase @/GeneTgt$ gene is associated with reduced survival after chemotherapy for testicular germ cell cancer . PURPOSE : Response to chemotherapy may be determined by gene polymorphisms involved in metabolism of cytotoxic drugs . A plausible candidate is the gene for @GeneTgt$ bleomycin hydrolase @/GeneTgt$ ( @GeneTgt$ BLMH @/GeneTgt$ ) , an enzyme that inactivates @ChemicalSrc$ bleomycin @/ChemicalSrc$ , an essential component of chemotherapy regimens for disseminated testicular germ-cell cancer ( TC ) . We investigated whether the single nucleotide polymorphism ( SNP ) A1450 G of the @GeneTgt$ BLMH @/GeneTgt$ gene ( rs1050565 ) is associated with survival . PATIENTS AND METHODS : Data were collected on survival and @GeneTgt$ BLMH @/GeneTgt$ genotype of 304 patients with TC treated with @ChemicalSrc$ bleomycin-containing @/ChemicalSrc$ chemotherapy at the University Medical Center Groningen , the Netherlands , between 1977 and 2003 . Survival according to genotype was analyzed using Kaplan-Meier curves with log-rank testing and Cox regression analysis with adjustment for confounders . RESULTS : @GeneTgt$ BLMH @/GeneTgt$ gene SNP A1450 G has a significant effect on TC-related survival ( log-rank P = .001 ) . The homozygous variant ( G/G ) genotype ( n = 31 ) is associated with decreased TC related survival compared with the heterozygous variant ( A/G ; n = 133 ) and the wild-type ( A/A ; n = 140 ) . With Cox regression the G/G genotype proves to be an unfavorable prognostic factor , in addition to the commonly used International Germ Cell Consensus Classification prognosis group , with a hazard ratio of 4.97 ( 95 % CI , 2.17 to 11.39 ) for TC-related death . Furthermore , the G/G genotype shows a higher prevalence of early relapses . CONCLUSION : The homozygous variant G/G of @GeneTgt$ BLMH @/GeneTgt$ gene SNP A1450 G is associated with reduced survival and higher prevalence of early relapses in TC patients treated with @ChemicalSrc$ bleomycin-containing @/ChemicalSrc$ chemotherapy . This association is hypothesis generating and may eventually be of value for risk classification and selection for alternative treatment strategies in patients with disseminated TC .	8 6 2|6 2|6 6 2|6 1 8 8 11 11 8 13 11 18 18 18 18 13 8 21 21 28 25 23 28 28 21 31 31 28 31 34 32 37 37 34 21 41 41 44 44 44 44 46 46|44|45 46|44|45 46|44 46|44|45 50 46|47 46 46|47 50 46 55 46 57 55 54|57 57 54|57 58 63 63 58 66 66 63 71 71 71 71 66 73 71 73 44 80 80 100 85 85 85 100 87 85 87 90 100 95 95 95|92 95 95|92 90 97 95 97 100 80 102 100 80 105 105 105 111 111 111 105 113 111 113 114|117 117 114|117 113 120 120 113 122 120 122 127 123|127 127 123|127 123 133 133 133 133 133 127 133 136 133 136 139 136 139 139 111 150 148 146 145 150 150 150 153 151 156 156 153 150 160 160 150 162 160 164 162 150 166 166 173|167 173 173|167 173 173 173 174 166 177 177 174 180 180 177 183 183 184 180 184 180 166 195 191 195 195 195 195 202 197 195 197 198 197 202 202 207 207 206 207 202 212 212 212 212 202 214 212 214 217 214 217 214 212 222 212 224 222 227 227 224 227 224 202 233 233 237 236 236 237 237 243 243 243 243 243 237 243 246 243 257 257 250 257 257 255 255 255 257 257 246 243 262 262 262 243 264 262 268 267 268 262 268 272 272 268 272 276 276 268 237 283 283 282 282 283 283 286 286 283 289 289 286 283 291 291 296 296 296 305 303 303|297 303 303|297 303 303 303 296 305 291 308 308 305 308 311 308 314 314 311 317 317 311 317 322 322|318 322 322|318 318 291 327 330 330 330 330 330 336 336 336 336 330 339 339 336 339 339 345 345 345 339 347 345 350 350 347 330	Association
18430057	Chemical	Gene	D019821	5444	True	0	What is [PHARMGKB] between @ChemicalSrc$ simvastatin @/ChemicalSrc$ and @GeneTgt$ PON1 @/GeneTgt$ ? [SEP] Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by @GeneTgt$ paraoxonase 1 @/GeneTgt$ in Chinese patients with coronary heart disease . 1 . We sought to determine the effects of Q192R polymorphism of @GeneTgt$ paraoxonase 1 @/GeneTgt$ ( @GeneTgt$ PON1 @/GeneTgt$ ) gene on plasma high-density lipoprotein-cholesterol ( HDL-C ) levels and the response to statin therapy in Chinese patients with coronary heart disease ( CHD ) . 2 . Two hundred and thirty-six patients with CHD were treated with @ChemicalSrc$ simvastatin @/ChemicalSrc$ 20 mg/day . Fasting serum lipids were determined before and after 12 weeks of treatment . 3 . No significant differences were detected among the @GeneTgt$ PON1 @/GeneTgt$ Q192R polymorphism with respect to plasma lipids . In addition , the effects of @ChemicalSrc$ simvastatin @/ChemicalSrc$ to increase HDL-C levels were significantly greater in patients with the RR genotype compared with patients with the QR or RR genotypes ( P & lt ; 0.05 ) . 4 . We conclude that the Q192R polymorphism of @GeneTgt$ PON1 @/GeneTgt$ significantly modulates the HDL-C response to @ChemicalSrc$ simvastatin @/ChemicalSrc$ in Chinese patients with CHD .	11 4 4 1 9 7 9 9 1 11 11 13 11|12|13 11|12|13 11|13 11|12|13 18 18 13 22 22 22 18 11 28 25 28 28 30 28 32 30 35 35 32 44 36|44 36|44 44 36|44 41 44|38 44 44|38 44 35 48 48 48 52 50 48 50 32 32 55 32 58 58 55 61 61 58 65 65 65 61 67 65 67 28 82 82 75 78 75 75 82 80 78 82 82 84 82|83 82 82|83 87 84 82 92 92 94 94 94 99 95 99 99 94 101 99 94 103 103 107 107 109 109 109 115 115 115|111 115 115|111 115 109 117 109 120 120 117 109 124 137 137 127 137 129 127|128 127 127|128 132 127 134 132 137 137 137 139 137 143 143 143 139 146 146 137 149 149 146 149 149 149 154 152 154 154 154 154 154 137 165 162 165 165 174 169 169 174 171 169|170 169 169|170 174 165 177 177 174 179 177 177 177 183 183 179 185 183 165	Association
18444945	Chemical	Gene	D016572	7124	False	4	What is [PHARMGKB] between @ChemicalSrc$ cyclosporine A @/ChemicalSrc$ and @GeneTgt$ TNF-alpha @/GeneTgt$ ? [SEP] Association of four DNA polymorphisms with acute rejection after kidney transplantation . Renal transplant outcomes exhibit large inter-individual variability , possibly on account of genetic variation in immune-response mediators and genes influencing the pharmacodynamics/pharmacokinetics of immunosuppressants . We examined 21 polymorphisms from 10 genes in 237 de novo renal transplant recipients participating in an open-label , multicenter study [ @ChemicalSrc$ Cyclosporine @/ChemicalSrc$ Avoidance Eliminates Serious Adverse Renal-toxicity ( CAESAR ) ] investigating renal function and biopsy-proven acute rejection ( BPAR ) with different @ChemicalSrc$ cyclosporine A @/ChemicalSrc$ regimens and mycophenolate mofetil . Genes were selected for their immune response and pharmacodynamic/pharmacokinetic relevance and were tested for association with BPAR . Four polymorphisms were significantly associated with BPAR . The ABCB1 2677 T allele tripled the odds of developing BPAR ( OR : 3.16 , 95 % CI [ 1.50 - 6.67 ] ; P=0.003 ) , as did the presence of at least one IMPDH2 3757C allele ( OR : 3.39 , 95 % CI [ 1.42 - 8.09 ] ; P=0.006 ) . BPAR was almost fivefold more likely in patients homozygous for IL-10 -592A ( OR : 4.71 , 95 % CI [ 1.52 - 14.55 ] ; P=0.007 ) and twice as likely in patients with at least one A allele of @GeneTgt$ TNF-alpha @/GeneTgt$ G-308A ( OR : 2.18 , 95 % CI [ 1.08 - 4.41 ] ; P=0.029 ) . There were no statistically significant interactions between polymorphisms , or the different treatment regimens . Variation in genes of immune response and pharmacodynamic/pharmacokinetic relevance may be important in understanding acute rejection after renal transplant .	1 5 5 5 1 8 8 1 11 11 8 1 15 15 16 16 19 19 16 19 16 23 21 26 26 23 29 29 26 29 29 31 34 32 36 34 16 39 39 41 39 44 44 41 51 51 51 47 51 51 44 51 58 58 58 58 58 52 63 62|59 62 62|59 63 41 66 66 63 68 66 68 63 41 73 71 73 77 77 73 79 77 79 86 86 86|81 86|81 86 86|81 77 86 89 86 39 95 95 95 99 99 99 95 99 102 99 95 105 95 107 105 109 107 95 112 115 115 115 115 117 115 115 123 123 123 123 124 124 126 124 128 126 128 137 137 133 137 133 136 137 124 141 141 141 137 141 137 137 144 137 148 137 150 148 157 153 154 157 156 157 150 161 161 161 157 161 164 165 148 169 169 167 165 169 137 137 172 124 180 180 178 179 180 180 182 180 182 186 186 183 188 190 190 194 190 193 194 180 198 198 198 194 198 201 194 201 194 206 206 194 208 206 214 211 212 214 214 208 218 215|218 218 215|218 214 226 226 222 226 222 225 226 194 230 230 230 226 230 226 226 226 194 238 238 242 241 242 238 244 242 244 244 250 250 250 244 238 263 254 252 257 257 254 257 260 257 263 263 263 265 263 267 265 270 270 265 263	Association
18591455	Chemical	Gene	D006852	65125	True	0	What is [PHARMGKB] between @ChemicalSrc$ hydrochlorothiazide @/ChemicalSrc$ and @GeneTgt$ WNK1 @/GeneTgt$ ? [SEP] Physiological interaction between alpha-adducin and @GeneTgt$ WNK1-NEDD4L @/GeneTgt$ pathways on sodium-related blood pressure regulation . The kidney plays an important role in salt and blood pressure ( BP ) homeostasis . In previous studies , variants in the genes for alpha-adducin ( ADD1 ) , @GeneTgt$ WNK1 @/GeneTgt$ , and NEDD4L , which all regulate renal sodium absorption , have been associated with increased BP . However , findings have been inconsistent . We tested whether this is because of physiological interactions between the effects of variants in these genes . We assessed the single and combined effects of the ADD1 ( Gly460Trp ) , @GeneTgt$ WNK1 @/GeneTgt$ ( rs880054 A/G ) , and NEDD4L ( rs4149601 G/A ) polymorphisms on renal and BP response to an acute Na load ( n=344 subjects ) , BP decrease after 1 month of treatment with 12.5 mg of @ChemicalSrc$ hydrochlorothiazide @/ChemicalSrc$ ( n=193 ) , and ambulatory 24-hour BP ( n=690 ) . Individually , the variants showed modest effects on some of the studied phenotypes . We found the ADD1 Trp allele to be permissive for the effects of variants of the other genes . In combination , the same variants ( ADD1 @GeneTgt$ Trp/WNK1 @/GeneTgt$ GG/Nedd4L GA+AA ) showed a consistent effect on renal Na handling ( P=0.009 ) and acute BP response to a saline infusion ( P=0.021 ) , BP lowering after thiazide treatment ( P=0.008 ) , and nocturnal systolic BP ( P=0.044 ) . Physiological interaction between the ADD1 and @GeneTgt$ WNK1-NEDD4L @/GeneTgt$ pathways influences the effects of variants in these genes on sodium-related BP regulation . Relatively common alleles in the ADD1 , @GeneTgt$ WNK1 @/GeneTgt$ , and NEDD4L genes when present in combination may have significant effects on renal sodium handling , BP , and antihypertensive response to thiazides .	2 2 4 2 4 8|5 8 8|5 4 13 13 13 13 2 2 17 18 18 21 21 18 23 30 23 26 23 28 26 28 18 18 34 34 54 54 54 39 39 36 41 39 43 41 43 41 41|45 41 41|45 46 41 41 50 53 54 54 57 57 54 54 61 61 54 64 64 61 54 72 72 72 72 72 72 72 75 75 75 76 76 82 79 82 76 85 85 82 87 85 90 90 87 75 93 93 98 98 95 95 93 101 101 98 103 101 103 101 101|105 101 101|105 110 110 106 110 101 101 119 117 117 114 117 98 121 98 121 121 121 129 129 129 129 98 132 132 129 132 136 136 93 139 139 136 141 139 144 144 141 146 144 144 144 149 146 149 144 139 155 155 139 157 155 157 93 166 166 165 166 166 168 166 170 168 174 174 174 170 166 177 177 181 181 181 184 184 184 177 187 187 184 189 187 193 193 193 189 177 196 208 208 200 200 208 206 206 202|206 206 202|206 206 200 206 208 211 211 208 215 215 215 211 217 215 217 215 222 222 215 226 226 226 222 228 226 228 208 208 231 235 235 232 237 235 237 235 235 243 243 235 245 243 245 208 250 258 253 253 250 253 257|254 257 257|254 253 258 260 258 262 260 265 265 262 269 269 269 260 258 273 274 290 277 277 274 277 277|278 277 277|278 277 277 284 277 286 274 288 286 290 290 292 290 296 296 296 292 296 296 296 296 302 296 304 302 290	Association
18794724	Chemical	Gene	D005473	5054	False	1	What is [PHARMGKB] between @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and @GeneTgt$ SERPINE1 @/GeneTgt$ ? [SEP] @GeneTgt$ Plasminogen activator inhibitor-1 @/GeneTgt$ gene is associated with major depression and antidepressant treatment response . OBJECTIVE : Evidence suggests that plasminogen activator inhibitor type 1 gene ( @GeneTgt$ SERPINE1 @/GeneTgt$ ) is a stress-related gene and serum plasminogen activator inhibitor type 1 levels are increased in patients with major depressive disorders ( MDD ) . METHODS : To investigate whether common genetic variation in the @GeneTgt$ SERPINE1 @/GeneTgt$ gene is associated with MDD and the therapeutic response to antidepressants , six polymorphisms ( rs2227631 , rs1799889 , rs6092 , rs6090 , rs2227684 and rs7242 ) of the @GeneTgt$ SERPINE1 @/GeneTgt$ gene were genotyped in 188 Chinese MDD patients and 346 controls . Among the MDD patients , 140 accepted selective serotonin reuptake inhibitor ( @ChemicalSrc$ fluoxetine @/ChemicalSrc$ or citalopram ) antidepressant treatment for 4 weeks with therapeutic evaluation before and after . RESULTS : In single-marker-based analysis , the rs2227684-G and rs7242-T alleles were more frequent in MDD patients than in controls ( P=0.010 and 0.010 , respectively ) . The haplotype derived from the rs6090-G , rs2227684-G and rs7242-T polymorphisms was 1.19-fold higher in patients with MDD than in controls ( P=0.0038 ) . Haplotype analysis in responders ( defined as a 50 % reduction of the initial Hamilton score ) and nonresponders after 4 weeks of antidepressant treatment showed that the haplotype derived from the rs2227631-G and rs1799889 - 4 G polymorphisms was lower in responders than nonresponders ( 11.4 vs. 22.4 % , P=0.014 ) . CONCLUSION : Our findings show , for the first time , that @GeneTgt$ SERPINE1 @/GeneTgt$ genetic variants may play a role in MDD susceptibility and in the acute therapeutic response to selective serotonin reuptake inhibitors .	0|5 0|5 0|5 5 0|5 7 7 7 10 10 7 10 14 14 10 7 20 17 20 20 35 27 27 27 27 27 35 29 27|28 27 27|28 29 35 35 35 20 35 43 43 43 43 43 43 45 45 20 47 45 51 51 51 47 53 51 53 20 60 60 60 60 71 64 64 71 69 69 66|69 69 66|69 64 71 60 73 71 73 77 77 73 79 77 102 82 102 84 82 84 84 84 84 84 84 84 84 92 84 84 100 100 96|100 100 96|100 82 102 60 107 107 107 107 102 107 110 107 60 117 117 117 120 120 120 120 124 124 124 120 126 132|125 132 132|125 126 126 126 132 124 135 135 132 138 138 132 120 139 139 120 144 144 148 148 157 157 151 157 151 151 151 157 157 144 160 160 157 163 163 157 165 163 165 165 165 165 165 144 173 185 173 177 177 174 177 177 179 179 173 185 185 185 187 185 189 187 192 192 185 194 192 194 185 198 222 200 198 202 200 207 207 206 207 202 212 212 212 212 207 212 207 207 218 218 207 221 221 218 222 237 225 237 225 229 229 226 229 233 233 235 235 237 237 222 239 237 241 239 246 246 243 243 241 246 246 246 222 255 255 254 255 255 255 260 260 260 255 255 268 266|262 266 266|262 266 268 268 255 270 268 273 273 268 273 279 279 279 279 273 284 284 284 284 279 255	Association
18794724	Chemical	Gene	D015283	5054	False	1	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ SERPINE1 @/GeneTgt$ ? [SEP] @GeneTgt$ Plasminogen activator inhibitor-1 @/GeneTgt$ gene is associated with major depression and antidepressant treatment response . OBJECTIVE : Evidence suggests that plasminogen activator inhibitor type 1 gene ( @GeneTgt$ SERPINE1 @/GeneTgt$ ) is a stress-related gene and serum plasminogen activator inhibitor type 1 levels are increased in patients with major depressive disorders ( MDD ) . METHODS : To investigate whether common genetic variation in the @GeneTgt$ SERPINE1 @/GeneTgt$ gene is associated with MDD and the therapeutic response to antidepressants , six polymorphisms ( rs2227631 , rs1799889 , rs6092 , rs6090 , rs2227684 and rs7242 ) of the @GeneTgt$ SERPINE1 @/GeneTgt$ gene were genotyped in 188 Chinese MDD patients and 346 controls . Among the MDD patients , 140 accepted selective serotonin reuptake inhibitor ( fluoxetine or @ChemicalSrc$ citalopram @/ChemicalSrc$ ) antidepressant treatment for 4 weeks with therapeutic evaluation before and after . RESULTS : In single-marker-based analysis , the rs2227684-G and rs7242-T alleles were more frequent in MDD patients than in controls ( P=0.010 and 0.010 , respectively ) . The haplotype derived from the rs6090-G , rs2227684-G and rs7242-T polymorphisms was 1.19-fold higher in patients with MDD than in controls ( P=0.0038 ) . Haplotype analysis in responders ( defined as a 50 % reduction of the initial Hamilton score ) and nonresponders after 4 weeks of antidepressant treatment showed that the haplotype derived from the rs2227631-G and rs1799889 - 4 G polymorphisms was lower in responders than nonresponders ( 11.4 vs. 22.4 % , P=0.014 ) . CONCLUSION : Our findings show , for the first time , that @GeneTgt$ SERPINE1 @/GeneTgt$ genetic variants may play a role in MDD susceptibility and in the acute therapeutic response to selective serotonin reuptake inhibitors .	0|5 0|5 0|5 5 0|5 7 7 7 10 10 7 10 14 14 10 7 20 17 20 20 35 27 27 27 27 27 35 29 27|28 27 27|28 29 35 35 35 20 35 43 43 43 43 43 43 45 45 20 47 45 51 51 51 47 53 51 53 20 60 60 60 60 71 64 64 71 69 69 66|69 69 66|69 64 71 60 73 71 73 77 77 73 79 77 102 82 102 84 82 84 84 84 84 84 84 84 84 92 84 84 100 100 96|100 100 96|100 82 102 60 107 107 107 107 102 107 110 107 60 117 117 117 120 120 120 120 124 124 124 120 126 132 126 126|127 126 126|127 126 132 124 135 135 132 138 138 132 120 139 139 120 144 144 148 148 157 157 151 157 151 151 151 157 157 144 160 160 157 163 163 157 165 163 165 165 165 165 165 144 173 185 173 177 177 174 177 177 179 179 173 185 185 185 187 185 189 187 192 192 185 194 192 194 185 198 222 200 198 202 200 207 207 206 207 202 212 212 212 212 207 212 207 207 218 218 207 221 221 218 222 237 225 237 225 229 229 226 229 233 233 235 235 237 237 222 239 237 241 239 246 246 243 243 241 246 246 246 222 255 255 254 255 255 255 260 260 260 255 255 268 266|262 266 266|262 266 268 268 255 270 268 273 273 268 273 279 279 279 279 273 284 284 284 284 279 255	Association
18816295	Chemical	Gene	D015742	54600	True	0	What is [PHARMGKB] between @ChemicalSrc$ propofol @/ChemicalSrc$ and @GeneTgt$ UGT1A9 @/GeneTgt$ ? [SEP] Effect of D256N and Y483D on @ChemicalSrc$ propofol @/ChemicalSrc$ glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase ( @GeneTgt$ UGT1A9 @/GeneTgt$ ) . Uridine 5'-diphosphate glucuronosyltransferases ( UGTs ) are part of a major elimination pathway for endobiotics and xenobiotics . @GeneTgt$ UGT1A9 @/GeneTgt$ is a UGT that catalyses the conjugation of endogenous oestrogenic and thyroid hormones , acetaminophen , SN-38 ( an active metabolite of irinotecan ) and phenols . @GeneTgt$ UGT1A9 @/GeneTgt$ is the only isoform that catalyses the glucuronidation of @ChemicalSrc$ propofol @/ChemicalSrc$ ( @ChemicalSrc$ 2,6-diisopropylphenol @/ChemicalSrc$ ) in the liver . In the present study , we analysed polymorphisms of @GeneTgt$ UGT1A9 @/GeneTgt$ in 100 healthy adult Japanese volunteers . A transversion of 766 G > A resulting in the amino acid substitution of D256N was detected in exon 1 . The allele frequency of D256N is 0.005 . We investigated the effects of D256N and Y483D , which is located on the common exon of UGT1 , on @ChemicalSrc$ propofol @/ChemicalSrc$ glucuronidation by an in vitro expression study . The K(m ) of wild-type , D256N and Y483D for @ChemicalSrc$ propofol @/ChemicalSrc$ glucuronidation were 111.2 , 43.6 and 64.5 microM , respectively . The V(max ) of D256N and Y483D were 8.1 % and 28.8 % , and the efficiencies ( V(max)/K(m ) ) were 19.1 % and 57.1 % of the wild-type , respectively . For mycophenolic acid , 1-naphthol and naringenin , the D256N variant lowered glucuronidation activity considerably , compared to Y483D . The V(max ) value of D256N variant for mycophenolic acid was only 9.5 % of the wild-type . This study shows the importance of D256N in differences between individuals concerning adverse effects of drugs that are catalysed primarily by @GeneTgt$ UGT1A9 @/GeneTgt$ . Carriers of D256N may be at risk of suffering adverse effects of @ChemicalSrc$ propofol @/ChemicalSrc$ and other substrates that are primarily metabolized by @GeneTgt$ UGT1A9 @/GeneTgt$ .	1 3 1 3 3 9 9|6 9 9|6 1 14 14 14 14 1 16 14 14 14 16 1 24 24 29 26 24 26 29 29 34 34 34 34 29 36 34 36 36 29 39|44 44 39|44 44 44 44 46 44 48 46 56 56 50 51 51 51 54 48 56 56 62 62 62 56 64 62 64 62 62 44 69|75 75 69|75 75 75 75 75 77 75 79 77 81 79 79 79 84 81 81 81 84 89 89 79 75 97 97 97 100 100 100 100 100 103 101|102 101 101|102 110 110 108 110 110 101 100 114 129 117 117 114 114 118 114 125 125 125 125 120 127 125 129 129 131 129 131 129 136 136 140 138 136 140 140 140 143 143 145 143 147 145 147 147 147 153 153 147 157 157 157 153 159 157 159 164 161|164 164 161|164 157 170 170 170 167 170 164 143 174 174 174 177 174 177 177 177 177 185 182|185 185 182|185 177 187 192 192 192 189 189 174 192 192 174 198 206 198 201 198 201 201 206 206 206 206 209 206 206 206 213 220 215 213 215 215 220 220 206 220 223 220 226 226 223 223 220 220 232 232 241 232 232 232 232 241 240 240 241 241 243 241 241 241 241 248 246 241 253 253 253 263 256 256 253 259 259 256 263 262 263 263 266 266 263 263 269 270 270 272 270 274 272 276 272 278 276 281 281 276 283 281 286 286 283 286 289 286|288 286 286|288 270 299 295 293 299 299 299 299 301 299 303 301 305 303|304 303 303|304 305 309 305 313 313 313 309 315 313 313 313 299	Association
18926547	Chemical	Gene	D000068180	1813	True	0	What is [PHARMGKB] between @ChemicalSrc$ aripiprazole @/ChemicalSrc$ and @GeneTgt$ DRD2 @/GeneTgt$ ? [SEP] Effects of @GeneTgt$ DRD2/ANKK1 @/GeneTgt$ gene variations and clinical factors on @ChemicalSrc$ aripiprazole @/ChemicalSrc$ efficacy in schizophrenic patients . OBJECTIVES : @ChemicalSrc$ Aripiprazole @/ChemicalSrc$ , a novel antipsychotic agent , acts as a partial agonist at dopamine D2 receptors ( @GeneTgt$ DRD2 @/GeneTgt$ ) . We investigate whether its efficacy is predictable by @GeneTgt$ DRD2/ANKK1 @/GeneTgt$ gene polymorphisms and clinical factors in Han Chinese hospitalized patients with acutely exacerbated schizophrenia . METHOD : After hospitalization , the patients ( n=128 ) were given @ChemicalSrc$ aripiprazole @/ChemicalSrc$ for up to 4 weeks . They were genotyped for four functional @GeneTgt$ DRD2/ANKK1 @/GeneTgt$ polymorphisms : -141 Ins/Del , Ser311Cys , C957 T , and TaqIA . Clinical factors such as gender , age , illness duration , education level , diagnostic subtype , and medication dosage were also recorded . Psychopathology was measured biweekly with the positive and negative syndrome scale ( PANSS ) . The effects of genetic and clinical factors on PANSS performance upon @ChemicalSrc$ aripiprazole @/ChemicalSrc$ treatment were analyzed by a mixed modeling approach ( SAS Proc MIXED ) . RESULTS : Compared to the patients with TaqI A2/A2 genotype , A1 carriers are associated with superior therapeutic response on positive symptoms after 4-week @ChemicalSrc$ aripiprazole @/ChemicalSrc$ treatment . Regarding the C957 T polymorphism , patients with C/C genotype were associated with poor @ChemicalSrc$ aripiprazole @/ChemicalSrc$ response for excitement symptoms when compared with T/T patients . The other two polymorphisms , -141 Ins/Del , and Ser311Cys , have no significant effects on PANSS performance . The clinical factors including medication dosage , illness duration , and diagnostic subtype could influence PANSS performance upon @ChemicalSrc$ aripiprazole @/ChemicalSrc$ treatment . CONCLUSION : This study suggests that @GeneTgt$ DRD2/ANKK1 @/GeneTgt$ gene variations and some clinical factors may predict individual response to @ChemicalSrc$ aripiprazole @/ChemicalSrc$ .	1 6 2|6 6 2|6 6 1 6 9 6 13 9|13 13 9|13 1 16 16 13 1 20 20 21|30 30 21|30 22 28 28 28 22 22 20 34 34 34 30 38 38 38 34 40 38 38 38 40 30 47 47 52 50 52 52 47 57 53|57 57 53|57 57 52 57 60 57 63 63 60 52 64 69 68 69 65 47 72 72 75 83 83 78 83 80 78 80 83 72 83 83 83 90 89 89 90 83 72 95 95 95 101 101 101 101|98 101 101|98 95 95 104 95 104 104 104 109 104 104 104 104 95 116 137 119 117 116 119 119 121 124 121 124 127 124 127 130 127 130 119 134 119 137 137 137 137 141 141 141 141 149 149 149 145 145 149 141 151 149 151 141 155 169 157 160 157 157 155 163 163 155 167 164|167 167 164|167 155 169 169 174 174 174 174 169 178 178 178 174 178 169 196 182 187 187 187 196 191 191 191 187 196 194 196 196 196 200 200 200 196 203 203 200 208 208 205|208 208 205|208 200 196 215 215 215 215 222 222 222 220 220 217 222 222 227 227 227|224 227 227|224 222 230 230 227 232 222 235 235 232 222 241 241 241 249 241 244 241 244 244 244 241 249 252 252 249 255 255 252 249 259 259 271 262 262 259 262 265 262 262 262 269 262 271 271 273 271 277 274|277 277 274|277 271 271 280 284 283 284 280 295 288|285 288 288|285 289 295 289 293 293 289 295 284 297 295 299 297 297 297 284	Association
18992959	Chemical	Gene	D000077156	1956	True	0	What is [PHARMGKB] between @ChemicalSrc$ gefitinib @/ChemicalSrc$ and @GeneTgt$ EGFR @/GeneTgt$ ? [SEP] Prospective phase II study of @ChemicalSrc$ gefitinib @/ChemicalSrc$ in non-small cell lung cancer with @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ gene mutations . BACKGROUND : This study prospectively assessed the efficacy of @ChemicalSrc$ gefitinib @/ChemicalSrc$ and the survival benefit for non-small cell lung cancer ( NSCLC ) patients with @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ ( @GeneTgt$ EGFR @/GeneTgt$ ) mutations . METHOD : Patients with either recurrent disease after undergoing surgery or advanced NSCLC disease ( IIIB or IV ) which demonstrated @GeneTgt$ EGFR @/GeneTgt$ mutations were eligible for this study . @GeneTgt$ EGFR @/GeneTgt$ mutations in exons 19 - 21 were examined . The patients with @GeneTgt$ EGFR @/GeneTgt$ mutations were enrolled in this study after obtaining their informed consent a second time , and they were thereafter treated with @ChemicalSrc$ gefitinib @/ChemicalSrc$ . RESULTS : @GeneTgt$ EGFR @/GeneTgt$ mutations were detected in 20 of 48 patients with NSCLC , and 19 patients were enrolled onto this study and treated with @ChemicalSrc$ gefitinib @/ChemicalSrc$ . Seven patients had an exon 19 deletion , 10 had L858R , 1 had both , and 1 had an exon 19 deletion and G796A . The overall response rate was 63.2 % , and the disease control rate was 89.5 % . In patients with an exon 19 del and L858R , the response rates were 71.4 % and 60.0 % , respectively . The median progression-free survival time was 7.1 months , and the median survival time was 20.0 months . No life-threatening toxicity was observed . Four of five acquired resistant tumors showed an acquired T790 M mutation . CONCLUSIONS : @GeneTgt$ EGFR @/GeneTgt$ mutations in exons 19 or 21 are considered to be a good predictor of the efficacy of @ChemicalSrc$ gefitinib @/ChemicalSrc$ .	4 4 4 4 6 4|5 4 4|5 12 12 12 12 6 20 12|20 12|20 12|20 12|20 20 12|20 20 12 4 24 24 27 29 29 24 31 29 33 31|32 31 31|32 31 38 38 31 47 43 43 43 47 45 47 47 38 58 47|49|58 47|49|58 47|49|58 47|49|58 49|58 47|49|58 55 49 49 49 55 47 29 63 63 88 69 69 69 65 71 65 71 72 76 76 72 78 76 78 78 78 83 72 86|83 86 86|83 83 88 63 91 91 88 88 93|96 96 93|96 103 98 96 98 101 98 103 103 103 107 113 111 108|111 111 108|111 107 113 113 116 116 113 118 113 121 121 118 124 124 118 113 113 130 130 130 113 132 130 130 130 130 137 137 138|141 141 138|141 143 143 137 145 143 148 148 145 150 148 143 143 154 156 156 143 159 159 156 156 156 163 161 161 161 137 169 170 170 174 174 174 170 177 177 170 177 177 181 177 181 177 177 186 177 190 190 190 186 190 190 177 197 197 197 200 200 200 200 200 200 206 205 206 209 209 209 200 209 212 226 217 217 217 217 212 217 217 226 223 223 226 226 226 226 226 229 226 229 226 226 237 237 237 237 240 240 240 240 240 240 246 246 246 249 249 249 240 249 253 253 255 255 255 255 259 259 260 262 262 263 263 268 268 268 268 263 263 270 270 271|274 274 271|274 281 276 274 276 277 277 281 270 286 286 286 286 281 289 289 286 291 289 289 289 270	Association
19027114	Chemical	Gene	D019821	2152	True	0	What is [PHARMGKB] between @ChemicalSrc$ simvastatin @/ChemicalSrc$ and @GeneTgt$ TF @/GeneTgt$ ? [SEP] @GeneTgt$ Tissue factor @/GeneTgt$ + 5466A&gt;G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of @ChemicalSrc$ simvastatin @/ChemicalSrc$ in patients with ischemic heart disease . OBJECTIVE : We examined the hypothesis that the + 5466A&gt;G variant ( rs3917643 ) of the @GeneTgt$ tissue factor @/GeneTgt$ ( @GeneTgt$ TF @/GeneTgt$ ) gene is associated with thrombin formation following @ChemicalSrc$ simvastatin @/ChemicalSrc$ in patients with ischemic heart disease ( IHD ) . METHODS AND RESULTS : Prothrombin 1.2 fragments ( F1.2 ) and thrombin-antithrombin complexes ( TAT ) were assessed in 95 men with stable IHD , aged 54.4+/-6.8 years , in blood collected every 60s from the bleeding-time wounds before and after a 3-month @ChemicalSrc$ simvastatin @/ChemicalSrc$ administration ( 40 mg/day ) . We identified 16 patients with the @GeneTgt$ TF @/GeneTgt$ + 5466AG genotype and 79 subjects with the + 5466AA genotype . Baseline maximum rates of F1.2 and TAT formation and their maximum levels at the site of vascular injury , but not in venous blood , were higher in + 5466 G allele carriers than in those with + 5466AA genotype ( P&lt;0.0001 ) . The magnitude of reduction in maximum rates of F1.2 and TAT formation following @ChemicalSrc$ simvastatin @/ChemicalSrc$ was larger ( P&lt;0.001 ) in + 5466 G allele carriers than in + 5466AA subjects . The degree of decrease in maximum local levels of F1.2 and TAT after @ChemicalSrc$ simvastatin @/ChemicalSrc$ was similar in both genotype groups . The presence of the + 5466 G allele was independently associated with the maximum velocity of F1.2 and TAT generation and maximum levels of both markers before and after @ChemicalSrc$ simvastatin @/ChemicalSrc$ in multiple regression models ( P&lt;0.01 for all analyses ) . Local thrombin generation , in + 5466AG and + 5466AA subjects , showed no significant correlations with lipid variables . CONCLUSIONS : Thrombin formation following vascular injury and thrombin-lowering effect of statins in patients with IHD are at least in part genetically determined by the @GeneTgt$ TF @/GeneTgt$ + 5466A&gt;G polymorphism .	0|1|7 0|1|7 1|7 0|1|7 1 6 1 7 9 7 12 12 9 12 15 12 17 14|15 15 14|15 20 12 24 24 24 20 7 28 31 31 28 33 31 53 51 35 38 35 40 38 40 51 51 43|51 43|51 51 43|51 51 51|45 51 51|45 51 53 53 33 56 56 53 58 54|56 56 54|56 61 58 65 65 65 61 67 65 67 31 90 73 73 90 79 79 90 81 79 81 79 85 79 87 85 87 90 90 93 93 90 96 96 93 96 100 100 90 90 103 104 90 106 104 110 110 110 104 118 111 111 118 118 115|118 118 115|118 104 121 121 118 121 90 126 126 128 126 131 131 128|130 128 128|130 131 135 131 128 138 128 143 143 140 140 138 126 148 148 172 150 148 150 150 150 148 157 157 148 160 160 157 163 163 160 163 166 169 169 169 157 148 172 172 178 173 178 178 178 172 181 181 172 185 182 185 181 187 185 187 172 191 206 193 191 196 196 193 198 196 198 198 206 203 201|202 201 201|202 206 206 208 206 208 215 210 215 214 215 206 220 216 217 217 206 206 224 239 226 224 230 230 230 226 232 230 232 232 236 224|235 224 224|235 239 239 243 243 243 239 239 247 256 253 253 249 253 253 247 256 256 256 260 260 260 256 262 260 262 262 262 262 262 262 271 271 268 275 272 272 274|260 260 274|260 280 280 280 275 282 280 285 285 282 282 256 291 291 301 301 292 293 293 295 295 299 292 301 301 304 304 301 307 307 304 301 309 309 312 329 315 315 312 315 318 315 320 318 322 320 324 322 329 329 326 329 309 331 329 334 334 333|331 331 333|331 334 338 334 309	Association
19205682	Chemical	Gene	D009553	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ nimodipine @/ChemicalSrc$ and @GeneTgt$ MDR1 @/GeneTgt$ ? [SEP] Effects of CYP3A5 , @GeneTgt$ MDR1 @/GeneTgt$ and CACNA1C polymorphisms on the oral disposition and response of @ChemicalSrc$ nimodipine @/ChemicalSrc$ in a Chinese cohort . PURPOSE : Our objective was to study the effects of polymorphic the CYP3A5 ( allele * 1 and * 3 ) , @GeneTgt$ MDR1 @/GeneTgt$ [ single nucleotide polymorphisms ( SNPs ) G2677 T , C3435 T ] and CACNA1C ( SNPs rs2239128 , rs2239050 , rs2238032 ) genes on @ChemicalSrc$ nimodipine @/ChemicalSrc$ oral disposition and response in healthy Chinese subjects . METHODS : Pharmacokinetics and pharmacodynamics data were obtained from a bioequivalence study , and the same 20 subjects were genotyped for CYP3A , @GeneTgt$ MDR1 @/GeneTgt$ and CACNA1C . An additional 41 healthy Chinese subjects were recruited to obtain an indication of the distribution of CACNA1C polymorphisms in the Chinese population . Racial differences in the frequency of CACNA1C alleles were assessed . The phenotype differences between genotypes were analyzed . RESULTS : The allelic frequencies of rs2239050 and rs2238032 in our Chinese cohort were different from those in a Caucasian population ( p & lt ; 0.01 ) . Subjects with mutant alleles ( * 3/*3 ) of the CYP3A5 gene had a decreased oral clearance of @ChemicalSrc$ nimodipine @/ChemicalSrc$ , with a higher lnC(max ) or 1n AUC(0-infinity ) compared with those subjects with the heterozygote ( * 1/*3 ) or wild type ( * 1/*1 ) gene . The CACNA1C rs2239128 C and rs2239050 G SNPs were associated with a stronger efficacy compared with their respective alleles , rs2239128 T and rs2239050 C. @GeneTgt$ MDR1 @/GeneTgt$ polymorphisms showed no significance in terms of @ChemicalSrc$ nimodipine @/ChemicalSrc$ disposition . CONCLUSIONS : The polymorphic CYP3A5 ( allele * 1 and * 3 ) and CACNA1C genes have effects on @ChemicalSrc$ nimodipine @/ChemicalSrc$ oral disposition and response in healthy Chinese subjects . The homozygous variant of CYP3A5 ( * 3/*3 ) was associated with significantly increased @ChemicalSrc$ nimodipine @/ChemicalSrc$ exposure . CACNA1C SNPs rs2239128 C and rs2239050 G were associated with a stronger efficacy .	1 3 9 3 3|4 3 3|4 3 3 1 13 13 13 1 13 13 17 15 15 15 22 22 22 15 1 26 26 29 30 32 32 26 34 32 40 40 40 40 40 73 40 40 40 45 40 45 40 47|40 40 47|40 48 53 53 73 55 53 55 58 73 58 61 58 58 58 58 66 58 66 67 67 67 67 66 34 78 73|78 78 73|78 78 34 78 78 84 84 84 78 26 95 95 93 90 90 95 95 95 99 99 99 95 95 95 105 105 105 107 107 95 109 107 109 109|110 109 109|110 109 109 95 122 122 122 122 122 124 124 124 126 124 128 126 131 131 128 134 134 131 138 138 138 131 124 141 149 144 144 141 147 147 144 149 149 149 153 153 157 155 153 157 157 157 159 159 163 163 173 165 163 165 165 171 171 171 167 173 159 175 173 179 179 179 175 181 185 181 181 185 173 185 159 200 191 191 188 194 194 188 194 199 199 199 188 200 204 204 204 200 206 204|205 204 204|205 200 212 212 212 200 212 212 216 212 212 200 221 221 218 224 224 221 227 227 224 227 224 231 236 234 234 236 236 224 200 242 242 242 248 242 242 246 248 248 248 252 252 252 248 252 257 257 257 253 248 260 267 260 263 266 263|266 266 263|266 267 248 269 267 271 267 275 271|275 275 271|275 271 267 279 279 285 283 285 285 295 285 285 285 290 285 290 285 294 285 279 295 301 297|301 301 297|301 301 296 301 301 307 307 307 301 279 312 312 320 314 312 317 317 312 317 320 320 326 323 326 326|323 326 326|323 320 320 330 337 332 337 332 335 332 337 337 341 341 341 337 337	Association
19205682	Chemical	Gene	D009553	775	True	0	What is [PHARMGKB] between @ChemicalSrc$ nimodipine @/ChemicalSrc$ and @GeneTgt$ CACNA1C @/GeneTgt$ ? [SEP] Effects of CYP3A5 , MDR1 and @GeneTgt$ CACNA1C @/GeneTgt$ polymorphisms on the oral disposition and response of @ChemicalSrc$ nimodipine @/ChemicalSrc$ in a Chinese cohort . PURPOSE : Our objective was to study the effects of polymorphic the CYP3A5 ( allele * 1 and * 3 ) , MDR1 [ single nucleotide polymorphisms ( SNPs ) G2677 T , C3435 T ] and @GeneTgt$ CACNA1C @/GeneTgt$ ( SNPs rs2239128 , rs2239050 , rs2238032 ) genes on @ChemicalSrc$ nimodipine @/ChemicalSrc$ oral disposition and response in healthy Chinese subjects . METHODS : Pharmacokinetics and pharmacodynamics data were obtained from a bioequivalence study , and the same 20 subjects were genotyped for CYP3A , MDR1 and @GeneTgt$ CACNA1C @/GeneTgt$ . An additional 41 healthy Chinese subjects were recruited to obtain an indication of the distribution of @GeneTgt$ CACNA1C @/GeneTgt$ polymorphisms in the Chinese population . Racial differences in the frequency of @GeneTgt$ CACNA1C @/GeneTgt$ alleles were assessed . The phenotype differences between genotypes were analyzed . RESULTS : The allelic frequencies of rs2239050 and rs2238032 in our Chinese cohort were different from those in a Caucasian population ( p & lt ; 0.01 ) . Subjects with mutant alleles ( * 3/*3 ) of the CYP3A5 gene had a decreased oral clearance of @ChemicalSrc$ nimodipine @/ChemicalSrc$ , with a higher lnC(max ) or 1n AUC(0-infinity ) compared with those subjects with the heterozygote ( * 1/*3 ) or wild type ( * 1/*1 ) gene . The @GeneTgt$ CACNA1C @/GeneTgt$ rs2239128 C and rs2239050 G SNPs were associated with a stronger efficacy compared with their respective alleles , rs2239128 T and rs2239050 C. MDR1 polymorphisms showed no significance in terms of @ChemicalSrc$ nimodipine @/ChemicalSrc$ disposition . CONCLUSIONS : The polymorphic CYP3A5 ( allele * 1 and * 3 ) and @GeneTgt$ CACNA1C @/GeneTgt$ genes have effects on @ChemicalSrc$ nimodipine @/ChemicalSrc$ oral disposition and response in healthy Chinese subjects . The homozygous variant of CYP3A5 ( * 3/*3 ) was associated with significantly increased @ChemicalSrc$ nimodipine @/ChemicalSrc$ exposure . @GeneTgt$ CACNA1C @/GeneTgt$ SNPs rs2239128 C and rs2239050 G were associated with a stronger efficacy .	1 3 9 3 3 3 3|6 3 3|6 1 13 13 13 1 13 13 17 15 15 15 22 22 22 15 1 26 26 29 30 32 32 26 34 32 40 40 40 40 40 73 40 40 40 45 40 45 40 40 48 52 52 73 54 52 54 57 73 57 60 57 57 57 57|62 57 57|62 66 57 66 67 67 67 67 66 34 78 73|78 78 73|78 78 34 78 78 84 84 84 78 26 95 95 93 90 90 95 95 95 99 99 99 95 95 95 105 105 105 107 107 95 109 107 109 109 109 112|109 109 112|109 95 122 122 122 122 122 124 124 124 126 124 128 126 131 131 128 135 132|135 135 132|135 131 139 139 139 131 124 143 152 146 146 143 150 150|147 150 150|147 146 152 152 152 157 157 161 159 157 161 161 161 163 163 167 167 177 169 167 169 169 175 175 175 171 177 163 179 177 183 183 183 179 185 189 185 185 189 177 189 163 204 195 195 192 198 198 192 198 203 203 203 192 204 208 208 208 204 210 208|209 208 208|209 204 216 216 216 204 216 216 220 216 216 204 225 225 222 228 228 225 231 231 228 231 228 235 240 238 238 240 240 228 204 247 243|247 247 243|247 247 253 247 247 251 253 253 253 257 257 257 253 257 262 262 262 258 253 265 271 265 268 270 270 271 253 273 271 275 271 279 275|279 279 275|279 275 271 283 283 289 287 289 289 300 289 289 289 294 289 294 289 299|296 299 299|296 289 283 300 306 306|301 306 306|301 306 301 306 306 312 312 312 306 283 318 318 326 320 318 323 323 318 323 326 326 332 329 332 332|329 332 332|329 326 326 334|337 337 334|337 344 339 344 339 342 339 344 344 348 348 348 344 344	Association
19247217	Chemical	Gene	D014700	9722	True	0	What is [PHARMGKB] between @ChemicalSrc$ verapamil @/ChemicalSrc$ and @GeneTgt$ NOS1AP @/GeneTgt$ ? [SEP] Calcium channel blockers , @GeneTgt$ NOS1AP @/GeneTgt$ , and heart-rate-corrected QT prolongation . OBJECTIVES : To study whether @GeneTgt$ NOS1AP @/GeneTgt$ single nucleotide polymorphisms ( SNPs ) , rs10494366 T&gt;G and rs10918594 C&gt;G , modify the heart-rate-corrected QT ( QTc ) prolonging effect of calcium channel blockers . BACKGROUND : Common variation in the @GeneTgt$ NOS1AP @/GeneTgt$ gene has been associated with QT interval variation in several large population samples . NOS1 is presumed to influence intracellular calcium . METHODS : The prospective population-based Rotterdam Study includes 16 603 ECGs from 7565 participants ( & gt;or=55 years ) , after exclusion of patients with left ventricular hypertrophy , left and right bundle branch block , as well as carriers of pacemakers . The endpoint was the length of the QTc interval in calcium channel blocker users and non-users with the minor alleles compared with the major alleles ( wild type ) . We used a repeated-measurement analysis , adjusted for all known confounders . RESULTS : Use of @ChemicalSrc$ verapamil @/ChemicalSrc$ was associated with a significant QTc interval prolongation [ 6.0 ms 95 % confidence interval ( CI ) 1.7 ; 10.2 ] compared with non-users . Furthermore , users of @ChemicalSrc$ verapamil @/ChemicalSrc$ with the rs10494366 GG genotype showed significantly more QTc prolongation than users with the TT genotype [ 25.4 ms ( 95 % CI : 5.9 - 44.9 ) ] ( P value for multiplicative interaction 0.0038 ) . Users of isradipine with the GG genotype showed more QTc prolongation than users with the TT genotype [ 19.8 ms ( 95 % CI : 1.9 - 37.7 ) ] ; however , SNP rs10494366 did not modify the effect on QTc interval on a multiplicative scale ( P=0.3563 ) . SNP rs10918594 showed similar results . CONCLUSION : In conclusion , we showed that the minor alleles of both @GeneTgt$ NOS1AP @/GeneTgt$ SNPs significantly potentiate the QTc prolonging effect of @ChemicalSrc$ verapamil @/ChemicalSrc$ .	3 3 3 3 3|4 3 3|4 5 5 5 11 5 3 14 17 17 14 34 23|18 23 23|18 23 23 34 25 23 25 23 29 23 23 32 23 34 17 37 37 34 39 37 39 34 41 46 45 46 42 14 49 49 52 60 57 57 57|54 57 57|54 52 60 60 49 64 64 64 60 69 69 69 69 64 60 74 74 74 76 74 78 76 74 87 80 86 86 86 86 87 87 89 90 87 93 93 90 93 93 93 90 90 87 101 87 103 101 107 107 107 103 103 103 109 109 113 114 103 114 103 116 116 103 121 119 87 124 127 127 127 127 131 131 131 127 136 136 136 136 131 136 136 142 142 142 138 147 147 147 147 127 150 150 147 150 127 154 154 157 157 154 157 157 163 163 163 159 154 165 165 172 169 167|168 167 167|168 172 165 178 178 178 178 178 172 181 181 178 183 181 185 183 187 183 187 183 183 181 191 178 195 193 165 209 209 209 202 200|201 200 200|201 208 208 208 208 200 209 211 213 213 209 215 213 219 219 219 215 222 222 226 225 225 226 213 226 230 230 226 230 226 235 235 213 238 238 235 238 235 209 250 245 243 249 249 249 243 250 253 253 250 255 253 259 259 259 255 262 262 266 265 265 266 253 266 270 270 266 266 250 250 280 280 277 280 280 280 250 282 280 285 285 282 289 289 289 280 291 289 291 250 295 296 296 298 296 296 300 306 303 306 306 306 300 317 310 310 317 313 313 315|312 315 315|312 310 317 306 319 317 317 320 323 321 321 321 300	Association
19302829	Chemical	Gene	D000068180	1814	True	0	What is [PHARMGKB] between @ChemicalSrc$ aripiprazole @/ChemicalSrc$ and @GeneTgt$ DRD3 @/GeneTgt$ ? [SEP] Effects of the @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly polymorphism on @ChemicalSrc$ aripiprazole @/ChemicalSrc$ efficacy in schizophrenic patients as modified by clinical factors . @ChemicalSrc$ Aripiprazole @/ChemicalSrc$ , a novel antipsychotic agent , has a unique pharmacological action ( partial agonist ) on the dopamine neurotransmission system . @ChemicalSrc$ Aripiprazole @/ChemicalSrc$ has high affinity for dopamine D2 and D3 receptors ( DRD2 and @GeneTgt$ DRD3 @/GeneTgt$ ) . We investigated whether the efficacy of @ChemicalSrc$ aripiprazole @/ChemicalSrc$ can be predicted by a functional @GeneTgt$ DRD3 @/GeneTgt$ gene polymorphism Ser9Gly ( rs6280 ) as modified by clinical factors in Han Chinese hospitalized patients with acutely exacerbated schizophrenia . After hospitalization , the patients ( n=128 ) were given @ChemicalSrc$ aripiprazole @/ChemicalSrc$ for up to four weeks . Patients were genotyped for @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly polymorphism by Restriction Fragment Length Polymorphism ( RFLP ) method . Clinical factors such as gender , age , duration of illness , education level , diagnostic subtype and medication dosage were recorded . Psychopathology was measured biweekly with the Positive and Negative Syndrome Scale ( PANSS ) . The effects of genetic and clinical factors on PANSS performance after @ChemicalSrc$ aripiprazole @/ChemicalSrc$ treatment were analyzed by a mixed model regression approach ( SAS Proc MIXED ) . We found that , although the Ser carriers have numerically larger score reductions when compared with non-carriers in almost all PANSS dimensions , the difference of their effects are statically not significant . However , the clinical factors , including dosage of @ChemicalSrc$ aripiprazole @/ChemicalSrc$ , age , duration of illness , and diagnostic subtype could influence PANSS performance after @ChemicalSrc$ aripiprazole @/ChemicalSrc$ treatment . This study suggests that @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly polymorphism may not contribute significantly to inter-individual differences in therapeutic efficacy of @ChemicalSrc$ aripiprazole @/ChemicalSrc$ , but some clinical factors may predict treatment efficacy .	1 7 7 3|7 7 3|7 7 1 11 11|7 11 11|7 1 14 14 11 16 1 19 19 16 1 22|31 31 22|31 23 29 29 29 23 23 31 35 35 35 31 38 38 35 38 44 44 43 44 31 31 46|49 49 46|49 49 51 49 54 54 51 54 57 54 59 57 59 59 59 59 59 49 68 68 77 71 77 73 71|72 71 71|72 77 77 68 87 87 87 87|79 87 87|79 87 87 87 87 77 87 90 77 93 93 90 96 96 93 68 97 102 101 102 98 68 107 115 115 110 115 112 110 112 115 115 115 115 115 122 121 121 122 115 115 127 127 127 132 132|128 132 132|128 132 127 141 141 141 137 141 139 137 139 127 127 145 165 148 146 145 148 148 148 148 154 152 154 157 154 157 160 148 160 160 160 165 165 165 169 169 169 169 177 177 177 173 173 177 169 179 177 179 169 183 197 185 188 185 185 183 191 191 183 195 192|195 195 192|195 183 197 197 203 203 203 203 203 197 207 207 207 203 207 197 212 212 242 242 221 218 218 221 221 221 242 223 221 225 221 227 225 232 230 232 232 227 242 235 242 238 238 235 242 242 242 212 212 266 266 248 248 266 248 251 248 253 251|252 251 251|252 253 253 253 253 260 258 260 260 264 251 266 266 268 266 272 268|272 272 268|272 266 266 277 278 278 286 283|279 283 283|279 283 286 286 286 278 286 290 290 286 293 293 290 295 293 293 293 278 278 301 301 303 303 278 305 303 278	Association
19303909	Chemical	Gene	D008691	2784	False	3	What is [PHARMGKB] between @ChemicalSrc$ methadone @/ChemicalSrc$ and @GeneTgt$ GNB3 @/GeneTgt$ ? [SEP] Intensity of opiate withdrawal in relation to the 825C&gt;T polymorphism of the @GeneTgt$ G-protein beta 3 @/GeneTgt$ subunit gene . OBJECTIVES : The intensity of withdrawal in opiate dependence shows a high inter-individual variability . The 825C&gt;T polymorphism ( rs5443 ) of the @GeneTgt$ G-protein beta 3 @/GeneTgt$ ( @GeneTgt$ GNB3 @/GeneTgt$ ) subunit gene has a strong influence on clinical signs of sympathetic activity in cardiac research . This study was carried out in order to test the hypothesis that carriers of the T allele have an increased sympathetic activity in opiate withdrawal . METHODS : Thirty-nine monovalent opiate addicted patients consecutively admitted to a detoxification ward were investigated . The main parameter for sympathetic activity was the pulse rate in the first 3 days after the regular end of gradual @ChemicalSrc$ methadone @/ChemicalSrc$ reduction . RESULTS : Thirty-three out of 39 patients achieved a drug-free state : 22 carried a T allele ( TT , CT ) , 11 belonged to the CC genotype group . The pulse rate was significantly ( p&lt;0.05 ) raised in the T allele group compared to the CC genotype group on the first 2 days after stopping @ChemicalSrc$ methadone @/ChemicalSrc$ administration . In addition , about a third of the T allele carriers needed clonidine treatment on the respective days , but only one patient among the 11 CC homozygotes . There was no significant difference between groups in systolic and diastolic blood pressures as well as in subjective withdrawal ratings . CONCLUSION : A group difference regarding pulse rate could be observed in a small sample and despite a higher degree of concomitant clonidine medication in T allele carriers . The failure to detect group differences in blood pressure and self-rated withdrawal symptoms may be attributed to the more complex regulation of blood pressure and the known weak correlation between objective and subjective withdrawal symptoms .	1 4 4 1 6 1 10 10 10 6 18 18 18|12 18|12 18|12 18 18|12 18 10 1 30 21 24 30 26 24 29 29 24 30 34 34 34 30 30 40 40 40 40 54 40 53 53 43|53 43|53 43|53 53 43|53 53 45|53 53 45|53 53 53 40 54 57 57 54 60 60 57 63 63 60 66 66 54 54 71 73 73 73 73 76 73 78 76 80 78 87 87 86 86 86 82 80 91 91 91 87 94 94 87 73 101 101 100 100 101 101 101 104 102 108 108 108 104 110 101 101 114 114 121 117 117 114 121 121 121 121 126 126 126 126 121 126 130 130 121 135 135 135|132 135 135|132 130 121 151 138 144 144 143 144 145 138 148 148 145 151 151 162 154 154 151 156 154 156 156 156 162 162 162 167 167 167 167 162 162 171 171 175 175 175 175 175 175 175 182 182 182 182 177 175 188 188 188 188 183 193 193 193 193 194 195 183 195|198 198 195|198 195 175 202 212 212 206 206 212 211 211 211 211 206 212 214 212 218 218 218 212 212 212 222 223 212 228 228 228 228 223 212 231 231 234 234 231 236 234 238 242 238 238 242 236 236 243 243 249 248 249 236 231 251 251 255 255 261 258 258 255 261 261 251 265 265 265 261 265 270 270 270 265 274 274 274 270 278 278 278 274 251 281 295 283 281 285 283 288 288 285 288 292 292 288 295 295 295 300 300 299 300 295 303 303 300 300 308 308 308 300 314 314 310 310 314 308 295	Association
19307503	Chemical	Gene	D000068437	4524	False	1	What is [PHARMGKB] between @ChemicalSrc$ pemetrexed @/ChemicalSrc$ and @GeneTgt$ MTHFR @/GeneTgt$ ? [SEP] Randomized phase II and pharmacogenetic study of @ChemicalSrc$ pemetrexed @/ChemicalSrc$ compared with @ChemicalSrc$ pemetrexed @/ChemicalSrc$ plus carboplatin in pretreated patients with advanced non-small-cell lung cancer . PURPOSE : We performed a randomized phase II trial comparing @ChemicalSrc$ pemetrexed @/ChemicalSrc$ with @ChemicalSrc$ pemetrexed @/ChemicalSrc$ plus carboplatin ( PC ) in patients experiencing relapse after platinum-based chemotherapy . PATIENTS AND METHODS : Main eligibility criteria were histologic or cytologic proof of advanced non-small-cell lung cancer ( NSCLC ) , relapse more than 3 months after platinum-based chemotherapy , normal organ function , and Eastern Cooperative Oncology Group performance status 0 to 2 . Patients were randomly assigned to @ChemicalSrc$ pemetrexed @/ChemicalSrc$ 500 mg/m(2 ) ( arm A ) or carboplatin area under the curve 5 and @ChemicalSrc$ pemetrexed @/ChemicalSrc$ 500 mg/m(2 ) ( arm B ) , both administered intravenously every 3 weeks . Response assessment was performed every 6 weeks ; toxicity assessment was performed every 3 weeks . Primary end point was time to progression ( TTP ) ; secondary end points were objective response rate ( ORR ) , overall survival ( OS ) , and toxicity . The study was designed to detect a 33 % decrease in the hazard of disease progression in the combination arm ( alpha = 0.05 , two-sided log-rank test ) . Polymorphisms of thymidylate synthase , the reduced folate carrier , gamma-glutamyl hydrolase , and @GeneTgt$ methylenetetrahydrofolate reductase @/GeneTgt$ ( @GeneTgt$ MTHF @/GeneTgt$ ) were investigated in peripheral WBCs of consenting patients . RESULTS : Two hundred forty patients were enrolled . Median TTP was 2.8 months for arm A versus 4.2 months for arm B ( hazard ratio , 0.67 ; 95 % CI , 0.51 to 0.89 ; P = .005 ) . Median OS was 7.6 months and 8.0 months and ORR was 4 % and 9 % for arms A and B , respectively . Subgroup analyses found adenocarcinoma to be associated with favorable outcome . Toxicities in both arms was negligible , with one potential toxic death in arm A. Patients with @GeneTgt$ MTHFR @/GeneTgt$ C677 T homozygous mutation had increased progression-free survival compared with patients with wild-type or heterozygous mutations ( P = .03 ) . CONCLUSION : PC as second-line treatment for relapsed NSCLC resulted in a significant 33 % reduction of the hazard of disease progression as compared with @ChemicalSrc$ pemetrexed @/ChemicalSrc$ alone .	2 2 2 2 6 2 8 6|7 6 6|7 2 12 10 10 10 12 12 18 18 12 23 23 23 23 18 2 30 30 30 30 35 35 35 35 30 35 36 36 36 40 36|38 36 36|38 40 40 45 43 45 48 40 48 49 53 53 50 30 57 57 57 57 63 63 65 65 57 65 65 65 73 73 73 73 68 75 73 75 73 57 81 79 82 78 85 85 78 57 89 89 57 57 57 95 95 95 97 97 57 57 98 98 57 105 105 105 105 110 110|106 110 110|106 110 105 110 114 114 110 114 110 118 110 127 127 127 121 121 121|122 121 121|122 127 118 127 131 131 127 131 105 135 105 135 139 139 135 105 144 146 146 146 149 149 146 154 152 154 154 146 157 157 154 154 161 161 163 163 163 165 163 167 165 167 163 172 172 176 176 176 176 163 178 176 178 176 182 176 184 182 184 176 176 176 163 191 193 193 193 195 193 199 198 199 195 202 202 199 205 205 202 209 209 209 199 211 209 211 212 212 217 217 211 211 193 242 223 223 220 220 228 228 228 220 228 231 228 228 228 228|233|234 228|233|234 228|234 228|233|234 238 235|234 234 235|234 238 242 242 245 245 242 247 242 247 242 252 252 255 256 257 259 259 252 259 262 265 265 265 265 268 268 265 268 271 268 277 274 277 277 277 265 277 265 279 283 283 265 283 287 287 283 290 290 283 290 290 265 295 298 298 298 298 298 301 298 298 306 306 306 298 306 309 306 312 312 306 312 312 306 306 306 319 320 320 320 324 324 320 327 327 324 320 334 332 332 329 334 334 334 340 340 340 340 353 344 344 344 340 351 345|351 351 345|351 351 351 351 344 353 334 355 353 358 358 353 360 358 360 360 360 365 360 365 366 365 334 380 371 371 376 376 380 379 379 376 380 386 386 386 386 386 380 389 389 386 392 392 389 394 380 396 394|395 394 394|395 396 380	Association
19373123	Chemical	Gene	D008691	1813	True	0	What is [PHARMGKB] between @ChemicalSrc$ methadone @/ChemicalSrc$ and @GeneTgt$ DRD2 @/GeneTgt$ ? [SEP] Genetic variants altering @GeneTgt$ dopamine D2 receptor @/GeneTgt$ expression or function modulate the risk of opiate addiction and the dosage requirements of @ChemicalSrc$ methadone @/ChemicalSrc$ substitution . AIM : Addictive behavior is importantly mediated by mesolimbic dopaminergic signaling . Here , we comprehensively analyzed the @GeneTgt$ DRD2 @/GeneTgt$ gene locus , and in addition , the ANKK1 rs1800497C&gt;T single nucleotide polymorphism ( SNP ) , formerly known as ' @GeneTgt$ dopamine D2 receptor @/GeneTgt$ Taq1A C&gt;T polymorphism ' , for associations with the risk of opiate addiction and the @ChemicalSrc$ methadone @/ChemicalSrc$ dosage requirements . METHODS : Allelic frequencies of @GeneTgt$ DRD2/ANKK1 @/GeneTgt$ polymorphisms were compared between 85 @ChemicalSrc$ methadone-substituted @/ChemicalSrc$ Caucasian patients and a random sample of 99 healthy Caucasian controls . Within patients , the average and maximum daily @ChemicalSrc$ methadone @/ChemicalSrc$ dose during the first year of treatment and the time when that maximum dose was reached were analyzed for an association with @GeneTgt$ DRD2/ANKK1 @/GeneTgt$ genetics . RESULTS : Compared with the control group , drug users carried more frequently the minor allele of @GeneTgt$ DRD2 @/GeneTgt$ SNP rs1076560G&gt;T SNP ( P=0.022 , odds ratio 2.343 ) or the ATCT haplotype of @GeneTgt$ DRD2 @/GeneTgt$ rs1799978A&gt;G , rs1076560G&gt;T , rs6277C&gt;T , ANKK1 rs1800497C&gt;T ( P=0.048 , odds ratio 2.23 ) , with similar tendencies for ANKK1 rs1800497C&gt;T ( P=0.056 , odds ratio 2.12 ) and the TCCTCTT haplotype of @GeneTgt$ DRD2 @/GeneTgt$ rs12364283T&gt;C , rs1799732C del , rs4648317C&gt;T , rs1076560G&gt;T , rs6275C&gt;T , rs6277C&gt;T , and ANKK1 rs1800497C&gt;T ( P=0.059 , odds ratio 2.31 ) . The average and maximum daily @ChemicalSrc$ methadone @/ChemicalSrc$ doses were significantly associated with the @GeneTgt$ DRD2 @/GeneTgt$ rs6275C&gt;T SNP ( P=0.016 and 0.005 for average and maximum dose , respectively ) . Carriers of the variant rs6275 T allele needed higher @ChemicalSrc$ methadone @/ChemicalSrc$ doses than noncarriers . In addition , this variant was associated with a longer time to reach the maximum @ChemicalSrc$ methadone @/ChemicalSrc$ dose ( P=0.025 ) . CONCLUSION : On the basis of an analysis spanning the whole gene locus , from the @GeneTgt$ DRD2 @/GeneTgt$ promoter to the ANKK1 rs1800497C&gt;T polymorphism , @GeneTgt$ DRD2 @/GeneTgt$ genetic polymorphisms modulate both the risk of opiate addiction , leading to the necessity of @ChemicalSrc$ methadone @/ChemicalSrc$ substitution therapy , and the course of this therapy in terms of dosage requirements .	2 11 2 8|3|4 8|3|4 8|3|4 8|4 8|3|4 3 8 8 11 13 11 16 16 13 13 20 20 13 24 24|18 24 24|18 20 11 28 28 31 34 34 34 28 38 38 38 34 34 44 44 44 44 44 49 49|45 49 49|45 49 44 49 49 53 60 60 60 60 60 60 60 49 62 60 62 60 66 60 75 75 67|75 67|75 67|75 75 67|75 75 75 66 60 60 79 60 82 82 79 85 85 82 82 91 83|91 91 83|91 91 82 44 96 96 99 105 103 103|100 103 103|100 99 105 96 111 111 111|106 111 111|106 111 105 111 115 115 111 120 120 120 120 115 105 125 151 151 128 126 128 128 134 131|134 134 131|134 128 138 138 138 128 140 138 138 143 151 149 147 147 149 149 143 151 151 154 154 151 158 158|154 158 158|154 154 151 172 162 168 168 168 168 172 172 171 172 172 174 172 177 177 172 183 178|181 181 178|181 183 183 177 185 183 185 188 185 188 185 183 194 194 183 198 194|198 198 194|198 194 198 198 198 198 202 205 202 207 205 207 210 207 210 207 177 216 216 177 219 219 216 221 219 221 224 221 224 221 219 230 230 219 234 234|229 234 234|229 230 234 237 234 237 219 219 219 219 219 243 243 243 219 249 219 251 249 251 254 251 254 251 172 268 268 262 262 266 268|265 268 268|265 271 271 271 271 277 277 277|272 277 277|272 277 271 279 277 279 279 286 286 283 283 279 286 286 279 271 300 299 299 299 299 299 293 300 304 301|304 304 301|304 300 306 304 300 310 315 315 313 315 315 315 319 319 319 315 321 315 326 326 326|323 326 326|323 321 328 326 328 315 332 361 336 336 361 339 339 336 339 344 344 344 340 344 350 350 347|350 350 347|350 344 355 355 355 355 340 361 355|359 359 355|359 360 361 332 364 364 361 367 367 364 361 361 372 372 369 377 371|377 377 371|377 377 372 361 361 381 332 384 384 381 386 381 389 389 386 332	Association
19396436	Chemical	Gene	D000077487	1814	True	0	What is [PHARMGKB] between @ChemicalSrc$ pramipexole @/ChemicalSrc$ and @GeneTgt$ DRD3 @/GeneTgt$ ? [SEP] Association of the DRD2 and @GeneTgt$ DRD3 @/GeneTgt$ polymorphisms with response to @ChemicalSrc$ pramipexole @/ChemicalSrc$ in Parkinson 's disease patients . OBJECTIVE : To evaluate the impact of the DRD2 TaqIA and @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly polymorphisms on the efficacy of @ChemicalSrc$ pramipexole @/ChemicalSrc$ in treating patients with Parkinson 's disease ( PD ) . METHODS : Thirty patients with PD prospectively received @ChemicalSrc$ pramipexole @/ChemicalSrc$ 0.25 mg three times daily for 2 months . Unified Parkinson Disease Rating Scale ( UPDRS ) assessments were conducted at baseline and 2 months after treatment initiation . Improvement by 20 % or more in the total score on the UPDRS was considered to indicate responsiveness . The PCR-restriction fragment length polymorphism analysis was used to analyze the DRD2 Taq1A and @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly genotype . RESULTS : The DRD2 Taq1A allele frequencies were A141.7 ( A1 ) and 58.3 % ( A2 ) , and the @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly allele frequencies were 68.3 ( Ser ) and 31.7 % ( Gly ) . When the subjects were grouped by the @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly polymorphism , the response rates for @ChemicalSrc$ pramipexole @/ChemicalSrc$ treatment were significantly higher in the Ser/Ser group ( 60 % ) than in the group containing the Gly allele ( 13 % ) . There was a significant association between the @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly polymorphism and response rate to @ChemicalSrc$ pramipexole @/ChemicalSrc$ in PD patients ( P = 0.024 ) . When the subjects were grouped by the DRD2 Taq1A polymorphism , there were no significant differences among the three Taq1A genotypes . CONCLUSIONS : @GeneTgt$ DRD3 @/GeneTgt$ Ser9Gly polymorphisms are significantly associated with the therapeutic efficacy of @ChemicalSrc$ pramipexole @/ChemicalSrc$ in Chinese patients with PD . A large-scale and multi-dose group study in patients with PD is necessary for evaluating the impact of the genetic polymorphisms of the dopamine receptor on the therapeutic effects of @ChemicalSrc$ pramipexole @/ChemicalSrc$ .	1 8 8 8 4 4|5 4 4|5 1 10 1 12 10 10 10 18 18 15 18 12 1 22 22 25 22 27 25 36 36 31 36 31 31|32 31 31|32 36 27 39 39 27 41 39 39 39 44 39 44 49 49 47 45 51 49 51 22 63 63 59 63 61 59 63 63 63 63 63 67 64 69 70 67 73 73 63 63 80 80 80 80 84 82 84 82 86 86 86 88 86 88 91 88 94 94 86 86 110 99 99 96 99 99 105 105 105 99 108 108 105 110 110 112 110 112 110 120 120 120 120 120 122 122 122 124 122 132 127 132 127 127|128 127 127|128 132 124 122 135 135 141 141 141 141 143 143 135 145 143 145 143 149 143 151 149 151 149 143 160 159|155 159 159|155 159 160 164 164 164 164 143 164 143 168 143 170 168 170 135 178 176 178 178 195 184 184 184|180 184 184|180 184 178 195 188 188 195 192 192|188 192 192|188 188 195 195 195 199 199 199 195 202 202 199 202 207 207 207 195 207 211 211 208 214 214 195 214 195 220 220 223 223 220 229 229 229|225 229 229|225 229 223 229 232 229 234 223|232 223 223|232 238 238 234 241 241 223 241 241 220 251 249 251 251 259 256 256 256 256 251 259 259 259 262 262 259 267 267 267 267 262 259 269 269 270|274 274 270|274 274 277 277 277 269 281 281 281 277 283 281 281 281 287 287 283 289 287 269 298 298 294 294 298 304 300 298 302 300 304 304 306 304 308 306 312 312 312 308 316 316 316 312 320 320 320 308 322 320|321 320 320|321 304	Association
19448608	Chemical	Gene	D004317	1535	True	0	What is [PHARMGKB] between @ChemicalSrc$ doxorubicin @/ChemicalSrc$ and @GeneTgt$ CYBA @/GeneTgt$ ? [SEP] Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 . Knowledge on the impact of pharmacogenetics in predicting outcome and toxicity in diffuse large B-cell lymphoma ( DLBCL ) is scant . We tested 106 consecutive DLBCL treated with R-CHOP21 for 19 single nucleotide polymorphisms ( SNPs ) from 15 genes potentially relevant to rituximab-CHOP ( R-CHOP ) pharmacogenetics . Associations of SNPs with event-free survival ( EFS ) and toxicity were controlled for multiple testing . Genotypic variants of nicotinamide adenine dinucleotide phosphate ( NAD(P)H ) oxidase @GeneTgt$ p22phox @/GeneTgt$ ( @GeneTgt$ CYBA @/GeneTgt$ rs4673 ) and alpha1 class glutathione S-transferase ( GSTA1 rs3957357 ) were independent predictors of EFS ( @GeneTgt$ CYBA @/GeneTgt$ rs4673 TT genotype : HR 2.06 , P=0.038 ; GSTA1 rs3957357 CT/TT genotypes : HR 0.38 , P=0.003 ) , after adjusting for International Prognostic Index ( IPI ) . @GeneTgt$ CYBA @/GeneTgt$ rs4673 and GSTA1 rs3957357 also predicted outcome in DLBCL subgroups by IPI . Impact of SNPs on toxicity was evaluated in 658 R-CHOP21 courses utilizing generalized estimating equations . NCF4 rs1883112 was an independent predictor against hematologic ( odds ratios ( OR ): 0.45 ; P=0.018 ) , infectious ( OR : 0.46 ; P=0.003 ) and cardiac toxicity ( OR : 0.37 ; P=0.023 ) . Overall , host SNPs affecting @ChemicalSrc$ doxorubicin @/ChemicalSrc$ pharmacodynamics ( @GeneTgt$ CYBA @/GeneTgt$ rs4673 ) and alkylator detoxification ( GSTA1 rs3957357 ) may predict outcome in R-CHOP21-treated DLBCL . Also , NCF4 rs1883112 , a SNP of NAD(P)H oxidase p40phox , may have a function in protecting against hematologic and nonhematologic toxicity . These results highlight the need to improve characterization of the host genetic background for a better prognostication of DLBCL .	1 6 6 6 6 1 8 6 10 8 10 10 17 17 17 17 10 17 20 18 1 42 25 25 22 27 25 29 25 29 30 30 37 37 37 37 30 39 37 39 42 42 42 45 45 48 48 45 48 51 49 56 56 56 56 49 58 56 58 62 62 56 64 62 70 70 68 66 68 64 45 84 74 72 77 77 72 79 77 79 77 77 84 84 87 87 84 84 90 118 95 95 95 95 100 100 100 100 100 90|99 90 90|99 105 105|101 105 105|101 100 105 100 111 111 111 100 113 111 113 113 118 118 118 120 118 126 126|119 126 126|119 126 126 120 126 136 128 128 128 128 128 136 136 126 136 136 138 138 138 138 118 145 118 149 149 149 145 151 149 149 118 156|159 159 156|159 164 159 159 159 164 164 164 168 168 165 170 165 164 179 175 173 177 173 179 179 183 183 183 179 183 187 187 184 179 190 194 194 194 194 194 196 194 199 199 196 201 205 201 201 205 199 205 199 196 212 212 212 208 212 212 214 212 218 196 222 222 222 218 222 222 222 194 248 248 230 248 230 234|231 234 234|231 231 238 234|238 238 234|238 234 238 234 242 234 245 245 242 245 248 248 248 252 252 249 248 269 269 259 269 259 262 259 266 266 266 262 259 269 269 271 269 273 271 278 278 275 275 273 269 281 282 282 284 282 286 284 286 292 292 292 292 287 296 296 296 286 298 296 282	Association
19448608	Chemical	Gene	D004317	4689	False	1	What is [PHARMGKB] between @ChemicalSrc$ doxorubicin @/ChemicalSrc$ and @GeneTgt$ p40phox @/GeneTgt$ ? [SEP] Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 . Knowledge on the impact of pharmacogenetics in predicting outcome and toxicity in diffuse large B-cell lymphoma ( DLBCL ) is scant . We tested 106 consecutive DLBCL treated with R-CHOP21 for 19 single nucleotide polymorphisms ( SNPs ) from 15 genes potentially relevant to rituximab-CHOP ( R-CHOP ) pharmacogenetics . Associations of SNPs with event-free survival ( EFS ) and toxicity were controlled for multiple testing . Genotypic variants of nicotinamide adenine dinucleotide phosphate ( NAD(P)H ) oxidase p22phox ( CYBA rs4673 ) and alpha1 class glutathione S-transferase ( GSTA1 rs3957357 ) were independent predictors of EFS ( CYBA rs4673 TT genotype : HR 2.06 , P=0.038 ; GSTA1 rs3957357 CT/TT genotypes : HR 0.38 , P=0.003 ) , after adjusting for International Prognostic Index ( IPI ) . CYBA rs4673 and GSTA1 rs3957357 also predicted outcome in DLBCL subgroups by IPI . Impact of SNPs on toxicity was evaluated in 658 R-CHOP21 courses utilizing generalized estimating equations . @GeneTgt$ NCF4 @/GeneTgt$ rs1883112 was an independent predictor against hematologic ( odds ratios ( OR ): 0.45 ; P=0.018 ) , infectious ( OR : 0.46 ; P=0.003 ) and cardiac toxicity ( OR : 0.37 ; P=0.023 ) . Overall , host SNPs affecting @ChemicalSrc$ doxorubicin @/ChemicalSrc$ pharmacodynamics ( CYBA rs4673 ) and alkylator detoxification ( GSTA1 rs3957357 ) may predict outcome in R-CHOP21-treated DLBCL . Also , @GeneTgt$ NCF4 @/GeneTgt$ rs1883112 , a SNP of NAD(P)H oxidase @GeneTgt$ p40phox @/GeneTgt$ , may have a function in protecting against hematologic and nonhematologic toxicity . These results highlight the need to improve characterization of the host genetic background for a better prognostication of DLBCL .	1 6 6 6 6 1 8 6 10 8 10 10 17 17 17 17 10 17 20 18 1 42 25 25 22 27 25 29 25 29 30 30 37 37 37 37 30 39 37 39 42 42 42 45 45 48 48 45 48 51 49 56 56 56 56 49 58 56 58 62 62 56 64 62 70 70 68 66 68 64 45 84 74 72 77 77 72 79 77 79 77 77 84 84 87 87 84 84 90 116 95 95 95 95 100 100 100 100 100 90 103 103 100 103 100 109 109 109 100 111 109 111 111 116 116 116 118 116 123 123 123 123 118 123 133 125 125 125 125 125 133 133 123 133 133 135 135 135 135 116 142 116 146 146 146 142 148 146 146 116 152 157 152 152 152 157 157 157 161 161 158 163 158 157 171 167 165 169 165 171 171 175 175 175 171 175 179 179 176 171 180|183 183 180|183 187 187 187 187 187 189 187 192 192 189 194 198 194 194 198 192 198 192 189 205 205 205 201 205 205 207 205 211 189 215 215 215 211 215 215 215 187 241 241 224 241 224 228|225 228 228|225 225 231 231 228 231 228 235 228 238 238 235 238 241 241 241 245 245 242 241 263 263 249|252 252 249|252 263 252 255 252 259 259 259 255|257 255 255|257 252 263 263 265 263 267 265 272 272 269 269 267 263 277 278 278 280 278 282 280 282 288 288 288 288 283 292 292 292 282 294 292 278	Association
19590397	Chemical	Gene	D017374	3362	False	1	What is [PHARMGKB] between @ChemicalSrc$ paroxetine @/ChemicalSrc$ and @GeneTgt$ HTR6 @/GeneTgt$ ? [SEP] 5-HTR1A , 5-HTR2A , @GeneTgt$ 5-HTR6 @/GeneTgt$ , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , @GeneTgt$ HTR6 @/GeneTgt$ ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine , @ChemicalSrc$ paroxetine @/ChemicalSrc$ or citalopram . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1 1 1|4 1 1|4 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63 70 68 70 70 70 70 70 63 63|76 63 63|76 80 77 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116 121 121|122 121 121|122 121 121 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19590397	Chemical	Gene	D017374	3356	False	1	What is [PHARMGKB] between @ChemicalSrc$ paroxetine @/ChemicalSrc$ and @GeneTgt$ HTR2A @/GeneTgt$ ? [SEP] 5-HTR1A , @GeneTgt$ 5-HTR2A @/GeneTgt$ , 5-HTR6 , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , @GeneTgt$ HTR2A @/GeneTgt$ ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine , @ChemicalSrc$ paroxetine @/ChemicalSrc$ or citalopram . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1|2 1 1|2 1 1 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63|67 63 63|67 71 68 71 71 71 71 71 63 63 80 78 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116 121 121|122 121 121|122 121 121 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19590397	Chemical	Gene	D015283	3356	False	1	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ HTR2A @/GeneTgt$ ? [SEP] 5-HTR1A , @GeneTgt$ 5-HTR2A @/GeneTgt$ , 5-HTR6 , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , @GeneTgt$ HTR2A @/GeneTgt$ ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine , paroxetine or @ChemicalSrc$ citalopram @/ChemicalSrc$ . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1|2 1 1|2 1 1 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63|67 63 63|67 71 68 71 71 71 71 71 63 63 80 78 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116 121 121 121 121|124 121 121|124 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	None-PHARMGKB
19590397	Chemical	Gene	D005473	121278	False	1	What is [PHARMGKB] between @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and @GeneTgt$ TPH2 @/GeneTgt$ ? [SEP] 5-HTR1A , 5-HTR2A , 5-HTR6 , TPH1 and @GeneTgt$ TPH2 @/GeneTgt$ polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and @GeneTgt$ TPH2 @/GeneTgt$ ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with @ChemicalSrc$ fluoxetine @/ChemicalSrc$ , paroxetine or citalopram . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1 1 1 1 1 7 8|7 7 8|7 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63 70 68 70 70 70 70 70 63 63 79 77 79 63 63 84 82 84 63 86|63 63 86|63 90 87 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116|120 116 116|120 121 121 121 121 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19590397	Chemical	Gene	D015283	3362	False	1	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ HTR6 @/GeneTgt$ ? [SEP] 5-HTR1A , 5-HTR2A , @GeneTgt$ 5-HTR6 @/GeneTgt$ , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , @GeneTgt$ HTR6 @/GeneTgt$ ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine , paroxetine or @ChemicalSrc$ citalopram @/ChemicalSrc$ . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1 1 1|4 1 1|4 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63 70 68 70 70 70 70 70 63 63|76 63 63|76 80 77 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116 121 121 121 121|124 121 121|124 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19590397	Chemical	Gene	D017374	121278	False	1	What is [PHARMGKB] between @ChemicalSrc$ paroxetine @/ChemicalSrc$ and @GeneTgt$ TPH2 @/GeneTgt$ ? [SEP] 5-HTR1A , 5-HTR2A , 5-HTR6 , TPH1 and @GeneTgt$ TPH2 @/GeneTgt$ polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and @GeneTgt$ TPH2 @/GeneTgt$ ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine , @ChemicalSrc$ paroxetine @/ChemicalSrc$ or citalopram . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1 1 1 1 1 7 8|7 7 8|7 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63 70 68 70 70 70 70 70 63 63 79 77 79 63 63 84 82 84 63 86|63 63 86|63 90 87 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116 121 121|122 121 121|122 121 121 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19590397	Chemical	Gene	D015283	3350	False	1	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ HTR1A @/GeneTgt$ ? [SEP] @GeneTgt$ 5-HTR1A @/GeneTgt$ , 5-HTR2A , 5-HTR6 , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ @GeneTgt$ HTR1A @/GeneTgt$ ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine , paroxetine or @ChemicalSrc$ citalopram @/ChemicalSrc$ . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	0|11 11 0|11 1 1 1 1 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61|62 61 61|62 66 63 66 63 63 71 69 71 71 71 71 71 63 63 80 78 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116 121 121 121 121|124 121 121|124 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19590397	Chemical	Gene	D005473	3350	False	1	What is [PHARMGKB] between @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and @GeneTgt$ HTR1A @/GeneTgt$ ? [SEP] @GeneTgt$ 5-HTR1A @/GeneTgt$ , 5-HTR2A , 5-HTR6 , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ @GeneTgt$ HTR1A @/GeneTgt$ ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with @ChemicalSrc$ fluoxetine @/ChemicalSrc$ , paroxetine or citalopram . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	0|11 11 0|11 1 1 1 1 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61|62 61 61|62 66 63 66 63 63 71 69 71 71 71 71 71 63 63 80 78 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116|120 116 116|120 121 121 121 121 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	None-PHARMGKB
19590397	Chemical	Gene	D015283	121278	False	1	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ TPH2 @/GeneTgt$ ? [SEP] 5-HTR1A , 5-HTR2A , 5-HTR6 , TPH1 and @GeneTgt$ TPH2 @/GeneTgt$ polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and @GeneTgt$ TPH2 @/GeneTgt$ ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine , paroxetine or @ChemicalSrc$ citalopram @/ChemicalSrc$ . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1 1 1 1 1 7 8|7 7 8|7 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63 70 68 70 70 70 70 70 63 63 79 77 79 63 63 84 82 84 63 86|63 63 86|63 90 87 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116 121 121 121 121|124 121 121|124 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19590397	Chemical	Gene	D017374	3350	False	1	What is [PHARMGKB] between @ChemicalSrc$ paroxetine @/ChemicalSrc$ and @GeneTgt$ HTR1A @/GeneTgt$ ? [SEP] @GeneTgt$ 5-HTR1A @/GeneTgt$ , 5-HTR2A , 5-HTR6 , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ @GeneTgt$ HTR1A @/GeneTgt$ ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine , @ChemicalSrc$ paroxetine @/ChemicalSrc$ or citalopram . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	0|11 11 0|11 1 1 1 1 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61|62 61 61|62 66 63 66 63 63 71 69 71 71 71 71 71 63 63 80 78 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116 121 121|122 121 121|122 121 121 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	None-PHARMGKB
19590397	Chemical	Gene	D005473	3362	False	1	What is [PHARMGKB] between @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and @GeneTgt$ HTR6 @/GeneTgt$ ? [SEP] 5-HTR1A , 5-HTR2A , @GeneTgt$ 5-HTR6 @/GeneTgt$ , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , HTR2A ( rs6313 , rs6311 and rs7997012 ) , @GeneTgt$ HTR6 @/GeneTgt$ ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with @ChemicalSrc$ fluoxetine @/ChemicalSrc$ , paroxetine or citalopram . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1 1 1|4 1 1|4 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63 70 68 70 70 70 70 70 63 63|76 63 63|76 80 77 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116|120 116 116|120 121 121 121 121 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19590397	Chemical	Gene	D005473	3356	False	1	What is [PHARMGKB] between @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and @GeneTgt$ HTR2A @/GeneTgt$ ? [SEP] 5-HTR1A , @GeneTgt$ 5-HTR2A @/GeneTgt$ , 5-HTR6 , TPH1 and TPH2 polymorphisms and major depression . Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors . In this study , we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [ HTR1A ( rs6295 ) , @GeneTgt$ HTR2A @/GeneTgt$ ( rs6313 , rs6311 and rs7997012 ) , HTR6 ( rs1805054 ) , TPH1 ( rs1800532 ) and TPH2 ( rs1386494 ) ] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors . Patients who met the criteria for major depressive disorder were treated for 6 weeks with @ChemicalSrc$ fluoxetine @/ChemicalSrc$ , paroxetine or citalopram . The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale , and according to predefined response criteria , the patients were divided into responders , nonresponders , remitters and nonremitters . Altogether , 86 patients completed the entire study according to the study protocol . We had also a control population ( N = 395 ) of healthy blood donors . None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals .	11 1 1|2 1 1|2 1 1 1 1 8 8 11 11 14 11 11 26 19 17 23 23 23 19 26 26 26 28 26 31 31 28 34 34 31 28 40 40 40 40 26 44 44 44 40 26 48 48 51 51 51 51 53 51 57 57 57 53 51 61 61 58 63 61 65 63 65 63 63|67 63 63|67 71 68 71 71 71 71 71 63 63 80 78 80 63 63 85 83 85 63 63 90 88 90 63 96 96 96 61 96 99 96 103 103 103 99 51 116 108 106 110 108 114 114 114 110 116 116 119 119 116 121 116|120 116 116|120 121 121 121 121 116 131 131 133 133 133 139 139 137 139 139 133 133 133 146 142 146 146 151 151 149 151 151 133 153 151 153 153 155 155 157 157 133 165 165 164 165 165 168 168 165 173 169 173 173 165 165 180 180 180 180 180 180 182 180 182 183 182 189 189 189 180 180 199 197 197 197 197 197 191 199 199 203 203 203 199 203 207 207 203 211 211 211 207 214 214 211 199	Association
19622037	Chemical	Gene	D000077152	5468	True	0	What is [PHARMGKB] between @ChemicalSrc$ olanzapine @/ChemicalSrc$ and @GeneTgt$ PPAR-gamma @/GeneTgt$ ? [SEP] The association of @ChemicalSrc$ olanzapine-induced @/ChemicalSrc$ weight gain with @GeneTgt$ peroxisome proliferator-activated receptor-gamma2 @/GeneTgt$ Pro12Ala polymorphism in patients with schizophrenia . @ChemicalSrc$ Olanzapine @/ChemicalSrc$ is a second-generation antipsychotic that may cause weight gain and metabolic syndrome in some cases . The @GeneTgt$ peroxisome proliferator-activated receptor (PPAR)-gamma @/GeneTgt$ is an important gene in the progress of type II diabetes and metabolic syndrome . In recent studies the polymorphism of the @GeneTgt$ PPAR-gamma @/GeneTgt$ has been studied in type II diabetes mellitus , polycystic ovary syndrome , and insulin resistance syndrome . It is aimed to evaluate the association between polymorphism of @GeneTgt$ PPAR-gamma @/GeneTgt$ gene and @ChemicalSrc$ olanzapine-induced @/ChemicalSrc$ weight gain . Our study comprised 95 unrelated subjects who strictly met Diagnostic and Statistical Manual of Mental Disorders , 4th edition ( DSM-IV ) criteria for schizophrenia , and all were of Turkish origin . All patients were evaluated with rating scales , and genetic analyses were performed . We found statistically significant differences between pretreatment and posttreatment body mass index and weight change in Pro12Ala polymorphism of PPAR-gamma2 . Our results suggest that genetic polymorphism of PPAR might be important in @ChemicalSrc$ olanzapine-induced @/ChemicalSrc$ weight gain and that genetic variance of people might be considered in antipsychotic medication selection .	2 2 7 3|7 7 3|7 7 2 14 14|7 14|7 14|7 14 14|7 14 7 16 14 18 16 2 21|27 27 21|27 27 27 27 27 30 30 27 32 30 32 35 32 38 38 30 27 42 41|42|50 41|42|50 41|42|50 41|42|50 42|50 41|42|50 50 50 50 50 53 53 50 57 57 57 53 57 60 57 50 65 65 74 67 74 70 70 67|69 67 67|69 74 74 74 79 79 79 79 74 79 83 83 79 79 79 88 88 79 74 93 93 93 95 93 97 95 99 97 103 100|103 103 100|103 99 103 108|103 108 108|103 108 103 93 113 114 114 117 117 114 120 120 117 124 121 121 120 127 127 124 127 130 134 132 134 134 124 136 134 134 134 134 143 143 143 114 114 146 148 148 148 151 151 148 151 151 155 157 157 148 157 160 160 162 163 160 165 163 165 165 170 170 165 170 173 170 176 176 165 178 176 160 181 182 182 190 185 190 187 185 190 190 182 195 195|191 195 195|191 195 190 190 204 199 204 201 199 204 204 190 208 208 208 204 182	Association
19636336	Chemical	Gene	D017374	133	True	0	What is [PHARMGKB] between @ChemicalSrc$ paroxetine @/ChemicalSrc$ and @GeneTgt$ ADM @/GeneTgt$ ? [SEP] Association of a functional polymorphism in the @GeneTgt$ adrenomedullin @/GeneTgt$ gene ( @GeneTgt$ ADM @/GeneTgt$ ) with response to @ChemicalSrc$ paroxetine @/ChemicalSrc$ . To identify genes that may be relevant to the molecular action of antidepressants , we investigated transcriptional changes induced by the selective serotonin reuptake inhibitor @ChemicalSrc$ paroxetine @/ChemicalSrc$ in a serotonergic cell line . We examined gene expression changes after acute treatment with @ChemicalSrc$ paroxetine @/ChemicalSrc$ and sought to validate microarray results by quantitative PCR ( qPCR ) . Concordant transcriptional changes were confirmed for 14 genes by qPCR and five of these , including the @GeneTgt$ adrenomedullin @/GeneTgt$ gene ( @GeneTgt$ Adm @/GeneTgt$ ) , either approached or reached statistical significance . Reporter gene assays showed that a SNP ( rs11042725 ) in the upstream flanking region of @GeneTgt$ ADM @/GeneTgt$ significantly altered expression . Association analysis demonstrated rs11042725 to be significantly associated with response to @ChemicalSrc$ paroxetine @/ChemicalSrc$ ( odds ratio=0.075 , P&lt;0.001 ) but not with response to either fluoxetine or citalopram . Our results suggest that @GeneTgt$ ADM @/GeneTgt$ is involved with the therapeutic efficacy of @ChemicalSrc$ paroxetine @/ChemicalSrc$ , which may have pharmacogenetic utility .	1 5 5 5 1 10 10 10|7 10 10|7 5 12 10 10 10 12 16 1 18 16|15 16 16|15 1 25 39 25 30 30 30 26 34 34 34 30 36 34 39 39 39 41 39 41 49 49 49 49 49 49 48|42 42 48|42 55 55 55 55 42 39 59 59 61 62 59 65 65 62 67 65|66 65 65|66 59 59 72 70 74 72 77 77 72 79 77 79 59 85 85 87 87 87 90 90 87 92 87 87 109 96 94 96 102 102 99|102 102 99|102 96 104 102 102 102 104 102 109 87 109 109 113 111 87 119 119 120 120 136 123 136 125 123 125 131 131 131 131 123 133 132|131 131 132|131 136 120 136 120 141 142 142 142 147 147 147 142 149 147 151 149|150 149 149|150 154 149 154 154 154 154 149 162 162 149 165 165 162 165 165 142 171 172 172 177 177|173 177 177|173 177 172 181 181 181 177 183 181 181 181 183 188 188 183 190 188 172	Association
19644963	Chemical	Gene	D009538	1129	True	0	What is [PHARMGKB] between @ChemicalSrc$ nicotine @/ChemicalSrc$ and @GeneTgt$ CHRM2 @/GeneTgt$ ? [SEP] Association of a variant in the muscarinic acetylcholine receptor 2 gene ( @GeneTgt$ CHRM2 @/GeneTgt$ ) with @ChemicalSrc$ nicotine @/ChemicalSrc$ addiction . Genetic factors contribute to the overall risk of developing @ChemicalSrc$ nicotine @/ChemicalSrc$ addiction , which is the major cause of preventable deaths in western countries . However , knowledge regarding specific polymorphisms influencing smoking phenotypes remains scarce . In the present study we provide evidence that a common single nucleotide polymorphism ( SNP ) in the 5 ' untranslated region of @GeneTgt$ CHRM2 @/GeneTgt$ , the gene coding for the muscarinic acetylcholine receptor 2 is associated with @ChemicalSrc$ nicotine @/ChemicalSrc$ addiction . @GeneTgt$ CHRM2 @/GeneTgt$ was defined as a candidate gene for @ChemicalSrc$ nicotine @/ChemicalSrc$ addiction based on previous evidence that linked variations in @GeneTgt$ CHRM2 @/GeneTgt$ to alcohol and drug dependence . A total of more than 5,500 subjects representative of the German population were genotyped and assessed regarding their smoking habits . The impact of three SNPs in @GeneTgt$ CHRM2 @/GeneTgt$ on smoking @ChemicalSrc$ behavior/nicotine @/ChemicalSrc$ addiction was investigated using logistic regression models or a quasi-Poisson regression model , respectively . We found the T allele of SNP rs324650 to be associated with an increased risk of @ChemicalSrc$ smoking/nicotine @/ChemicalSrc$ dependence according to three different models , the recessive models of regular or heavy smokers vs. never-smokers ( odds ratio 1.17 in both analyses ) and according to the Fagerstrom index of @ChemicalSrc$ nicotine @/ChemicalSrc$ addiction . In the analysis stratified by gender this association was only found in females . Our data provide further evidence that variations in @GeneTgt$ CHRM2 @/GeneTgt$ may be associated with the genetic risk of addiction in general or with certain personality traits that predispose to the development of addiction . Alternatively , variations in @GeneTgt$ CHRM2 @/GeneTgt$ could modulate presynaptic auto-regulation in cholinergic systems and may thereby affect an individual 's response to @ChemicalSrc$ nicotine @/ChemicalSrc$ more specifically .	1 4 4 1 11 11 11 11 11 11 4 13 11|12 11 11|12 13 19 19|15 19 19|15 1 1 24 25 25 29 29 29 25 31 29 31|34 34 31|34 31 34 40 40 40 40 34 43 43 40 46 46 43 25 58 58 58 54 54 51 54 57 55 58 58 58 64 64 64 66 66 66 66 97 73 73 73 73 97 75 73 75 82 82 82 82 82 73 84 82|83 82 82|83 84 88 84 88 94 94 94 94 89 94 97 67 101 101|97 101 101|97 97 66 104|108 108 104|108 108 108 112 112 112 108 116 112|116 116 112|116 112 120 120 120 108 122 120 122 125 122|123 123 122|123 128 123 128 128 128 108 137 149 142 141 141 142 137 142 147 147 147 143 149 149 149 149 155 155 155 151 149 158 171 161 161 158 163 161|162 161 161|162 166 158 165|169 169 165|169 166 171 171 171 175 175 172 175 180 180 180 175 180 172 171 187 187 190 190 187 193 193 190 196 196 187 200 200 200 196 204 201|204 204 201|204 200 209 205 209 209 200 209 213 213 209 218 218 215 215 213 218 218 223 223 209 223 227 227 223 223 209 234 230 234 234 209 238 234|238 238 234|238 234 187 244 244 252 244 247 245 249 252 252 252 252 254 252 252 257 258 258 260 258 268 268 264 263|262 262 263|262 268 268 260 272 272 272 268 274 272 276 274 276 281 281 281 272 283 281 286 286 283 288 286 258 298 298 298 295 293|294 293 293|294 298 298 300 298 303 303 300 298 307 307 298 309 311 311 307 313 311 311 311 316 307 298	Association
19842935	Chemical	Gene	D000077340	9429	True	0	What is [PHARMGKB] between @ChemicalSrc$ fluvastatin @/ChemicalSrc$ and @GeneTgt$ ABCG2 @/GeneTgt$ ? [SEP] Different effects of the @GeneTgt$ ABCG2 @/GeneTgt$ c.421C&gt;A SNP on the pharmacokinetics of @ChemicalSrc$ fluvastatin @/ChemicalSrc$ , pravastatin and simvastatin . AIMS : This study aimed to investigate possible effects of the @GeneTgt$ ABCG2 @/GeneTgt$ c.421C&gt;A ( p. Gln141Lys ; rs2231142 ) genotype on @ChemicalSrc$ fluvastatin @/ChemicalSrc$ , pravastatin and simvastatin pharmacokinetics . MATERIALS & amp ; METHODS : In a crossover study , five healthy volunteers with the @GeneTgt$ ABCG2 @/GeneTgt$ c.421A/A genotype , four with the c.421C/A genotype and 23 with the c.421C/C genotype ingested a single 40-mg dose of @ChemicalSrc$ fluvastatin @/ChemicalSrc$ , pravastatin and simvastatin , with a washout period of 1 week . Plasma statin concentrations were measured up to 12 h. RESULTS : The estimated marginal mean area under the plasma concentration-time curve from 0 h to infinity ( AUC(0-infinity ) ) of @ChemicalSrc$ fluvastatin @/ChemicalSrc$ was 97 % ( p = 0.015 ) or 72 % ( p = 0.009 ) larger in participants with the A/A genotype than in those with the C/A or C/C genotype . The AUC(0-infinity ) of simvastatin lactone was 111 % ( p = 0.005 ) larger in participants with the A/A genotype than in participants with the C/C genotype . The simvastatin acid : lactone AUC(0-infinity ) ratio was 46 % ( p = 0.017 ) smaller in individuals with the A/A genotype than in those with the C/C genotype . The @GeneTgt$ ABCG2 @/GeneTgt$ genotype had no significant effect on simvastatin acid or pravastatin pharmacokinetics . CONCLUSIONS : Genetic variability in @GeneTgt$ ABCG2 @/GeneTgt$ markedly affects the pharmacokinetics of @ChemicalSrc$ fluvastatin @/ChemicalSrc$ and simvastatin lactone , but has no significant effect on pravastatin or active simvastatin acid . Genotyping for @GeneTgt$ ABCG2 @/GeneTgt$ in addition to SLCO1B1 and ABCB1 polymorphisms could help in predicting statin pharmacokinetics when selecting a statin and its dose for an individual patient .	2 2 5 5 8|4 8 8|4 8 2 11 11 2 13 11 11 11 13 13 13 13 2 22 25 25 22 25 28 26 30 28 33 33 32|35 35 32|35 42 38 38 42 38 38 40 30 44 42 42 42 44 44 44 50 44 22 54 54 54 54 54 54 63 63 63 86 86 67 67 86 73 73 69|72 72 69|72 73 67 86 86 79 79 79 75 75 75 85 85 85 75 54 90 90 90 86 92 90 90 90 92 92 92 92 86 102 102 102 86 105 105 102 86 111 111 113 113 113 116 116 118 118 113 113 124 124 124 124 113 129 129 129 129 124 132 132 124 134 113 136 134 136 134 140 134|139 134 134|139 144 144 113 147 147 144 147 147 144 152 144 155 155 152 155 155 144 160 158 164 164 164 160 167 167 158 170 170 167 170 170 170 113 177 184 177 181 181 177 184 184 184 187 187 184 187 187 184 192 190 196 196 196 192 199 199 190 203 203 203 199 184 207 207 215 207 210 207 210 215 215 215 221 218 218 215 218 218 221 223 221 227 227 227 223 230 230 221 234 234 234 230 221 239 236|239 239 236|239 240 240 243 243 240 246 246 243 246 249 246 240 252 252 255 260 257 255|256 255 255|256 260 252 262 260 264 262 262 262 264 268 264 260 260 260 274 274 271 276 274 276 280 280 276 252 296 286 284|285 284 284|285 289 296 291 289 291 291 296 296 296 298 296 300 298 302 298 304 302 304 307 304 311 311 311 302 296	Association
19893579	Chemical	Gene	D000068180	2195	True	0	What is [PHARMGKB] between @ChemicalSrc$ aripiprazole @/ChemicalSrc$ and @GeneTgt$ FAT @/GeneTgt$ ? [SEP] No influence of @GeneTgt$ FAT @/GeneTgt$ polymorphisms in response to @ChemicalSrc$ aripiprazole @/ChemicalSrc$ . The aim of this study was to investigate possible influences of a set of markers in the @GeneTgt$ FAT @/GeneTgt$ gene ( rs2306987 , rs2306990 , rs2637777 and rs2304865 ) on efficacy and tolerability of @ChemicalSrc$ aripiprazole @/ChemicalSrc$ in the treatment of schizophrenic patients . Efficacy was assessed at baseline and weeks 1 , 2 , 4 , 6 , 8 and 12 using the Clinical Global Impression Severity and Improvement scale ( CGI-S ; CGI-I ) , the Brief Psychiatric Rating Scale and the Schedule for the Assessment of Negative Symptoms scale . Side effects were evaluated by means of the Simpson-Angus Scale for Extrapyramidal Symptoms , the Barnes Akathisia Scale and the Abnormal Involuntary Movement Scale . Multivariate analyses were employed to test possible influences of single nucleotide polymorphisms on clinical and safety variables . Analysis of haplotypes was also performed . No relevant association between @GeneTgt$ FAT @/GeneTgt$ variants and clinical or safety scores was observed . Haplotype analysis did not reveal any significant association with clinical and safety scores at any time as well . Our data suggest no association between investigated alleles and genotypes in @GeneTgt$ FAT @/GeneTgt$ and response to @ChemicalSrc$ aripiprazole @/ChemicalSrc$ . However , because several limitations characterize the present study , further investigations on larger studies are required .	2 2 6 3|6 6 3|6 2 8 2 10 8 8 8 2 16 20 19 19 16 20 22 20 24 22 27 27 24 29 27 34 34 31|34 34 31|34 24 36 34 36 36 36 36 40 36 36 45 24 45 45 49 47 47 47 53 53 45 56 56 53 20 62 62 62 64 62 64 64 64 67 67 67 67 67 67 67 64 64 64 62 86 86 82 83 86 83 83 78 88 86 88 88 90 88 97 97 97 97 88 97 100 97 103 103 100 107 107 107 103 62 110 112 112 112 114 112 118 118 118 114 121 121 118 118 126 126 126 118 126 132 132 131 132 126 112 135 137 137 137 139 137 141 139 145 145 145 141 150 150 147 147 139 137 157 154 152 157 157 157 157 161 161 172 165 162|165 165 162|165 161 165 165 167 167 165 172 172 172 176 179 179 179 179 182 182 179 187 187 184 184 182 190 190 182 192 179 179 195 196 196 198 196 201 201 198 201 201 205 201|204 201 201|204 205 205 210 208 208 208 196 231 231 220 219 220 231 223 223 220 231 226 231 229 229 226 231 231 231	Association
20022809	Chemical	Gene	D000077156	1956	True	0	What is [PHARMGKB] between @ChemicalSrc$ gefitinib @/ChemicalSrc$ and @GeneTgt$ EGFR @/GeneTgt$ ? [SEP] @ChemicalSrc$ Gefitinib @/ChemicalSrc$ versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ ( WJTOG3405 ): an open label , randomised phase 3 trial . BACKGROUND : Patients with non-small-cell lung cancer harbouring mutations in the @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ ( @GeneTgt$ EGFR @/GeneTgt$ ) gene respond well to the @GeneTgt$ EGFR-specific @/GeneTgt$ tyrosine kinase inhibitor @ChemicalSrc$ gefitinib @/ChemicalSrc$ . However , whether @ChemicalSrc$ gefitinib @/ChemicalSrc$ is better than standard platinum doublet chemotherapy in patients selected by @GeneTgt$ EGFR @/GeneTgt$ mutation is uncertain . METHODS : We did an open label , phase 3 study ( WJTOG3405 ) with recruitment between March 31 , 2006 , and June 22 , 2009 , at 36 centres in Japan . 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring @GeneTgt$ EGFR @/GeneTgt$ mutations ( either the exon 19 deletion or L858R point mutation ) were randomly assigned , using a minimisation technique , to receive either gefitinib ( 250 mg/day orally ; n=88 ) or cisplatin ( 80 mg/m(2 ) , intravenously ) plus docetaxel ( 60 mg/m(2 ) , intravenously ; n=89 ) , administered every 21 days for three to six cycles . The primary endpoint was progression-free survival . Survival analysis was done with the modified intention-to-treat population . This study is registered with UMIN ( University Hospital Medical Information Network in Japan ) , number 000000539 . FINDINGS : Five patients were excluded ( two patients were found to have thyroid and colon cancer after randomisation , one patient had an exon 18 mutation , one patient had insufficient consent , and one patient showed acute allergic reaction to docetaxel ) . Thus , 172 patients ( 86 in each group ) were included in the survival analyses . The @ChemicalSrc$ gefitinib @/ChemicalSrc$ group had significantly longer progression-free survival compared with the cisplatin plus docetaxel goup , with a median progression-free survival time of 9.2 months ( 95 % CI 8.0 - 13.9 ) versus 6.3 months ( 5.8 - 7.8 ; HR 0.489 , 95 % CI 0.336 - 0.710 , log-rank p&lt;0.0001 ) . Myelosuppression , alopecia , and fatigue were more frequent in the cisplatin plus docetaxel group , but skin toxicity , liver dysfunction , and diarrhoea were more frequent in the @ChemicalSrc$ gefitinib @/ChemicalSrc$ group . Two patients in the @ChemicalSrc$ gefitinib @/ChemicalSrc$ group developed interstitial lung disease ( incidence 2.3 % ) , one of whom died . INTERPRETATION : Patients with lung cancer who are selected by @GeneTgt$ EGFR @/GeneTgt$ mutations have longer progression-free survival if they are treated with @ChemicalSrc$ gefitinib @/ChemicalSrc$ than if they are treated with cisplatin plus docetaxel . FUNDING : West Japan Oncology Group ( WJOG ): a non-profit organisation supported by unrestricted donations from several pharmaceutical companies .	0|1 1 0|1 1 1 4 4 8 1 12 12 12 8 12 13 17 17 17|14|15 17|14|15 17|14|15 17|14|15 17|14 17|14|15 23 17 23 27 27 1 1 32 32 32 1 1 57 36 57 42 42 42 38 38 43 56 56 46|56 46|56 46|56 46|56 56 46|56 56 56|48 56 56|48 56 44 57 57 66 66 55|66 66 55|66 66 66 66 59|57 57 59|57 57 93 93 79 75|79 79 75|79 79 93 84 84 83 84 79 86 84 86 91 91|87 91 91|87 87 93 93 93 100 100 100 100 103 103 100 100 107 107 100 109 107 109 112 107 114 112 114 114 114 114 114 114 120 120 120 107 127 127 107 129 127 100 133 133 167 133 136 134 136 136 134 134 146 146 146 146 146 140 146 149 167 149 150|153 153 150|153 150 159 159 159 159 159 153 159 163 163 159 159 167 167 167 167 167 172 172 169 167 175 167 177 175 180 180 177 180 183 180 183 180 180 189 189 186 189 180 180 180 177 177 198 198 195 198 177 175 203 167 203 167 167 209 209 206 214 213 213 214 206 167 219 219 222 222 222 222 222 225 227 227 227 232 232 232 232 227 227 235 237 237 237 245 245 245 242 245 245 245 237 247 245 245 245 245 250 237 258 258 256 258 258 258 263 261 263 263 258 265 263 269 266 266 265 271 265 275 274 275 283 279 279 279 275 283 282 283 258 285 283 283 258 289 290 258 293 293 290 295 293 290 258 309 309 301 309 303 301 306 306 303 303 309 309 313 313 313 309 309 318 315|318 318 315|318 321 321 321 321 323 321 327 327 327 321 327 327 327 321 337 337 337 337 337 321 340 340 337 344 343 344 337 347 347 344 347 344 351 344 355 355 355 351 355 362 357 357 361 357 365 365 365 344 365 368 365 344 321 380 372 372 374 372 372 380 380 380 383 383 380 383 383 383 380 380 390 380 390 393 390 393 390 399 399 399 380 404 404 404|401 404 404|401 399 399 408 414 413 413 410|413 413 410|413 408 414 417 417 414 419 417 421 419 419 417 427 426 424 417 414 430 430 443 435 435 432 438 438 435 442 439|442 442 439|442 438 430 446 446 443 450 450 450 443 452 450 450 450 458 458 458 458 450 460 458 460 460 443 466 466 469 471 471 466 473 471 473 477 477 471 477 481 481 478 485 485 485 481 466	Association
20116071	Chemical	Gene	D003024	2675	True	0	What is [PHARMGKB] between @ChemicalSrc$ clozapine @/ChemicalSrc$ and @GeneTgt$ GFRA2 @/GeneTgt$ ? [SEP] Genetic association of the GDNF alpha-receptor genes with schizophrenia and @ChemicalSrc$ clozapine @/ChemicalSrc$ response . GDNF ( glial-cell-line derived neurotrophic factor ) is a potent neurotrophic factor for dopaminergic neurons . Neuropsychiatric diseases and their treatments are associated with alterations in the levels of both GDNF and its receptor family ( GDNF family receptor alpha or GFRA ) . GFRA1 , @GeneTgt$ GFRA2 @/GeneTgt$ and GFRA3 are located in chromosomal regions with suggestive linkage to schizophrenia . In this study we analyzed polymorphisms located in all four known GFRA genes and examined association with schizophrenia and @ChemicalSrc$ clozapine @/ChemicalSrc$ response . We examined SNPs across the genes GFRA1 - 4 in 219 matched case-control subjects , 85 small nuclear families and 140 schizophrenia patients taking @ChemicalSrc$ clozapine @/ChemicalSrc$ for 6months . We observed that GFRA3 rs11242417 and GFRA1 rs11197557 variants were significantly associated with schizophrenia after combining results from both schizophrenia samples . Furthermore , we found an overtransmission of the G-C GFRA1 rs7920934-rs730357 haplotype to subjects with schizophrenia and association of A-T-G-G GFRA3 rs10036665-rs10952-rs11242417-rs7726580 with schizophrenia in the case-control sample . On the other hand , @GeneTgt$ GFRA2 @/GeneTgt$ variants were not associated with schizophrenia diagnosis but subjects carrying T-G-G rs1128397-rs13250096-rs4567028 haplotype were more likely to respond to @ChemicalSrc$ clozapine @/ChemicalSrc$ treatment . The statistical significance of results survived permutation testing but not Bonferroni correction . We also found nominally-significant evidence for interactions between GFRA1 , 2 and 3 associated with schizophrenia and @ChemicalSrc$ clozapine @/ChemicalSrc$ response , consistent with the locations of these three genes within linkage regions for schizophrenia .	2 2 7 7 7 7 2 9 13 9 9|10 9 9|10 2 2 19 18 16 19 21 19 21 27 27 27 27 19 30 30 27 19 33 38 33 36 38 38 38 40 38 43 43 40 46 46 43 46 50 50 46 55 55 55 55 50 55 55 55 38 67 60 60|61 60 60|61 60 60 67 67 70 70 67 73 73 70 75 73 67 80 80 82 82 82 82 83 90 90 90 90 90 84 82 82 92 95 99 95 95|96 95 95|96 93 82 103 103 103 107 107 104 107 108 108 115 115 115 115 108 104 120 120 120 104 120 124 124 120 124 125 125 125 129 125 103 133 133 143 140 135 136 136 135 143 143 143 133 145 143 147 143 147 152 152 152 148 133 157 157 157 157 159 157 165 165 165 165 165 159 167 159 169 167 169 169 175 175 175 171 177 171 181 181 181 159 157 186 186 186 193 193 190|187 190 190|187 193 193 193 193 196 196 193 196 205 198 202 200 199 205 205 193 207 205 211 207|211 211 207|211 207 205 217 217 220 219 217 220 222 220 224 226 226 222 220 230 230 230 232 230 234 232 236 234 236 236 236 236 234 243 247 243 243|244 243 243|244 241 234 230 252 252 249 256 256 256 252 259 259 252 261 259 230	Association
20231857	Chemical	Gene	D009538	1139	False	1	What is [PHARMGKB] between @ChemicalSrc$ nicotine @/ChemicalSrc$ and @GeneTgt$ CHRNA7 @/GeneTgt$ ? [SEP] Why do young women smoke ? VI . A controlled study of @ChemicalSrc$ nicotine @/ChemicalSrc$ effects on attention : pharmacogenetic interactions . In prior studies we found that young , female smokers manifest poorer performance than non-smokers on attention-related tasks and that these findings can be moderated by variation in nicotinic acetylcholine receptor ( nAChR ) genes . We predicted that under controlled conditions ( 1 ) @ChemicalSrc$ nicotine @/ChemicalSrc$ would improve functioning on attentional tasks in smokers who previously manifested relatively poor performance , and that ( 2 ) smokers who carry genetic variations associated with poorer attention performance would derive greater benefit from @ChemicalSrc$ nicotine @/ChemicalSrc$ . To test these hypotheses , 31 young female smokers , who participated in our previous study , performed the Matching Familiar Figures Test ( MFFT ) , Tower of London Test and Continuous Performance Task ( CPT ) in a double-blind , within-between subject design , placebo or @ChemicalSrc$ nicotine @/ChemicalSrc$ ( 4 mg as gum ) serving as the within factor and genetic profile as the between factor . Repeated measures ANCOVA controlling for attention deficit symptomatology , substance abuse and @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence showed better performance under @ChemicalSrc$ nicotine @/ChemicalSrc$ among participants with higher levels of attention deficit symptoms ( MFFT errors : P=0.04 ; CPT commissions : P=0.01 ) and @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence ( CPT stability of response : P=0.04 ) and greater consumption of caffeine ( CPT stability of response : P=0.04 ) . An interactive effect of genetic profile was demonstrated for SNP rs2337980 in @GeneTgt$ CHRNA7 @/GeneTgt$ . These findings suggest that @ChemicalSrc$ nicotine @/ChemicalSrc$ may have stronger short-term facilitating effects on attention in women who have more attention deficit symptoms and consume more @ChemicalSrc$ nicotine @/ChemicalSrc$ and caffeine . This effect may be modified by a specific genetic make-up . Such individuals may be at increased risk for @ChemicalSrc$ nicotine @/ChemicalSrc$ addiction and for greater difficulties in smoking cessation .	5 5 4 5 5 5 7 7 11 11 11 15 12|15 15 12|15 11 17 11 11 20 11 11 25 25 27 27 27 33 32 32 32 33 27 35 33 37 35 40 40 35 33 47 44 47 47 47 33 49 47 57 57 57 57 57 57 57 49 27 60 60 71 64 64 71 71 71 66 67|71 71 67|71 71 60 71 75 75 72 77 75 80 80 77 82 83 80 71 71 101 88 90 88 101 92 90 94 92 94 99 99 99 95 101 71 103 101 105 103 103 103 60 111 127 113 111 127 118 118 118 127 118 121 118 125 125 125 121 118 127 132 132 131 132 127 134 132 134 132 132 140 140 137 140 144 144 140 146 144 146 154 154 154 154 153 154 127 154 154 156 157|156 156 157|156 162 162 158 162 162 162 154 173 173 170 173 170 170 166 177 177 177 166 127 181 183 183 195 187 186 187 183 187 190 187 190 191|194 194 191|194 190 195 197 195 199 197 197 197 202 197 205 205 202 209 209 209 205 212 212 197 212 212 214 217 214 217 217 219 219 219|224 224 219|224 219 227 227 214 229 227 231 214 231 214 235 214 237 235 240 240 214 242 240 244 214 244 195 252 252 257 255 255 252 257 257 260 260 257 262 260|261 260 260|261 257 267 268 268 273 273|269 273 273|269 273 268 277 277 277 273 279 277 281 279 283 281 287 287 287 283 283 283 291 289 289 289 291 291 268 299 302 302 302 302 307 307 307 307 302 302 310 315 315 315 315 315 315 319 316|319 319 316|319 315 315 323 323 315 326 326 323 315	Association
20352314	Chemical	Gene	D000077261	154	True	0	What is [PHARMGKB] between @ChemicalSrc$ carvedilol @/ChemicalSrc$ and @GeneTgt$ beta2-AR @/GeneTgt$ ? [SEP] Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with @ChemicalSrc$ carvedilol @/ChemicalSrc$ in patients with chronic heart failure . BACKGROUND : Beta-blockers are mainstay of current treatment of heart failure ( HF ) . Beta-adrenergic receptors ( AR ) single nucleotide gene polymorphisms ( SNPs ) may influence the sensitivity and density of beta-AR . We assessed the relation between three common beta-AR SNPs and the response to @ChemicalSrc$ carvedilol @/ChemicalSrc$ administration . METHODS AND RESULTS : We studied 183 consecutive patients with chronic HF due to ischemic or nonischemic cardiomyopathy , a LV ejection fraction ( LVEF ) & lt ; or = 0.35 , not previously treated with beta-blockers . Each patient underwent gated-SPECT radionuclide ventriculography , cardiopulmonary exercise testing and invasive hemodynamic monitoring at baseline and after 12 months of @ChemicalSrc$ carvedilol @/ChemicalSrc$ administration at maintenance dosages . The beta1-AR gene Arg389Gly and the @GeneTgt$ beta2-AR @/GeneTgt$ gene Arg16Gly SNPs were not related to the response to @ChemicalSrc$ carvedilol @/ChemicalSrc$ administration . Homozygotes for the Glu27Glu allele showed a greater increase in the LVEF , compared to the other patients ( + 13.0 + /- 12.2 % versus + 7.1 + /- 8.1 % in the Gln27Gln homozygotes , and 8.3 + /- 11.4 % units in the Gln27Glu heterozygotes ; p = 0.022 by ANOVA ) . Glu27Glu homozygotes also showed a greater decline in the pulmonary wedge pressure both at rest and at peak exercise . Gln27Glu SNP was selected amongst the determinants of the LVEF response to @ChemicalSrc$ carvedilol @/ChemicalSrc$ at multivariable analysis , in addition to the cause of cardiomyopathy , baseline systolic blood pressure and the dose of @ChemicalSrc$ carvedilol @/ChemicalSrc$ administered . CONCLUSION : Beta1-AR Arg389Gly and @GeneTgt$ beta2-AR @/GeneTgt$ Arg16Gly SNPs are not related to the response to @ChemicalSrc$ carvedilol @/ChemicalSrc$ therapy . In contrast , the Gln27Glu SNP is a determinant of the LVEF response to this agent in patients with chronic HF .	1 6 6 6 6 1 10 10 10 1 12 10 14 12|13 12 12|13 17 10 21 21 21 17 1 24 24 28 28 24 31 31 28 34 34 31 36 34 36 28 40 47 42 47 42 47 47 47 52 49 47 49 52 52 54 52 54 54 58 54 52 61 61 63 61 68 68 68 68 63 68 71 68 75 75|72 75 75|72 71 61 78 78 78 83 83 78 86 86 83 89 89 86 92 90 86 92 92 92 95 100 100 100 86 102 100 102 100 100 100 86 86 108 108 113 113 108 115 113 83 118 119 119 121 122 119 119 126 126 119 126 130 130 126 132 126 132 136 136 132 140 140|137 140 140|137 136 143 143 126 119 149 149 149 159 149 156 156|151 156 156|151 155 156 159 159 159 159 162 162 159 166 162|166 166 162|166 162 159 175 174 174 174 170 175 178 178 175 181 181 178 175 175 187 187 187 183 187 187 187 190 175 194 175 194 194 194 197 175 201 175 205 205 205 201 201 201 201 208 201 212 213 201 217 217 217 213 220 220 175 220 223 220 220 175 227 229 229 229 232 232 229 237 237 237 237 232 240 240 229 240 244 244 240 229 247 249 249 249 252 252 249 256 256 256 252 258 256|257 256 256|257 262 262 249 249 265 249 268 268 265 270 268 270 275 275 275 270 270 278 270 280 278 278 278 280 249 286 286 289 294 289 293|290 293 293|290 294 297 297 297 286 300 300 297 304 304|300 304 304|300 300 297 309 316 316 313 313 316 316 316 316 320 320 320 316 323 323 320 325 323 328 328 325 316	Association
20362026	Chemical	Gene	D009538	9607	True	0	What is [PHARMGKB] between @ChemicalSrc$ nicotine @/ChemicalSrc$ and @GeneTgt$ CART @/GeneTgt$ ? [SEP] @GeneTgt$ Cocaine and amphetamine regulated transcript @/GeneTgt$ ( @GeneTgt$ CART @/GeneTgt$ ) gene in the comorbidity of schizophrenia with alcohol use disorders and @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence . Studies have shown a genetic susceptibility to develop schizophrenia , alcohol use disorders and @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence . Brain areas related to reward and reinforcement show high expression of the @GeneTgt$ cocaine and amphetamine regulated transcript @/GeneTgt$ ( @GeneTgt$ CART @/GeneTgt$ ) . @ChemicalSrc$ Nicotine @/ChemicalSrc$ and alcohol are also able to modulate @GeneTgt$ CART @/GeneTgt$ expression in the hypothalamic areas . In this study , we evaluated whether @GeneTgt$ CART @/GeneTgt$ variants would influence the predisposition of schizophrenia subjects to alcohol use disorders and @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence . Clinical and genetic data were obtained from 190 unrelated Caucasian schizophrenia subjects collected at the Centre for Addiction and Mental Health . We found no association of @GeneTgt$ CART @/GeneTgt$ variants with alcohol use disorders or @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence . We found a trend for allelic association of rs11575893 with the heaviness of smoking behaviour ( p=0.057 ) . Our results indicate that genetic variants in the @GeneTgt$ CART @/GeneTgt$ gene may not play a major role in the vulnerability of schizophrenia subjects to concurrent alcohol use disorders and @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence . Additional association studies in independent samples can evaluate whether @GeneTgt$ CART @/GeneTgt$ gene is playing a role in the schizophrenia comorbidity with alcohol use disorders and @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence .	0|1|11 0|1|11 0|1|11 0|1|11 0|1|11 1|11 0|1|11 8 2|11 11 2|11 11 1 14 14 1 16 14 20 20 20 14 20 24|15 24 24|15 20 1 31 31 31 34 34 31 36 34 36 37 41 41 37 41 45|42 45 45|42 41 31 49 55 49 52 50 52 52 55 57 55 60 60 55|57|59|60 55|57|59|60 55|57|59|60 55|57|59|60 55|57|59|60 55|57|60 55|57|59|60 67 60|61 60 60|61 67 55 72|79 79 72|79 73 73 79 79 79 81 79 80|84 84 80|84 81 88 88 88 81 79 94 94 97 97 97 97 103 101|98 101 101|98 103 103 97 105 103 108 108 105 110 103 112 110 112 116|112 116 116|112 112 97 125 120 120 120 125 125 131 131 131 131 131 125 131 135 135 132 137 140 137 137 132 125 143 143 145 143 149 149|146 149 149|146 145 153 153 153 145 153 157|153 157 157|153 153 143 162 162 164 162 167 167 164 169 167 172 172 167 175 175 172 177 167 177 162 181 182 182 193 185 193 190 190 187|190 190 187|190 185 193 193 182 196 196 193 199 199 193 202 202 199 207 205 207 207 199 207 211|207 211 211|207 207 182 217 217 222 220 220 217 222 222 228 223|226 226 223|226 228 228 222 230 228 234 234 234 230 238 238 238 234 238 238|242 242 238|242 238 222	Association
20417680	Chemical	Gene	D014635	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ valproate @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Absence of a general association between @GeneTgt$ ABCB1 @/GeneTgt$ genetic variants and response to antiepileptic drugs in epilepsy patients . Over-expression of efflux transporter @GeneTgt$ P-glycoprotein @/GeneTgt$ ( @GeneTgt$ PgP @/GeneTgt$ ) encoded by @GeneTgt$ ABCB1 @/GeneTgt$ gene has been implicated in poor responsive epilepsy . Several genetic variants have been shown to influence the expression levels of @GeneTgt$ P-glycoprotein @/GeneTgt$ . The aim of the present study was to investigate the role of @GeneTgt$ ABCB1 @/GeneTgt$ polymorphisms : C1236 T , G2677T/A and C3435 T in determining drug response to first line antiepileptic drugs ( AEDs ) namely phenobarbitone , phenytoin , carbamazepine and @ChemicalSrc$ valproate @/ChemicalSrc$ in North Indian cohort of epilepsy patients . DNA samples were obtained from 392 consecutive epilepsy patients , out of which 228 had completed follow-up evaluation at 12 months . After attaining steady state of the AEDs in the first two months of study , 133 patients showed complete freedom from seizures ( no-seizure group ) and 95 patients continued to have seizures ( recurrent-seizures group ) in the remaining period of study . Comparison of " no-seizure " and " recurrent-seizures " groups revealed no significant differences in allelic , genotypic and haplotypic frequencies for all the studied variants . In conclusion , our finding disproves a general association between @GeneTgt$ ABCB1 @/GeneTgt$ polymorphisms and drug response in epilepsy patients .	1 5 5 5 1 10 10|6 10 10|6 10 5 10 10 15 15 12 18 18 12 1 38 25 25 25 21|24 21 21|24 28 25|26 25 25|26 28 25 35 30|35 35 30|35 31 38 38 38 42 42 42 38 38 49 49 52 52 52 52 54 52 57 57 54 59 57|58 57 57|58 52 64 69 68 68 68 64 69 71 69 73 71 77 74|77 77 74|77 73 69 80 69 80 80 80 80 80 87 80 89 87 94 94 94 94 89 96 94 96 99 96 99 99 99 99 99 103|99 99 103|99 110 109 110 99 113 113 110 69 118 120 120 120 125 125 125 125 120 125 125 129 127 132 132 125 134 132 137 137 132 120 140 156 142 140 145 145 142 150 150 150 150 140 152 150 156 155 156 156 158 156 160 158 163 163 160 163 160 167 160 158 170 168 170 174 174 171 174 179 179 179 170 181 179 156 193 186 186 192 186 186 190 186 192 183 193 196 196 193 198 196 198 198 198 198 198 208 208 208 208 193 193 211 215 215 214 215 215 218 218 215 222 219|222 222 219|222 218 222 225 222 228 228 218 215	Association
20417680	Chemical	Gene	D010634	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ phenobarbitone @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Absence of a general association between @GeneTgt$ ABCB1 @/GeneTgt$ genetic variants and response to antiepileptic drugs in epilepsy patients . Over-expression of efflux transporter @GeneTgt$ P-glycoprotein @/GeneTgt$ ( @GeneTgt$ PgP @/GeneTgt$ ) encoded by @GeneTgt$ ABCB1 @/GeneTgt$ gene has been implicated in poor responsive epilepsy . Several genetic variants have been shown to influence the expression levels of @GeneTgt$ P-glycoprotein @/GeneTgt$ . The aim of the present study was to investigate the role of @GeneTgt$ ABCB1 @/GeneTgt$ polymorphisms : C1236 T , G2677T/A and C3435 T in determining drug response to first line antiepileptic drugs ( AEDs ) namely @ChemicalSrc$ phenobarbitone @/ChemicalSrc$ , phenytoin , carbamazepine and valproate in North Indian cohort of epilepsy patients . DNA samples were obtained from 392 consecutive epilepsy patients , out of which 228 had completed follow-up evaluation at 12 months . After attaining steady state of the AEDs in the first two months of study , 133 patients showed complete freedom from seizures ( no-seizure group ) and 95 patients continued to have seizures ( recurrent-seizures group ) in the remaining period of study . Comparison of " no-seizure " and " recurrent-seizures " groups revealed no significant differences in allelic , genotypic and haplotypic frequencies for all the studied variants . In conclusion , our finding disproves a general association between @GeneTgt$ ABCB1 @/GeneTgt$ polymorphisms and drug response in epilepsy patients .	1 5 5 5 1 10 10|6 10 10|6 10 5 10 10 15 15 12 18 18 12 1 38 25 25 25 21|24 21 21|24 28 25|26 25 25|26 28 25 35 30|35 35 30|35 31 38 38 38 42 42 42 38 38 49 49 52 52 52 52 54 52 57 57 54 59 57|58 57 57|58 52 64 69 68 68 68 64 69 71 69 73 71 77 74|77 77 74|77 73 69 80 69 80 80 80 80 80 87 80 89 87 94 94 94 94 89 96 94 96 99 96|97 96 96|97 99 99 99 99 99 99 110 109 110 99 113 113 110 69 118 120 120 120 125 125 125 125 120 125 125 129 127 132 132 125 134 132 137 137 132 120 140 156 142 140 145 145 142 150 150 150 150 140 152 150 156 155 156 156 158 156 160 158 163 163 160 163 160 167 160 158 170 168 170 174 174 171 174 179 179 179 170 181 179 156 193 186 186 192 186 186 190 186 192 183 193 196 196 193 198 196 198 198 198 198 198 208 208 208 208 193 193 211 215 215 214 215 215 218 218 215 222 219|222 222 219|222 218 222 225 222 228 228 218 215	Association
20436376	Chemical	Gene	D019808	185	True	0	What is [PHARMGKB] between @ChemicalSrc$ Losartan @/ChemicalSrc$ and @GeneTgt$ hAT1 @/GeneTgt$ ? [SEP] A single-nucleotide polymorphism of alanine to threonine at position 163 of the human @GeneTgt$ angiotensin II type 1 receptor @/GeneTgt$ impairs @ChemicalSrc$ Losartan @/ChemicalSrc$ affinity . BACKGROUND AND OBJECTIVE : @GeneTgt$ AT1 @/GeneTgt$ is the principal receptor for angiotensin II ( AngII ) , which regulates blood pressure and osmotic homeostasis . Earlier studies have shown that position 163 interacts with the antihypertensive nonpeptide antagonist , @ChemicalSrc$ Losartan @/ChemicalSrc$ . A recently discovered polymorphism found in humans ( rs12721226 ) coding for residue 163 led us to determine whether this polymorphism would affect @ChemicalSrc$ Losartan @/ChemicalSrc$ antihypertensive therapies . The pharmacological properties of the A163 T @GeneTgt$ hAT1 @/GeneTgt$ variant are described . METHOD AND RESULTS : The A163 T @GeneTgt$ hAT1 @/GeneTgt$ mutation was evaluated by testing its affinity by dose displacement of AngII analogs in COS-7 cells expressing either wild-type @GeneTgt$ hAT1 @/GeneTgt$ or the A163 T @GeneTgt$ hAT1 @/GeneTgt$ . The expressions of the receptors were evaluated by saturation binding and the efficacies were assessed by measuring the 3H-inositol phosphate production . The results showed that the A163 T @GeneTgt$ hAT1 @/GeneTgt$ receptor is comparable with the affinity , expression , and efficacy of native @GeneTgt$ hAT1 @/GeneTgt$ towards peptide ligands . The affinities were also tested with nonpeptide antagonists @ChemicalSrc$ Losartan @/ChemicalSrc$ , L-158 809 , valsartan , telmisartan , irbesartan , candesartan , and EXP3174 . @ChemicalSrc$ Losartan @/ChemicalSrc$ and EXP3174 displayed a 7-fold loss in affinity towards A163 T @GeneTgt$ hAT1 @/GeneTgt$ . The ability of @ChemicalSrc$ Losartan @/ChemicalSrc$ to inhibit AngII-induced inositol triphosphate production also confirmed a loss in efficacy . Molecular modeling showed a higher steric and hydrophilic hindrance of the A163 T @ChemicalSrc$ hAT1-Losartan @/ChemicalSrc$ complex . CONCLUSION : The polymorphism that codes for the A163 T @GeneTgt$ hAT1 @/GeneTgt$ variant results in a receptor with normal physiological properties toward the endogenous hormone . However , the significant reduction in affinity to @ChemicalSrc$ Losartan @/ChemicalSrc$ and its active metabolite , EXP3174 , could significantly impair the clinical effectiveness of an antihypertensive therapy using @ChemicalSrc$ Losartan @/ChemicalSrc$ with patients bearing the A163 T polymorphism .	3 3 20 5 3 7 3 9 7 9 14 14 14 9|13|14 9|13|14 9|13|14 9|13|14 9|13|14 9|14 9|13|14 20 23|15 23 23|15 20 20 27 27 27 36 36|30 36 36|30 36 36 36 27 41 41 41 41 36 41 36 45 36 47 45 47 50 47 36 54 56 56 56 60 60 58 56 65 65 65 65 60 65 65|66 65 65|66 56 74 73 74 85 74 77 75 79 77 79 77 83 81 83 85 85 88 85 93 91 93 93 88 97|93 97 97|93 97 93 85 102 102 111 109 109 109 109 109|106 109 109|106 102 111 111 111 114 114 114 114 123 123 123 123|120 123 123|120 125 125 114 127 125 129 127 132 132 129 135 135 132 138 138 135 138 142 142 139|140 139 139|140 142 148 148 148 145|142 142 145|142 125 155 160 158 158 155 160 160 163 163 160 160 166 168 168 160 170 168 174 174 174 170 160 177 178 178 187 185 185 185 185|182 185 185|182 187 187 178 190 190 187 190 190 190 187 187 198 198 195|196 195 195|196 202 202 195 178 207 210 210 210 210 213 213 210 213 213 213 214 214 217 214 214 214 214 214 214 214 214 214 214 214 210 231|236 236 231|236 232 232 236 239 239 236 241 239 245 245 245 241|243 241 241|243 236 251 262 253 251|252 251 251|252 256 251 260 260 260 256 262 262 264 262 266 264 262 270 271 271 277 277 277 274 274 271 284 284 284 284 284|281 284 284|281 277 271 287 287 290 300 292 290 299 299 299 299 296|299 299 296|299 292 287 303 303 300 307 307 305 303 311 311 311 307 300 333 333 318 318 333 320 318 322 321|320 320 321|320 322 327 327 322 322 322 333 333 333 333 336 336 333 340 340 340 336 333 340|341 341 340|341 345 341 345 350 350 350 346 333	Association
20452607	Chemical	Gene	D003024	6532	True	0	What is [PHARMGKB] between @ChemicalSrc$ clozapine @/ChemicalSrc$ and @GeneTgt$ 5-HTT @/GeneTgt$ ? [SEP] Influence of @GeneTgt$ serotonin transporter @/GeneTgt$ gene polymorphisms on @ChemicalSrc$ clozapine @/ChemicalSrc$ response in Brazilian schizophrenics . Schizophrenia is a severe mental illness affecting around 1 % of adults with a high degree of morbidity and mortality . Affected individuals are at increased risk for unemployment , handicap , obesity , diabetes mellitus , hearth attack and suicide . Antipsychotic drugs are the best treatment for this disease , but about 20 % of patients display drug resistance , or refractoriness , and may receive a special neuroleptic named @ChemicalSrc$ Clozapine @/ChemicalSrc$ . Despite its superiority from other neuroleptics , only 30 - 60 % of drug-resistant patients are responsive to @ChemicalSrc$ clozapine @/ChemicalSrc$ . @ChemicalSrc$ Clozapine @/ChemicalSrc$ 's action results from interactions between dopaminergic and serotonergic neurotransmitter systems and since @ChemicalSrc$ clozapine @/ChemicalSrc$ appears to exert its effect strongly through the serotonergic systems , alterations in serotonin synaptic levels may influence antipsychotic response . The @GeneTgt$ serotonin transporter @/GeneTgt$ ( @GeneTgt$ 5-HTT @/GeneTgt$ ) is responsible for pre-synaptic re-uptake of serotonin , making this transporter a logical candidate gene for prediction of @ChemicalSrc$ clozapine @/ChemicalSrc$ response and to increase understanding about mechanisms of refractoriness . Therefore , we investigated the influence of two polymorphisms in the @GeneTgt$ 5-HTT @/GeneTgt$ gene ( HTTLPR/rs25531 and VNTR Stin2 ) in @ChemicalSrc$ clozapine @/ChemicalSrc$ response in a sample of 116 schizophrenic individuals of European descent from South-Brazil . Significant differences between responders and non-responders to @ChemicalSrc$ clozapine @/ChemicalSrc$ were observed for the HTTLPR/rs25531 polymorphism . Nonresponders to clozapine showed a higher frequency of S'-allele ( P = 0.01 ) and also were more likely to be S'/S ' homozygous or S'/L ' heterozygous than those who did respond ( P = 0.04 ) . After controlling for confounding variables , logistic regression analyses confirmed this association ( OR = 3.15 ; 95 % CI : 1.13 - 8.80 ) . The observed association suggests that increased availability of extracellular serotonin concentrations at all synapses may reduce @ChemicalSrc$ clozapine @/ChemicalSrc$ effect .	1 7 2|7 2|7 7 2|7 7 1 11 11|6 11 11|6 1 14 14 11 1 23 23 23 23 23 23 23 26 27 24 29 27 33 33 33 24 35 33 35 35 23 40 44 44 44 44 44 46 44 46 46 48 48 50 53 50 53 56 53 56 56 44 61 65 65 65 65 65 68 68 65 65 65 72 73 76 75 73 65 78 76 78 78 78 76 76 85 76 88 88 85 88 89 89 89 65 96 96 110 99 99 96 110 102 105 104 102 110 108 108 105 110 110 112 110|111 110 110|111 110 115|119 119 115|119 116 120 120 122 120 124 122 124 124 128 124 124 124 133|129 133 133|129 120 135 133 137 135 135 142 142 142 135 150 150 148 148 148 144 150 120 152 150 150 157 156|157|165 156|157|165 157|165 156|157|165 161 157|158 157 157|158 161 165 165 168 168 165 170 168 165 165 174 178 178 178 178 172 180 178 184 184|178 184 184|178 180 178 187 178 187 190 188 192 190 165 200 200 200 200 202 200 205 205 202 210 210 207|210 210 207|210 205 212 210 212 212 212 215 220 220|216 220 220|216 202 223 223 220 227 227 227 223 230 230 227 232 230 200 237 246 239 237 239 239 243 239|242 239 239|242 246 246 250 250 250 246 246 256 255 253 256 259 259 256 261 259 263 261 263 264 264 256 271 271 271 256 276 276 276 274 271 276 276 278 276 282 271 285 285 282 287 285 287 288 287 256 293 301 296 296 293 301 300 300 301 301 303 301 306 306 303 306 306 310 311 306 311 315 315 311 306 301 320 320 321 321 333 324 333 328 328 328 324 331 331 324 333 321 333|336 336 333|336 333 321	Association
20514076	Chemical	Gene	D008691	409	True	0	What is [PHARMGKB] between @ChemicalSrc$ methadone @/ChemicalSrc$ and @GeneTgt$ ARRB2 @/GeneTgt$ ? [SEP] beta-Arrestin2 influences the response to @ChemicalSrc$ methadone @/ChemicalSrc$ in opioid-dependent patients . beta-Arrestin2 ( @GeneTgt$ ARRB2 @/GeneTgt$ ) is a component of the G-protein-coupled receptor complex and is involved in mu-opioid and dopamine D(2 ) receptor signaling , two central processes in @ChemicalSrc$ methadone @/ChemicalSrc$ signal transduction . We analyzed 238 patients in @ChemicalSrc$ methadone @/ChemicalSrc$ maintenance treatment ( MMT ) and identified a haplotype block ( rs34230287 , rs3786047 , rs1045280 and rs2036657 ) spanning almost the entire @GeneTgt$ ARRB2 @/GeneTgt$ locus . Although none of these single nucleotide polymorphisms ( SNPs ) leads to a change in amino-acid sequence , we found that for all the SNPs analyzed , with exception of rs34230287 , homozygosity for the variant allele confers a nonresponding phenotype ( n=73 ; rs1045280C and rs2036657 G : OR=3.1 , 95 % CI=1.5 - 6.3 , P=0.004 ; rs3786047A : OR=2.5 , 95 % CI=1.2 - 5.1 , P=0.02 ) also illustrated by a 12-fold shorter period of negative urine screening ( P=0.01 ) . The @GeneTgt$ ARRB2 @/GeneTgt$ genotype may thus contribute to the interindividual variability in the response to MMT and help to predict response to treatment .	2 2 4 2 6 4|5 4 4|5 10 10 4 2 20 15 13|14 13 13|14 15 20 20 20 25 25 25 25 20 20 28 20 30 36 30 33 30 33 36 28 36 40 40 20 45 45|40 45 45|40 45 40 20 50 50 52 50 57 57|53 57 57|53 57 52 59 57 59 50 50 65 65 62 67 65 67 67 67 67 67 67 67 65 81 81 81 81|77 81 81|77 75 50 95 95 91 91 91 91 86 93 91 93 104 98 98 95 101 101 98 104 104 104 122 110 109 109 110 122 110 113 122 115 113 122 122 121 121 121 117 104 125 125 122 127 125 127 127 129 129 134 134 129 134 137 134 137 138 137 134 134 134 122 144 144 146 149 150 146 152 150 146 146 146 157 144 162 162 161 162 157 166 166 166 162 168 166 168 104 174 171|174 174 171|174 177 177 177 177 181 181 181 177 184 184 181 186 184 177 177 190 188 190 193 191 177	Association
20631561	Chemical	Gene	D000077152	2166	False	1	What is [PHARMGKB] between @ChemicalSrc$ olanzapine @/ChemicalSrc$ and @GeneTgt$ FAAH @/GeneTgt$ ? [SEP] Endocannabinoid Pro129Thr @GeneTgt$ FAAH @/GeneTgt$ functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain . Several candidate genes have been associated with antipsychotic-induced body weight ( BW ) gain . Because the endocannabinoid system is deeply involved in BW regulation , endocannabinoid genes may have a role in the antipsychotic-induced weight gain . Therefore , we investigated the 1359 G/A ( rs1049353 ) single nucleotide polymorphisms ( SNP ) of the cannabinoid receptor 1 ( CNR1 ) gene , which codes the endocannabinoid CB1 receptor , and the complementary DNA ( cDNA ) 385C/A ( rs324420 ) SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene , which codes the endocannabinoid degrading enzyme , for their role in BW changes induced by antipsychotic drugs . Eighty-three white psychotic patients who underwent a naturalistic treatment with different antipsychotics ( clozapine , @ChemicalSrc$ olanzapine @/ChemicalSrc$ , risperidone , quetiapine , and haloperidol ) and completed a 24-week treatment period were included into the study together with 80 age- and sex-matched white healthy controls . At the 24th week of treatment , 41 patients gained more than 7 % of their baseline BW . No significant differences between patients and controls emerged in genotype and allele frequencies of both SNPs . Genotype and allele frequencies of the @GeneTgt$ FAAH @/GeneTgt$ cDNA 385C/A SNP but not of the CNR1 1359 G/A SNP significantly differed between subjects who gained more than 7 % of BW and those who did not , with both AC and AA genotypes and the A allele being significantly more frequent in patients who gained more than 7 % of their baseline BW . Present findings , although obtained in a small population and in a naturalistic setting , suggest that the cDNA 385C/A SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene may predispose subjects to get a clinically meaningful weight gain after antipsychotic exposure .	6 6 2|6 6 2|6 6 13 8 6 6 11 13 13 13 17 17 17 13 13 22 22 25 25 25 25 33 29 29 33 31 29 31 25 25 41 38 38 41 41 41 49 44 44 41 49 47 49 49 49 51 49 56 56 56 56 51 49 61 61 61 61 70 70 63 66 70 70 70 70 61 72 70 72 82 82 82 82 82 82 82 82 70 82 85 82 89 89 89 85 70 70 102 102 102 96 102 102 97 100 102 102 70 107 107 107|104 107 107|104 102 102 110 102 114 114 114 110 102 118 118 70 121 121 118 121 125 125 122 61 131 131 131 154 133 131 136 136 133 139 139 136 141 139 141 141|142 141 141|142 141 141 141 141 141 141 141 141 131 154 158 158 158 154 160 154 163 163 160 163 172 172 172 167 167 172 170 163 154 178 178 178 184 180 178 184 183 184 184 187 187 188 184 192 192 192 188 184 196 196 201 198 196 198 198 201 203 201 203 203 203 209 209 206 201 214 211 211 231 221 221 221|216 221 221|216 221 221 214 221 226 226 226 229 229 229 221 231 231 233 231 235 233 238 238 239 235 241 239 239 239 245 243 245 235 250 250 235 250 250 250 250 257 257 250 261 260 261 231 263 261 265 263 268 268 269 265 273 273 273 269 231 277 291 291 280 291 284 284 284 280 284 289 289 289 284 291 291 303 296 296 296 303 301 301 301|298 301 301|298 296 303 291 303 306 303 311 309 311 311 306 314 314 306 291	Association
20631561	Chemical	Gene	D000069348	2166	False	1	What is [PHARMGKB] between @ChemicalSrc$ quetiapine @/ChemicalSrc$ and @GeneTgt$ FAAH @/GeneTgt$ ? [SEP] Endocannabinoid Pro129Thr @GeneTgt$ FAAH @/GeneTgt$ functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain . Several candidate genes have been associated with antipsychotic-induced body weight ( BW ) gain . Because the endocannabinoid system is deeply involved in BW regulation , endocannabinoid genes may have a role in the antipsychotic-induced weight gain . Therefore , we investigated the 1359 G/A ( rs1049353 ) single nucleotide polymorphisms ( SNP ) of the cannabinoid receptor 1 ( CNR1 ) gene , which codes the endocannabinoid CB1 receptor , and the complementary DNA ( cDNA ) 385C/A ( rs324420 ) SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene , which codes the endocannabinoid degrading enzyme , for their role in BW changes induced by antipsychotic drugs . Eighty-three white psychotic patients who underwent a naturalistic treatment with different antipsychotics ( clozapine , olanzapine , risperidone , @ChemicalSrc$ quetiapine @/ChemicalSrc$ , and haloperidol ) and completed a 24-week treatment period were included into the study together with 80 age- and sex-matched white healthy controls . At the 24th week of treatment , 41 patients gained more than 7 % of their baseline BW . No significant differences between patients and controls emerged in genotype and allele frequencies of both SNPs . Genotype and allele frequencies of the @GeneTgt$ FAAH @/GeneTgt$ cDNA 385C/A SNP but not of the CNR1 1359 G/A SNP significantly differed between subjects who gained more than 7 % of BW and those who did not , with both AC and AA genotypes and the A allele being significantly more frequent in patients who gained more than 7 % of their baseline BW . Present findings , although obtained in a small population and in a naturalistic setting , suggest that the cDNA 385C/A SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene may predispose subjects to get a clinically meaningful weight gain after antipsychotic exposure .	6 6 2|6 6 2|6 6 13 8 6 6 11 13 13 13 17 17 17 13 13 22 22 25 25 25 25 33 29 29 33 31 29 31 25 25 41 38 38 41 41 41 49 44 44 41 49 47 49 49 49 51 49 56 56 56 56 51 49 61 61 61 61 70 70 63 66 70 70 70 70 61 72 70 72 82 82 82 82 82 82 82 82 70 82 85 82 89 89 89 85 70 70 102 102 102 96 102 102 97 100 102 102 70 107 107 107|104 107 107|104 102 102 110 102 114 114 114 110 102 118 118 70 121 121 118 121 125 125 122 61 131 131 131 154 133 131 136 136 133 139 139 136 141 139 141 141 141 141 141 146|141 141 146|141 141 141 141 141 131 154 158 158 158 154 160 154 163 163 160 163 172 172 172 167 167 172 170 163 154 178 178 178 184 180 178 184 183 184 184 187 187 188 184 192 192 192 188 184 196 196 201 198 196 198 198 201 203 201 203 203 203 209 209 206 201 214 211 211 231 221 221 221|216 221 221|216 221 221 214 221 226 226 226 229 229 229 221 231 231 233 231 235 233 238 238 239 235 241 239 239 239 245 243 245 235 250 250 235 250 250 250 250 257 257 250 261 260 261 231 263 261 265 263 268 268 269 265 273 273 273 269 231 277 291 291 280 291 284 284 284 280 284 289 289 289 284 291 291 303 296 296 296 303 301 301 301|298 301 301|298 296 303 291 303 306 303 311 309 311 311 306 314 314 306 291	Association
20631561	Chemical	Gene	D018967	2166	False	1	What is [PHARMGKB] between @ChemicalSrc$ risperidone @/ChemicalSrc$ and @GeneTgt$ FAAH @/GeneTgt$ ? [SEP] Endocannabinoid Pro129Thr @GeneTgt$ FAAH @/GeneTgt$ functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain . Several candidate genes have been associated with antipsychotic-induced body weight ( BW ) gain . Because the endocannabinoid system is deeply involved in BW regulation , endocannabinoid genes may have a role in the antipsychotic-induced weight gain . Therefore , we investigated the 1359 G/A ( rs1049353 ) single nucleotide polymorphisms ( SNP ) of the cannabinoid receptor 1 ( CNR1 ) gene , which codes the endocannabinoid CB1 receptor , and the complementary DNA ( cDNA ) 385C/A ( rs324420 ) SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene , which codes the endocannabinoid degrading enzyme , for their role in BW changes induced by antipsychotic drugs . Eighty-three white psychotic patients who underwent a naturalistic treatment with different antipsychotics ( clozapine , olanzapine , @ChemicalSrc$ risperidone @/ChemicalSrc$ , quetiapine , and haloperidol ) and completed a 24-week treatment period were included into the study together with 80 age- and sex-matched white healthy controls . At the 24th week of treatment , 41 patients gained more than 7 % of their baseline BW . No significant differences between patients and controls emerged in genotype and allele frequencies of both SNPs . Genotype and allele frequencies of the @GeneTgt$ FAAH @/GeneTgt$ cDNA 385C/A SNP but not of the CNR1 1359 G/A SNP significantly differed between subjects who gained more than 7 % of BW and those who did not , with both AC and AA genotypes and the A allele being significantly more frequent in patients who gained more than 7 % of their baseline BW . Present findings , although obtained in a small population and in a naturalistic setting , suggest that the cDNA 385C/A SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene may predispose subjects to get a clinically meaningful weight gain after antipsychotic exposure .	6 6 2|6 6 2|6 6 13 8 6 6 11 13 13 13 17 17 17 13 13 22 22 25 25 25 25 33 29 29 33 31 29 31 25 25 41 38 38 41 41 41 49 44 44 41 49 47 49 49 49 51 49 56 56 56 56 51 49 61 61 61 61 70 70 63 66 70 70 70 70 61 72 70 72 82 82 82 82 82 82 82 82 70 82 85 82 89 89 89 85 70 70 102 102 102 96 102 102 97 100 102 102 70 107 107 107|104 107 107|104 102 102 110 102 114 114 114 110 102 118 118 70 121 121 118 121 125 125 122 61 131 131 131 154 133 131 136 136 133 139 139 136 141 139 141 141 141 144|141 141 144|141 141 141 141 141 141 141 131 154 158 158 158 154 160 154 163 163 160 163 172 172 172 167 167 172 170 163 154 178 178 178 184 180 178 184 183 184 184 187 187 188 184 192 192 192 188 184 196 196 201 198 196 198 198 201 203 201 203 203 203 209 209 206 201 214 211 211 231 221 221 221|216 221 221|216 221 221 214 221 226 226 226 229 229 229 221 231 231 233 231 235 233 238 238 239 235 241 239 239 239 245 243 245 235 250 250 235 250 250 250 250 257 257 250 261 260 261 231 263 261 265 263 268 268 269 265 273 273 273 269 231 277 291 291 280 291 284 284 284 280 284 289 289 289 284 291 291 303 296 296 296 303 301 301 301|298 301 301|298 296 303 291 303 306 303 311 309 311 311 306 314 314 306 291	Association
20631561	Chemical	Gene	D003024	2166	False	1	What is [PHARMGKB] between @ChemicalSrc$ clozapine @/ChemicalSrc$ and @GeneTgt$ FAAH @/GeneTgt$ ? [SEP] Endocannabinoid Pro129Thr @GeneTgt$ FAAH @/GeneTgt$ functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain . Several candidate genes have been associated with antipsychotic-induced body weight ( BW ) gain . Because the endocannabinoid system is deeply involved in BW regulation , endocannabinoid genes may have a role in the antipsychotic-induced weight gain . Therefore , we investigated the 1359 G/A ( rs1049353 ) single nucleotide polymorphisms ( SNP ) of the cannabinoid receptor 1 ( CNR1 ) gene , which codes the endocannabinoid CB1 receptor , and the complementary DNA ( cDNA ) 385C/A ( rs324420 ) SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene , which codes the endocannabinoid degrading enzyme , for their role in BW changes induced by antipsychotic drugs . Eighty-three white psychotic patients who underwent a naturalistic treatment with different antipsychotics ( @ChemicalSrc$ clozapine @/ChemicalSrc$ , olanzapine , risperidone , quetiapine , and haloperidol ) and completed a 24-week treatment period were included into the study together with 80 age- and sex-matched white healthy controls . At the 24th week of treatment , 41 patients gained more than 7 % of their baseline BW . No significant differences between patients and controls emerged in genotype and allele frequencies of both SNPs . Genotype and allele frequencies of the @GeneTgt$ FAAH @/GeneTgt$ cDNA 385C/A SNP but not of the CNR1 1359 G/A SNP significantly differed between subjects who gained more than 7 % of BW and those who did not , with both AC and AA genotypes and the A allele being significantly more frequent in patients who gained more than 7 % of their baseline BW . Present findings , although obtained in a small population and in a naturalistic setting , suggest that the cDNA 385C/A SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene may predispose subjects to get a clinically meaningful weight gain after antipsychotic exposure .	6 6 2|6 6 2|6 6 13 8 6 6 11 13 13 13 17 17 17 13 13 22 22 25 25 25 25 33 29 29 33 31 29 31 25 25 41 38 38 41 41 41 49 44 44 41 49 47 49 49 49 51 49 56 56 56 56 51 49 61 61 61 61 70 70 63 66 70 70 70 70 61 72 70 72 82 82 82 82 82 82 82 82 70 82 85 82 89 89 89 85 70 70 102 102 102 96 102 102 97 100 102 102 70 107 107 107|104 107 107|104 102 102 110 102 114 114 114 110 102 118 118 70 121 121 118 121 125 125 122 61 131 131 131 154 133 131 136 136 133 139 139 136 141 139|140 139 139|140 141 141 141 141 141 141 141 141 141 141 131 154 158 158 158 154 160 154 163 163 160 163 172 172 172 167 167 172 170 163 154 178 178 178 184 180 178 184 183 184 184 187 187 188 184 192 192 192 188 184 196 196 201 198 196 198 198 201 203 201 203 203 203 209 209 206 201 214 211 211 231 221 221 221|216 221 221|216 221 221 214 221 226 226 226 229 229 229 221 231 231 233 231 235 233 238 238 239 235 241 239 239 239 245 243 245 235 250 250 235 250 250 250 250 257 257 250 261 260 261 231 263 261 265 263 268 268 269 265 273 273 273 269 231 277 291 291 280 291 284 284 284 280 284 289 289 289 284 291 291 303 296 296 296 303 301 301 301|298 301 301|298 296 303 291 303 306 303 311 309 311 311 306 314 314 306 291	Association
20631561	Chemical	Gene	D006220	2166	False	1	What is [PHARMGKB] between @ChemicalSrc$ haloperidol @/ChemicalSrc$ and @GeneTgt$ FAAH @/GeneTgt$ ? [SEP] Endocannabinoid Pro129Thr @GeneTgt$ FAAH @/GeneTgt$ functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain . Several candidate genes have been associated with antipsychotic-induced body weight ( BW ) gain . Because the endocannabinoid system is deeply involved in BW regulation , endocannabinoid genes may have a role in the antipsychotic-induced weight gain . Therefore , we investigated the 1359 G/A ( rs1049353 ) single nucleotide polymorphisms ( SNP ) of the cannabinoid receptor 1 ( CNR1 ) gene , which codes the endocannabinoid CB1 receptor , and the complementary DNA ( cDNA ) 385C/A ( rs324420 ) SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene , which codes the endocannabinoid degrading enzyme , for their role in BW changes induced by antipsychotic drugs . Eighty-three white psychotic patients who underwent a naturalistic treatment with different antipsychotics ( clozapine , olanzapine , risperidone , quetiapine , and @ChemicalSrc$ haloperidol @/ChemicalSrc$ ) and completed a 24-week treatment period were included into the study together with 80 age- and sex-matched white healthy controls . At the 24th week of treatment , 41 patients gained more than 7 % of their baseline BW . No significant differences between patients and controls emerged in genotype and allele frequencies of both SNPs . Genotype and allele frequencies of the @GeneTgt$ FAAH @/GeneTgt$ cDNA 385C/A SNP but not of the CNR1 1359 G/A SNP significantly differed between subjects who gained more than 7 % of BW and those who did not , with both AC and AA genotypes and the A allele being significantly more frequent in patients who gained more than 7 % of their baseline BW . Present findings , although obtained in a small population and in a naturalistic setting , suggest that the cDNA 385C/A SNP of the @GeneTgt$ FAAH @/GeneTgt$ gene may predispose subjects to get a clinically meaningful weight gain after antipsychotic exposure .	6 6 2|6 6 2|6 6 13 8 6 6 11 13 13 13 17 17 17 13 13 22 22 25 25 25 25 33 29 29 33 31 29 31 25 25 41 38 38 41 41 41 49 44 44 41 49 47 49 49 49 51 49 56 56 56 56 51 49 61 61 61 61 70 70 63 66 70 70 70 70 61 72 70 72 82 82 82 82 82 82 82 82 70 82 85 82 89 89 89 85 70 70 102 102 102 96 102 102 97 100 102 102 70 107 107 107|104 107 107|104 102 102 110 102 114 114 114 110 102 118 118 70 121 121 118 121 125 125 122 61 131 131 131 154 133 131 136 136 133 139 139 136 141 139 141 141 141 141 141 141 141 141 149|141 141 149|141 141 131 154 158 158 158 154 160 154 163 163 160 163 172 172 172 167 167 172 170 163 154 178 178 178 184 180 178 184 183 184 184 187 187 188 184 192 192 192 188 184 196 196 201 198 196 198 198 201 203 201 203 203 203 209 209 206 201 214 211 211 231 221 221 221|216 221 221|216 221 221 214 221 226 226 226 229 229 229 221 231 231 233 231 235 233 238 238 239 235 241 239 239 239 245 243 245 235 250 250 235 250 250 250 250 257 257 250 261 260 261 231 263 261 265 263 268 268 269 265 273 273 273 269 231 277 291 291 280 291 284 284 284 280 284 289 289 289 284 291 291 303 296 296 296 303 301 301 301|298 301 301|298 296 303 291 303 306 303 311 309 311 311 306 314 314 306 291	Association
20829635	Chemical	Gene	D000068180	84062	True	0	What is [PHARMGKB] between @ChemicalSrc$ aripiprazole @/ChemicalSrc$ and @GeneTgt$ DTNBP1 @/GeneTgt$ ? [SEP] No influence of @GeneTgt$ DTNBP1 @/GeneTgt$ polymorphisms on the response to @ChemicalSrc$ aripiprazole @/ChemicalSrc$ . AIMS : The aim of the present study was to investigate possible influences of a panel of markers in the @GeneTgt$ dysbindin @/GeneTgt$ gene @GeneTgt$ DTNBP1 @/GeneTgt$ ( rs3213207 , rs1011313 , rs2005976 , rs760761 and rs2619522 ) on the clinical outcome and side effects associated to the treatment with @ChemicalSrc$ aripiprazole @/ChemicalSrc$ in schizophrenic patients . METHODS : Efficacy was assessed at baseline and weeks 1 , 2 , 4 , 6 and 8 using the Clinical Global Impression Severity and Improvement Scales , the Brief Psychiatric Rating Scale and the Schedule for the Assessment of Negative Symptoms . Side effects were evaluated by the Simpson-Angus , Barnes Akathisia and Abnormal Involuntary Movement Scales . Multivariate analysis of covariance was used to test possible influences of single nucleotide polymorphisms on clinical and safety scores . Analysis of haplotypes was also performed . RESULTS : No relevant association between @GeneTgt$ DTNBP1 @/GeneTgt$ variants and clinical or safety scores was observed . Additionally , haplotype analysis did not reveal any significant association with clinical and safety scores at any time as well . CONCLUSION : Our data suggest no association between the investigated alleles and genotypes in @GeneTgt$ DTNBP1 @/GeneTgt$ and the response to @ChemicalSrc$ aripiprazole @/ChemicalSrc$ . However , because several limitations characterize the present study , further investigations are required .	2 2 6 3|6 6 3|6 2 9 9 2 11 9 9 9 2 24 16 19 24 23 23 23 19 24 26 24 28 26 31 31 28 33 31 39 39 39|35 39 39|35 39 33|37 33 33|37 42 39 42 42 42 42 42 42 42 42 42 55 55 55 28 55 55 55 58 62 62 59 64 61|62 62 61|62 68 68 62 24 77 77 77 77 77 79 77 79 79 79 82 82 82 79 79 79 79 79 77 99 99 95 96 99 96 96 91 99 105 105 105 105 99 105 108 105 111 111 108 114 114 111 77 117 119 119 119 122 122 119 122 125 122 125 130 129 130 125 119 133 137 135 133 137 137 139 137 141 139 145 145 145 141 150 150 147 147 139 137 157 154 152 157 157 157 157 159 159 163 163 174 167 167|164 167 167|164 163 167 172 169 169 167 174 159 174 183 183 180 183 183 183 183 186 186 183 191 191 188 188 186 194 194 186 196 183 183 198 202 201 202 198 204 202 208 208 208 204 208 208 212 208|211 208 208|211 208 216 208 218 216 216 216 202 236 236 228 227 228 236 231 231 228 236 234 236 236 236 236	Association
20925579	Chemical	Gene	D013999	1565	True	0	What is [PHARMGKB] between @ChemicalSrc$ timolol @/ChemicalSrc$ and @GeneTgt$ CYP2D6 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ CYP2D6 @/GeneTgt$ single-nucleotide polymorphism with response to ophthalmic @ChemicalSrc$ timolol @/ChemicalSrc$ in primary open-angle Glaucoma -- a pilot study . OBJECTIVES : We aimed to investigate whether @GeneTgt$ CYP2D6 @/GeneTgt$ polymorphisms were associated with the intraocular pressure (IOP)-lowering effect and systemic complications ( especially bradycardia ) of ophthalmic @ChemicalSrc$ timolol @/ChemicalSrc$ . METHODS : One hundred twenty-three primary open-angle glaucoma subjects ( 123 eyes ) were treated with 0.5 % aqueous formulations of ophthalmic @ChemicalSrc$ timolol @/ChemicalSrc$ . IOP and heart rate were measured before and after @ChemicalSrc$ timolol @/ChemicalSrc$ administration . DNA was extracted from venous leukocytes of all the subjects . Two single-nucleotide polymorphisms ( SNPs ) of @GeneTgt$ CYP2D6 @/GeneTgt$ , for example , rs16947 ( 2850C&gt;T , R296C ) and rs1135840 ( 4180C&gt;G , S486 T ) , were detected by restriction fragment length polymorphism analysis . RESULTS : Neither rs16947 ( P = 0.339 ) nor rs1135840 ( P = 0.903 ) genotype was statistically correlated with the IOP-lowering effect of @ChemicalSrc$ timolol @/ChemicalSrc$ eye drops . The rs16947 genotype was significantly associated with occurrence of bradycardia in primary open-angle glaucoma patients ( P = 0.021 ) . The patients with rs16947 CT ( P = 0.043 ) or TT ( P = 0.043 ) were more inclined to bradycardia than those with rs16947 CC , although there was no significant difference between CT and TT ( P = 0.177 ) . The analysis of variance showed no significant difference in heart rate ( P = 0.559 ) among GG , GC , and CC groups . CONCLUSIONS : @GeneTgt$ CYP2D6 @/GeneTgt$ SNP rs16947 may confer susceptibility to @ChemicalSrc$ timolol-induced @/ChemicalSrc$ bradycardia . Patients with CC genotype were unlikely to suffer from @ChemicalSrc$ timolol-induced @/ChemicalSrc$ bradycardia , whereas those with TT genotype were found to suffer from @ChemicalSrc$ timolol-induced @/ChemicalSrc$ bradycardia .	20 6 2|6 6 2|6 6 1 8 1 11 11 8|9 8 8|9 16 16 16 8 20 20 20 20 20 24 27 27 24 29 27 35 33|30 33 33|30 35 35 29 39 39 39 35 41 39 41 44 41 47 47 44 47 51 51 47|49 47 47|49 27 70 70 59 60 64 64 64 64 70 67 67 64 67 70 70 75 73 75 75 70 78 78 75|77 75 75|77 70 87 82 85 82 87 87 93 88 88 90|93 93 90|93 87 87 98 98 98 101 101 98 105 105 105 101 98 109 109 136 111 109 111 114 111|113 111 111|113 111 118 111 111 111 124 121 124 120 124 111 111 129 127 129 129 129 129 111 136 136 142 142 142 142 142 136 136 164 145 148 151 150 151 145 151 151 145 161 161 161 157 158 158 164 164 164 164 168 168 168 164 173 169|173 173 169|173 173 168 164 178 178 181 181 181 181 183 181 185 183 190 190 190 190 185 193 193 190 193 193 181 198 216 201 201 198 204 204 201 204 205 204 204 210 208 210 211 210 216 216 216 218 216 220 218 223 223 220 216 227 227 216 230 230 227 232 230 232 232 236 237 232 237 216 216 242 245 244 242 245 248 248 245 251 251 248 254 254 251 254 254 258 254 258 258 258 258 258 258 245 266 266 267|271 271 267|271 271 273 273 266 273 278 274|278 278 274|278 274 266 287 285 285 282 287 287 289 287 293 290|293 293 290|293 289 287 301 301 299 299 296 301 287 303 301 307 307|303 307 307|303 303 287	Association
20938339	Chemical	Gene	D000077204	2950	True	0	What is [PHARMGKB] between @ChemicalSrc$ TMZ @/ChemicalSrc$ and @GeneTgt$ GSTP1 @/GeneTgt$ ? [SEP] @ChemicalSrc$ Temozolomide-induced @/ChemicalSrc$ severe myelosuppression : analysis of clinically associated polymorphisms in two patients . Genotyping of putative determinants of @ChemicalSrc$ temozolomide @/ChemicalSrc$ @ChemicalSrc$ (TMZ)-induced @/ChemicalSrc$ life-threatening bone marrow suppression was performed in two patients with glioma treated with adjuvant @ChemicalSrc$ TMZ @/ChemicalSrc$ and radiation therapy . DNA was extracted from the patients ' mononuclear cells and genotyping of O-methylguanine-DNA-methyltransferase ( MGMT ) , multidrug resistance ( MDR1 ; also known as ABCB1 ) , NQO1 , and @GeneTgt$ GSTP1 @/GeneTgt$ genes and analysis for the epigenetic silencing of specific MGMT gene promoters were carried out to evaluate the possible genetic determinants of increased risk of severe @ChemicalSrc$ TMZ-induced @/ChemicalSrc$ myelosuppression . Although both patients were heterozygous for all ABCB1 single nucleotide polymorphisms and for rs12917 and rs1803965 in the MGMT gene , patient 1 was heterozygous for rs1695 in @GeneTgt$ GSTP1 @/GeneTgt$ and rs2308327 in the MGMT gene . This patient also exhibited GG genotype for the MGMT single nucleotide polymorphisms , rs2308321 , which is noteworthy for its 0.7 % frequency globally . Epigenetic silencing of MGMT gene was not detected in either patient . Two single nucleotide polymorphisms identified in patient 1 ( missense I143V and K178R polymorphisms ; rs2308321 and rs2308327 , respectively ) have recently been shown to correlate with an increased risk of severe @ChemicalSrc$ TMZ-induced @/ChemicalSrc$ myelosuppression . The polymorphisms identified in patient 2 have not been associated with an increased risk of severe @ChemicalSrc$ TMZ-induced @/ChemicalSrc$ myelosuppression . Genotyping analyses of larger patient populations administered @ChemicalSrc$ TMZ @/ChemicalSrc$ are required to validate the genetic determinants of severe @ChemicalSrc$ TMZ-induced @/ChemicalSrc$ myelosuppression .	0|4 4 0|4 4 4 4 4 10 9 10 6 13 13 10 4 30 19 19 16 28 23|20 23 23|20 28|21 28 28|21 28 28 28 19 30 30 33 33 30 35 33 35 39 39 36 36 36 39 43 39 30 50 50 50 56 53 56 53 56 50 50 50 60 58 62 60 62 60 66 58 68 66 68 71 68 73 71 73 68 68 68 68 68|78 68 68|78 68 50 94 87 87 87 83 92 92 92 92 87 94 50 94 97 94 101 101 101 97 104 104 101 109 109 105|109 109 105|109 104 50 117 115 117 117 137 123 123 123 123 123 117 123 126 123 126 126 132 132 132 126 137 137 134 137 137 139 137 141 139|140 139 139|140 139 139 148 148 148 144 137 152 154 154 154 156 154 162 162 162 162 162 156 162 162 162 168 168 162 173 173 172 173 168 173 154 177 183 180 180 177 183 183 183 186 186 183 183 191 191 191 192 192 194 192 194 198 198 194 198 198 198 198 198 203 203 198 198 198 212 212 212 192 214 212 218 218 218 214 223 223 220|223 223 220|223 218 192 227 235 227 230 228 230 235 235 235 235 239 239 239 235 244 244 241|244 244 241|244 239 235 248 253 252 252 252 248 253 253 253 253 257 253 259 257 262 262 259 267 267 263|267 267 263|267 262 253	Association
20938339	Chemical	Gene	D000077204	4255	True	0	What is [PHARMGKB] between @ChemicalSrc$ TMZ @/ChemicalSrc$ and @GeneTgt$ MGMT @/GeneTgt$ ? [SEP] @ChemicalSrc$ Temozolomide-induced @/ChemicalSrc$ severe myelosuppression : analysis of clinically associated polymorphisms in two patients . Genotyping of putative determinants of @ChemicalSrc$ temozolomide @/ChemicalSrc$ @ChemicalSrc$ (TMZ)-induced @/ChemicalSrc$ life-threatening bone marrow suppression was performed in two patients with glioma treated with adjuvant @ChemicalSrc$ TMZ @/ChemicalSrc$ and radiation therapy . DNA was extracted from the patients ' mononuclear cells and genotyping of @GeneTgt$ O-methylguanine-DNA-methyltransferase @/GeneTgt$ ( @GeneTgt$ MGMT @/GeneTgt$ ) , multidrug resistance ( MDR1 ; also known as ABCB1 ) , NQO1 , and GSTP1 genes and analysis for the epigenetic silencing of specific @GeneTgt$ MGMT @/GeneTgt$ gene promoters were carried out to evaluate the possible genetic determinants of increased risk of severe @ChemicalSrc$ TMZ-induced @/ChemicalSrc$ myelosuppression . Although both patients were heterozygous for all ABCB1 single nucleotide polymorphisms and for rs12917 and rs1803965 in the @GeneTgt$ MGMT @/GeneTgt$ gene , patient 1 was heterozygous for rs1695 in GSTP1 and rs2308327 in the @GeneTgt$ MGMT @/GeneTgt$ gene . This patient also exhibited GG genotype for the @GeneTgt$ MGMT @/GeneTgt$ single nucleotide polymorphisms , rs2308321 , which is noteworthy for its 0.7 % frequency globally . Epigenetic silencing of @GeneTgt$ MGMT @/GeneTgt$ gene was not detected in either patient . Two single nucleotide polymorphisms identified in patient 1 ( missense I143V and K178R polymorphisms ; rs2308321 and rs2308327 , respectively ) have recently been shown to correlate with an increased risk of severe @ChemicalSrc$ TMZ-induced @/ChemicalSrc$ myelosuppression . The polymorphisms identified in patient 2 have not been associated with an increased risk of severe @ChemicalSrc$ TMZ-induced @/ChemicalSrc$ myelosuppression . Genotyping analyses of larger patient populations administered @ChemicalSrc$ TMZ @/ChemicalSrc$ are required to validate the genetic determinants of severe @ChemicalSrc$ TMZ-induced @/ChemicalSrc$ myelosuppression .	0|4 4 0|4 4 4 4 4 10 9 10 6 13 13 10 4 30 19 19 16 28 23|20 23 23|20 28|21 28 28|21 28 28 28 19 30 30 33 33 30 35 33 35 39 39 36 36 36 39 43 39 30 50 50 50 56 53 56 53 56 50 50 50 60 58|59 58 58|59 63 60|61 60 60|61 63 60 68 58 70 68 70 73 70 75 73 75 70 70 70 70 70 70 50 96 88 88 88 84 94 94 88|94 94 88|94 94 88 96 50 96 99 96 103 103 103 99 106 106 103 111 111 111|105 111 111|105 106 50 121 119 121 121 142 127 127 127 127 127 121 127 130 127 130 130 137 137 134|137 137 134|137 130 142 142 139 142 142 144 142 146 144 144 144 153 153 149|153 153 149|153 148 142 158 160 160 160 162 160 169 169 164|169 169 164|169 169 169 162 169 169 169 175 175 169 180 180 179 180 175 180 160 185 192 189 186|189 189 186|189 185 192 192 192 195 195 192 192 201 201 201 202 202 204 202 204 208 208 204 208 208 208 208 208 213 213 208 208 208 222 222 222 202 224 222 228 228 228 224 233 233 230|233 233 230|233 228 202 237 245 237 240 238 240 245 245 245 245 249 249 249 245 254 254 251|254 254 251|254 249 245 258 263 262 262 262 258 263 263 263 263 267 263 269 267 272 272 269 277 277 273|277 277 273|277 272 263	Association
21063236	Chemical	Gene	D010644	6810	False	2	What is [PHARMGKB] between @ChemicalSrc$ phenprocoumon @/ChemicalSrc$ and @GeneTgt$ STX4A @/GeneTgt$ ? [SEP] Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 , CYP2C9 , and CYP4F2 genes . BACKGROUND : Genome-wide association studies ( GWAS ) on warfarin and acenocoumarol showed that interindividual dosage variation is mainly associated with single nucleotide polymorphisms ( SNPs ) in VKORC1 and to a lesser extent in CYP2C9 and CYP4F2 . For phenprocoumon dosage , the genes encoding CYP3A4 and ApoE might play a role . OBJECTIVE : To assess the association between common genetic variants within VKORC1 , CYP2C9 , CYP4F2 , CYP3A4 , and ApoE and phenprocoumon maintenance dosage , and to identify novel signals using GWAS . METHODS : We selected all participants from the Rotterdam study who were treated with @ChemicalSrc$ phenprocoumon @/ChemicalSrc$ . For each SNP , we tested the association between the above-mentioned genotypes and age , sex , body mass index , and target INR adjusted-phenprocoumon maintenance dosage . RESULTS : Within our study population ( N=244 ) , VKORC1 , CYP2C9 , CYP4F2 genotypes together explained 46 % of @ChemicalSrc$ phenprocoumon @/ChemicalSrc$ maintenance dosage variation . Each additional VKORC1 variant allele reduced @ChemicalSrc$ phenprocoumon @/ChemicalSrc$ maintenance dosage by 4.8 mg/week ( P&lt;0.0001 ) and each additional CYP2C9 variant allele by 2.2 mg/week ( P=0.002 ) . Each additional variant allele of CYP4F2 increased @ChemicalSrc$ phenprocoumon @/ChemicalSrc$ dosage by 1.5 mg/week ( P=0.022 ) . Variant alleles of CYP3A41*B and ApoE showed no association with phenprocoumon dosage . Genome-wide significant SNPs were all related to VKORC1 activity . Best associated were two SNPs in complete linkage disequilibrium with each other and with SNPs within VKORC1 : rs10871454 [ @GeneTgt$ Syntaxin 4A @/GeneTgt$ ( @GeneTgt$ STX4A @/GeneTgt$ ) ] and rs11150604 ( ZNF646 ) , each with a P value of 2.1x10 - 22 . Each reduced phenprocoumon maintenance dosage weekly by 4.9 mg per variant allele . CONCLUSION : Similar to earlier findings with warfarin and acenocoumarol , @ChemicalSrc$ phenprocoumon @/ChemicalSrc$ maintenance dosage depended on polymorphisms in the VKORC1 gene . CYP2C9 and CYP4F2 were of modest relevance .	1 4 4 1 6 4 9 9 6 9 9 9 9 9 9 1 17 17 21 21 29 23 21 23 26 21 26 26 17 36 33 33 36 36 36 29 40 40 40 36 42 40 42 45 40 45 50 50 50 40 52 50 52 52 17 58 58 67 67 61 67 61 62 63 63 67 67 69 67 67 71 74 74 71 76 74 80 80 80 76 82 80 82 82 82 82 82 82 82 82 82 82 94 95 82 80 74 99 74 101 99 101 102 71 108 108 108 108 110 108 114 114 114 110 117 117 114 119 117|118 117 117|118 108 125 125 128 128 128 128 130 128 134 134 134 130 134 134 136 136 138 142 142 138 142 138 149 147 149 149 138 128 151 151 156 156 156 168 158 156 158 158 158 161 161 168 166 168 168 151 170 168 176 175|171 175 175|171 175 176 170 151 183 183 183 183 184 184 188|184 188 188|184 188 184 191 191 184 193 191 193 191 200 200 200 200 191 203 203 200 205 203 205 184 212 212 212 215 214 212 215 218|215 218 218|215 215 221 221 215 223 221 223 215 228 233 230 228 230 230 233 235 233 238 238 235 233 242 242 245 245 245 245 248 248 245 245 251 254 254 254 254 258 258 258 254 261 261 258 261 264 261 266 264 254 279 279 269|270 269|270 269|270 269|270 274 270|271 270 270|271 274 274 270 254 281 279 281 279 254 288 288 288 284 290 288 292 290 254 297 297 300 300 297 297 304 304 297 307 307 304 297 309 309 324 314 314 311 316 314 316 316 324 319|323 323 319|323 323 324 309 326 324 330 330 330 326 309 339 333 333 339 339 339 339 339	Association
21121774	Chemical	Gene	D017374	1544	True	0	What is [PHARMGKB] between @ChemicalSrc$ paroxetine @/ChemicalSrc$ and @GeneTgt$ CYP1A2 @/GeneTgt$ ? [SEP] @GeneTgt$ CYP1A2 @/GeneTgt$ genetic polymorphisms are associated with treatment response to the antidepressant @ChemicalSrc$ paroxetine @/ChemicalSrc$ . AIM : @ChemicalSrc$ Paroxetine @/ChemicalSrc$ is a drug of choice in the treatment of major depressive disorder ( MDD ) . Its metabolism has recently been reported to be mediated through the CYP enzymes 1A2 and 2D6 . In our current study , we tested whether genetic polymorphisms in @GeneTgt$ CYP1A2 @/GeneTgt$ are associated with the treatment efficacy and side effects of @ChemicalSrc$ paroxetine @/ChemicalSrc$ . MATERIALS & amp ; METHODS : A total of 241 MDD patients who had taken @ChemicalSrc$ paroxetine @/ChemicalSrc$ continually for 8 weeks were recruited , and their steady state @ChemicalSrc$ paroxetine @/ChemicalSrc$ concentrations were measured at weeks 2 , 4 and 8 . The genotypes of these patients were then assessed for the presence of nine SNPs , which were selected from either the HapMap Chinese ethnic group , the literature report or through their functional role in the @GeneTgt$ CYP1A2 @/GeneTgt$ gene . RESULTS : The allele types for SNPs rs4646425 ( permutation p = 0.03 ) , rs2472304 ( permutation p = 0.01 ) and rs2470890 ( permutation p = 0.004 ) demonstrated significant associations with @ChemicalSrc$ paroxetine @/ChemicalSrc$ treatment remission at week 8 . Response rates in the Hamilton Rating Scale for Depression ( HAM-D ) and for The Hamilton Rating Scale for Anxiety ( HAM-A ) were significantly associated with the SNPs rs4646425 ( p = 0.0126 and 0.0088 for HAM-D and HAM-A , respectively ) and rs4646427 ( p = 0.0067 and 0.0196 for HAM-D and HAM-A , respectively ) . The inducible SNP rs762551 had a significant association with @ChemicalSrc$ paroxetine @/ChemicalSrc$ dose at week 4 ( permutation p = 0.012 ) . We did not find an association between these SNPs and the side effects or serum concentrations of @ChemicalSrc$ paroxetine @/ChemicalSrc$ . CONCLUSION : Genetic variants in the @GeneTgt$ CYP1A2 @/GeneTgt$ region may be indicators of treatment response in MDD patients to @ChemicalSrc$ paroxetine @/ChemicalSrc$ .	0|4 4 0|4 4 6 6 6 9 9 6 13 13 13 9|11 9 9|11 6 24 24 19|24 24 19|24 24 24 24 26 24 29 29 24 33 33 33 29 35 33 35 24 40 44 44 44 44 44 47 47 44 51 51 51 47 51 52 52 44 59 59 59 62 62 62 62 70 65 70 67 65|66 65 65|66 70 62 74 74 74 70 74 77 74 79 74|77 74 74|77 62 84 84 84 84 84 84 91 106 95 95 95 91 98 98 95 98 98 98 98 104 104 98 106 84 106 106 114 114 114 110|114 114 110|114 116 116 106 118 116 118 119 119 119 119 106 128 134 131 131 128 134 134 134 137 137 134 140 140 137 140 144 144 140 151 151 148 151 151 151 144 140 155 155 137 155 160 160 160 155 165 165 162|165 165 162|165 160 134 198 168 172 172 198 174 172 174 178 178 175 178 179 178 174 174 187 186 187 183 187 187 174 174 195 194 195 172 195 195 198 200 198 205 201|205 205 201|205 205 200 207 200 207 198 211 235 216 216 216 216 211 218 216 220 218 220 216 227 227 227 227 216 229 227 231 229 231 235 235 235 238 238 235 238 242 242 238 242 242 242 247 242 247 247 242 242 242 238 238 257 257 238 257 257 257 262 257 262 262 257 257 257 235 273 273 273 274 274 277 277 274 281 278|281 281 278|281 277 283 277 283 288 287 288 277 288 288 274 296 296 296 296 298 296 301 301 298 301 305 305 301 305 308 305 310 309|305 305 309|305 296 314 314 317 325 322 322 322|319 322 322|319 317 325 325 314 328 328 325 331 331 328 333 331|328 328 331|328 325	Association
21159314	Chemical	Gene	D012254	596	True	0	What is [PHARMGKB] between @ChemicalSrc$ ribavirin @/ChemicalSrc$ and @GeneTgt$ BCL-2 @/GeneTgt$ ? [SEP] Genetic variation in @GeneTgt$ BCL-2 @/GeneTgt$ and response to interferon in hepatitis C virus type 4 patients . The prevalence of hepatitis C virus ( HCV ) infection varies across the world , with the highest number of infections reported in Egypt . @GeneTgt$ BCL-2 @/GeneTgt$ gene polymorphism at codon 43 ( 127G/A ) has been found to be a reliable and sensitive marker for the prediction of response to interferon therapy during viral infections . This study examined the correlation of @GeneTgt$ BCL-2 @/GeneTgt$ gene polymorphism with the response to treatment with pegylated-IFN-alfa2b and @ChemicalSrc$ ribavirin @/ChemicalSrc$ . Eighty patients with type 4 HCV and 40 healthy volunteers as controls were enrolled in a prospective study . Quantification of HCV-RNA by real-time PCR was performed for every patient , and gene polymorphism of @GeneTgt$ BCL-2 @/GeneTgt$ ( ala 43 Thr ) was performed for all patients and controls . There was a statistically significant difference between non-responder patients and control group as regards the 43 Thr genotype and allele ( P&lt;0.05 ) . Also , there was a statistically significant difference between responders and non-responders ( P&lt;0.05 ) as regards 43 Thr genotype and alleles . We conclude that @GeneTgt$ BCL-2 @/GeneTgt$ gene polymorphism at codon 43 ( 127G/A ) is a new biological marker to potentially identify responders and non-responders of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN in combination with @ChemicalSrc$ ribavirin @/ChemicalSrc$ .	2 2 4 2|3 2 2|3 4 4 9 7 16 16 16 16 16 16 2 2 20 29 28 24 24 28 26 24 26 20 29 32 32 29 29 37 37 37 29 39 37 39 42 40 29 43|47 47 43|47 47 56 49 47 49 52 49 52 56 56 56 63 63 63 63 60 60 56 66 66 63 68 66 71 71 68 74 74 68 56 78 79 79 81 79 86 86|82 86 86|82 86 81 89 89 81 91 89 93 91 93 93 93 93 79 101 113 103 105 105 101 105 109 109 105 111 109 113 113 117 117 117 113 113 126 121 119 124 124 119 126 126 129 129 126 129 129 133 143 135 134|133 133 134|133 140 140 140 135 140 143 126 146 146 143 146 146 126 152 152 156 155 156 152 159 159 156 159 162 159 164 152 168 168 168 164 168 168 172 170 172 152 178 178 178 178 182 181 182 178 184 182 184 184 188 184 188 191 178 194 194 191 194 194 178 199 199 215 200|204 204 200|204 204 215 206 204 206 209 206 209 215 215 215 215 199 218 218 215 218 219 219 226 224 226 226 219 228 218 232 232 232 228 234 232 236 234 238 234 240 238 238 238 199	Association
21174621	Chemical	Gene	D000077339	2099	True	0	What is [PHARMGKB] between @ChemicalSrc$ leflunomide @/ChemicalSrc$ and @GeneTgt$ ESR1 @/GeneTgt$ ? [SEP] The effect of @GeneTgt$ ESR1 @/GeneTgt$ and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with @ChemicalSrc$ leflunomide @/ChemicalSrc$ . AIM : @ChemicalSrc$ Leflunomide @/ChemicalSrc$ is the drug used in the therapy for rheumatoid arthritis ( RA ) . Previous studies indicated that the efficacy of the therapy with antirheumatic drugs is more effective in men than in women . Moreover , estrogens can decrease the anti-inflammatory action of @ChemicalSrc$ leflunomide @/ChemicalSrc$ . Estrogens act through the estrogen receptors @GeneTgt$ ESR1 @/GeneTgt$ and ESR2 . In @GeneTgt$ ESR1 @/GeneTgt$ and ESR2 genes , several polymorphisms have been detected . The aim of the present study was to examine the association between polymorphisms in the @GeneTgt$ ESR1 @/GeneTgt$ and ESR2 genes and the response to treatment of RA patients with @ChemicalSrc$ leflunomide @/ChemicalSrc$ . MATERIALS & amp ; METHODS : The study was carried out on 115 women , mean age 54.1 + - 11.0 years , diagnosed with RA and treated with @ChemicalSrc$ leflunomide @/ChemicalSrc$ ( 20 mg daily ) . RESULTS : Our results indicated a better response to treatment in patients with @GeneTgt$ ESR1 @/GeneTgt$ rs9340799 AA and rs2234693 TT genotypes after 12 months of therapy . In these patients , the improvement of erythrocyte sedimentation rate , patient 's global assessment of disease activity on a 100 mm visual analog scale and disease activity score values was greater than in patients with other genotypes . The @GeneTgt$ ESR1 @/GeneTgt$ rs9340799-rs2234693 A-T haplotype was associated with a better response to treatment , the G-C haplotype with a worse response and the A-C haplotype was neutral . There were no statistically significant associations of response to treatment with ESR2 gene rs4986938 and rs1256049 polymorphisms . CONCLUSION : The results of the present study suggest that @GeneTgt$ ESR1 @/GeneTgt$ gene polymorphisms in females with RA may be associated with the response to treatment with @ChemicalSrc$ leflunomide @/ChemicalSrc$ .	2 2 4 2|3 2 2|3 4 4 9 4 12 12 2 16 16 16 12 18 16 16 16 2 29 29 24|29 29 24|29 29 29 29 29 33 33 30 36 36 33 38 36 38 29 43 44 44 56 47 56 50 50 47 53 53 50 56 56 44 58 56 61 61 56 44 67 67 67 67 67 70 70 67 72 70|71 70 70|71 67 77 77 81 81 81 77 81 81 81 82 82 77 89 88|99 99 88|99 89 89 89 99 96 99 99 99 99 99 103 108 107 107 107 103 108 110 108 112 110 114 112 117 117 114|116 114 114|116 117 117 117 114 124 114 126 124 129 129 126 131 126|129 126 126|129 108 136 136 136 136 136 136 143 145 145 136 145 149 149 145 149 136 151 157 153 156 153 136 136 136 161 159 159 159 165 163|164 163 163|164 169 169 170 163 136 136 174 174 177 178 174 181 181 178 183 181 185 183 190 190|186 190 190|186 190 185 190 190 194 190 197 197 178 199 197 178 204 204 216 216 207 216 211 211 211 207 211 216 213 216 216 219 219 216 226 226 223 226 226 226 216 226 229 231 231 233 233 216 236 236 233 239 239 236 233 246 241|246 246 241|246 242 246 248 248 248 252 252 252 248 254 252 268 258 258 268 262 262 262 258 262 266 266 268 268 248 268 272 272 276 275 276 272 278 276 280 278 284 283 284 280 284 284 284 272 289 297 292 297 296 296 296 292 289 309 298|302 302 298|302 302 309 304 302 306 304 309 309 297 312 312 309 314 312 316 314 314 314 289	Association
21174621	Chemical	Gene	D000077339	2100	True	0	What is [PHARMGKB] between @ChemicalSrc$ leflunomide @/ChemicalSrc$ and @GeneTgt$ ESR2 @/GeneTgt$ ? [SEP] The effect of ESR1 and @GeneTgt$ ESR2 @/GeneTgt$ gene polymorphisms on the outcome of rheumatoid arthritis treatment with @ChemicalSrc$ leflunomide @/ChemicalSrc$ . AIM : @ChemicalSrc$ Leflunomide @/ChemicalSrc$ is the drug used in the therapy for rheumatoid arthritis ( RA ) . Previous studies indicated that the efficacy of the therapy with antirheumatic drugs is more effective in men than in women . Moreover , estrogens can decrease the anti-inflammatory action of @ChemicalSrc$ leflunomide @/ChemicalSrc$ . Estrogens act through the estrogen receptors ESR1 and @GeneTgt$ ESR2 @/GeneTgt$ . In ESR1 and @GeneTgt$ ESR2 @/GeneTgt$ genes , several polymorphisms have been detected . The aim of the present study was to examine the association between polymorphisms in the ESR1 and @GeneTgt$ ESR2 @/GeneTgt$ genes and the response to treatment of RA patients with @ChemicalSrc$ leflunomide @/ChemicalSrc$ . MATERIALS & amp ; METHODS : The study was carried out on 115 women , mean age 54.1 + - 11.0 years , diagnosed with RA and treated with @ChemicalSrc$ leflunomide @/ChemicalSrc$ ( 20 mg daily ) . RESULTS : Our results indicated a better response to treatment in patients with ESR1 rs9340799 AA and rs2234693 TT genotypes after 12 months of therapy . In these patients , the improvement of erythrocyte sedimentation rate , patient 's global assessment of disease activity on a 100 mm visual analog scale and disease activity score values was greater than in patients with other genotypes . The ESR1 rs9340799-rs2234693 A-T haplotype was associated with a better response to treatment , the G-C haplotype with a worse response and the A-C haplotype was neutral . There were no statistically significant associations of response to treatment with @GeneTgt$ ESR2 @/GeneTgt$ gene rs4986938 and rs1256049 polymorphisms . CONCLUSION : The results of the present study suggest that ESR1 gene polymorphisms in females with RA may be associated with the response to treatment with @ChemicalSrc$ leflunomide @/ChemicalSrc$ .	2 2 4 2 4 4|5 4 4|5 9 4 12 12 2 16 16 16 12 18 16 16 16 2 29 29 24|29 29 24|29 29 29 29 29 33 33 30 36 36 33 38 36 38 29 43 44 44 56 47 56 50 50 47 53 53 50 56 56 44 58 56 61 61 56 44 67 67 67 67 67 70 70 67 72 70|71 70 70|71 67 77 77 81 81 81 77 81 82 83|82 82 83|82 77 89 99 89 89|90 89 89|90 89 99 96 99 99 99 99 99 103 108 107 107 107 103 108 110 108 112 110 114 112 117 117 114 117 117|118 117 117|118 117 114 124 114 126 124 129 129 126 131 126|129 126 126|129 108 136 136 136 136 136 136 143 145 145 136 145 149 149 145 149 136 151 157 153 156 153 136 136 136 161 159 159 159 165 163|164 163 163|164 169 169 170 163 136 136 174 174 177 178 174 181 181 178 183 181 185 183 189 189 189 185 189 189 193 189 196 196 178 198 196 178 202 202 214 214 205 214 209 209 209 205 209 214 211 214 214 217 217 214 224 224 221 224 224 224 214 224 227 229 229 231 231 214 234 234 231 237 237 234 231 243 243 240 243 245 245 245 249 249 249 245 251 249 265 255 255 265 259 259 259 255 259 263 263 265 265 245 265 268 268 272 271 272 268 274 272 276 274 281 277|280 280 277|280 281 276 281 281 281 268 287 295 290 295 294 294 294 290 287 306 299 299 306 301 299 303 301 306 306 295 309 309 306 311 309 313 311|312 311 311|312 287	Association
21228734	Chemical	Gene	D008558	1493	False	3	What is [PHARMGKB] between @ChemicalSrc$ melphalan @/ChemicalSrc$ and @GeneTgt$ CTLA4 @/GeneTgt$ ? [SEP] Genetic variation associated with bortezomib-induced peripheral neuropathy . OBJECTIVE : To develop a predictive genetic signature for the development of bortezomib-induced peripheral neuropathy ( PN ) . METHODS : Two thousand and sixteen single-nucleotide polymorphisms ( SNPs ) were genotyped in 139 samples from myeloma patients treated with @ChemicalSrc$ bortezomib-melphalan-prednisone @/ChemicalSrc$ in the VISTA phase 3 trial . Single-marker association analysis for PN onset and time/cumulative dose to PN onset using the Cox proportional hazards model and multiple covariates was performed under additive , dominant , and recessive genotypic models , followed by correction for multiplicity . Associations were also pursued in a cohort of 212 samples from patients treated with bortezomib-dexamethasone in the IFM 2005 - 01 phase 3 trial . RESULTS : In the VISTA cohort , after Bonferroni correction , two SNPs significantly associated with time to onset of PN [ @GeneTgt$ CTLA4 @/GeneTgt$ rs4553808 , false discovery rate (FDR)=0.002 ] and time to onset of grade of at least 2 PN ( PSMB1 rs1474642 , FDR=0.014 ) . Using FDR less than 0.05 as the threshold , two additional SNPs significantly associated with time to onset of grade of at least 2 ( CTSS rs12568757 , FDR=0.027 ) or grade of at least 3 PN ( GJE1 rs11974610 , FDR=0.041 ) . DYNC1I1 rs916758 significantly associated ( FDR=0.012 ) with cumulative dose to onset of grade of at least 2 PN . These associations were generally not detected in the IFM 2005 - 01 cohort , although @GeneTgt$ CTLA4 @/GeneTgt$ rs4553808 showed the same trend in association with time to onset ( P=0.138 ) . In addition , in the IFM 2005 - 01 cohort , TCF4 rs1261134 significantly associated with onset of any neurologic event ( FDR=0.048 ) . CONCLUSION : Genes associated with immune function ( @GeneTgt$ CTLA4 @/GeneTgt$ , CTSS ) , reflexive coupling within Schwann cells ( GJE1 ) , drug binding ( PSMB1 ) , and neuron function ( TCF4 , DYNC1I1 ) associated with bortezomib-induced PN in this study .	2 2 2 7 7 7 3 2 9 9 12 9 16 16 16 12 19 19 16 23 23 23 19 25 23 25 9 40 40 31 35 31 31 35 40 37 35 37 40 40 43 43 40 46 46 43 46 49 47|48 47 47|48 56 56 56 56 56 47 40 61 61 81 64 64 61 64 67 64 69 70 61 61 76 74 76 76 71 76 79 81 81 81 90 90 83 83 83 83 83 90 81 81 81 94 92 96 94 81 101 101 101 101 104 104 101 107 107 104 109 107 109 112 110 121 121 121 118 118 119 121 121 110 101 123 123 128 128 128 137 137 132 132 137 137 135 137 137 123 139 137 141 137 143 141 147 147|144 147 147|144 143 147 151 151 152 147 152 147 147 157 141 159 157 164 162 163 164 159 167 167 164 167 167 167 123 186 173 177 175 173 180 180 173 186 184 184 186 186 186 188 186 190 186 192 190 199 195 196 199 199 199 192 199 199 201 192 192 209 207 208 209 204 211 212 209 209 209 186 186 218 220 220 220 222 220 222 226 226 222 228 220 230 228 235 233 234 235 230 220 238 242 242 242 242 242 249 249 249 248 248 249 242 242 255 254|251 254 254|251 255 242 258 258 255 260 258 262 260 264 260 266 264 266 242 271 282 282 279 279 279 278 278 279 282 282 282 282 284 282 286 284 290 290 290 286 292 290 292 282 295 295 295 297 301 301 298 303 302|301 301 302|301 303 303 303 301 310 297 313 313 310 315 313 315 313 319 310 321 319 321 297 297 326 297 328 326 328 328 328 297 335 335 332 338 338 332 295	Association
21228734	Chemical	Gene	D000069286	1493	True	0	What is [PHARMGKB] between @ChemicalSrc$ bortezomib @/ChemicalSrc$ and @GeneTgt$ CTLA4 @/GeneTgt$ ? [SEP] Genetic variation associated with @ChemicalSrc$ bortezomib-induced @/ChemicalSrc$ peripheral neuropathy . OBJECTIVE : To develop a predictive genetic signature for the development of @ChemicalSrc$ bortezomib-induced @/ChemicalSrc$ peripheral neuropathy ( PN ) . METHODS : Two thousand and sixteen single-nucleotide polymorphisms ( SNPs ) were genotyped in 139 samples from myeloma patients treated with @ChemicalSrc$ bortezomib-melphalan-prednisone @/ChemicalSrc$ in the VISTA phase 3 trial . Single-marker association analysis for PN onset and time/cumulative dose to PN onset using the Cox proportional hazards model and multiple covariates was performed under additive , dominant , and recessive genotypic models , followed by correction for multiplicity . Associations were also pursued in a cohort of 212 samples from patients treated with @ChemicalSrc$ bortezomib-dexamethasone @/ChemicalSrc$ in the IFM 2005 - 01 phase 3 trial . RESULTS : In the VISTA cohort , after Bonferroni correction , two SNPs significantly associated with time to onset of PN [ @GeneTgt$ CTLA4 @/GeneTgt$ rs4553808 , false discovery rate (FDR)=0.002 ] and time to onset of grade of at least 2 PN ( PSMB1 rs1474642 , FDR=0.014 ) . Using FDR less than 0.05 as the threshold , two additional SNPs significantly associated with time to onset of grade of at least 2 ( CTSS rs12568757 , FDR=0.027 ) or grade of at least 3 PN ( GJE1 rs11974610 , FDR=0.041 ) . DYNC1I1 rs916758 significantly associated ( FDR=0.012 ) with cumulative dose to onset of grade of at least 2 PN . These associations were generally not detected in the IFM 2005 - 01 cohort , although @GeneTgt$ CTLA4 @/GeneTgt$ rs4553808 showed the same trend in association with time to onset ( P=0.138 ) . In addition , in the IFM 2005 - 01 cohort , TCF4 rs1261134 significantly associated with onset of any neurologic event ( FDR=0.048 ) . CONCLUSION : Genes associated with immune function ( @GeneTgt$ CTLA4 @/GeneTgt$ , CTSS ) , reflexive coupling within Schwann cells ( GJE1 ) , drug binding ( PSMB1 ) , and neuron function ( TCF4 , DYNC1I1 ) associated with @ChemicalSrc$ bortezomib-induced @/ChemicalSrc$ PN in this study .	2 2 2 8 8|4 8 8|4 8 3 2 11 11 14 11 18 18 18 14 21 21 18 26 26|22 26 26|22 26 21 28 26 28 11 44 44 35 39 35 35 39 44 41 39 41 44 44 47 47 44 50 50 47 50 53 51|52 51 51|52 60 60 60 60 60 51 44 65 65 85 68 68 65 68 71 68 73 74 65 65 80 78 80 80 75 80 83 85 85 85 94 94 87 87 87 87 87 94 85 85 85 98 96 100 98 85 105 105 105 105 108 108 105 111 111 108 113 111 113 116 114|115 114 114|115 126 126 126 123 123 124 126 126 114 105 129 129 134 134 134 143 143 138 138 143 143 141 143 143 129 145 143 147 143 149 147 153 153|150 153 153|150 149 153 157 157 158 153 158 153 153 163 147 165 163 170 168 169 170 165 173 173 170 173 173 173 129 192 179 183 181 179 186 186 179 192 190 190 192 192 192 194 192 196 192 198 196 205 201 202 205 205 205 198 205 205 207 198 198 215 213 214 215 210 217 218 215 215 215 192 192 224 226 226 226 228 226 228 232 232 228 234 226 236 234 241 239 240 241 236 226 244 248 248 248 248 248 255 255 255 254 254 255 248 248 261 260|257 260 260|257 261 248 264 264 261 266 264 268 266 270 266 272 270 272 248 277 288 288 285 285 285 284 284 285 288 288 288 288 290 288 292 290 296 296 296 292 298 296 298 288 301 301 301 303 307 307 304 309 308|307 307 308|307 309 309 309 307 316 303 319 319 316 321 319 321 319 325 316 327 325 327 303 303 332 303 334 332 334 334 334 303 342 342|338 342 342|338 338 345 345 338 301	Association
21261619	Chemical	Gene	D006852	5972	True	0	What is [PHARMGKB] between @ChemicalSrc$ HCTZ @/ChemicalSrc$ and @GeneTgt$ renin @/GeneTgt$ ? [SEP] Genetic variation in @GeneTgt$ renin @/GeneTgt$ predicts the effects of thiazide diuretics . BACKGROUND : While genetic variants of @GeneTgt$ renin-angiotensin-aldosterone @/GeneTgt$ system ( RAAS ) may modify the blood pressure ( BP ) response to thiazide diuretics , there was no evidence of genetic variations in @GeneTgt$ renin @/GeneTgt$ ( @GeneTgt$ REN @/GeneTgt$ ) playing a role . This study aimed to address the potential effects of genetic variations of RAAS on the response to initial treatment of @ChemicalSrc$ hydrochlorothiazide @/ChemicalSrc$ ( @ChemicalSrc$ HCTZ @/ChemicalSrc$ ) . MATERIALS AND METHODS : We enrolled nondiabetic hypertensive patients with a systolic blood pressure ( SBP ) & gt;=140 or a diastolic blood pressure ( DBP ) & gt;=90mmHg , who were either previously untreated or unsatisfactorily treated . After lifestyle modification and diet instruction for 2weeks , 90 patients with persistently elevated BP were given @ChemicalSrc$ HCTZ @/ChemicalSrc$ 50 mg every morning for 2 weeks . Single nucleotide polymorphism markers were selected from genes involving in RAAS , including rs7079 and rs699 of angiotensinogen , rs4293 and rs4353 of angiotensin-converting enzyme and rs1464816 and rs11240688 of @GeneTgt$ REN @/GeneTgt$ . RESULTS : The patients were divided into three groups according to the SBP response after @ChemicalSrc$ HCTZ @/ChemicalSrc$ . The upper 1/3 responders had older age ( P=0 035 ) , higher SBP ( P=0 039 ) , higher pulse pressure ( P=0 006 ) and lower plasma @GeneTgt$ REN @/GeneTgt$ activity ( PRA ) ( P=0 020 ) when compared with the lower 1/3 responders . @GeneTgt$ Renin @/GeneTgt$ rs11240688 CC polymorphism ( beta=9 931 , corrected P=0 012 ) , Log PRA ( beta=7 451 , P=0 004 ) and baseline SBP ( beta=0 299 , P=0 006 ) were the independent predictors for the BP lowering response . CONCLUSIONS : In addition to PRA , @GeneTgt$ renin @/GeneTgt$ rs11240688 CC polymorphism may also independently predict the effect of @ChemicalSrc$ HCTZ @/ChemicalSrc$ .	2 6 4 2|3 2 2|3 6 8 6 11 11 8 6 14 14 27 18 27 22 22|19 22 22|19 18 24 22 24 27 40 34 30 34 32 30 34 27 37 37 34 40 40 14 42 40 45 45 42 47 45 45 45 50 47 47 47 50 45 55 53 40 61 62 62 64 62 67 67 64 70 70 67 72 70 75 75 67 78 78 75 80 78|79 78 78|79 83 80|81 80 80|81 83 62 89 89 89 89 94 89 97 97 94 102 102 102 102 97 104 102 104 102 102 107 112 112 112 107 114 112 114 112 112 102 123 123 123 123 102 123 126 123 89 130 130 144 130 133 130 135 133 135 138 144 142 141 142 138 144 144 144|148 148 144|148 148 144 150 148 153 153 144 144 159 159 159 161 161 161 163 161 163 166 164 166 169 166 169 169 173 169 173 173 173 173 180 180 169 180 180 169 169 186 184|185 184 184|185 161 190 190 193 195 195 190 198 198 195 203 199 203 203 195 205 203|204 203 203|204 195 212 212 212 213 213 215 213 217 215 217 217 215 222 215 224 222 224 224 222 230 230 222 232 230 232 232 230 240 240 240|237 240 240|237 230 242 240 242 245 240 245 245 249 213 254 254 254 254 249 213 256|261 261 256|261 257 261 293 263 261 263 263 267 263 267 263 261 272 261 274 272 274 274 274 277 274 261 282 261 284 282 284 284 284 287 284 293 293 293 293 298 298 298 298 293 293 301 301 304 316 306 304 316 312|307 312 312|307 308 312 316 316 316 316 301 318 316 320 318 318 318 301	Association
21269061	Chemical	Gene	D006852	1585	True	0	What is [PHARMGKB] between @ChemicalSrc$ HCTZ @/ChemicalSrc$ and @GeneTgt$ CYP11B2 @/GeneTgt$ ? [SEP] Interaction of ACE and @GeneTgt$ CYP11B2 @/GeneTgt$ genes on blood pressure response to @ChemicalSrc$ hydrochlorothiazide @/ChemicalSrc$ in Han Chinese hypertensive patients . To valuate whether angiotensin converting enzyme ( ACE ) gene insertion/deletion ( I/D ) polymorphism and @GeneTgt$ aldosterone synthase @/GeneTgt$ ( @GeneTgt$ CYP11B2 @/GeneTgt$ ) gene -344T/C polymorphism are associated with individual response to @ChemicalSrc$ hydrochlorothiazide @/ChemicalSrc$ ( @ChemicalSrc$ HCTZ @/ChemicalSrc$ ) in the Han Chinese population with essential hypertension . We enrolled 829 mild/moderate hypertensive patients and 12.5 mg of @ChemicalSrc$ HCTZ @/ChemicalSrc$ was given daily . After 6 weeks , the results showed that the ACE I/D polymorphism , not the @GeneTgt$ CYP11B2 @/GeneTgt$ -344T/C polymorphism , was associated with systolic blood pressure ( SBP ) response to @ChemicalSrc$ HCTZ @/ChemicalSrc$ ( P = 0.009 ) in the Han Chinese population with essential hypertension , with no interaction .	1 3 1 3 3|4 3 3|4 3 11 11 11 1 13 11 11 11 19 19 19 19 11 1 24 24 50 37 28 26 30 33 33 33 28 35 33 35 50 37 38|39|48 38|39|48 39|48 38|39|48 48 40|48 48 40|48 48 48 48 37 50 24 53 53 50 55 51|53 53 51|53 58 55|53 55 55|53 58 65 65 64 65 53 68 68 65 24 75 75 79 79 79 75 79 82 79 84 82|83 82 82|83 87 75 87 75 93 93 97 97 96 97 97 112 102 102 102 112 102 109 109 109|105 109 109|105 109 102 102 112 97 120 116 116 120 118 120 120 112 122 120 120 120 126 126 122 126 126 133 133 132 133 120 136 136 133 112 140 140 112 97	Association
21280081	Chemical	Gene	C071192	1312	True	0	What is [PHARMGKB] between @ChemicalSrc$ entacapone @/ChemicalSrc$ and @GeneTgt$ COMT @/GeneTgt$ ? [SEP] The @GeneTgt$ COMT @/GeneTgt$ Val158Met polymorphism affects the response to @ChemicalSrc$ entacapone @/ChemicalSrc$ in Parkinson 's disease : a randomized crossover clinical trial . OBJECTIVE : In Parkinson disease ( PD ) , the selective @GeneTgt$ C-O-methyltransferase @/GeneTgt$ ( @GeneTgt$ COMT @/GeneTgt$ ) inhibitor @ChemicalSrc$ entacapone @/ChemicalSrc$ prolongs the effect of levodopa on motor symptoms ( ON time ) by increasing its bioavailability . The @GeneTgt$ COMT @/GeneTgt$ Val158Met polymorphism is equally distributed in PD patients and modulates @GeneTgt$ COMT @/GeneTgt$ activity , which can be high ( Val/Val , @GeneTgt$ COMT(HH @/GeneTgt$ ) ) , intermediate ( Val/Met , @GeneTgt$ COMT(HL @/GeneTgt$ ) ) , or low ( Met/Met , @GeneTgt$ COMT(LL @/GeneTgt$ ) ) . The objective of this study was to determine the response to @ChemicalSrc$ entacapone @/ChemicalSrc$ in @GeneTgt$ COMT(HH @/GeneTgt$ ) and @GeneTgt$ COMT(LL @/GeneTgt$ ) PD patients . METHODS : Thirty-three PD patients , homozygous for the @GeneTgt$ COMT @/GeneTgt$ alleles @GeneTgt$ COMT(HH @/GeneTgt$ ) ( n = 17 ) and @GeneTgt$ COMT(LL @/GeneTgt$ ) ( n = 16 ) , were randomized in a double-blind crossover trial consisting of 2 successive acute levodopa challenges associated with 200 mg @ChemicalSrc$ entacapone @/ChemicalSrc$ or placebo . The primary endpoint was the gain in the best ON time . Secondary endpoints were levodopa pharmacokinetics and @GeneTgt$ COMT @/GeneTgt$ activity in red blood cells . RESULTS : The gain in the best ON time was higher in @GeneTgt$ COMT(HH @/GeneTgt$ ) than in @GeneTgt$ COMT(LL @/GeneTgt$ ) patients ( 39 + - 10 vs 9 + - 9 minutes , p = 0.04 , interaction between treatment and genotype ) . Area under the concentration over time curve of levodopa increased more after @ChemicalSrc$ entacapone @/ChemicalSrc$ in @GeneTgt$ COMT(HH @/GeneTgt$ ) than in @GeneTgt$ COMT(LL @/GeneTgt$ ) patients ( + 62 + - 6 % vs + 34 + - 8 % , p = 0.01 ) . @GeneTgt$ COMT @/GeneTgt$ inhibition by @ChemicalSrc$ entacapone @/ChemicalSrc$ was higher in @GeneTgt$ COMT(HH @/GeneTgt$ ) than in @GeneTgt$ COMT(LL @/GeneTgt$ ) patients ( -0.54 + - 0.07 vs -0.31 + - 0.06 pmol/min/mg protein , p = 0.02 ) . INTERPRETATION : The @GeneTgt$ COMT(HH @/GeneTgt$ ) genotype in PD patients enhances the effect of @ChemicalSrc$ entacapone @/ChemicalSrc$ on the pharmacodynamics and pharmacokinetics of levodopa . The response to @ChemicalSrc$ entacapone @/ChemicalSrc$ after repeated administrations and in heterozygous patients remains to be determined .	5 1|5 5 1|5 5 6 6 8 6 10 8 8 8 15 15 13 8 6 21 21 21 21 6 6 25 45 29 29 45 31 29 31 45 42 42 42|35 42 42|35 39 42|37 42 42|37 42 43 40|45 45 40|45 25 47 45 49 47 52 52 47 55 55 52 55 58 45 60 58 45 69 65|69 69 65|69 69 72 72 72 72 75 75 72 72 72 80|76 80 80|76 77 80 85 85 85 80 87 85 89 86|87 87 86|87 89 87 87 87 96 94 96 96|94 96 96|94 96 96 87 87 87 106 104 106 106|103 106 106|103 106 87 72 119 123 122 122 119 123 125 123 127 125 129 127|128 127 127|128 132 127|130 127 127|130 132 127 133|140 140 133|140 140 140 127 123 176 176 149 149 176 149 149 156 156 153|156 156 153|156 151 155|149 149 155|149 157 161 162 149 162 162 149 163|149 149 163|149 166 170 166 170 171 170 149 176 176 181 181 181 181 176 181 188 188 188 188 188 182 188 192 192 189 192|189 192 192|189 193 193 176 204 204 207 207 207 207 212 212 212 212 207 207 215 218 218 218 218 218 222|219 222 222|219 218 226 226 226 218 218 229 229 232 239 237 237 237 237 232 239 229 241 239|240 239 239|240 241 249 249 244|249 249 244|249 249 239 260 260 251 254 251 254 251 251 251 251 249 263 263 260 263 263 260 268 266 268 268 260 229 284 278 278 275 281 281 278 283 281 284 284 287 284|286 284 284|286 290 284|288 284 284|288 290 298 298 298|292 298 298|292 298 284 298 298 305 301 304 301 298 298 298 312 308 308 308 315 315 315 298 315 298 284 321|324 324 321|324 329 326 324 324 324 329 329 331 329|328 329 329|328 331 339 339 339|332 339 339|332 339 329 351 351 341 344 341 344 341 341 349 341 351 339 354 354 351 354 354 329 362 362 368 364|368 368 364|368 365 372 371 371 368 362 374 372 376 374 374 374 380 380 374 380 380 384 380 362 389 400 391 389|390 389 389|390 395 395 389 395 399 399 395 400 403 403 400 400	Association
21327421	Chemical	Gene	D016190	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ carboplatin @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer . PURPOSE : Paclitaxel has a broad spectrum of anti-tumor activity and is useful in the treatment of ovarian , breast , and lung cancer . Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by @GeneTgt$ P-glycoprotein @/GeneTgt$ . The dose-limiting toxicities are neuropathy and neutropenia , but the interindividual variability in toxicity and also survival is large . The main purpose of this study was to investigate the impact of genetic variants in CYP2C8 and @GeneTgt$ ABCB1 @/GeneTgt$ on toxicity and survival . METHODS : The 182 patients previously treated for ovarian cancer with @ChemicalSrc$ carboplatin @/ChemicalSrc$ and paclitaxel in either the AGO-OVAR-9 or the NSGO-OC9804 trial in Denmark or Sweden were eligible for this study . Genotyping was carried out on formalin-fixed tissue . The patients ' toxicity profiles and survival data were derived from retrospective data . CYP2C8 * 3 , @GeneTgt$ ABCB1 @/GeneTgt$ C1236 T , G2677T/A , and C3435 T were chosen a priori for primary analysis ; a host of other variants were entered into an exploratory analysis . RESULTS : Clinical data and tissue were available from a total of 119 patients . Twenty-two single nucleotide polymorphisms ( SNPs ) in 10 genes were determined . Toxicity registration was available from 710 treatment cycles . In the primary analysis , no statistically significant correlation was found between CYP2C8 * 3 , @GeneTgt$ ABCB1 @/GeneTgt$ C1236 T , G2677T/A , and C3435 T and neutropenia , sensoric neuropathy , and overall survival . CONCLUSION : CYP2C8 * 3 and the @GeneTgt$ ABCB1 @/GeneTgt$ SNPs C1236 T , G2677T/A , and C3435 T were not statistically significantly correlated to overall survival , sensoric neuropathy , and neutropenia in 119 patients treated for ovarian cancer with @ChemicalSrc$ paclitaxel/carboplatin @/ChemicalSrc$ .	2 2 5 5 2 8 8 5 11 11 5 11 11 15 11 18 18 15 2 23 23 23 23 26 26 23 29 29 26 23 32 23 35 35 32 37 43 37 37 37 37 43 35 23 47 47 47 50 50 47 52 47 52 52 47 47 58 56|57 56 56|57 47 64 64 66 66 66 66 66 66 66 73 73 80 75 73 73 73 73 80 66 80 84 84 88 87 87 84 88 90 88 92 90 95 95 92 97 95 97 97|98 97 97|98 102 92 102 102 88 135 135 111 111 135 113 111 116 116 113 118 116|117 116 116|117 118 118 125 125 125 113 125 129 129 125 131 129 131 131 135 135 138 138 135 135 143 143 143 143 147 147 143 143 150 158 150 153 150 153 156 153 158 158 161 161 158 158 178 163 163 163 170|166 170 170|166 170 163 163 163 163 163 176 163 178 178 180 178 183 183 180 178 186 191 189 189 186 191 178 195 195 195 191 191 198 198 201 205 201 201 205 198 208 208 205 211 211 208 205 216 216 216 224 218 216 218 222 222 216 224 224 224 227 229 229 229 233 233 233 229 229 238 238 238 245 245 243 242 243 245 245 245 247 245 247 247 247 250|254 254 250|254 254 247 247 247 247 247 260 247 260 260 247 265 247 247 247 269 247 245 272 272 294 274 274 274 281 281|278 281 281|278 274 283 281 283 283 283 283 289 283 294 294 294 294 272 297 297 294 297 300 297 297 297 297 306 306 297 306 310 310 307 312 310 310 310 294	Association
21332319	Chemical	Gene	D003024	2902	True	0	What is [PHARMGKB] between @ChemicalSrc$ clozapine @/ChemicalSrc$ and @GeneTgt$ GRIN1 @/GeneTgt$ ? [SEP] Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and @ChemicalSrc$ clozapine @/ChemicalSrc$ response . AIMS : To investigate the possible association and gene-gene interaction effects of polymorphisms in NMDA receptor subunit ( @GeneTgt$ GRIN1 @/GeneTgt$ , GRIN2A and GRIN2B ) and dopamine receptor ( DRD1 , DRD2 and DRD3 ) genes with @ChemicalSrc$ clozapine @/ChemicalSrc$ response . MATERIALS & amp ; METHODS : @GeneTgt$ GRIN1 @/GeneTgt$ rs11146020 ( G1001C ) , GRIN2A GT-repeat and GRIN2B rs10193895 ( G-200 T ) polymorphisms were tested for association in a Caucasian ( n = 183 ) and an African-American ( n = 49 ) sample using chi(2 ) and ANOVA tests . Logistic regression and two-way ANOVA were used to explore gene-gene interaction effects with dopamine receptor gene variants . RESULTS & amp ; CONCLUSION : This study does not support the involvement of the NMDA receptor subunit gene polymorphisms in @ChemicalSrc$ clozapine @/ChemicalSrc$ response . All tests for an association were negative . Gene-gene interaction analyses however yielded promising leads , including an observed effect between DRD1 rs686 and DRD3 Ser9Gly polymorphisms on @ChemicalSrc$ clozapine @/ChemicalSrc$ response ( p = 0.002 ) .	3 3 3 7 7 7 3 7 12 12 12 7 7 16|13 16 16|13 7 3 22 22 22 22 25 25 22 25 29 29 25 31 25 35 35 35 54 37 35|36 35 35|36 37 37 37 37 37 35 46 35 48 46 48 48 48 48 48 25 58 58|54 58 58|54 25 22 62 62 62 62 62 66 70|67 70 70|67 84 72 70 72 70 76 70 76 79 70 82 82 84 82 86 86 62 88 86 91 91 105 93 94 91 94 94 91 99 91 101 99 101 102 105 88 105 106 107 105 111 105 62 115 120 115 118 115 120 120 122 120 125 125 122 130 130 130 130 125 120 132 132 132 132 132 132 139 142 142 142 132 144 142 151 151 151 151 151 151 144 155 155|152 155 155|152 144 142 159 164 162 162 159 164 164 164 168 168 170 170 170 172 170 172 177 177 177 172 179 180 177 180 180 184 180 188 185|188 188 185|188 184 191 191 180 191 191 170	Association
21427285	Chemical	Gene	D000069059	3156	True	0	What is [PHARMGKB] between @ChemicalSrc$ atorvastatin @/ChemicalSrc$ and @GeneTgt$ HMGCR @/GeneTgt$ ? [SEP] Effect of @GeneTgt$ HMGCR @/GeneTgt$ variant alleles on low-density lipoprotein cholesterol-lowering response to @ChemicalSrc$ atorvastatin @/ChemicalSrc$ in healthy Korean subjects . The investigators quantified the relationship between the genetic polymorphism of @GeneTgt$ HMGCR @/GeneTgt$ ( 3-hydroxy-3-methylglutaryl coenzyme A reductase ) and the low-density lipoprotein cholesterol (LDL-C)-lowering effects of @ChemicalSrc$ atorvastatin @/ChemicalSrc$ in a prospective clinical study . Twenty-four healthy participants were grouped into @GeneTgt$ HMGCR @/GeneTgt$ rs3846662 GG ( n = 13 ) and AA ( n = 11 ) genotypes and given @ChemicalSrc$ atorvastatin @/ChemicalSrc$ ( 20 mg/d ) for 14 days . Serum levels of LDL-C , high-density lipoprotein cholesterol , total cholesterol , triglycerides , and creatinine kinase ( CK ) were measured before ( day 1 ) and 7 , 13 , 14 , 15 , 16 , 21 , and 28 days after dosing initiation . Blood samples for pharmacokinetics were taken on days 14 through 16 . The levels of LDL-C in the GG group were significantly higher than in the AA group at all observation times , with mean differences of 18 % to 33 % ( P & lt ; .05 ) . The area under the LDL-C-time curve and the minimum value of LDL-C in the GG group were 24 % and 23 % higher than in the AA group , respectively ( P & lt ; .01 ) . There was no significant difference in other lipids , CK , and pharmacokinetic parameters . The @GeneTgt$ HMGCR @/GeneTgt$ rs3846662 GG genotype was quantitatively documented to be a significant determinant for higher LDL-C level in basal state and possibly in response to @ChemicalSrc$ atorvastatin @/ChemicalSrc$ .	1 6 2|6 6 2|6 6 1 11 11 10 11 1 13 11 11 11 18 18 18 11 1 23 24 24 26 24 30 30 30 26 32 30|31 30 30|31 38 38 38 38 32 38 30 44 44 44 46 46 30 48 46 46 46 54 54 54 54 24 24 60 60 62 62 62 67 67|63 67 67|63 67 80 69 67 69 70 70 69 69 76 74 76 77 76 62 80 80 81|82 82 81|82 87 87 83 87 91 91 82 62 96 116 98 96 98 102 102 98 98 105 98 98 98 98 98 111 98 113 111 113 116 116 119 119 116 119 119 116 137 123 123 123 123 123 123 123 123 123 123 123 123 123 138 140 140 116 116 143 147 145 143 147 147 149 147 149 152 149 147 155 164 157 155 161 161 161 155 164 164 164 169 169 169 169 164 173 173 173 164 164 177 177 164 180 180 177 183 183 177 185 183 185 185 185 164 189 164 193 210 197 197 197 193 193 201 201 193 203 201 207 207 207 201 210 210 210 210 213 214 210 219 219 219 219 214 214 214 223 214 223 223 223 223 223 210 231 231 234 234 231 237 237 234 237 237 237 237 243 237 231 250 245|250 250 245|250 250 250 253 253 253 253 258 258 258 258 253 262 262 262 258 265 265 262 265 269 269 265 271 269 269 269 253	Association
21437990	Chemical	Gene	D008094	4318	True	0	What is [PHARMGKB] between @ChemicalSrc$ lithium @/ChemicalSrc$ and @GeneTgt$ MMP-9 @/GeneTgt$ ? [SEP] Functional polymorphism of @GeneTgt$ matrix metalloproteinase-9 @/GeneTgt$ ( @GeneTgt$ MMP-9 @/GeneTgt$ ) gene and response to @ChemicalSrc$ lithium @/ChemicalSrc$ prophylaxis in bipolar patients . OBJECTIVE : @GeneTgt$ Matrix metalloproteinase 9 @/GeneTgt$ ( @GeneTgt$ MMP-9 @/GeneTgt$ ) has been implicated in a number of pathological conditions including cancer and heart diseases , and recently also in such neuropsychiatric disorders as schizophrenia and bipolar illness . Therefore , we investigated a possible association between functional polymorphisms of the @GeneTgt$ MMP-9 @/GeneTgt$ gene and the response to @ChemicalSrc$ lithium @/ChemicalSrc$ , the main mood-stabilizing drug in bipolar illness . METHODS : One hundred and nine bipolar patients treated with @ChemicalSrc$ lithium @/ChemicalSrc$ for at least 5 years were analyzed . The @ChemicalSrc$ lithium @/ChemicalSrc$ response was assessed as -- excellent : no affective episodes during @ChemicalSrc$ lithium @/ChemicalSrc$ treatment ; partial : 50 % or more reduction in the episode index ; no response : less than 50 % reduction , no change or worsening in the episode index . The -1562C/T @GeneTgt$ MMP-9 @/GeneTgt$ gene polymorphism ( rs3918242 ) was assessed by PCR-RFLP method . RESULTS : Genotype distributions were not in Hardy-Weinberg equilibrium . No association was found between polymorphism studied and the quality of response to prophylactic @ChemicalSrc$ lithium @/ChemicalSrc$ administration . CONCLUSION : The functional polymorphism of the @GeneTgt$ MMP-9 @/GeneTgt$ gene , analyzed in this study , may not be associated with the treatment response to @ChemicalSrc$ lithium @/ChemicalSrc$ in bipolar patients .	2 2 11 11|3 11|3 11 11|3 11 11|5 11 11|5 11 2 11 11 17 17|11 17 17|11 13 20 20 17 2 25 25 26|27|37 26|27|37 26|27|37 27|37 26|27|37 32 27|28 27 27|28 32 37 37 25 40 40 37 43 43 40 45 43 45 48 45 45 45 37 37 56 56 56 37 58 37 58 58 58 37 68 68 68 68 71 71 68 74 74 71 79 79 76|79 79 76|79 74 74 82 74 84 82 82 82 74 90 90 90 74 93 93 90 68 115 115 100 104 100 100 104 115 104 107 105|106 105 105|106 113 111 112 113 105 115 115 115 121 118|121 121 118|121 123 123 123 130 124 124 126 130 130 123 134 134|130 134 134|130 123 123 123 139 139 136 139 139 139 146 146 146 142 136 149 136 149 153 151 154 155 149 155 158 155 158 158 164 164 164 158 123 173 173 169|173 173 169|173 173 178 175 173 175 178 178 181 181 178 178 192 184 187 184 192 192 191 192 192 192 195 197 197 197 199 197 199 199 203 199 205 203 210 210 210|207 210 210|207 205 197 213 213 217 217 232 222 222 222|219 222 222|219 217 217 217 227 227 224 217 232 232 232 213 236 236 236 232 238 236 236 236 242 242 236 213	Association
21652606	Chemical	Gene	D018967	11255	True	0	What is [PHARMGKB] between @ChemicalSrc$ risperidone @/ChemicalSrc$ and @GeneTgt$ HRH3 @/GeneTgt$ ? [SEP] A pharmacogenetic study of @ChemicalSrc$ risperidone @/ChemicalSrc$ on @GeneTgt$ histamine H3 receptor @/GeneTgt$ gene ( @GeneTgt$ HRH3 @/GeneTgt$ ) in Chinese Han schizophrenia patients . Evidence suggests that the human @GeneTgt$ histamine H3 receptor @/GeneTgt$ ( @GeneTgt$ HRH3 @/GeneTgt$ ) may be involved in the pharmacodynamics of @ChemicalSrc$ risperidone @/ChemicalSrc$ and influence clinical efficacy . More information on the pharmacogenetics of this receptor may therefore be useful in developing individualized therapy . However , to our knowledge , no study has been reported in this area . The aim of this investigation was to clarify whether H3 receptor polymorphism could affect @ChemicalSrc$ risperidone @/ChemicalSrc$ efficacy . We genotyped tag single nucleotide polymorphisms ( SNPs ) of the @GeneTgt$ HRH3 @/GeneTgt$ gene ( rs3787429 and rs3787430 ) and analyzed their association with the reduction of Brief Psychiatric Rating Scale ( BPRS ) score in Chinese Han schizophrenia patients ( N = 129 ) , following an eight-week period of @ChemicalSrc$ risperidone @/ChemicalSrc$ monotherapy . The confounding effects of non-genetic factors were estimated , and then the significant one was included as the covariate for adjustment in statistical analysis . Baseline symptom score was the only significant confounding effect and thus the covariate . After adjustment , significant association of @GeneTgt$ HRH3 @/GeneTgt$ with antipsychotic efficacy was detected ( for rs3787429 , p = 0.013 , 0.087 after 4 weeks and 8 weeks of treatment , respectively ; for rs3787430 , p = 0.024 , 0.010 after 4 weeks and 8 weeks of treatment , respectively ) and stood up to conservative Bonferroni correction . Our results demonstrate that polymorphism of the @GeneTgt$ HRH3 @/GeneTgt$ gene may be a potential genetic marker for predicting the therapeutic effect of @ChemicalSrc$ risperidone @/ChemicalSrc$ , and suggest novel pharmacological links between @GeneTgt$ HRH3 @/GeneTgt$ and @ChemicalSrc$ risperidone @/ChemicalSrc$ . Further studies with larger samples and different ethnic populations are warranted to confirm our results .	3 3 3 5 3|4 3 3|4 12 12|6 12|6 12|6 12 12|6 5 14 9|12 12 9|12 14 21 21 21 21 12 3 27 27 41 31 31 41|30|31 41|30|31 41|30|31 41|31 41|30|31 36 31|32 31 31|32 36 41 41 27 44 44 41 46 41|44 44 41|44 41 41 51 49 27 57 67 60 60 57 63 63 60 67 67 67 67 69 67 71 69 67 83 83 77 77 83 83 80 83 83 83 83 86 86 83 83 89 93 92 92 89 93 95 93 101 99 99 101 101 95 104|101 104 104|101 101 93 108 108 112 112 112 108 114 112 114 120 120 117|120 120 117|120 112 122 120 122 122 122 108 108 129 127 132 132 129 137 137 137 137 141 139 137 139 132 146 146 146 146 141 148 146 148 149 148 127 156 156 156 127 160 156|160 160 156|160 156 108 166 166 171 169 169 166 171 171 171 171 179 177 177 179 179 171 182 182 179 184 182 187 187 184 179 191 191 197 197 197 195 197 197 197 197 197 201 197 197 204 215 215 207 215 209 207|208 207 207|208 213 213 207 215 215 221 218 221 221 221 215 221 221 227 227 227 215 227 230 227 232 230 215 215 215 237 240 240 240 215 240 240 240 246 246 240 240 249 240 251 249 240 240 240 215 215 256 259 256 261 259 215 265 266 266 279 279 273 273 273|270 273 273|270 268 279 279 279 279 279 266 281 279 284 284 281 286 284 284 284 266 266 266 293 293 290 295 292|293 293 292|293 295 295|294 295 295|294 266 306 315 309 309 306 309 313 313 309 315 315 317 315 319 317 315	Association
21658141	Chemical	Gene	D016642	6532	True	0	What is [PHARMGKB] between @ChemicalSrc$ Bupropion @/ChemicalSrc$ and @GeneTgt$ serotonin transporter @/GeneTgt$ ? [SEP] Genetic variants in the @GeneTgt$ serotonin transporter @/GeneTgt$ influence the efficacy of @ChemicalSrc$ bupropion @/ChemicalSrc$ and nortriptyline in smoking cessation . AIMS : We investigated whether variants in the @GeneTgt$ serotonin transporter @/GeneTgt$ gene ( @GeneTgt$ SLC6A4 @/GeneTgt$ ) influence smoking cessation rates using antidepressant therapy ( i.e. @ChemicalSrc$ bupropion @/ChemicalSrc$ and nortriptyline ) . DESIGN : Pharmacogenetic ( secondary ) analysis of a randomized , placebo-controlled efficacy trial of @ChemicalSrc$ bupropion @/ChemicalSrc$ and nortriptyline for smoking cessation . SETTING : Single-centre study , Maastricht University , the Netherlands . PARTICIPANTS : A total of 214 of 255 ( 84 % ) current daily smokers participating in a randomized controlled efficacy trial . MEASUREMENTS : Subjects were genotyped for three functional variants in @GeneTgt$ SLC6A4 @/GeneTgt$ ( @GeneTgt$ 5-HTTLPR @/GeneTgt$ , STin2 , rs25531 ) . Primary outcome measures were prolonged abstinence from weeks 4 - 12 , 4 - 26 and 4 - 52 . Secondary outcome measures included 7-day point prevalence abstinence at weeks 4 , 12 , 26 and 52 . FINDINGS : Carriers of the @GeneTgt$ 5-HTTLPR @/GeneTgt$ high-activity L-variant had higher prolonged cessation rates with @ChemicalSrc$ bupropion @/ChemicalSrc$ than placebo [ odds ratio ( OR ) = 1.44 , 95 % confidence interval ( CI ) = 1.01 - 2.05 , P = 0.04 ] . Combining the three variants resulted in increased prolonged cessation rates for both @ChemicalSrc$ bupropion @/ChemicalSrc$ and nortriptyline among carriers of four to five high-activity variants ( @ChemicalSrc$ bupropion @/ChemicalSrc$ : OR = 2.00 , 95 % CI = 1.21 - 3.29 , P = 0.01 ; nortriptyline : OR = 1.91 , 95 % CI = 1.02 - 3.56 , P = 0.04 ) . Similar results were found for point prevalence abstinence . CONCLUSIONS : @ChemicalSrc$ Bupropion @/ChemicalSrc$ and nortriptyline seem to be more effective in smoking cessation among @GeneTgt$ SLC6A4 @/GeneTgt$ high-activity variant carriers , probably by blocking the increased @GeneTgt$ serotonin transporter @/GeneTgt$ activity , thereby increasing serotonin levels . Prospective studies have to assess if this can improve cessation rates when treatment is targeted at individuals based on their genotypes .	2 8 5 5 2|4|5 2|4|5 2|5 2|4|5 8 10 8 12 9|10 10 9|10 12 12 18 18 10 8 25 25 25 25 38 38 33 33 29|33 29|33 33 29|33 27 35 32|33 33 32|33 35 25 38 41 39 38 44 42 47 47 43|44 44 43|44 47 47 47 25 62 62 62 60 62 62 62 69 69 69 65 65 69 62 71 69|70 69 69|70 71 71 77 77 69 62 80 80 83 91 83 86 83 86 89 86 91 80 91 94 91 96 94 98 96 101 101 98 101 105 105 91 105 112 112 112 112 112 106 91 114 114 118 118 114 122 122 122 118 124 122|123 122 122|123 130 130|125 130 130|125 130 124 130 130 130 114 139 139 141 141 141 141 144 142 144 145 145 147 147 151 149 151 145 155 144 141 159 159 160 160 164 164 164 160 166 164 166 167 167 167 167 171 171 160 184 175 184 183 183 182|179 182 182|179 183 177 184 188 188 188 184 190 184|188 184 184|188 193 184 196 196 184 198 196 198 196 200 200 204 206 206 200 208 206 208 206 213 213 210 216 216 200 216 216 184 226 225 225 222 226 231 231 231 231 226 234 234 231|233 231 231|233 234 234 239 234 245 243 243 245 245 239 247 245 245 245 247 251 247 251 251 255 256 251 256 257 257 257 263 263 257 263 263 263 266 269 247 269 269 273 274 269 274 278 278 275 281 281 269 281 247 226 288 290 290 290 294 293 294 290 290 296 296 297|302 302 297|302 298 298 296 306 306 306 302 309 309 306 315 315|309 315 315|309 315 315 309 306 319 319 306 325 325 319|325 319|325 325 319|325 319 302 328 302 330 328 296 336 337 337 339 337 343 343 343 339 345 343 349 349 349 343 351 349 349 355 355 352 337	Association
21658141	Chemical	Gene	D009661	6532	True	0	What is [PHARMGKB] between @ChemicalSrc$ nortriptyline @/ChemicalSrc$ and @GeneTgt$ serotonin transporter @/GeneTgt$ ? [SEP] Genetic variants in the @GeneTgt$ serotonin transporter @/GeneTgt$ influence the efficacy of bupropion and @ChemicalSrc$ nortriptyline @/ChemicalSrc$ in smoking cessation . AIMS : We investigated whether variants in the @GeneTgt$ serotonin transporter @/GeneTgt$ gene ( @GeneTgt$ SLC6A4 @/GeneTgt$ ) influence smoking cessation rates using antidepressant therapy ( i.e. bupropion and @ChemicalSrc$ nortriptyline @/ChemicalSrc$ ) . DESIGN : Pharmacogenetic ( secondary ) analysis of a randomized , placebo-controlled efficacy trial of bupropion and @ChemicalSrc$ nortriptyline @/ChemicalSrc$ for smoking cessation . SETTING : Single-centre study , Maastricht University , the Netherlands . PARTICIPANTS : A total of 214 of 255 ( 84 % ) current daily smokers participating in a randomized controlled efficacy trial . MEASUREMENTS : Subjects were genotyped for three functional variants in @GeneTgt$ SLC6A4 @/GeneTgt$ ( @GeneTgt$ 5-HTTLPR @/GeneTgt$ , STin2 , rs25531 ) . Primary outcome measures were prolonged abstinence from weeks 4 - 12 , 4 - 26 and 4 - 52 . Secondary outcome measures included 7-day point prevalence abstinence at weeks 4 , 12 , 26 and 52 . FINDINGS : Carriers of the @GeneTgt$ 5-HTTLPR @/GeneTgt$ high-activity L-variant had higher prolonged cessation rates with bupropion than placebo [ odds ratio ( OR ) = 1.44 , 95 % confidence interval ( CI ) = 1.01 - 2.05 , P = 0.04 ] . Combining the three variants resulted in increased prolonged cessation rates for both bupropion and @ChemicalSrc$ nortriptyline @/ChemicalSrc$ among carriers of four to five high-activity variants ( bupropion : OR = 2.00 , 95 % CI = 1.21 - 3.29 , P = 0.01 ; @ChemicalSrc$ nortriptyline @/ChemicalSrc$ : OR = 1.91 , 95 % CI = 1.02 - 3.56 , P = 0.04 ) . Similar results were found for point prevalence abstinence . CONCLUSIONS : Bupropion and @ChemicalSrc$ nortriptyline @/ChemicalSrc$ seem to be more effective in smoking cessation among @GeneTgt$ SLC6A4 @/GeneTgt$ high-activity variant carriers , probably by blocking the increased @GeneTgt$ serotonin transporter @/GeneTgt$ activity , thereby increasing serotonin levels . Prospective studies have to assess if this can improve cessation rates when treatment is targeted at individuals based on their genotypes .	2 8 5 5 2|4|5 2|4|5 2|5 2|4|5 8 10 8 12 10 12 11|12 12 11|12 18 18 10 8 25 25 25 25 38 38 33 33 29|33 29|33 33 29|33 27 35 32|33 33 32|33 35 25 38 41 39 38 44 42 47 47 44 47 45|47 47 45|47 47 25 62 62 62 60 62 62 62 69 69 69 65 65 69 62 71 69 71 71|72 71 71|72 77 77 69 62 80 80 83 91 83 86 83 86 89 86 91 80 91 94 91 96 94 98 96 101 101 98 101 105 105 91 105 112 112 112 112 112 106 91 114 114 118 118 114 122 122 122 118 124 122|123 122 122|123 130 130|125 130 130|125 130 124 130 130 130 114 139 139 141 141 141 141 144 142 144 145 145 147 147 151 149 151 145 155 144 141 159 159 160 160 164 164 164 160 166 164 166 167 167 167 167 171 171 160 184 175 184 183 183 182|179 182 182|179 183 177 184 188 188 188 184 190 184 192 184 195 195 184 197 195 197 195 199 199 203 205 205 199 207 205 207 205 212 212 209 215 215 199 215 215 184 224 223 223 220 224 229 229 229 229 224 232 232 229 232 232|233 232 232|233 237 232 243 241 241 243 243 237 245 243 245 248 245 248 248 252 253 248 253 254 254 254 260 260 254 260 260 260|261 260 260|261 263 267 245 267 267 271 272 267 272 276 276 273 279 279 267 279 245 224 286 288 288 288 292 291 292 288 288 294 294 300 296 296|297 296 296|297 294 304 304 304 300 307 307 304 313 313|307 313 313|307 313 313 307 304 317 317 304 323 323 317|323 317|323 323 317|323 317 300 326 300 328 326 294 334 335 335 337 335 341 341 341 337 343 341 347 347 347 341 349 347 347 353 353 350 335	Association
21747410	Chemical	Gene	D000077152	2696	True	0	What is [PHARMGKB] between @ChemicalSrc$ olanzapine @/ChemicalSrc$ and @GeneTgt$ GIPR @/GeneTgt$ ? [SEP] Association between the @GeneTgt$ GIPR @/GeneTgt$ gene and the insulin level after glucose loading in schizophrenia patients treated with @ChemicalSrc$ olanzapine @/ChemicalSrc$ . Several studies have shown increased rates of hyperglycemia and diabetes in schizophrenic patients treated with @ChemicalSrc$ olanzapine @/ChemicalSrc$ . However , the underlying mechanism is poorly understood . Glucose-dependent insulinotropic polypeptide ( GIP ) is known to affect insulin secretion by pancreatic beta cells . Recently , a meta-analysis study reported an association between a @GeneTgt$ GIP receptor @/GeneTgt$ ( @GeneTgt$ GIPR @/GeneTgt$ ) gene polymorphism ( rs10423928 ) and insulin secretion measured by an oral glucose tolerance test ( OGTT ) . We assessed the influence of this @GeneTgt$ GIPR @/GeneTgt$ gene polymorphism on glucose metabolism in 60 schizophrenic patients treated with @ChemicalSrc$ olanzapine @/ChemicalSrc$ and 103 healthy controls . The @GeneTgt$ GIPR @/GeneTgt$ gene polymorphism was determined using TaqMan methods . We performed repeated-measures analysis of variance ( ANOVA ) and one-way ANOVA for the glucose and insulin levels during OGTTs in four groups divided by the @GeneTgt$ GIPR @/GeneTgt$ gene polymorphism and cohort ( schizophrenia or control ) . We found significant effects of the @GeneTgt$ GIPR @/GeneTgt$ gene and cohort on the insulin levels at 30 min . Our findings suggest that schizophrenic patients with the A allele of @GeneTgt$ GIPR @/GeneTgt$ rs10423928 are at risk of developing hyperinsulinemia when treated with antipsychotics .	1 6 6 3|6 6 3|6 1 6 10 10 6 13 13 10 16 16 13 16 19 17 17 17 1 25 27 27 27 29 27 31 29 31 31 36 36 29 36 39 37|38 37 37|38 27 50 50 47 47 50 50 50 50 50 54 54 59 56 54 56 59 59 61 59 63 61 67 67 67 61 59 74 74 73 73 74 74 76 74 87 87 78|87 78|87 87 78|87 87 87|80 87 87|80 87 87 76 89 87 89 87 93 87 93 100 100 100 100 100 94 102 100 102 74 108 108 110 108 116 116 116|112 116 116|112 116 110 119 119 116 123 123 123 110 123 126 124 124 124 126 131 131 126 108 139 135|139 139 135|139 139 141 141 141 141 144 142 141 148 148 150 148 152 150 154 152 154 152 158 152 161 161 150 161 161 161 166 161 169 169 166 169 176 176 172|176 176 172|176 176 170 176 176 180 178 180 180 180 148 187 187 189 187 194 194 194|191 194 194|191 189 194 194 200 200 200 196 203 203 196 187 207 208 208 222 211 222 215 215 215 211 219 216|219 219 216|219 215 222 222 208 224 222 224 227 224 229 227 208	Association
21857094	Chemical	Gene	D016559	6934	True	0	What is [PHARMGKB] between @ChemicalSrc$ tacrolimus @/ChemicalSrc$ and @GeneTgt$ TCF7L2 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ transcription factor 7-like 2 @/GeneTgt$ ( @GeneTgt$ TCF7L2 @/GeneTgt$ ) gene polymorphism with posttransplant diabetes mellitus in kidney transplant patients medicated with @ChemicalSrc$ tacrolimus @/ChemicalSrc$ . New onset posttransplant diabetes mellitus ( PTDM ) has a high incidence after kidney transplantation in patients medicated with @ChemicalSrc$ tacrolimus @/ChemicalSrc$ . PTDM can adversely affect patient and graft survival . The pathophysiology of PTDM closely mimics type 2 diabetes mellitus ( T2DM ) . One of the possible genetic factors predisposing individuals to PTDM might be a polymorphism in the @GeneTgt$ transcription factor 7-like 2 @/GeneTgt$ gene ( @GeneTgt$ TCF7L2 @/GeneTgt$ ) . This polymorphism has previously been associated with increased risk of T2DM in the general population . Therefore , the present study aimed to evaluate @GeneTgt$ TCF7L2 @/GeneTgt$ polymorphisms in PTDM in kidney transplant patients medicated with @ChemicalSrc$ tacrolimus @/ChemicalSrc$ . Non-diabetic kidney transplant patients medicated with @ChemicalSrc$ tacrolimus @/ChemicalSrc$ ( n = 234 ) were genotyped for the presence of @GeneTgt$ TCF7L2 @/GeneTgt$ gene variants ( rs12255372 and rs7903146 ) using TaqMan probes . Of the 234 patients , 66 patients had developed PTDM and 168 had not . Frequencies of the studied single nucleotide polymorphisms ( SNPs ) did not differ significantly between the study groups . Moreover , haplotype analyses failed to detect any associations between @GeneTgt$ TCF7L2 @/GeneTgt$ haplotypes and PTDM . However , in late-onset PTDM ( developed later that 2 weeks from transplantation ) , frequencies of the rs7903146 TT genotype and T minor allele were significantly increased compared to non-PTDM controls ( 17.9 % vs. 5.9 % , p = 0.017 , OR : 4.13 , 95 % CI : 1.19 - 14.33 for TT genotype , 39.3 % vs. 25.9 % , p = 0.038 for T allele ) . If the application of @GeneTgt$ TCF7L2 @/GeneTgt$ rs7903146 SNPs as a marker for PTDM is confirmed by further independent studies , replacing @ChemicalSrc$ tacrolimus @/ChemicalSrc$ with other immunosuppressants could be warranted in patients at high risk of PTDM , as diagnosed by @GeneTgt$ TCF7L2 @/GeneTgt$ genotyping .	1 3 2|3|13 2|3|13 2|3|13 2|3|13 3|13 2|3|13 9 4|13 13 4|13 13 13 1 17 17 17 13 21 21 21 13 21 24 18|22 22 18|22 1 31 34 34 34 38 36 34 36 38 41 41 38 44 44 41 46 44 46 49 47|48 47 47|48 38 56 56 56 56 56 57 57 57 56 63 67 65 63 67 67 71 71 71 67 73 71 73 67 89 81 81 81 81 76 81 82 85 83 89 89 89 89 92 92 91|92|97 91|92|97 91|92|97 91|92|97 92|97 91|92|97 89 99 94|97 97 94|97 99 89 106 110 110 110 110 110 113 113 110 115 113 119 119 119 113 110 126 126 125 125 126 126 128 126 128|131 131 128|131 128 133 131 137 137 137 131 137 140 138 138 138 126 148 148 148 149 149 151 149|150 149 149|150 154 151 154 155 154 159 149 162 162 159 167 162|167 167 162|167 167 162 169 167 169 169 169 159 175 173 149 182 182 182 187 187 185 187 187 187 187 188 191 187 191 187 206 200 200 200 200 200 194 202 200 202 206 206 206 206 211 211 211 206 206 217 217 216 217 217 219 217 221 219 225 222|225 225 222|225 221 225 225 217 234 234 234 234 234 236 234 257 257 240 257 242 240 240 257 257 250 250 250 250 245 250 253 254 250 257 257 236 236 261 261 258 264 264 261 264 267 264 270 270 264 270 270 264 264 278 275 278 279 264 264 283 283 264 286 286 283 283 289 264 289 292 264 295 295 264 295 299 299 295 264 234 309 304 309 308 305|308 308 305|308 304 316 312 312 309 314 312 316 316 320 320 320 316 320 320 321|322 322 321|322 327 327 323 330 330 316 332 330 335 335 332 337 335 330 340 330 344 344|339 344 344|339 340 316	Association
21887680	Chemical	Gene	D004317	4522	False	6	What is [PHARMGKB] between @ChemicalSrc$ Adriamycin @/ChemicalSrc$ and @GeneTgt$ MTHFD1 @/GeneTgt$ ? [SEP] Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma : a pilot study . BACKGROUND : Osteosarcoma is the most common malignant bone tumor in children and young people . Efficacy of multiagent MAP ( methotrexate , @ChemicalSrc$ doxorubicin @/ChemicalSrc$ [ @ChemicalSrc$ Adriamycin @/ChemicalSrc$ ] , cisplatin ) chemotherapy may be influenced by multiple cellular pathways . This pilot study aimed to investigate the association of 36 candidate genetic polymorphisms in MAP pathway genes with histological response , survival , and grade 3 - 4 chemotherapy toxicity in osteosarcoma . METHODS : Blood samples were obtained from 60 patients who had completed MAP chemotherapy . All patients were manually genotyped for 5 polymorphisms . The remaining 31 polymorphisms were genotyped in 50 patients using the Illumina 610-Quad microarray . Associations between candidate polymorphisms and histological response , progression-free survival , and toxicity were estimated using Pearson chi-square and Fisher exact tests , the Kaplan-Meier method , the log-rank test , and the Cox proportional hazards model . RESULTS : Poor histological response was increased in variants of ABCC2 c.24C&gt;T ( P = .011 ) and GSTP1 c.313A&gt;G p. Ile(105)Val ( P = .009 ) , whereas @GeneTgt$ MTHFD1 @/GeneTgt$ c.1958G&gt;A p. Arg(653)Gln was protective ( P = .03 ) . Methotrexate toxicity was increased in variants of MTHFR c.1298A&gt;C p. Glu(429)Ala ( P = .038 ) , ABCB1 c.3435T&gt;C Ile(145)Ile ( P = .027 ) , and ABCC2 c.3563T&gt;A p. Val(1188)Glu ( P = .028 ) . Variants of GSTP1 c.313A&gt;G p. Ile(105)Val were at increased risk of myelosuppression ( P = .024 ) and cardiac damage ( P = .008 ) . CONCLUSIONS : This pilot study represents the most comprehensive study to date examining the role of genetic polymorphisms in osteosarcoma . Although small and retrospective , it shows that several polymorphisms appear to significantly influence toxicity and clinical outcome . These deserve prospective validation in the hope of optimizing treatment for resistant disease and reducing the late effects burden .	3 3 5 5 5 7 5 7 10 7 12 7 5 16 16 5 5 18 18 27 27 27 24 27 27 27 18 29 27 29 32 29 18 53 37 37 50 39 50 39 39|40 39 39|40 39 42|39 39 42|39 44 39 39 50 34 53 53 53 57 57 57 53 53 63 63 64 64 66 64 68 66 73 73 73 73 68 77 77 77 68 80 80 68 80 80 82 80 90 88 88 90 90 80 92 90 64 99 99 97 99 99 99 102 102 99 105 105 102 107 105 99 110 113 113 113 113 116 116 113 113 121 121 121 123 123 123 126 126 123 126 131 130 131 127 123 147 136 136 133 136 139 136 136 142 136 136 136 136 147 147 147 150 148 150 150 154 150 147 158 158 147 158 162 162 158 162 158 169 167 169 169 158 147 171 171 175 175 177 177 171 179 177 182 182 179 184 185 182 185 185 182 192 192 192 182 194 192 194 195 194 177 177 204|199 204 204|199 204 204 206 206 177 209 209 206 209 209 171 215 217 217 217 219 217 224 224 224 224 219 226 227 224 227 227 224 233 233 219 235 236 233 236 236 219 217 242 217 244 242 247 247 244 247 247 242 260 253 256 253 256 251 260 260 260 260 262 260 265 265 262 265 265 262 270 262 272 270 272 273 272 260 277 277 281 281 282 277 286 285 286 282 288 286 282 291 289 294 294 291 296 291 277 299 304 299 299 304 304 304 308 307 308 304 311 311 308 311 312 312 312 304 318 318 320 318 323 323 320 326 326 323 329 329 326 318 318 334 334 335 318 318	Association
21887680	Chemical	Gene	D002945	4522	False	6	What is [PHARMGKB] between @ChemicalSrc$ cisplatin @/ChemicalSrc$ and @GeneTgt$ MTHFD1 @/GeneTgt$ ? [SEP] Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma : a pilot study . BACKGROUND : Osteosarcoma is the most common malignant bone tumor in children and young people . Efficacy of multiagent MAP ( methotrexate , doxorubicin [ Adriamycin ] , @ChemicalSrc$ cisplatin @/ChemicalSrc$ ) chemotherapy may be influenced by multiple cellular pathways . This pilot study aimed to investigate the association of 36 candidate genetic polymorphisms in MAP pathway genes with histological response , survival , and grade 3 - 4 chemotherapy toxicity in osteosarcoma . METHODS : Blood samples were obtained from 60 patients who had completed MAP chemotherapy . All patients were manually genotyped for 5 polymorphisms . The remaining 31 polymorphisms were genotyped in 50 patients using the Illumina 610-Quad microarray . Associations between candidate polymorphisms and histological response , progression-free survival , and toxicity were estimated using Pearson chi-square and Fisher exact tests , the Kaplan-Meier method , the log-rank test , and the Cox proportional hazards model . RESULTS : Poor histological response was increased in variants of ABCC2 c.24C&gt;T ( P = .011 ) and GSTP1 c.313A&gt;G p. Ile(105)Val ( P = .009 ) , whereas @GeneTgt$ MTHFD1 @/GeneTgt$ c.1958G&gt;A p. Arg(653)Gln was protective ( P = .03 ) . Methotrexate toxicity was increased in variants of MTHFR c.1298A&gt;C p. Glu(429)Ala ( P = .038 ) , ABCB1 c.3435T&gt;C Ile(145)Ile ( P = .027 ) , and ABCC2 c.3563T&gt;A p. Val(1188)Glu ( P = .028 ) . Variants of GSTP1 c.313A&gt;G p. Ile(105)Val were at increased risk of myelosuppression ( P = .024 ) and cardiac damage ( P = .008 ) . CONCLUSIONS : This pilot study represents the most comprehensive study to date examining the role of genetic polymorphisms in osteosarcoma . Although small and retrospective , it shows that several polymorphisms appear to significantly influence toxicity and clinical outcome . These deserve prospective validation in the hope of optimizing treatment for resistant disease and reducing the late effects burden .	3 3 5 5 5 7 5 7 10 7 12 7 5 16 16 5 5 18 18 27 27 27 24 27 27 27 18 29 27 29 32 29 18 52 37 37 49 39 49 39 39 39 39 43 39 45|39 39 45|39 49 34 52 52 52 56 56 56 52 52 61 61 62 62 64 62 66 64 71 71 71 71 66 75 75 75 66 78 78 66 78 78 80 78 88 86 86 88 88 78 90 88 62 97 97 95 97 97 97 100 100 97 103 103 100 105 103 97 108 111 111 111 111 114 114 111 111 119 119 119 121 121 121 124 124 121 124 129 128 129 125 121 145 134 134 131 134 137 134 134 140 134 134 134 134 145 145 145 148 146 148 148 152 148 145 156 156 145 156 160 160 156 160 156 167 165 167 167 156 145 169 169 173 173 175 175 169 177 175 180 180 177 182 183 180 183 183 180 190 190 190 180 192 190 192 193 192 175 175 202|197 202 202|197 202 202 204 204 175 207 207 204 207 207 169 213 215 215 215 217 215 222 222 222 222 217 224 225 222 225 225 222 231 231 217 233 234 231 234 234 217 215 240 215 242 240 245 245 242 245 245 240 258 251 254 251 254 249 258 258 258 258 260 258 263 263 260 263 263 260 268 260 270 268 270 271 270 258 275 275 279 279 280 275 284 283 284 280 286 284 280 289 287 292 292 289 294 289 275 297 302 297 297 302 302 302 306 305 306 302 309 309 306 309 310 310 310 302 316 316 318 316 321 321 318 324 324 321 327 327 324 316 316 332 332 333 316 316	Association
21902502	Chemical	Gene	D016572	1576	True	0	What is [PHARMGKB] between @ChemicalSrc$ CsA @/ChemicalSrc$ and @GeneTgt$ CYP3A4 @/GeneTgt$ ? [SEP] Effect of a new functional @GeneTgt$ CYP3A4 @/GeneTgt$ polymorphism on calcineurin inhibitors ' dose requirements and trough blood levels in stable renal transplant patients . AIMS : @GeneTgt$ CYP3A4 @/GeneTgt$ is involved in the oxidative metabolism of many drugs and xenobiotics including the immunosuppressants tacrolimus ( Tac ) and @ChemicalSrc$ cyclosporine @/ChemicalSrc$ ( @ChemicalSrc$ CsA @/ChemicalSrc$ ) . The objective of the study was to assess the potential influence of a new functional SNP in @GeneTgt$ CYP3A4 @/GeneTgt$ on the pharmacokinetic parameters assessed by dose requirements and trough blood levels of both calcineurin inhibitors ( CNI ) in stable renal transplant patients . PATIENTS & amp ; METHODS : A total of 99 stable renal transplant patients receiving either Tac ( n = 49 ) or @ChemicalSrc$ CsA @/ChemicalSrc$ ( n = 50 ) were genotyped for the @GeneTgt$ CYP3A4 @/GeneTgt$ intron 6 C&gt;T ( rs35599367 ) and CYP3A5 * 3 SNPs . Trough blood levels ( [Tac](0 ) or @ChemicalSrc$ [CsA](0 @/ChemicalSrc$ ) in ng/ml ) , dose-adjusted [Tac](0 ) or @ChemicalSrc$ [CsA](0 @/ChemicalSrc$ ) ( ng/ml per mg/kg bodyweight ) as well as doses ( mg/kg bodyweight ) required to achieve target concentrations were compared among patients according to allelic status for @GeneTgt$ CYP3A4 @/GeneTgt$ and CYP3A5 . RESULTS : Dose-adjusted concentrations were 2.0- and 1.6-fold higher in T-variant allele carriers for the @GeneTgt$ CYP3A4 @/GeneTgt$ intron 6 C&gt;T SNP compared with homozygous CC for Tac and CsA , respectively . When @GeneTgt$ CYP3A4/CYP3A5 @/GeneTgt$ genotypes were combined , the difference was even more striking as the so-defined @GeneTgt$ CYP3A @/GeneTgt$ poor metabolizer group presented dose-adjusted concentration 1.6- and 4.1-fold higher for Tac , and 1.5- and 2.2-fold higher for @ChemicalSrc$ CsA @/ChemicalSrc$ than the intermediate metabolizer and extensive metabolizer groups , respectively . Multiple linear regression analysis revealed that , taken together , both @GeneTgt$ CYP3A4 @/GeneTgt$ intron 6 and CYP3A5 * 3 SNPs explained more than 60 and 20 % of the variability observed in dose-adjusted [Tac](0 ) and [CsA](0 ) , respectively . CONCLUSION : The @GeneTgt$ CYP3A4 @/GeneTgt$ intron 6 C&gt;T polymorphism is associated with altered Tac and @ChemicalSrc$ CsA @/ChemicalSrc$ metabolism . @GeneTgt$ CYP3A4 @/GeneTgt$ intron 6 C&gt;T along with CYP3A5 * 3 ( especially for Tac ) pharmacogenetic testing performed just before transplantation may help identifying patients at risk of CNI overexposure and contribute to limit CNI-related nephrotoxicity by refining the starting dose according to their genotype . Original submitted 5 May 2011 ; Revision submitted 29 June 2011 .	1 8 8 8 8 8|5 8 8|5 1 14 11 14 11 14 8 14 18 18 14 23 23 23 23 14 1 26 26 27|31 31 27|31 31 26 35 35 35 31 38 38 35 38 38 44 44 44 38 46 44 46 44 44|47 44 44|47 52 49 49 49 52 31 60 64 63 63 60 64 66 64 69 69 66 74 74 74 74 69 76 74|75 74 74|75 81 81 81 69 81 85 85 82 85 89 89 85 93 93 93 89 95 93 95 101 101 101 101 85 64 104 104 104 104 104 104 111 135 117 117 117 117 117 111 117 120 118 122 123 120 123 123 120 120|126 120 120|126 130 127 130 131 130 135 104 140 140 136|140 140 136|140 135 142 140 144 142 144 142 140 147 150 135 135 156 156 169 158 169 158 158 158|160 158 158|160 158 165 158 165 158 169 169 169 169 170|176 176 170|176 176 176 189 179 179 176 179 176 181 181 176 187 187 184 187 195 191 189 193 191 195 169 197 195 201 198 201 197 203 201|200 201 201|200 203 203 169 211 211 214 216 216 219 216 216 211 223 223 223 219 231 231 228|225 228 228|225 231 230 231 223 211 235 235 232 237 235 237 237 235 235 211 249 244|247 247 244|247 249 249 256 256 252 256 256 255 256 256 265 264 264 264|258 264 264|258 264 264 265 256 267 265 267 267 271 267 273 271 273 273 273 276 276 256 281 278|279 279 278|279 286 286 286 279 286 290 290 286 279 279 256 300 300 300 301 301 304 304 317 304 317 310 307|310 310 307|310 317 310 310 310 313 316 317 301 320 320 323 320 320 317 326 326 323 326 330 330 327 330 330 330 330 317 317 301 339 339 347 341|344 344 341|344 347 347 347 349 349 339 352 352 349 352 356|352 356 356|352 352 339 359|362 362 359|362 364 364 364 367 367 364 367 367 367 376 376 376 376 376 364 376 382 382 382 382 364 382 383 386 384 389 389 386 382 382 393 391 395 393 397 393 400 400 397 404 401 404 397 364 408 414 410 408 410 414 414 414 416 414 416 414	Association
21902503	Chemical	Gene	D053139	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ oseltamivir @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] @GeneTgt$ ABCB1 @/GeneTgt$ polymorphisms and neuropsychiatric adverse events in @ChemicalSrc$ oseltamivir-treated @/ChemicalSrc$ children during influenza H1N1/09 pandemia . AIMS : To examine the safety profile of @ChemicalSrc$ oseltamivir @/ChemicalSrc$ in children and evaluate the impact of @GeneTgt$ P-glycoprotein @/GeneTgt$ polymorphisms on the incidence of neuropsychiatric adverse events ( NPAE ) in @ChemicalSrc$ oseltamivir-treated @/ChemicalSrc$ children . SUBJECTS & amp ; METHODS : This prospective cohort study was conducted in our tertiary care pediatric hospital ( University Hospitals of Geneva , Switzerland ) during the H1N1 pandemia , between 1 October 2009 and 31 January 2010 . All newborn to 18 year-old patients presenting at the emergency department with a flu-like illness were eligible for inclusion . Adverse events were systematically recorded by pediatricians and/or by parents at home using a diary card , with a 30-day follow-up period . The causality assessment of @ChemicalSrc$ oseltamivir @/ChemicalSrc$ in NPAE was performed by two clinical pharmacologists . After informed consent , enrolled patients were also genotyped for @GeneTgt$ ABCB1 @/GeneTgt$ 3435C&gt;T ( rs1045642 ) and 2677G&gt;T/A ( rs2032582 ) polymorphisms . RESULTS : Among the 42 H1N1-infected , @ChemicalSrc$ oseltamivir-treated @/ChemicalSrc$ children who were genotyped for @GeneTgt$ ABCB1 @/GeneTgt$ 3435C&gt;T and 2677G&gt;T/A variants , 36 % presented NPAE . When examining the association between the diplotype and the development of NPAE , we observed that the frequency of NPAE displayed a ' genotype-trend effect ' with the variant and the wild-type subgroups at the two far ends . A total of 11 % of the 2677GG-3435CC individuals ( wild-type homozygous ) presented NPAE , compared with 39 % of the individuals being heterozygous for at least one variant allele and 67 % of the 2677TT-3435TT individuals ( homozygous variants ) ( p = 0.149 , nonsignificant ) . CONCLUSION : These observations suggest a potential influence of @GeneTgt$ ABCB1 @/GeneTgt$ polymorphisms in @ChemicalSrc$ oseltamivir-related @/ChemicalSrc$ NPAE , maybe as a result of an enhanced permeability of the blood-brain barrier to @ChemicalSrc$ oseltamivir @/ChemicalSrc$	0|3 3 0|3 3 3 7 7 3 11 11|7 11 11|7 7 15 15 15 3 3 19 22 22 19 25 25 22 27 26|25 25 26|25 30 25 22 22 34 32 38 34|38 38 34|38 34 41 41 34 45 45 45 41 47 45 47 52 52|47 52 52|47 41 19 57 57 57 57 57 57 66 66 66 68 68 57 74 74 72 74 74 68 77 77 74 79 77 79 79 77 86 86 86 68 86 90 90 86 90 90 94 90 94 68 98 113 102 102 102 98 102 107 107 107 103 111 111 111 107 113 113 115 113 113 118 121 121 121 121 123 121 123 126 123 128 126 121 132 132 129 129 138 138 137 138 129 121 142 142 149 144 142|143 142 142|143 147 142 149 149 153 153 153 149 149 158 158 164 164 161 164 164 164 164 166 165|177 177 165|177 166 170 166 170 166 166 175 177 177 164 164 180 180 189 189 185 189 189 189|186 189 189|186 203 192 192 189 194 199|192 199 199|192 194 194 194 192 203 202 203 180 203 180 209 222 211 209 214 214 211 214 217 214 219 217 222 222 222 228 225 228 227 225 222 232 232 232 228 232 236 236 232 236 240 240 236 245 245 245 243 228 222 248 260 251 251 248 255 255 255 251 258 258 248 258 260 260 260 260 266 266 263 269 269 266 271 260 277 274 275 277 277 271 277 280 277 284 284 284 280 287 287 280 287 291 291 287 291 291 291 291 260 297 301 300 301 297 304 304 301 308 305|308 308 305|308 304 312 312|308 312 312|308 304 301 317 317 317 301 321 321 321 317 325 325 325 321 327 321|324 321 321|324	Association
21996196	Chemical	Gene	D009173	3615	False	1	What is [PHARMGKB] between @ChemicalSrc$ MPA @/ChemicalSrc$ and @GeneTgt$ IMPDH2 @/GeneTgt$ ? [SEP] Lymphocyte counts in kidney allograft recipients are associated with @GeneTgt$ IMPDH2 @/GeneTgt$ 3757T&gt;C gene polymorphism . Inosine monophosphate dehydrogenase ( IMPDH ) , the rate-limiting enzyme for de novo synthesis of guanine nucleotides , is required for lymphocyte proliferation . Inhibition of IMPDH by @ChemicalSrc$ mycophenolic acid @/ChemicalSrc$ ( @ChemicalSrc$ MPA @/ChemicalSrc$ ) constitutes part of an immunosuppressive therapy in kidney allograft recipients . The 3757T&gt;C polymorphic variant ( rs11706052 ) of the @GeneTgt$ IMPDH2 @/GeneTgt$ gene , which encodes 1 of 2 IMPDH isoenzymes , has been associated with increased IMPDH activity and reduced ability of MPA to exert antiproliferative effects on lymphocytes . The association of @GeneTgt$ IMPDH2 @/GeneTgt$ 3757T&gt;C SNP with posttransplant courses of kidney allograft recipients remains unclear . Therefore , the aim of the present study was to evaluate associations between this single nucleotide polymorphism and common posttransplant complications among Polish kidney allotransplant recipients . We observed that the frequency of @GeneTgt$ IMPDH2 @/GeneTgt$ 3757C allele in this group ( n=177 ) did not differ significantly from a control cohort representing the background population of Poland ( n=550 ) . There were no significant differences between patients carrying the @GeneTgt$ IMPDH2 @/GeneTgt$ 3757CT and TT genotypes with respect to acute rejection risk , neutropenia , or incidences of serious infections or gastrointestinal side effects . However , we noted that the 3757C allele was associated with higher lymphocyte counts and a reduced incidence of lymphopenia among kidney allograft recipients . Our findings may be of practical significance to tailor immunosuppressive regimens in kidney transplant recipients .	2 8 6 6 6 2 8 8 14 9|12 12 9|12 14 14 8 8 19 19 36 21 19 21 19 26 26 19 30 30 28 26 33 33 30 19 36 36 39 39 36 36 52 43 41 45 41|44|45 41|44|45 41|45 41|44|45 49 45|46 45 45|46 49 52 52 57 57 57 53 61 61 61 57 52 68 68 68 88 70 68 70 76 76 73|76 76 73|76 68 76 79 76 82 82 84 84 79 68 88 88 88 92 92 92 88 88 95 88 97 95 99 95 101 99 103 101 88 107 120 109 107|108 107 107|108 112 107 115 115 107 119 119 119 115 120 120 120 132 132 127 132 131 131 131 127 132 134 132 134 140 140 140 140 135 140 144 144 140 149 148 148 149 144 132 152 152 169 155 169 160 160|156 160 160|156 160 155 163 163 160 165 160 165 169 169 152 169 174 174 174 169 174 178 178 175 180 178 182 180 182 152 187 187 190 190 187 192 190 192 197 194|197 197 194|197 193 197 197 197 202 193 206 206 206 202 206 206 208 206 206 214 214 211 214 218 218 214 187 224 224 224 224 230 228 228 230 230 224 234 234 234 230 234 238 238 234 240 238 244 244 244 238 224 247 252 252 252 252 252 252 254 252 256 254 260 260 260 254 252	Association
22158331	Chemical	Gene	D010984	2073	True	0	What is [PHARMGKB] between @ChemicalSrc$ platinum @/ChemicalSrc$ and @GeneTgt$ xpg @/GeneTgt$ ? [SEP] DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer . Epithelial ovarian cancer has a poor prognosis owing to late diagnosis and frequent relapse after first-line therapy . Analysis of individual genetic variability could aid in the identification of markers , which could help in stratifying patients with the aim of optimizing individual therapy . In this study we assessed polymorphisms in three genes important in drugs ' response in 97 early and 235 late-stage ovarian cancer patients . The Asp1104His polymorphism in @GeneTgt$ xpg @/GeneTgt$ , a gene important for removal of @ChemicalSrc$ platinum @/ChemicalSrc$ adducts , was associated with progression-free survival in early- and late-stage ovarian cancer . Our data indicate that a simple diagnostic analysis such as @GeneTgt$ xpg @/GeneTgt$ genotyping can help in predicting response , and extension to other possibly relevant genotypes could be useful in selecting patients with epithelial ovarian cancer for optimal therapy and hence increase the chance of response .	4 4 4 4 4 7 4 10 10 7 4 14 14 15 15 18 18 15 22 22 22 15 22 25 22 28 28 22 15 36 34 34 34 30 36 36 39 39 36 41 39 41 45 45 41 47 45 47 51 51 48 53 51 55 53 36 59 59 61 61 61 61 65 65 62 65 70 70 68 66 79 79 79 73 73 79 79 79 70 61 83 83 99 85 83|84 83 83|84 85 89 85 89 92 90 96 96|92 96 96|92 92 83 99 99 102 102 99 104 102 104 104 108 104 99 113 114 114 126 119 119 117 126 124 120 121|124 124 121|124 119 126 114 128 126 128 129 129 140 137 137 136 137 132 140 140 126 142 140 142 147 147 147 143 150 150 147 140 153 140 155 153 157 155 114	Association
22264780	Chemical	Gene	D016559	3767	True	0	What is [PHARMGKB] between @ChemicalSrc$ Tacrolimus @/ChemicalSrc$ and @GeneTgt$ KCNJ11 @/GeneTgt$ ? [SEP] Association between a common @GeneTgt$ KCNJ11 @/GeneTgt$ polymorphism ( rs5219 ) and new-onset posttransplant diabetes in patients treated with @ChemicalSrc$ Tacrolimus @/ChemicalSrc$ . @GeneTgt$ KCNJ11 @/GeneTgt$ polymorphisms have been linked to the risk of developing type 2 diabetes . Our aim was to define the contribution of @GeneTgt$ KCNJ11 @/GeneTgt$ to new-onset diabetes after transplantation ( NODAT ) among patients treated with @ChemicalSrc$ Tacrolimus @/ChemicalSrc$ ( Tac ) . A total of 115 NODAT and 205 non-NODAT were genotyped for rs5219 ( p. E23 K ) . AA+AG genotypes were significantly associated with NODAT-risk ( p=0.004 ; OR=2.10 ) . The reported effect of this @GeneTgt$ KCNJ11 @/GeneTgt$ polymorphism on insulin release by beta cells could explain this association .	1 7 7 7 4|7 7 4|7 1 9 7 9 7 14 14 7 16 14 16 19 17 17 17 1 23|26 26 23|26 29 29 29 29 32 32 29 37 37 37 37 32 29 41 44 44 44 44 46 44 48 47|46 46 47|46 52 52 46 54 46 56 54 56 59 54 59 62 60 60 60 65 62 65 44 71 79 74 74 71 74 77 74 79 79 81 79 85 85 85 81 85 79 89 92 92 92 92 94 92 96 98 98 94 98 92 103 103 116 108 108 108|105 108 108|105 103 111 111 103 114 114 103 116 116 118 116 116	Association
22293084	Chemical	Gene	C545203	1080	True	0	What is [PHARMGKB] between @ChemicalSrc$ ivacaftor @/ChemicalSrc$ and @GeneTgt$ CFTR @/GeneTgt$ ? [SEP] @ChemicalSrc$ Ivacaftor @/ChemicalSrc$ potentiation of multiple @GeneTgt$ CFTR @/GeneTgt$ channels with gating mutations . BACKGROUND : The investigational @GeneTgt$ CFTR @/GeneTgt$ potentiator @ChemicalSrc$ ivacaftor @/ChemicalSrc$ ( VX-770 ) increased @GeneTgt$ CFTR @/GeneTgt$ channel activity and improved lung function in subjects with CF who have the G551D @GeneTgt$ CFTR @/GeneTgt$ gating mutation . The aim of this in vitro study was to determine whether @ChemicalSrc$ ivacaftor @/ChemicalSrc$ potentiates mutant @GeneTgt$ CFTR @/GeneTgt$ with gating defects caused by other @GeneTgt$ CFTR @/GeneTgt$ gating mutations . METHODS : The effects of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ on CFTR channel open probability and chloride transport were tested in electrophysiological studies using Fischer rat thyroid ( FRT ) cells expressing different CFTR gating mutations . RESULTS : @ChemicalSrc$ Ivacaftor @/ChemicalSrc$ potentiated multiple mutant @GeneTgt$ CFTR @/GeneTgt$ forms with defects in @GeneTgt$ CFTR @/GeneTgt$ channel gating . These included the G551D , G178R , S549N , S549R , G551S , G970R , G1244E , S1251N , S1255P and G1349D @GeneTgt$ CFTR @/GeneTgt$ gating mutations . CONCLUSION : These in vitro data suggest that @ChemicalSrc$ ivacaftor @/ChemicalSrc$ has a similar effect on all @GeneTgt$ CFTR @/GeneTgt$ forms with gating defects and support investigation of the potential clinical benefit of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ in CF patients who have @GeneTgt$ CFTR @/GeneTgt$ gating mutations beyond G551D .	0|3 3 0|3 3 8 8 8|4 8 8|4 3 11 11 3 3 27 27 22 22 22|18 22 22|18 22 27|20 27 27|20 25 22 25 27 31|25 31 31|25 31 27 27 35 35 27 37 35 39 37 41 37 47 47 47|40 47 47|40 47 41 27 54 60 56 59 59 57 54 60 62 60 66 63|66 66 63|66 62 68 66 66 66 72 72 66 72 79 79 79|73 79 79|73 79 73 60 100 100 87 100 89 87|88 87 87|88 95 93 95 95 87 95 98 95 100 100 103 103 100 103 111 111 111 109 111 111 104 111 116 116 116 112 100 123 119 120|123 123 120|123 123 128 128 128|124 128 128|124 123 130 128 135 135|129 135 135|129 135 130 123 141 141 143 141 143 143 145 145 145 143 143 143 143 143 143 143 143 143 143 143 143 143 165|161 165 165|161 165 143 141 174 174 173 173 171 174 174 178 175|178 178 175|178 174 181 181 178 184 184 181|182 181 181|182 178 188 192 188 188 188 178 197 197 197 197 192 199 196|197 197 196|197 203 203 197 205 203 209|202 209 209|202 209 205 211 209 174	Association
22664479	Chemical	Gene	D000077146	116328	False	2	What is [PHARMGKB] between @ChemicalSrc$ irinotecan @/ChemicalSrc$ and @GeneTgt$ C8orf34 @/GeneTgt$ ? [SEP] A genome-wide association study for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities in patients with advanced non-small-cell lung cancer . The identification of patients who are at high risk for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe diarrhea and neutropenia is clinically important . We conducted the first genome-wide association study ( GWAS ) to search for novel susceptibility genes for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities , such as diarrhea and neutropenia , in non-small-cell lung cancer ( NSCLC ) patients treated with @ChemicalSrc$ irinotecan @/ChemicalSrc$ chemotherapy . The GWAS putatively identified 49 single-nucleotide polymorphisms ( SNPs ) associated with grade 3 diarrhea ( G3D ) and 32 SNPs associated with grade 4 neutropenia ( G4N ) . In the replication series , the SNPs rs1517114 ( @GeneTgt$ C8orf34 @/GeneTgt$ ) , rs1661167 ( FLJ41856 ) and rs2745761 ( PLCB1 ) were confirmed as being associated with G3D , whereas rs11128347 ( PDZRN3 ) and rs11979430 and rs7779029 ( SEMAC3 ) were confirmed as being associated with G4N . The final imputation analysis of our GWAS and replication study showed significant overlaps of association signals within these novel variants . This GWAS screen , along with subsequent validation and imputation analysis , identified novel SNPs associated with @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities .	4 4 4 4 9 9|5 9 9|5 9 4 11 9 16 16 16 16 11 4 20 37 22 20 27 27 27 27 22 32 28|32 32 28|32 32 27 32 32 37 37 37 37 41 41 46 46 46 46 41 48 46 48 51 41 55 55 55 51 60 56|60 60 56|60 60 55 60 64 62 60 64 64 51 75 75 71 75 73 75 75 51 75 80 80|76 80 80|76 76 41 85 87 87 87 90 90 87 92 90 92 90 98 98 98 94 100 98 100 98 104 98 104 109 109 109 105 111 109 111 87 117 117 117 137 137 121 121 137 123 121|122 121 121|122 123 121 121 129 127 129 127 121 134 132 134 137 137 140 140 137 142 140 137 137 157 147 145 147 145 145 150 150 154 152 154 157 137 160 160 157 162 160 157 168 168 168 175 171 171 168 171 174 171 175 177 175 180 180 177 184 184 184 180 175 188 188 198 198 193 193 193 198 193 196 193 198 198 200 198 200 206 202|206 206 202|206 206 201 198	Association
22664479	Chemical	Gene	D000077146	23024	False	2	What is [PHARMGKB] between @ChemicalSrc$ irinotecan @/ChemicalSrc$ and @GeneTgt$ PDZRN3 @/GeneTgt$ ? [SEP] A genome-wide association study for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities in patients with advanced non-small-cell lung cancer . The identification of patients who are at high risk for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe diarrhea and neutropenia is clinically important . We conducted the first genome-wide association study ( GWAS ) to search for novel susceptibility genes for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities , such as diarrhea and neutropenia , in non-small-cell lung cancer ( NSCLC ) patients treated with @ChemicalSrc$ irinotecan @/ChemicalSrc$ chemotherapy . The GWAS putatively identified 49 single-nucleotide polymorphisms ( SNPs ) associated with grade 3 diarrhea ( G3D ) and 32 SNPs associated with grade 4 neutropenia ( G4N ) . In the replication series , the SNPs rs1517114 ( C8orf34 ) , rs1661167 ( FLJ41856 ) and rs2745761 ( PLCB1 ) were confirmed as being associated with G3D , whereas rs11128347 ( @GeneTgt$ PDZRN3 @/GeneTgt$ ) and rs11979430 and rs7779029 ( SEMAC3 ) were confirmed as being associated with G4N . The final imputation analysis of our GWAS and replication study showed significant overlaps of association signals within these novel variants . This GWAS screen , along with subsequent validation and imputation analysis , identified novel SNPs associated with @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities .	4 4 4 4 9 9|5 9 9|5 9 4 11 9 16 16 16 16 11 4 20 37 22 20 27 27 27 27 22 32 28|32 32 28|32 32 27 32 32 37 37 37 37 41 41 46 46 46 46 41 48 46 48 51 41 55 55 55 51 60 56|60 60 56|60 60 55 60 64 62 60 64 64 51 75 75 71 75 73 75 75 51 75 80 80|76 80 80|76 76 41 85 87 87 87 90 90 87 92 90 92 90 98 98 98 94 100 98 100 98 104 98 104 109 109 109 105 111 109 111 87 117 117 117 136 136 121 121 136 123 121 123 121 121 128 126 128 126 121 133 131 133 136 136 139 139 136 141 139 136 136 157 146 145|144 144 145|144 146 144 144 150 150 154 152 154 157 136 160 160 157 162 160 157 168 168 168 175 171 171 168 171 174 171 175 177 175 180 180 177 184 184 184 180 175 188 188 198 198 193 193 193 198 193 196 193 198 198 200 198 200 206 202|206 206 202|206 206 201 198	Association
22664479	Chemical	Gene	D000077146	23236	False	2	What is [PHARMGKB] between @ChemicalSrc$ irinotecan @/ChemicalSrc$ and @GeneTgt$ PLCB1 @/GeneTgt$ ? [SEP] A genome-wide association study for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities in patients with advanced non-small-cell lung cancer . The identification of patients who are at high risk for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe diarrhea and neutropenia is clinically important . We conducted the first genome-wide association study ( GWAS ) to search for novel susceptibility genes for @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities , such as diarrhea and neutropenia , in non-small-cell lung cancer ( NSCLC ) patients treated with @ChemicalSrc$ irinotecan @/ChemicalSrc$ chemotherapy . The GWAS putatively identified 49 single-nucleotide polymorphisms ( SNPs ) associated with grade 3 diarrhea ( G3D ) and 32 SNPs associated with grade 4 neutropenia ( G4N ) . In the replication series , the SNPs rs1517114 ( C8orf34 ) , rs1661167 ( FLJ41856 ) and rs2745761 ( @GeneTgt$ PLCB1 @/GeneTgt$ ) were confirmed as being associated with G3D , whereas rs11128347 ( PDZRN3 ) and rs11979430 and rs7779029 ( SEMAC3 ) were confirmed as being associated with G4N . The final imputation analysis of our GWAS and replication study showed significant overlaps of association signals within these novel variants . This GWAS screen , along with subsequent validation and imputation analysis , identified novel SNPs associated with @ChemicalSrc$ irinotecan-related @/ChemicalSrc$ severe toxicities .	4 4 4 4 9 9|5 9 9|5 9 4 11 9 16 16 16 16 11 4 20 37 22 20 27 27 27 27 22 32 28|32 32 28|32 32 27 32 32 37 37 37 37 41 41 46 46 46 46 41 48 46 48 51 41 55 55 55 51 60 56|60 60 56|60 60 55 60 64 62 60 64 64 51 75 75 71 75 73 75 75 51 75 80 80|76 80 80|76 76 41 85 87 87 87 90 90 87 92 90 92 90 98 98 98 94 100 98 100 98 104 98 104 109 109 109 105 111 109 111 87 117 117 117 137 137 121 121 137 123 121 123 121 121 128 126 128 126 121 133 131|132 131 131|132 133 137 137 140 140 137 142 140 137 137 157 147 145 147 145 145 150 150 154 152 154 157 137 160 160 157 162 160 157 168 168 168 175 171 171 168 171 174 171 175 177 175 180 180 177 184 184 184 180 175 188 188 198 198 193 193 193 198 193 196 193 198 198 200 198 200 206 202|206 206 202|206 206 201 198	Association
22725681	Chemical	Gene	D002945	1317	True	0	What is [PHARMGKB] between @ChemicalSrc$ cisplatin @/ChemicalSrc$ and @GeneTgt$ CTR1 @/GeneTgt$ ? [SEP] Genetic polymorphism of @GeneTgt$ copper transporter protein 1 @/GeneTgt$ is related to platinum resistance in Chinese non-small cell lung carcinoma patients . 1 . Chemotherapeutic resistance to platinum-based anticancer drugs is a major obstacle in the successful treatment of lung cancer . Cellular uptake and platinum accumulation are considered the most important factors contributing to platinum resistance . The copper transporter family is the major plasma membrane transporter for platinum uptake . @GeneTgt$ Copper transporter protein 1 @/GeneTgt$ ( @GeneTgt$ CTR1 @/GeneTgt$ ) plays an essential role in @ChemicalSrc$ cisplatin @/ChemicalSrc$ influx and is closely related to platinum resistance by influencing platinum uptake and accumulation . The aim of the present study was to determine whether @GeneTgt$ CTR1 @/GeneTgt$ polymorphisms are associated with platinum resistance in non-small cell lung carcinoma ( NSCLC ) patients . 2 . A total of 282 incident Chinese Han NSCLC patients were enrolled in the study and followed up at three different institutions . All patients underwent at least two cycles of platinum-based chemotherapy . Twenty single-nucleotide polymorphisms of @GeneTgt$ CTR1 @/GeneTgt$ were detected from genomic DNA samples . 3 . Genetic polymorphisms of @GeneTgt$ CTR1 @/GeneTgt$ at rs7851395 and rs12686377 were associated with platinum resistance in NSCLC patients . Patients with a GT haplotype presented with increased susceptibility to platinum resistance ( P & lt ; 0.05 ) , whereas an AG haplotype contributed to longer survival ( P & lt ; 0.05 ) . 4 . In conclusion , a significant relationship was found between rs7851395 and rs12686377 polymorphisms and platinum resistance , as well as clinical outcomes , in Chinese NSCLC patients . Thus , @GeneTgt$ CTR1 @/GeneTgt$ plays an essential role in platinum resistance and could be considered a predictive marker for the pretreatment evaluation of NSCLC patients .	2 10 4 2|3|4 2|3|4 2|3|4 2|3|4 2|4 2|3|4 10 10 13 13 10 20 20 20 20 20 20 13 10 23 23 26 34 30 30 30 26 34 34 34 34 38 38 38 34 41 41 38 34 44 49 44 47 44 49 49 53 52 53 49 53 57 57 54 49 62 62 62 68 68 68 68 68 68 68 71 71 68 68 72|73|82 72|73|82 72|73|82 72|73|82 73|82 72|73|82 79 73|74 73 73|74 79 82 85 85 82 89 81|89 89 81|89 82 82 93 93 82 96 96 93 98 93 100 98 100 100 82 108 113 112 112 112 108 113 115 113 121 116|119 119 116|119 121 121 115 124 124 121 133 133 129 129 133 131 133 133 124 113 136 136 139 148 146 142 146 146 146 146 139 148 148 151 151 148 148 148 153 158 158 158 153 148 161 162 162 164 165 166 162 169 169 166 162 173 173 178 175 173|174 173 173|174 178 178 182 182 182 178 178 185 185 188 197 190 188|189 188 188|189 193 190 193 193 197 197 200 200 197 203 203 200 197 211 210 210 210 206 211 214 214 211 217 217 214 219 217 219 219 219 219 219 211 230 229 229 230 211 233 233 230 235 233 235 235 235 235 235 211 242 242 245 251 251 249 249 251 251 251 256 256 253 253 251 256 259 256 256 256 261 261 265 256 256 270 270 270 256 251 276 276 273|276 276 273|276 276 279 279 276 282 282 276 276 286 286 276 289 289 286 293 293 293 289 296 296 293 276	Association
22735389	Chemical	Gene	D008687	6580	True	0	What is [PHARMGKB] between @ChemicalSrc$ metformin @/ChemicalSrc$ and @GeneTgt$ OCT1 @/GeneTgt$ ? [SEP] Association of genetic variation in the organic cation transporters @GeneTgt$ OCT1 @/GeneTgt$ , OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in @ChemicalSrc$ metformin-treated @/ChemicalSrc$ type 2 diabetes patients . OBJECTIVE : @ChemicalSrc$ Metformin @/ChemicalSrc$ is the most widely used oral antidiabetic drug for the treatment of type 2 diabetes ( T2D ) . So far , the number of polymorphisms in @GeneTgt$ SLC22A1 @/GeneTgt$ , SLC22A2 , and SLC47A1 genes coding for @GeneTgt$ organic cation transporter 1 @/GeneTgt$ ( @GeneTgt$ OCT1 @/GeneTgt$ ) , OCT2 , and multidrug and toxin extrusion transporter 1 ( MATE1 ) metformin transporters have been described in association with the efficacy of @ChemicalSrc$ metformin @/ChemicalSrc$ . However , there is no information on the influence of genetic variations within these genes on the side effects of @ChemicalSrc$ metformin @/ChemicalSrc$ . In this study , we assessed whether five single-nucleotide polymorphisms and two indel polymorphisms are associated with the side effects of @ChemicalSrc$ metformin @/ChemicalSrc$ in patients with T2D . METHODS : Seven polymorphisms in @GeneTgt$ OCT1 @/GeneTgt$ , OCT2 , and MATE1 genes were compared between 53 T2D patients with side effects of @ChemicalSrc$ metformin @/ChemicalSrc$ and 193 @ChemicalSrc$ metformin @/ChemicalSrc$ users without symptoms of @ChemicalSrc$ metformin @/ChemicalSrc$ intolerance . RESULTS : We found a statistically significant association between the A allele of the rs628031 ( P=0.012 , odds ratio=0.389 , confidence interval 95 % [ 0.186 - 0.815 ] ) as well as 8 bp insertion ( rs36056065 ) in the @GeneTgt$ OCT1 @/GeneTgt$ gene ( P=0.002 , odds ratio=0.405 , confidence interval 95 % [ 0.226 - 0.724 ] ) and the presence of the side effects of @ChemicalSrc$ metformin @/ChemicalSrc$ . CONCLUSION : Two genetic variations in @GeneTgt$ OCT1 @/GeneTgt$ that are in strong linkage disequilibrium may predispose toward an increased prevalence of the side effects of @ChemicalSrc$ metformin @/ChemicalSrc$ in patients with T2D .	1 4 4 1 9 9 9 9 4 9 9 9 10 10 10 10 10 22 22 22 22 22 10 27 27 27 27 1 27 30 27 37 37|30 37 37|30 37 37 37 27 1 41 52 42|52 52 42|52 52 52 48 49 52 52 52 41 55 55 52 59 59 59 55 61 59 61 41 66 109 109 69 109 71 69 73 72|71 71 72|71 73 73 73 73 80 73 80 83 81|106|83 81|106|83 81|106|83 81|106|83 106|83 81|106|83 89 83 83 83 89 83 83 93 83 83 83 100 100 106 106 106 106 106 106 81 109 109 109 111 109 114 114 111 116 114|109 114 114|109 109 126 126 126 126 128 126 131 131 128 134 134 131 137 137 134 141 141 141 131 143 141|142 141 141|142 126 149 149 152 152 152 152 162 156 156 162 156 160 160 156 162 152 166 166 166 162 168 166|167 166 166|167 171 166 173 171 152 190 190 179 190 181 179|180 179 179|180 181 181 181 181 181 181 190 190 194 194 194 190 197 197 194 199 197 197 197 199 203 200|205 205 200|205 199 207 197 211 211|205 211 211|205 207 190 217 217 220 217 224 223 224 220 228 228 228 224 231 231 228 233 231 233 236 233 233 239 233 241 239 245 245 245 241 245 233 231 248 248 253 253 228 255 253 255 261 261 258|261 261 258|261 253 263 261 263 263 265 263 269 263 271 269 275 275 273 271 275 263 228 280 228 284 284 284 280 286 284 284 284 217 291 291 295 295 291 297 295|296 295 295|296 306 306 304 304 304 306 306 295 310 310 310 306 314 314 314 310 316 314 314 314 319 314 321 319 291	Association
22838948	Chemical	Gene	D015122	2346	False	1	What is [PHARMGKB] between @ChemicalSrc$ 6-mercaptopurine @/ChemicalSrc$ and @GeneTgt$ GCPII @/GeneTgt$ ? [SEP] Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL . AIM : The rationale of this study was to explore the contribution of genetic variants of the folate pathway to toxicity of @ChemicalSrc$ 6-mercaptopurine @/ChemicalSrc$ @ChemicalSrc$ (6-MP)-mediated @/ChemicalSrc$ hematological toxicity in children with acute lymphoblastic leukemia ( ALL ) and to explore the interaction of these variants with TPMT and ITPA haplotypes using multifactor dimensionality reduction analysis . MATERIALS & amp ; METHODS : Children with ALL ( n = 96 ) were screened for @GeneTgt$ GCPII @/GeneTgt$ C1561 T , RFC1 G80A , cSHMT C1420 T , TYMS 5 -UTR 2R3R , TYMS 3 -UTR ins6/del6 , MTHFR C677 T , MTR A2756 G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques . RESULTS : @GeneTgt$ GCPII @/GeneTgt$ C1561 T showed independent association with toxicity . The following synergetic interactions appeared to increase the toxicity of @ChemicalSrc$ 6-mercaptopurine @/ChemicalSrc$ : TPMT*12 x RFC1 G80A ; TPMT CTTAT haplotype x RFC1 G80A ; TPMT CTTAT haplotype x RFC1 G80A x TYMS 2R3R . The genetic variants of thiopurine and folate pathway cumulatively appeared to increase the predictability of toxicity ( r(2 ) = 0.41 ) in a multiple linear regression model . For the observed toxicity grades of 1 , 2 , 3 and 4 , the respective predicted toxicity grades were 1.65 + - 0.29 , 1.68 + - 0.24 , 2.56 + - 0.58 and 2.99 + - 1.03 , p(trend ) & lt ; 0.0001 . CONCLUSION : Gene-gene interaction between thiopurine and folate pathways inflate the 6-MP-mediated toxicity in Indian children with ALL illustrating the importance of ethnicity in the toxicity of 6-MP .	2 9 4 2 4 4 8 4 9 12 12 9 15 15 12 9 26 17 20 24 23 23 20 26 26 26 28 26 31 31 28 35 35 35 31 37 28 44 44|38 44 44|38 44|39 44 44|39 44 37 46 44 50 50 50 46 52 50 52 26 56 26 58 56 61 61 58 63 58 63 66 63 56 71 71 71 67 26 90 75 75 75 75 79 90 83 81 85 83 85 86 85 90 90 95 91|95 95 91|95 95 90 95 98 95 95 101 95 95 95 107 107 107 95 95 112 112 112 95 95 116 116 95 95 121 121 121 95 90 122 123 123 129 129 129 123 90 138 132 133|137 137 133|137 137 138 138 140 138 142 140 138 148 148 148 149 149 151 149 153 151 155 153|154 153 153|154 149 149 158 161 158 158 165 165 158 165 168 165 158 178 178 178 172 178 178 178 178 158 149 183 183 190 185 183 185 185 185 190 190 192 190 194 192 196 194 198 196 198 196 200 200 208 208 208 208 208 194 190 214 214 214 214 214 216 214 216 216 216 216 216 216 216 228 228 228 228 238 238 238 230 233 230 233 230 235 238 216 238 238 240 243 240 243 238 238 248 238 238 238 238 216 216 216 216 214 257 257 260 266 262 260 262 262 262 257 269 269 266 272 272 269 274 272 266 277 275 279 277 282 282 277 284 282 266	Association
23041303	Chemical	Gene	D016559	6934	False	3	What is [PHARMGKB] between @ChemicalSrc$ tacrolimus @/ChemicalSrc$ and @GeneTgt$ TCF7L2 @/GeneTgt$ ? [SEP] Association between donor and recipient @GeneTgt$ TCF7L2 @/GeneTgt$ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population . BACKGROUNDS & amp ; AIMS : New-onset diabetes mellitus ( NODM ) is a frequent and serious complication arising after liver transplantation ( LT ) . @GeneTgt$ Transcription factor 7-like 2 @/GeneTgt$ ( @GeneTgt$ TCF7L2 @/GeneTgt$ ) polymorphisms have been reported to strongly associate with type 2 diabetes . In addition , the donor liver plays a vital role in regulating blood glucose levels . In this study , we aim at evaluating the association between donor and recipient @GeneTgt$ TCF7L2 @/GeneTgt$ gene polymorphisms with NODM after LT . METHODS : A total of 125 patients undergoing primary LT , without a history of diabetes were included . Four single nucleotide polymorphisms ( rs290487 , rs7903146 , rs11196205 , and rs12255372 ) , closely associated with type 2 diabetes in the Eastern Asia population , were genotyped and analyzed . RESULTS : Both donor and recipient rs290487 polymorphisms ( CC vs. TT genotype ) were found to be significantly associated with NODM . In multivariate analysis , donor rs290487 genetic variation ( OR = 2.172 per each C allele , p = 0.015 ) , blood @ChemicalSrc$ tacrolimus @/ChemicalSrc$ levels at 1 month post-LT & gt;10 ng/ml ( OR = 3.264 , p = 0.017 ) , and recipient age & gt;55 years ( OR = 2.638 , p = 0.043 ) were identified as independent risk factors of NODM . Furthermore , donor rs290487 CC genotype could predict a high probability ( & gt;40 % ) of the onset of NODM . Predictive model containing donor rs290487 polymorphism showed a significantly higher prognostic ability on NODM than the model with only clinical parameters ( p = 0.031 ) . CONCLUSIONS : Donor @GeneTgt$ TCF7L2 @/GeneTgt$ rs290487 polymorphism is associated with an increased risk of NODM after LT and has a potential clinical value for the prediction of NODM .	1 3 1 3 3 9|5 9 9|5 9 3 3 12 3 16 16 16 12 19 19 1 24 24 24 24 19 1 44 27 27 27 27 31 35 35 31 37 35 37 44 44 44 41 41 44 44 48 48 45 50 48 50 44 52|53|62 52|53|62 52|53|62 52|53|62 53|62 52|53|62 59 53|54 53 53|54 59 65 65 65 65 68 68 65 72 72 72 68 65 77 82 82 81 81 82 82 85 85 82 87 82 90 90 87 82 94 94 97 97 97 97 99 97 101 99 103 101 103 103 109|105 109 109|105 109 103 111 103 113 101 97 133 133 119 133 122 122 119 122 125 123 119 129 129 119 131 129 133 133 133 138 138 138 163 140 138 140 140 140 140 140 140 140 140 138 151 138 155 155 155 151 160 160 159 160 155 138 163 163 163 163 163 167 167 170 182 170 170 174 170 176 174 176 179 176 176 182 167 186 186 186 182 188 186 167 192 192 249 249 197 197 197 249 200 200 197 200 205 205 205 201 208 208 200 208 208 200 215 215|212 215 215|212 249 219 218 219 215 219 219 219 225 225 222 225 229 229 225 229 229 225 225 225 225 235 238 235 241 241 238 241 245 245 241 245 241 249 249 253 253 253 249 255 253 249 265 265 263 263 263 265 265 265 268 268 265 268 268 272 268 272 276 276 268 278 276 265 281 286 281 285 285 282 286 291 289 291 291 286 293 291 296 296 291 300 300 300 296 303 303 300 303 303 286 307 307 313 309|313 313 309|313 313 315 315 307 319 319 319 315 321 319 323 319 315 315 329 329 329 325 332 332 325 334 332 307	Association
23069858	Chemical	Gene	D008727	1244	True	0	What is [PHARMGKB] between @ChemicalSrc$ MTX @/ChemicalSrc$ and @GeneTgt$ ABCC2 @/GeneTgt$ ? [SEP] Impact of @GeneTgt$ ABCC2 @/GeneTgt$ polymorphisms on high-dose @ChemicalSrc$ methotrexate @/ChemicalSrc$ pharmacokinetics in patients with lymphoid malignancy . Human @GeneTgt$ multidrug resistance-related protein 2 @/GeneTgt$ ( @GeneTgt$ MRP2 @/GeneTgt$ , encoded by @GeneTgt$ ABCC2 @/GeneTgt$ ) is involved in the transport of anionic drugs such as @ChemicalSrc$ methotrexate @/ChemicalSrc$ ( @ChemicalSrc$ MTX @/ChemicalSrc$ ) . We prospectively investigated the influence of four common @GeneTgt$ ABCC2 @/GeneTgt$ genetic variants ( rs717620 , rs2273697 , rs8187694 and rs8187710 ) on @ChemicalSrc$ MTX @/ChemicalSrc$ pharmacokinetics parameters . @ChemicalSrc$ MTX @/ChemicalSrc$ concentrations were monitored in 50 patients with lymphoid malignancy ( 27 males ; mean age : 53 + -17 years ) receiving high-dose @ChemicalSrc$ MTX @/ChemicalSrc$ ( 5.13 + -1.88 g m(-)(2 ) in a 4-h perfusion ) . The population pharmacokinetics modelling showed that @GeneTgt$ ABCC2 @/GeneTgt$ -24 T allele ( rs717620 ) had a combined influence on both @ChemicalSrc$ MTX @/ChemicalSrc$ elimination and distribution . The @ChemicalSrc$ MTX @/ChemicalSrc$ clearance and distribution volume were significantly higher in carriers of at least one copy of the -24 T allele as compared with noncarriers : 8.6 + -2.2 vs 6.7 + - 2.5 l h(-1 ) , P&lt;0.01 and 30.7 + -7.7 vs 22.1 + -8.8 l , P&lt;0.001 , respectively . Consequently , -24 T allele carriers were more prone to reach @ChemicalSrc$ MTX @/ChemicalSrc$ nontoxic levels , 48 h after administration .	1 5 2|5 5 2|5 1 10 10 10|6 10 10|6 1 12 10 15 15 12 1 20 19|20|35 19|20|35 19|20|35 19|20|35 35|20 19|20|35 26 20|21 20 20|21 26 26 31 29|25 29 29|25 26 35 35 38 38 35 41 41 38 44 42 37|41 41 37|41 47 44|39 44 44|39 47 35 58 58 58 60 58 67 67 67 63|67 67 63|67 67 60 69 67 69 69 69 69 69 69 69 81 81|76 81 81|76 81 60 58 84|87 87 84|87 89 89 89 92 92 89 95 95 92 98 98 92 98 101 89 106 106 103 103 101 106 101 110 108 108 108 117 117 113 113 117 101 117 122 122 122 101 101 89 130 129 130 131 131 141 137|132 137 137|132 137 137 141 139 137 139 131 144 144 141 149 149 145|149 149 145|149 144 149 149 131 158 155|158 158 155|158 164 158 161 158 164 164 164 166 164 171 169 170 171 166 176 176 176 176 171 178 164 180 178 191 191 182 182 184 182 186 189 186 191 180 191 180 180 194 194 196 196 198 203 200 200 194 205 203 205 164 164 218 218 215 215 215 218 218 218 218 220 218 220|224 224 220|224 224 220 224 227 218 229 227 218	Association
23238479	Chemical	Gene	D005472	51733	True	0	What is [PHARMGKB] between @ChemicalSrc$ 5-FU @/ChemicalSrc$ and @GeneTgt$ UPB1 @/GeneTgt$ ? [SEP] Contribution of the @GeneTgt$ beta-ureidopropionase @/GeneTgt$ ( @GeneTgt$ UPB1 @/GeneTgt$ ) gene alterations to the development of fluoropyrimidine-related toxicity . BACKGROUND : An impairment of the @ChemicalSrc$ 5-fluorouracil @/ChemicalSrc$ ( @ChemicalSrc$ 5-FU @/ChemicalSrc$ ) catabolic pathway , represented by alterations in the dihydropyrimidine dehydrogenase ( DPYD ) gene , is considered a crucial factor contributing to the development of @ChemicalSrc$ 5-FU-related @/ChemicalSrc$ toxicity . The @GeneTgt$ beta-ureidopropionase @/GeneTgt$ ( @GeneTgt$ BUP1 @/GeneTgt$ ) enzyme catalyzes the final step in the @ChemicalSrc$ 5-FU @/ChemicalSrc$ catabolic pathway ; however , alterations in the @GeneTgt$ UPB1 @/GeneTgt$ gene coding for the @GeneTgt$ BUP1 @/GeneTgt$ enzyme have not yet been analyzed in fluoropyrimidine (FP)-treated patients suffering from @ChemicalSrc$ 5-FU-related @/ChemicalSrc$ toxicity . METHODS : We have performed a mutation analysis of the entire coding sequence of @GeneTgt$ UPB1 @/GeneTgt$ based on denaturing high-performance liquid chromatography in 113 cancer patients treated by FP-containing regimes . These patients included 67 individuals suffering from severe @ChemicalSrc$ 5-FU-related @/ChemicalSrc$ toxicity and 46 individuals with excellent tolerance of chemotherapy . RESULTS : Nine @GeneTgt$ UPB1 @/GeneTgt$ variants were detected in the subpopulation of patients with severe toxicity , including a novel mutation affecting the coding sequence ( c.872_873 + 11del13 ) . An analysis of @GeneTgt$ UPB1 @/GeneTgt$ variants on @ChemicalSrc$ 5-FU-related @/ChemicalSrc$ toxicity in the population of all analyzed patients revealed an association between the c.-80C&gt;G ( rs2070474 ) variant and gastrointestinal toxicity . A strong positive correlation was found between the carriers of the c.-80 GG genotype and the development of severe ( grade 3 - 4 ) mucositis ( OR = 7.5 ; 95 % CI = 2.60 - 21.60 ; p = 0.0002 ) . CONCLUSION : Our results suggest that @GeneTgt$ UPB1 @/GeneTgt$ variants may contribute to the development of @ChemicalSrc$ 5-FU-related @/ChemicalSrc$ toxicity in some FP-treated patients ; however , the role of @GeneTgt$ UPB1 @/GeneTgt$ alterations is probably less significant than that of DPYD alterations .	1 11 11 11|3 11 11|3 7 11|5 11 11|5 11 11 1 14 14 1 17 17 14 1 49 21 24 21 34 34 26|34 34 26|34 30 28|27 27 28|27 30 34 24 34 34 38 36 46 46 46 46 46 46 46 38 21 49 49 52 52 49 52 56 56 53 60 60|55 60 60|55 56 49 72 72|65 72 72|65 69 66|67 66 66|67 69 73 73 76 76 73 82 82 81|76 81 81|76 82 76 73 102 102 102 91 91 91|85 91 91|85 86 91 97 97 97|90 97 97|90 92 102 102 102 102 73 106 106 106 102 106 111 111|103 111 111|103 107 73 123 123 123 123 123 126 126 123 131 131 131 131 126 133 131|132 131 131|132 123 137 135 140 140 137 144 144 144 137 144 148 148 145 123 152 153 153 155 153 155 161 161 158|161 161 158|161 156 161 164 161 167 167 156 169 167 153 172 172 177 174|177 177 174|177 179 179 172 182 182 179 184 182 187 187 184 187 192 192 192 187 192 196 196 193 198 196 198 198 198 172 205 221 209 206|209 209 206|209 205 213 213|209 213 213|209 205 216 216 213 218 220 220 216 221 223 221 230 230 230 228 226 228 223 230 233 230 221 240 240 238 242 242 242 245 245 242 250 250 250 250 245 250 253 245 262 262 262 262 262 260 258 260 253 264 262 264 265 265 269 270 253 270 274 274 271 277 277 242 277 277 242 285 285 284 285 285 291 289|286 289 289|286 291 291 285 294 294 291 298 298|294 298 298|294 294 302 302 302 294 291 315 315 307 315 311 306|311 311 306|311 307 315 315 315 291 317 315 320 320 317 285	Association
23252721	Chemical	Gene	D019259	6582	True	0	What is [PHARMGKB] between @ChemicalSrc$ lamivudine @/ChemicalSrc$ and @GeneTgt$ SLC22A2 @/GeneTgt$ ? [SEP] Effects of @GeneTgt$ OCT2 @/GeneTgt$ c.602C & gt ; T genetic variant on the pharmacokinetics of @ChemicalSrc$ lamivudine @/ChemicalSrc$ . 1 . The renal excretion of organic cation drugs , including @ChemicalSrc$ lamivudine @/ChemicalSrc$ , is mostly mediated by @GeneTgt$ OCT2 @/GeneTgt$ in vitro . To date , three putatively relevant single nucleotide polymorphisms ( SNPs ) , including c.596C & gt ; T ( p. Thr199Ile ) , c.602C & gt ; T ( p. Thr201Met ) , and c.808 G & gt ; T ( p. Ala270Ser ) have been observed in Asians . The effects of the @GeneTgt$ SLC22A2 @/GeneTgt$ c.602C & gt ; T genetic variant on the pharmacokinetics of @ChemicalSrc$ lamivudine @/ChemicalSrc$ were studied with healthy Korean subjects . 2 . Nineteen healthy subjects carrying either the @GeneTgt$ SLC22A2 @/GeneTgt$ c.602CC ( n = 12 ) or c.602CT ( n = 7 ) genotype volunteered for this study . A single 100 mg dose of @ChemicalSrc$ lamivudine @/ChemicalSrc$ was orally administered to each subject . Blood samples were collected for up to 24 h and the plasma concentrations of @ChemicalSrc$ lamivudine @/ChemicalSrc$ were measured using liquid chromatography-tandem mass spectrometry . 3 . The mean plasma concentration-time profiles of @ChemicalSrc$ lamivudine @/ChemicalSrc$ in the c.602CC and c.602CT genotype groups were similar . There was no significant difference in the overall pharmacokinetic parameters of @ChemicalSrc$ lamivudine @/ChemicalSrc$ between the c.602CC and c.602CT genotype groups . Differences in renal clearance and tubular secretion clearance were also not statistically significant between the two genotype groups . 4 . The @GeneTgt$ SLC22A2 @/GeneTgt$ c.602C & gt ; T genotype did not affect the pharmacokinetics of @ChemicalSrc$ lamivudine @/ChemicalSrc$ in humans in vivo . Dose adjustment of @ChemicalSrc$ lamivudine @/ChemicalSrc$ is not required between individuals with c.602CC and c.602CT genotypes .	11 5 2|5 5 2|5 1 5 5 11 10 11 11 14 14 11 16 14 14 14 11 21 21 25 25 37 29 29 29 25 29 32 31|29 29 31|29 29 37 37 37 39 37 37 37 42 37 37 47 93 93 54 51 54 54 54 93 56 54 56 54 60 54 60 60 60 60 66 64 66 66 64 64 70 70 60 60 77 77 74 77 60 60 82 60 82 82 60 60 89 89 86 89 93 93 93 95 93 93 98 117 103 103 100|103 103 100|103 98 103 103 98 108 109 98 112 112 109 114 112 112 112 117 117 121 121 119 117 117 125 125 129 129 149 129 135 135 135|132 135 135|132 130 137 138 135 138 138 135 135 148 148 144 145 145 149 149 152 152 149 149 159 159 158 159 165 161 159|160 159 159|160 165 165 165 168 168 165 165 172 174 174 174 179 178 178 179 174 174 183 183 188 185 183|184 183 183|184 188 174 188 193 193 193 189 174 196 196 202 202 202 202 214 204 202|203 202 202|203 212 212 207 208 208 212 202 214 214 214 218 218 221 221 218 226 226 226 226 221 228 226|227 226 226|227 236 236 231 232 232 236 226 218 251 242 242 239 242 246 246 242 251 251 251 251 251 256 256 256 256 251 251 258 258 263 260|263 263 260|263 271 263 263 271 268 271 271 271 271 273 271 275 273 273 273 278 273 280 271 271 285 291 287 285|286 285 285|286 291 291 291 293 291 295 298 295 295 293 291	Association
23263738	Chemical	Gene	D019821	10599	True	0	What is [PHARMGKB] between @ChemicalSrc$ simvastatin @/ChemicalSrc$ and @GeneTgt$ SLCO1B1 @/GeneTgt$ ? [SEP] Lack of association between @GeneTgt$ SLCO1B1 @/GeneTgt$ polymorphism and the lipid-lowering effects of atorvastatin and @ChemicalSrc$ simvastatin @/ChemicalSrc$ in Chinese individuals . PURPOSE : There is significant inter-individual variability in the lipid-lowering effects of atorvastatin and @ChemicalSrc$ simvastatin @/ChemicalSrc$ . Our goal was to investigate the impact of @GeneTgt$ SLCO1B1 @/GeneTgt$ genetic polymorphism on the lipid-lowering effects of atorvastatin and @ChemicalSrc$ simvastatin @/ChemicalSrc$ . METHODS : We recruited 363 unrelated hyperlipidemic patients with the CYP3A4 1/1 , CYP3A5 1/1 , and CYP3AP1 1/1 genotypes : 189 of these were treated with atorvastatin and 174 were treated with @ChemicalSrc$ simvastatin @/ChemicalSrc$ as a single-agent therapy ( 20 mg day(-1 ) orally ) for 4 weeks . The genotyping of @GeneTgt$ SLCO1B1 @/GeneTgt$ c.521 T & gt ; C ( p. V174A , OATP-C5 ) was performed with allele-specific polymerase chain reaction ( AS-PCR ) , and PCR restriction fragment length polymorphism ( RFLP ) was performed to detect the carriers of @GeneTgt$ SLCO1B1 @/GeneTgt$ c.388A & gt ; G ( p. N130D , OATP-C1b ) . Serum triglyceride ( TGs ) , total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , and high-density lipoprotein cholesterol ( HDL-C ) levels were determined before and after treatment . RESULTS : The frequencies of the @GeneTgt$ SLCO1B1 @/GeneTgt$ 521 T & gt ; C and 388A & gt ; G variant alleles in Chinese hyperlipidemic patients were found to be 16.2 % and 72.1 % respectively . After treatment with 20 mg simvastatin or atorvastatin daily for 4 weeks , TC , TG , and LDL-C concentrations were lower than at baseline , on average , by 18.1 + - 3.7 % , 25.8 + - 9.7 % , 27.7 + - 5.4 % in the simvastatin-treated group , and 17.5 + - 3.7 % , 22.6 + - 8.6 % , 27.5 + - 5.5 % in the atorvastatin-treated group respectively , and the mean relative reduction in serum HDL cholesterol did not reach statistical significance ( -1.0 + - 10.9 % , 0.5 + - 9.3 % ) . However , no significant differences were observed in the lipid-lowering effects of atorvastatin and @ChemicalSrc$ simvastatin @/ChemicalSrc$ between subjects with different @GeneTgt$ SLCO1B1 @/GeneTgt$ genotypes . CONCLUSION : The @GeneTgt$ SLCO1B1 @/GeneTgt$ 521 T & gt ; C and 388A & gt ; G variants were found to be relatively common in Chinese patients with essential hyperlipidemia . These frequencies were found to be similar to those observed in healthy Chinese and Japanese individuals , but significantly different from Caucasians and blacks . @GeneTgt$ SLCO1B1 @/GeneTgt$ 521 T & gt ; C and 388A & gt ; G polymorphisms may not be associated with the lipid-lowering effects of atorvastatin and @ChemicalSrc$ simvastatin @/ChemicalSrc$ .	1 3 1 7 4|7 7 4|7 3 7 11 11 7 13 11 13 13 13 13 19 19 11 1 23 23 26 23 29 29 26 33 33 33 29 35 33 35 35|36 35 35|36 26 42 45 45 45 45 47 45 52 48|52 52 48|52 52 47 56 56 56 47 58 56 58 58 58 58 45 68 68 68 68 72 72 72 68 75 75 72 75 75 75 78 75 75 84 84 72 84 90 88 86 90 84 92 90 90 96 96 90 98 96|97 96 96|97 103 103 103 96 107 106 107 103 107 103 103 113 113 96 68 117 134 122 118|122 122 118|122 122 117 122 122 134 129 129 129 134 129 129 129 134 134 139 139 139 139 134 141 139 141 139 139 149 149 149 149 154 151 149 151 154 134 156 154 158 156 162 158|162 162 158|162 158 162 162 158 158 169 169 166 169 169 169 134 177 202 179 177 179 177 183 177 185 183 185 183 190 190 183 192 190 192 183 183 198 198 183 200 198 200 204 204 204 208 205 208 204 204 237 210 213 210 219 219 219|215 219 219|215 219 213 219 219 213 213 223 223 225 225 213 231 231 237 235 235 235 231 237 237 241 241 241 237 241 244 241 241 237 249 269 253 252 253 249 253 253 253 259 259 253 253 253 261 261 261 253 267 253 269 269 272 272 269 272 275 272 269 282 282 278 281 278 269 282 288 284 287 288 282 288 294 290 293 290 282 298 298 298 294 282 282 305 301 304 301 282 311 311 307 311 311 305 311 317 313 316 313 305 321 321 321 317 282 269 269 328 328 328 335 332 332 332 328 335 335 269 337 335 339 343 339 342 339 335 343 349 345 348 345 343 343 269 358 358 356 356 358 358 358 362 362 362 358 364 362 364 364|365 364 364|365 369 362 374 374 370|374 374 370|374 369 358 397 378 384 380|384 384 380|384 384 378 384 384 384 384 388 388 390 390 397 395 397 397 397 401 401 401 397 404 404 401 407 407 404 397 411 413 413 413 416 416 413 418 416 418 425 422 425 422 422 419 413 413 429 413 431 429 431 431 413 434|453 453 434|453 438 435 438 438 435 435 442 442 444 444 453 449 453 453 453 453 453 457 457 457 453 459 457 459 459 459 459 453	Association
23274376	Chemical	Gene	D002945	4036	True	0	What is [PHARMGKB] between @ChemicalSrc$ cisplatin @/ChemicalSrc$ and @GeneTgt$ megalin @/GeneTgt$ ? [SEP] @ChemicalSrc$ Cisplatin-induced @/ChemicalSrc$ ototoxicity in pediatric solid tumors : the role of glutathione S-transferases and @GeneTgt$ megalin @/GeneTgt$ genetic polymorphisms . @ChemicalSrc$ Cisplatin-induced @/ChemicalSrc$ ototoxicity , an important dose-limiting side effect , has proven high interindividual variability . Glutathione S-transferases ( GSTs ) are isoenzymes involved in cellular detoxification processes . @GeneTgt$ Megalin @/GeneTgt$ has been demonstrated to bind aminoglycosides , known to be similar to @ChemicalSrc$ cisplatin @/ChemicalSrc$ for their ototoxicity . The GSTs and @GeneTgt$ megalin @/GeneTgt$ expression is genetically polymorphic , which might be responsible for the variability in @ChemicalSrc$ cisplatin-induced @/ChemicalSrc$ ototoxicity . The genotyping of GSTM1 , GSTT1 polymorphisms , and 2 nonsynonymous single nucleotide polymorphisms ( SNPs ) at @GeneTgt$ megalin @/GeneTgt$ genes , rs2075252 and rs2228171 , were performed in 68 children diagnosed with solid tumors who received @ChemicalSrc$ cisplatin-based @/ChemicalSrc$ chemotherapy . After the end of treatment , audiometry demonstrated hearing loss in 79.4 % of patients according to Brock classification . The cumulative @ChemicalSrc$ cisplatin @/ChemicalSrc$ dose & gt;400 mg/m is associated with increased risk of @ChemicalSrc$ cisplatin-induced @/ChemicalSrc$ ototoxicity [ odds ratio ( OR ) , 17.5 ; 95 % confidence interval ( CI ) , 3.09 - 98.62 ] . GSTT1 wild genotype and C-allele of rs2228171 SNPs of @GeneTgt$ megalin @/GeneTgt$ gene occurred with higher frequency in patients with ototoxicity ( P=0.023 ; OR , 10 ; 95 % CI , 1.80 - 56.00 and P=0.034 ; OR , 2.67 ; 95 % CI , 1.22 - 5.82 , respectively ) . In conclusion , our results suggested that GSTT1 wild genotype and C-allele of rs2228171 SNPs might be risk factors for ototoxicity . The cumulative @ChemicalSrc$ cisplatin @/ChemicalSrc$ dose & lt;400 mg/m should be beneficial in order to ameliorate ototoxicity .	0|3 3 0|3 3 7 7 7 3 3 10 3 13 13 10 13 18|13 18 18|13 18 13 3 21|24 24 21|24 33 24 30 30 30 30 24 24 33 33 36 36 33 33 40 45 42 40 42 45 45 45 50 50 50 46 45 51|56 56 51|56 56 56 56 58 56 58 59 59 64 64 61 66 64 64 64 70 70 66 56 75 82 75 76|79 79 76|79 75 82 82 82 82 87 87 87 82 90 90 87 94 90|94 94 90|94 90 82 99 125 101 99 101 101 101 101 101 111 111 111 111 101 113 111 113 118 115|118 118 115|118 99 118 118 120 120 99 125 125 128 128 125 128 132 132 129 134 132 137|133 137 137|133 134 125 143 143 148 145 143 148 148 148 148 149 153 153 149 155 153 159 156 159 155 148 165 165 162|165 165 162|165 170 165 168 165 170 170 173 173 170 177 177|173 177 177|173 173 180 180 177 182 180 182 180 180 180 188 190 190 180 192 190 192 190 197 197 190 180 170 204 204 214 204 204 209 209 206 213 210|213 213 210|213 209 214 217 217 214 219 217 221 219 223 221 223 223 223 223 223 230 231 223 231 223 223 223 235 235 223 223 223 223 223 244 245 223 245 249 249 245 223 223 223 214 256 260 260 259 260 260 273 264 264 273 264 264 269 269 266 273 273 273 260 275 273 260 281 281 278|281 281 278|281 287 281 284 281 287 287 287 289 287 291 289 291 287	Association
23275066	Chemical	Gene	D000077144	1066	True	0	What is [PHARMGKB] between @ChemicalSrc$ clopidogrel @/ChemicalSrc$ and @GeneTgt$ CES1 @/GeneTgt$ ? [SEP] @GeneTgt$ Carboxylesterase 1 @/GeneTgt$ as a determinant of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ metabolism and activation . @ChemicalSrc$ Clopidogrel @/ChemicalSrc$ pharmacotherapy is associated with substantial interindividual variability in clinical response , which can translate into an increased risk of adverse outcomes . @ChemicalSrc$ Clopidogrel @/ChemicalSrc$ , a recognized substrate of hepatic @GeneTgt$ carboxylesterase 1 @/GeneTgt$ ( @GeneTgt$ CES1 @/GeneTgt$ ) , undergoes extensive hydrolytic metabolism in the liver . Significant interindividual variability in the expression and activity of @GeneTgt$ CES1 @/GeneTgt$ exists , which is attributed to both genetic and environmental factors . We determined whether @GeneTgt$ CES1 @/GeneTgt$ inhibition and @GeneTgt$ CES1 @/GeneTgt$ genetic polymorphisms would significantly influence the biotransformation of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ and alter the formation of the active metabolite . Coincubation of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ with the @GeneTgt$ CES1 @/GeneTgt$ inhibitor bis(4-nitrophenyl ) phosphate in human liver s9 fractions significantly increased the concentrations of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ , 2-oxo-clopidogrel , and @ChemicalSrc$ clopidogrel @/ChemicalSrc$ active metabolite , while the concentrations of all formed carboxylate metabolites were significantly decreased . As anticipated , @ChemicalSrc$ clopidogrel @/ChemicalSrc$ and 2-oxo-clopidogrel were efficiently hydrolyzed by the cell s9 fractions prepared from wild-type @GeneTgt$ CES1 @/GeneTgt$ transfected cells . The enzymatic activity of the @GeneTgt$ CES1 @/GeneTgt$ variants G143E and D260fs were completely impaired in terms of catalyzing the hydrolysis of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ and 2-oxo-clopidogrel . However , the natural variants G18V , S82L , and A269S failed to produce any significant effect on @GeneTgt$ CES1-mediated @/GeneTgt$ hydrolysis of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ or 2-oxo-clopidogrel . In summary , deficient @GeneTgt$ CES1 @/GeneTgt$ catalytic activity resulting from @GeneTgt$ CES1 @/GeneTgt$ inhibition or @GeneTgt$ CES1 @/GeneTgt$ genetic variation may be associated with higher plasma concentrations of @ChemicalSrc$ clopidogrel-active @/ChemicalSrc$ metabolite , and hence may enhance antiplatelet activity . Additionally , @GeneTgt$ CES1 @/GeneTgt$ genetic variants have the potential to serve as a biomarker to predict @ChemicalSrc$ clopidogrel @/ChemicalSrc$ response and individualize @ChemicalSrc$ clopidogrel @/ChemicalSrc$ dosing regimens in clinical practice .	0|1 0|1 1 0|1 6 6 1 10 10|5 10 10|5 6 10 10 1 15|18 18 15|18 20 20 20 24 24 24 20 27 27 24 27 31 31 27 35 35 35 31 38 38 35 20 40|57 57 40|57 41 46 46 41 53 53 53|47 53|47 53 53|47 53 49|46 46 49|46 53 41 57 60 60 57 63 63 57 57 70 70 79 73 73 70 73 73 77 76|73 73 76|73 79 79 83 83 79 86 86 83 86 86 86 79 93 93 105 94|97 97 94|97 105 97 101|97 101 101|97 102 97 105 105 93 107 105 109 107|106 107 107|106 105 105 114 112 118 118 118 114 93 141 125 123|124 123 123|124 134 134 134|127 134 134|127 134 134 134 123 139 139 139 139 123 141 141 143 141 145 142|143 143 142|143 145 145 148 145 147|145 145 147|145 154 145 141 161 158 161 160 158 141 163 161 166 166 141 141 173 181 181 181|174 181 181|174 175 175 181 181 181 186 186 186 186 181 186 193 193 188|193 193 188|193 193 187 181 199 199 210 204 204 204|201 204 204|201 199 204 199 199 210 210 210 212 210 214 212 216 214 218 216 216 216 218 218 210 236 236 229 229 236 229 230 230 230 230 230 236 238 236 241 241 238 245 242|245 245 242|245 241 247 245 245 245 247 247 236 255 274 274 261 261|257 261 261|257 261 274 261 266 262|266 266 262|266 262 266 271|265 271 271|265 271 266 274 274 274 278 278 278 274 282 282|276 282 282|276 278 274 274 287 287 274 289 287 274 301 301 296|300 300 296|300 300 301 301 303 301 305 303 308 308 305 310 305 313|309 313 313|309 310 313 313 319|313 319 319|313 319 315 322 322 313 301	Association
23275066	Chemical	Gene	C540904	1066	True	0	What is [PHARMGKB] between @ChemicalSrc$ 2-oxo-clopidogrel @/ChemicalSrc$ and @GeneTgt$ CES1 @/GeneTgt$ ? [SEP] @GeneTgt$ Carboxylesterase 1 @/GeneTgt$ as a determinant of clopidogrel metabolism and activation . Clopidogrel pharmacotherapy is associated with substantial interindividual variability in clinical response , which can translate into an increased risk of adverse outcomes . Clopidogrel , a recognized substrate of hepatic @GeneTgt$ carboxylesterase 1 @/GeneTgt$ ( @GeneTgt$ CES1 @/GeneTgt$ ) , undergoes extensive hydrolytic metabolism in the liver . Significant interindividual variability in the expression and activity of @GeneTgt$ CES1 @/GeneTgt$ exists , which is attributed to both genetic and environmental factors . We determined whether @GeneTgt$ CES1 @/GeneTgt$ inhibition and @GeneTgt$ CES1 @/GeneTgt$ genetic polymorphisms would significantly influence the biotransformation of clopidogrel and alter the formation of the active metabolite . Coincubation of clopidogrel with the @GeneTgt$ CES1 @/GeneTgt$ inhibitor bis(4-nitrophenyl ) phosphate in human liver s9 fractions significantly increased the concentrations of clopidogrel , @ChemicalSrc$ 2-oxo-clopidogrel @/ChemicalSrc$ , and clopidogrel active metabolite , while the concentrations of all formed carboxylate metabolites were significantly decreased . As anticipated , clopidogrel and @ChemicalSrc$ 2-oxo-clopidogrel @/ChemicalSrc$ were efficiently hydrolyzed by the cell s9 fractions prepared from wild-type @GeneTgt$ CES1 @/GeneTgt$ transfected cells . The enzymatic activity of the @GeneTgt$ CES1 @/GeneTgt$ variants G143E and D260fs were completely impaired in terms of catalyzing the hydrolysis of clopidogrel and @ChemicalSrc$ 2-oxo-clopidogrel @/ChemicalSrc$ . However , the natural variants G18V , S82L , and A269S failed to produce any significant effect on @GeneTgt$ CES1-mediated @/GeneTgt$ hydrolysis of clopidogrel or @ChemicalSrc$ 2-oxo-clopidogrel @/ChemicalSrc$ . In summary , deficient @GeneTgt$ CES1 @/GeneTgt$ catalytic activity resulting from @GeneTgt$ CES1 @/GeneTgt$ inhibition or @GeneTgt$ CES1 @/GeneTgt$ genetic variation may be associated with higher plasma concentrations of clopidogrel-active metabolite , and hence may enhance antiplatelet activity . Additionally , @GeneTgt$ CES1 @/GeneTgt$ genetic variants have the potential to serve as a biomarker to predict clopidogrel response and individualize clopidogrel dosing regimens in clinical practice .	0|1 0|1 1 0|1 6 6 1 9 9 6 9 9 1 15 17 17 17 21 21 21 17 24 24 21 24 28 28 24 32 32 32 28 35 35 32 17 52 37 41 41 37 48 48 48|43 48|43 48 48|43 48 45|41 41 45|41 48 37 52 55 55 52 58 58 52 52 64 64 73 67 67 64 67 67 71 70|67 67 70|67 73 73 77 77 73 80 80 77 80 80 80 73 87 87 99 88|91 91 88|91 99 91 95|91 95 95|91 96 91 99 99 87 101 99 103 101 99 99 107 105 111 111 111 107 87 132 117 115 125 125 125|119 125 125|119 125 125 125 115 130 130 130 130 115 132 132 134 132 136 134 136 136 136 136 138 136 136 144 136 132 151 148 151 150 148 132 153 151 156 156 132 132 161 169 169 169 163 163|164 163 163|164 169 169 169 174 174 174 174 169 174 181 181 176|181 181 176|181 181 175 169 187 187 198 192 192 192|189 192 192|189 187 192 187 187 198 198 198 200 198 202 200 204 202 206 204 206 206 206 206 198 224 224 217 217 224 217 218 218 218 218 218 224 226 224 229 229 226 233 230|233 233 230|233 229 235 233 235 235 235 235 224 243 262 262 249 249|245 249 249|245 249 262 249 254 250|254 254 250|254 250 254 259|253 259 259|253 259 254 262 262 262 266 266 266 262 269 269 266 262 262 274 274 262 276 274 262 287 287 282|286 286 282|286 286 287 287 289 287 291 289 294 294 291 296 291 298 296 298 298 303 303 300 306 306 298 287	Association
23421954	Chemical	Gene	D000077210	2321	True	0	What is [PHARMGKB] between @ChemicalSrc$ sunitinib @/ChemicalSrc$ and @GeneTgt$ VEGFR1 @/GeneTgt$ ? [SEP] @GeneTgt$ VEGFR1 @/GeneTgt$ single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with @ChemicalSrc$ sunitinib @/ChemicalSrc$ - a multicentric retrospective analysis . BACKGROUND : There are no validated markers that predict outcome in metastatic renal cell cancer ( mRCC ) patients treated with @ChemicalSrc$ sunitinib @/ChemicalSrc$ . Recently , single nucleotide polymorphism ( SNP ) rs9582036 in @GeneTgt$ VEGFR1 @/GeneTgt$ has been proposed as a predictor of progression-free survival ( PFS ) and overall survival ( OS ) to bevacizumab in patients with pancreatic cancer and rs7993418 in @GeneTgt$ VEGFR1 @/GeneTgt$ as predictor for PFS in mRCC-patients treated with bevacizumab . Here , we aim to study the impact of these SNPs in mRCC patients treated with @ChemicalSrc$ sunitinib @/ChemicalSrc$ . METHODS : We included patients with mRCC treated in 15 institutions in France and Belgium . Patients received @ChemicalSrc$ sunitinib @/ChemicalSrc$ as first-line targeted therapy . We assessed response , time-to-tumor progression ( TTP ) , OS , and clinical and biochemical parameters associated with outcome . We genotyped rs9582036 and rs7993418 as well as three other surrounding SNPs in @GeneTgt$ VEGFR1 @/GeneTgt$ : rs9554320 , rs9554316 and rs9513070 . Association between SNPs and treatment outcome were studied by univariate analysis and by multivariate Cox regression using relevant clinical factors associated with TTP and OS as covariates . FINDINGS : Ninety-one patients were included . We found that mRCC patients with the CC-variant in rs9582036 in @GeneTgt$ VEGFR1 @/GeneTgt$ have a poorer response rate ( RR ) ( 0 % vs. 46 % , p = 0.028 ) , a poorer PFS ( 10 vs. 18 months , p = 0.033 on univariate and 0.06 on multivariate analysis ) and a poorer OS ( 14 vs. 31 months , p = 0.019 on univariate and 0.008 on multivariate analysis ) compared to patients with the AC- and AA-genotypes . mRCC patients with the AA-variant in rs9554320 in @GeneTgt$ VEGFR1 @/GeneTgt$ have a poorer PFS ( 12 vs. 21 months , p = 0.0066 on univariate and 0.005 on multivariate analysis ) and a poorer OS ( 22 vs. 34 months , p = 0.019 on univariate and 0.067 on multivariate analysis ) compared to patients with the AC- and CC-genotypes . Interpretation . mRCC patients with the CC-genotype in @GeneTgt$ VEGFR1 @/GeneTgt$ SNP rs9582036 have a poorer response rate , PFS and OS when treated with @ChemicalSrc$ sunitinib @/ChemicalSrc$ . These findings are in agreement with the association of rs9582036 and outcome observed in bevacizumab treated pancreatic cancer patients . Prospective validation of this SNP is warranted .	0|5 5 0|5 5 5 24 5 8 6 10 8 15 15 15 15 10 15 18 16 16 16 10 24 24 24 24 24 28 31 31 28 34 34 31 36 34 36 46 46 46 42 46 44 46 46 37 46 49 47|48 47 47|48 28 67 67 57 57 61 59 61 61 67 63 61|62 61 61|62 67 67 67 70 70 67 73 73 70 75 73 75 73 79 73 81 79 81 84 70 86 84 89 89 86 89 89 93 86|91 86 86|91 96 86 98 96 100 98 100 103 101 67 110 110 110 110 112 110 114 112 117 117 114 120 120 114 120 123 122|121 121 122|121 110 130 130 130 130 130 133 131 131 137 137 134 139 137 139 139 130 144 144 144 144 144 150 150 150 144 144 154 154 154 155 158 155 160 158 160 158 158 163 158 155 166 166 166 169 172 170 154 175 175 175 176 176 176 179 179 183 185 185 176 187 175|186 175 175|186 175 175 190 190 192 192 175 204 199 197 199 202 199 204 204 207 207 204 207 212 212 212 207 212 216 216 213 216 219 217 219 219 223 217 204 230 230 228 230 230 230 230 233 233 245 236 245 239 239 236 241 239 243 241|242 241 241|242 233 249 249 249 245 251 249 251 255 255 249 255 258 255 261 261 255 261 261 255 267 267 255 272 272 269 269 267 275 275 245 275 278 275 278 278 283 283 275 275 245 288 288 245 293 293 290 290 288 296 296 288 296 299 296 299 299 304 304 296 296 308 308 245 311 311 308 311 311 233 317 326 320 320 317 322 320 324 323|320 320 323|320 326 329 329 326 334 334 331 331 329 337 337 326 337 340 337 337 337 345 345 337 337 326 350 350 326 355 355 352 352 350 358 358 350 358 361 358 361 361 366 366 358 358 370 370 326 373 373 370 373 373 326 378 378 381 390 384 384 381 389 389|385 389 389|385 389 381 390 394 394 394 390 394 394 396 396 400 390 402 400 400 400 390 408 411 411 411 411 414 414 411 416 414 416 416 414 421 419 411 425 425 422 411 428 433 431 431 428 433 433 433	Association
23459444	Chemical	Gene	D013629	3480	True	0	What is [PHARMGKB] between @ChemicalSrc$ TAM @/ChemicalSrc$ and @GeneTgt$ IGF1R @/GeneTgt$ ? [SEP] Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with @ChemicalSrc$ tamoxifen @/ChemicalSrc$ . Compelling evidence points to a key role for insulin-like growth factor 1 ( IGF1 ) signaling in breast cancer development and progression . In addition , @GeneTgt$ IGF1 receptor @/GeneTgt$ ( @GeneTgt$ IGF1R @/GeneTgt$ ) expression has been correlated and functionally linked with estrogen receptor ( ER ) signaling . Recent translational studies support a cross talk between @GeneTgt$ IGF1R @/GeneTgt$ and ERalpha at different levels and data suggest enhanced @GeneTgt$ IGF1R @/GeneTgt$ signaling as a causative mechanism of @ChemicalSrc$ tamoxifen @/ChemicalSrc$ ( @ChemicalSrc$ TAM @/ChemicalSrc$ ) resistance . We tested whether functional germline variations in the IGF pathway are associated with clinical outcome in ER-positive primary invasive breast cancer patients , who were treated with surgery and adjuvant TAM . Tissue samples of 222 patients with ER+ primary invasive breast cancer , who had undergone surgery at Charing Cross Hospital , London , UK between 1981 and 2003 , were analyzed . Genomic DNA was extracted from formalin-fixed , paraffin-embedded tissue samples and six functional IGF1 pathway polymorphisms were analyzed using direct DNA sequencing and PCR-restriction fragment length polymorphism . In multivariable analysis , patients with primary invasive breast cancer carrying IGF1R_rs2016347 G allele had a significantly increased risk of early tumor progression ( hazard ratio ( HR ) 2.01 ; adjusted P=0.004 ) and death ( HR 1.84 ; adjusted P=0.023 ) compared with patients carrying G/T or T/T , independent of established clinicopathological determinants . This association remained significant after adjusting for multiple testing . In addition , we were able to demonstrate that IRS1_rs1801123 and IGFBP3_rs2854744 were significantly associated with lymph node involvement and tumor size , respectively . We provide the first evidence for IGF1R_rs2016347 as an independent prognostic marker for ER+ breast cancer patients treated with @ChemicalSrc$ TAM @/ChemicalSrc$ and support a rational for combined treatment strategies .	5 5 5 5 6 6 8 6 14 14 14 14 14 8 14 17 16|15 15 16|15 6 23 23 23 27 27 27 23 36 31 31 36 34 34 31 34 27 39 39 40 36 40 40 23 45 57 57 54|46|47 54|46|47 54|47 54|46|47 51 47|48 47 47|48 51 57 57 57 57 57 60 57 67 63 67 65 63 65 60 57 73 73 74 74 77 77 74 79 78|77 77 78|77 79 79 85 85 77 85 85 74 88 88|92 92 88|92 89 96 96 96 92 104 95|104 104 95|104 101 97|98 98 97|98 101 96 74 111 111 121 115 115 121 119 119 119 115 121 111 124 124 121 131 131 131 131 131 131 124 131 135 135 131 137 135 137 140 137 111 143 172 146 146 143 152 152 152 152 152 146 146 156 156 146 156 161 160 161 156 161 161 163 163 167 165 167 167 143 172 172 172 175 177 177 177 179 177 179 179 183 179 179 189 189 189 189 191 191 177 191 195 195 192 195 200 200 200 195 177 204 204 216 216 216 211 211 211 211 206 211 215 215 212 216 220 219 220 216 224 224 224 220 227 227 220 229 227 229 229 229 234 229 234 229 229 239 237 239 239 243 239 243 220 247 245 247 248 249 249 247 247 257 257 257 253 216 260 261 261 261 264 261 267 267 264 261 270 274 274 274 274 274 276 274 283 283 278 278 283 283 276 287 287 287 283 287 290 287 283 283 274 295 295 298 298 295 300 298 305 305 305 305 298 310 310 310 310 305 310 313 311|312 311 311|312 295 295 318 316 322 322 322 318 295	Association
23510446	Chemical	Gene	D015283	121278	True	0	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ TPH2 @/GeneTgt$ ? [SEP] Additive effects of 5-HTTLPR ( serotonin transporter ) and tryptophan hydroxylase 2 G-703 T gene polymorphisms on the clinical response to @ChemicalSrc$ citalopram @/ChemicalSrc$ among children and adolescents with depression and anxiety disorders . OBJECTIVE : The purpose of this study was to evaluate the association between polymorphisms in two serotonin pathway genes and the clinical response to @ChemicalSrc$ citalopram @/ChemicalSrc$ among children and adolescents with depression and/or anxiety disorders . METHODS : Eighty-three children and adolescents with depression and/or anxiety disorders were treated with @ChemicalSrc$ citalopram @/ChemicalSrc$ for 8 weeks . We assessed the association between the response to @ChemicalSrc$ citalopram @/ChemicalSrc$ and polymorphisms in the @GeneTgt$ tryptophan hydroxylase-2 @/GeneTgt$ ( @GeneTgt$ TPH2 @/GeneTgt$ ) and the serotonin transporter gene . The polymorphisms included single nucleotide polymorphisms ( SNPs ) in the transcriptional control region ( G-703 T ) of the @GeneTgt$ TPH2 @/GeneTgt$ gene and the serotonin transporter gene-linked promoter region ( 5-HTTLPR ) . RESULTS : Fifty patients of the 83 ( 60.2 % ) achieved satisfactory response ( Clinical Global Impressions - Improvement & lt;=2 ) . We observed an additive effect of the two genes on the clinical response to @ChemicalSrc$ citalopram @/ChemicalSrc$ . Patients carrying the combination of @GeneTgt$ TPH2 @/GeneTgt$ -703 G and the 5-HTTLPR L alleles were the most likely to respond ( 80 % ) . In contrast , patients carrying the combination of @GeneTgt$ TPH2 @/GeneTgt$ -703 T and the 5-HTTLPR S alleles were least likely to respond ( 31 % ) . The other patients ( with -703G/5-HTTLPR S and -703T/5-HTTLPR L alleles ) showed intermediate response ( 67 % ) . CONCLUSIONS : This finding suggests that 5-HTTLPR and @GeneTgt$ TPH2 @/GeneTgt$ genes may act in concert to modulate the clinical response to @ChemicalSrc$ citalopram @/ChemicalSrc$ among children and adolescents with depression and/or anxiety disorders .	2 2 4 2 7 7 4 7 4 4 16 16 16 16 16 4 20 20 20 2 22 20|21 20 20|21 25 22 25 25 29 25 29 29 29 2 35 35 38 42 41 41 38 35 44 42 46 44 48 46 53 53 53 53 48 48 57 57 48 59 58|57 57 58|57 62 59 62 62 66 57 66 69 66 42 84 84 75 84 75 75 79 75 79 82 79 84 84 86 84|85 84 84|85 90 90 84 84 94 94 96 94 99 99 96 101 100|99 99 100|99 101 101 107 107 99|105|107 99|105|107 99|107 99|105|107 111 107 107 107 111 107 118 118 118 107 94 124 125 125 128 128 125 130 128 130 136 136 136 136 128 139 139 136 139 145 145 142|145 145 142|145 136 136 152 150 150 152 152 136 154 152 154 125 158 158 161 169 164 164 167 167 167 161 167 158 171 169 177 177 177 177 177 171 177 177 177 158 183 183 186 186 183 190 190 190 186 194 194 194 186 196 194|195 194 194|195 183 217 200 203 201 205 208|204 208 208|204 208 203 200 213 213 213 200 217 217 217 217 219 217 222 222 219 222 217 227 245 245 245 229 232 230 234 233|237 237 233|237 237 232 232 242 242 242 245 245 245 245 247 245 250 250 247 250 245 256 256 266 260 260 260 256 260 260 264 260 260 266 268 266 271 271 268 271 266 274 274 277 278 274 286 286 280 281|280 280 281|280 280 286 278 288 290 290 286 293 293 290 295 293 293 293 298 293 298 298 302 293 302 305 302 274	Association
23524664	Chemical	Gene	D008939	1555	True	0	What is [PHARMGKB] between @ChemicalSrc$ mitotane @/ChemicalSrc$ and @GeneTgt$ CYP2B6 @/GeneTgt$ ? [SEP] Influence of the @GeneTgt$ CYP2B6 @/GeneTgt$ polymorphism on the pharmacokinetics of @ChemicalSrc$ mitotane @/ChemicalSrc$ . OBJECTIVE : The aim of this study was to assess the potential impact of the pharmacogenetic variability of @GeneTgt$ CYP2B6 @/GeneTgt$ and ABCB1 genes on the pharmacokinetics of @ChemicalSrc$ mitotane @/ChemicalSrc$ . METHODS : A retrospective analysis was carried out on 27 patients with adrenocortical carcinoma on postoperative adjunctive @ChemicalSrc$ mitotane @/ChemicalSrc$ . @GeneTgt$ CYP2B6 @/GeneTgt$ and ABCB1 polymorphisms were genotyped and tested for an association with plasma trough concentration after 3 , 6 , 9 , and 12 months of therapy . RESULTS : Patients with the GT/TT genotype had higher @ChemicalSrc$ mitotane @/ChemicalSrc$ plasma concentrations compared with patients with GG at 3 months ( 14.80 vs. 8.01 mug/ml ; P=0.008 ) and 6 months ( 17.70 vs. 9.75 mug/ml ; P=0.015 ) . Multivariate logistic regression analysis showed that only the @GeneTgt$ CYP2B6 @/GeneTgt$ rs3745274GT/TT genotype ( odds ratio=10.7 ; P=0.017 ) was a predictor of @ChemicalSrc$ mitotane @/ChemicalSrc$ plasma concentrations of at least 14 microg/ml after 3 months of treatment . @ChemicalSrc$ Mitotane @/ChemicalSrc$ concentrations were not influenced by the polymorphisms of the ABCB1 gene . CONCLUSION : Evaluation of the @GeneTgt$ CYP2B6 @/GeneTgt$ polymorphism enabled prediction of the individual response to adjuvant @ChemicalSrc$ mitotane @/ChemicalSrc$ treatment .	1 6 6 3|6 6 3|6 1 9 9 1 11 9 9 9 1 16 16 19 23 22 22 19 16 25 23 28 28 25 32 32 32 28 34 32|33 32 32|33 34 34 34 41 41 32 43 41 41 41 23 54 54 52 52 54 54 54 54 58 58 54 61 61 58 65 65 65 64|54 54 64|54 54 68|73 73 68|73 69 69 75 75 75 75 75 80 80 77 84 84 84 80 94 94 86 86 88 86 86 86 86 80 96 94 75 106 99 106 105 105 105 101 106 111 107|111 111 107|111 111 106 114 114 106 116 114 119 119 106 121 124 121 121 106 124 124 126 124 130 124 135 135 132 132 130 135 135 135 106 144 144 144 145 145 161 152 152 148|152 152 148|152 152 161 155 155 152 155 155 157 161 161 145 166 166|161 166 166|161 166 161 171 170 170 171 166 174 174 161 176 174 145 179|182 182 179|182 185 185 185 185 188 188 185 192 192 192 188 185 195 203 203 202 202 202|199 202 202|199 197 195 203 208 208 208 204 213 213 213|209 213 213|209 208 195	Association
23692149	Chemical	Gene	D000077144	8714	True	0	What is [PHARMGKB] between @ChemicalSrc$ clopidogrel @/ChemicalSrc$ and @GeneTgt$ ABCC3 @/GeneTgt$ ? [SEP] Efffect of the @GeneTgt$ ABCC3 @/GeneTgt$ -211C/T polymorphism on @ChemicalSrc$ clopidogrel @/ChemicalSrc$ responsiveness in patients with percutaneous coronary intervention . Multidrug resistance protein 3 ( MPR3 ) , encoded by the ATP-binding cassette , subfamily C ( CFTR/MRP ) , member 3 ( @GeneTgt$ ABCC3 @/GeneTgt$ ) gene , functions as an important drug efflux transporter . The @GeneTgt$ ABCC3 @/GeneTgt$ -211C/T polymorphism is associated with decreased @GeneTgt$ MRP3 @/GeneTgt$ mRNA expression , and low @GeneTgt$ MRP3 @/GeneTgt$ mRNA expression is associated with increased @ChemicalSrc$ clopidogrel @/ChemicalSrc$ response in patients . The aim of the present study was to determine whether the -211C/T polymorphism is associated with altered antiplatelet effects and clinical outcomes in @ChemicalSrc$ clopidogrel-treated @/ChemicalSrc$ patients . A subcohort of 249 patients not carrying the CYP2C19 * 2 , * 3 or * 17 variant was identified from a total of 617 consecutive @ChemicalSrc$ clopidogrel-treated @/ChemicalSrc$ patients undergoing percutaneous coronary intervention and then categorized into three groups on the basis of their @GeneTgt$ ABCC3 @/GeneTgt$ -211C/T genotype . Baseline data , clinical characteristics and DNA samples were collected for all patients . Light transmittance aggregometry was used to determine ADP-induced maximum platelet aggregation ( MPA ) in blood samples obtained from patients on Day 3 after starting daily @ChemicalSrc$ clopidogrel @/ChemicalSrc$ maintenance doses . Genotyping of CYP2C19 * 2 , * 3 and * 17 variants and the @GeneTgt$ ABCC3 @/GeneTgt$ -211C/T polymorphism was performed using matrix-assisted laser desorption ionization time-of-flight ( MALDI-TOF ) mass spectrometry . The primary clinical end-point was a definite stent thrombosis ( ST ) episode , whereas secondary end-points were other major adverse cardiovascular events within 12 months after stenting . There were no differences in MPA values according to @GeneTgt$ ABCC3 @/GeneTgt$ -211C/T genotype . A multiple linear regression model revealed that the @GeneTgt$ ABCC3 @/GeneTgt$ -211C/T polymorphism was not independently associated with ADP-induced MPA measurements ; a multiple logistic regression model revealed that carrying the @GeneTgt$ ABCC3 @/GeneTgt$ -211C allele was not associated with the risk of developing an ST event in @ChemicalSrc$ clopidogrel-treated @/ChemicalSrc$ patients not harbouring CYP2C19 * 2 , * 3 and * 17 variants . In conclusion , the @GeneTgt$ ABCC3 @/GeneTgt$ -211C/T polymorphism seems not to be associated with altered antiplatelet effects and clinical outcomes in @ChemicalSrc$ clopidogrel-treated @/ChemicalSrc$ patients .	1 7 7 3|7 7 3|7 7 1 11 11|7 11 11|7 7 13 11 17 17 17 13 1 23 23 49 23 26 23 26 23 23 33 33 33 29 33 36 33 38 36 38 33 47 47 47 47|43 47 47|43 47 33 23 49 55 55 55 55 55 49 49 62 58|62 62 58|62 62 64 64 64 70 70 65|70 70 65|70 70 64 64 64 77 77|71 77 77|71 77 79 79 64 84 84 84|78 84 84|78 79 86 84 64 93 98 97 97 97 93 98 100 98 106 104 104 106 106 100 110 110 110 106 110 113 110 117 117|114 117 117|114 110 98 121 139 124 124 121 126 121 128 126 130 137 130 130 130 133 137 137 139 139 139 142 142 139 148 148 148 145|148 148 145|148 142 148 152 152 149 139 155 139 158 158 155 161 161 155 167 167 167|162 167 167|162 167 161 139 172 180 172 175 180 175 178 175 180 180 183 183 180 180 187 187 189 189 189 191 189 195 195 195 191 197 195 197 201 201 195 201 204 202 206 204 206 209 191 214 210|214 214 210|214 214 209 189 236 219 217 219 219 219 219 228 224 228 228 236 228 234 234|230 234 234|230 234 228 236 236 236 241 241 241 237 241 244 247 247 247 241 236 253 253 253 262 262 262 262 262 262 260 258 260 262 262 272 266 272 272 272 272 272 272 262 275 275 272 277 272 262 280 280 282 280 285 285 282 291 286 287|291 291 287|291 291 285 280 298 298 298 298 299 299 309 305 301|305 305 301|305 305 309 309 309 309 299 313 313 313 309 320 319 319 319 319 320 299 330 330 327 327|322 327 327|322 327 322 330 330 320 333 333 330 335 333 338 338 335 342 342|337 342 342|337 338 344 342 344 345 345 345 345 345 350 354 354 333 299 360 367 367 366 366|362 366 366|362 366 367 367 371 371 371 367 375 375 375 371 375 378 375 382 382|378 382 382|378 375 367	Association
23757359	Chemical	Gene	C545203	1080	True	0	What is [PHARMGKB] between @ChemicalSrc$ ivacaftor @/ChemicalSrc$ and @GeneTgt$ CFTR @/GeneTgt$ ? [SEP] Effects of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ on severely ill patients with cystic fibrosis carrying a G551D mutation . BACKGROUND : Recently , @ChemicalSrc$ ivacaftor @/ChemicalSrc$ , a @GeneTgt$ CFTR-potentiator @/GeneTgt$ , has been shown to be effective and safe in patients with cystic fibrosis carrying a G551D mutation and moderately impaired lung function . The objective of this retrospective study was to assess efficacy and safety of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ in severely ill patients with at least one G551D mutation . METHODS : Data from 14 patients with a FEV1 & lt;40 % predicted who received @ChemicalSrc$ ivacaftor @/ChemicalSrc$ on a " named patient program " base in Germany were analyzed . RESULTS : One patient took @ChemicalSrc$ ivacaftor @/ChemicalSrc$ at a lower than recommended dose due to abundant mucus and a feeling to " suffocate . " No additional severe adverse events were reported . One further patient stopped @ChemicalSrc$ ivacaftor @/ChemicalSrc$ due to lung transplantation , one due to perceived poor effectiveness , one due to pregnancy , and one stopped standard therapy . The remaining patients took @ChemicalSrc$ ivacaftor @/ChemicalSrc$ regularly and did not change other therapies . FEV1 increased by more than 5 % predicted in 5 of the 14 patients from baseline ( average FEV1 during the year prior to @ChemicalSrc$ ivacaftor @/ChemicalSrc$ ) . On average , FEV1 increased significantly by 5.2 + -5.6%predicted ( p&lt;0.01 ) . The relative improvement in FEV1 was 19.7 + -22.1 % . CONCLUSION : @ChemicalSrc$ Ivacaftor @/ChemicalSrc$ was effective in many patients with poor lung function . The response was , however , variable . Although the drug appeared safe for most of these patients , increased bronchial secretions may warrant intensified physiotherapy and intravenous antibiotic treatment when @ChemicalSrc$ ivacaftor @/ChemicalSrc$ is initiated .	1 3 1|2 1 1|2 8 7 8 1 11 11 8 11 15 15 12 1 18 18 22 22 21|31 31 21|31 22 26 22|24 22 22|24 22 31 31 18 34 34 31 34 34 38 34 41 41 38 41 45 45 42 45 48 50 50 18 18 55 60 59 59 59 55 60 62 60 62 63 63 67 63|66 63 63|66 72 71 72 63 78 76 74 78 78 72 60 93 93 93 86 86 83 89 89 86 89 92 89 93 95 93 95 95 95 105 105 103 103 103 105 105 95 107 105 109 93 93 112 112 115 116 112 116 116 116 121 121 116 124 124 121 128 125 128 121 128 131 128 134 134 116 112 112 141 141 141 141 143 143 112 112 148 148 149 149 149 149 149 155 152 155 149 149 149 162 158 162 162 157 162 162 167 165 164 164 149 171 149 173 171 171 178 178 179 179 179 179 179 179 179 186 186 179 188 186 179 192 192 197 196 196 197 192 197 200 198 204 204 204 200 206 209 209 209 204 212 212 198 215 213 214|198 198 214|198 192 192 221 224 224 224 224 224 227 224 227 227 231 227 231 224 236 236 243 238 236 243 243 240 240 243 243 250 250 246|250 250 246|250 250 250 253 253 250 257 257 257 253 250 261 266 266 266 266 266 266 266 271 270 271 279 271 274 279 277 277 274 274 281 281 283 283 283 285 283 285 289 289 285 294 294|290 294 294|290 294 283 283	Association
23891399	Chemical	Gene	C545203	1080	True	0	What is [PHARMGKB] between @ChemicalSrc$ ivacaftor @/ChemicalSrc$ and @GeneTgt$ CFTR @/GeneTgt$ ? [SEP] Effect of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ on @GeneTgt$ CFTR @/GeneTgt$ forms with missense mutations associated with defects in protein processing or function . BACKGROUND : @ChemicalSrc$ Ivacaftor @/ChemicalSrc$ ( KALYDECO , VX-770 ) is a @GeneTgt$ CFTR @/GeneTgt$ potentiator that increased @GeneTgt$ CFTR @/GeneTgt$ channel activity and improved lung function in patients age 6 years and older with CF who have the @GeneTgt$ G551D-CFTR @/GeneTgt$ gating mutation . The aim of this in vitro study was to evaluate the effect of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ on mutant @GeneTgt$ CFTR @/GeneTgt$ protein forms with defects in protein processing and/or channel function . METHODS : The effect of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ on CFTR function was tested in electrophysiological studies using a panel of Fischer rat thyroid ( FRT ) cells expressing 54 missense CFTR mutations that cause defects in the amount or function of CFTR at the cell surface . RESULTS : @ChemicalSrc$ Ivacaftor @/ChemicalSrc$ potentiated multiple mutant @GeneTgt$ CFTR @/GeneTgt$ protein forms that produce functional @GeneTgt$ CFTR @/GeneTgt$ at the cell surface . These included mutant @GeneTgt$ CFTR @/GeneTgt$ forms with mild defects in @GeneTgt$ CFTR @/GeneTgt$ processing or mild defects in @GeneTgt$ CFTR @/GeneTgt$ channel conductance . CONCLUSIONS : These in vitro data indicated that @ChemicalSrc$ ivacaftor @/ChemicalSrc$ is a broad acting @GeneTgt$ CFTR @/GeneTgt$ potentiator and could be used to help stratify patients with CF who have different @GeneTgt$ CFTR @/GeneTgt$ genotypes for studies investigating the potential clinical benefit of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ .	8 3 1|2 1 1|2 6 1|4 1 1|4 8 11 11 8 11 14 12 17 17 14 17 17 8 23 23 24|36 36 24|36 28 25 28 28 28 36 36 32|36 36 32|36 23 38 36 42|36 42 42|36 42 38 38 38 46 44 48 46 48 51 48 48 48 55 53 57 55 62 62|55 62 62|55 62 57 23 69 75 71 74 74 72 69 75 77 75 79 77 81 79|80 79 79|80 88 88 83|87 87 83|87 88 79 90 88 93 93 90 93 96 93 75 111 111 103 111 105 103|104 103 103|104 109 109 103 111 111 114 114 111 114 117 115 125 125 125 125 123 125 125 117 125 130 130 130 126 132 130 132 136 136 133 136 136 140 138 144 144 144 138 111 151 147 148|151 151 148|151 151 157 157 157|152 157 157|152 157 151 159 157 161 158|159 159 158|159 166 166 166 159 151 172 172 176 173|176 176 173|176 172 179 179 176 183 179|183 183 179|183 179 183 186 183 191 191|185 191 191|185 191 176 172 196 196 201 201 199 202 196 212 203|212 212 203|212 212 212 212 212 212|208 212 212|208 202 202 216 216 202 218 216 218 219 222 220 224 220 228 228|223 228 228|223 224 230 228 230 235 235 235 231 237 235|233 235 235|233 202	Association
23963056	Chemical	Gene	D006220	1312	True	0	What is [PHARMGKB] between @ChemicalSrc$ haloperidol @/ChemicalSrc$ and @GeneTgt$ COMT @/GeneTgt$ ? [SEP] The association study of polymorphisms in DAT , DRD2 , and @GeneTgt$ COMT @/GeneTgt$ genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with @ChemicalSrc$ haloperidol @/ChemicalSrc$ . Extrapyramidal symptoms ( EPSs ) are common adverse effects of antipsychotics . The development of acute EPSs could depend on the activity of dopaminergic system and its gene variants . The aim of this study was to determine the association between dopaminergic type 2 receptor ( DRD2 ) dopamine transporter ( SLC6A3 ) and @GeneTgt$ catechol-O-methyltransferase @/GeneTgt$ ( @GeneTgt$ COMT @/GeneTgt$ ) gene polymorphisms and acute EPSs in 240 male schizophrenic patients treated with @ChemicalSrc$ haloperidol @/ChemicalSrc$ ( 15-mg/d ) over a period of 2 weeks . Acute EPSs were assessed with Simpson-Angus Scale . Three dopaminergic gene polymorphisms , the DRD2 Taq1A , the SLC6A3 VNTR , and the @GeneTgt$ COMT @/GeneTgt$ Val158Met , were determined . Extrapyramidal symptoms occurred in 116 ( 48.3 % ) of patients . Statistically significant associations were found for SLC6A3 VNTR and @GeneTgt$ COMT @/GeneTgt$ Val158Met polymorphisms and EPS susceptibility . Patients with SLC6A3 9/10 genotype had almost twice the odds to develop EPSs compared with those with all other SLC6A3 genotypes ( odds ratio , 1.9 ; 95 % confidence interval , 1.13 - 3.30 ) , and patients with @GeneTgt$ COMT @/GeneTgt$ Val/Met genotype had 1.7 times greater odds to develop EPSs than those with all other @GeneTgt$ COMT @/GeneTgt$ genotypes ( odds ratio , 1.7 ; 95 % confidence interval , 1.01 - 2.88 ) . There was no statistically significant association between genotype and allele frequencies of DRD2 , SLC6A3 , or @GeneTgt$ COMT @/GeneTgt$ polymorphisms and the development of particular EPSs . In conclusion , the results of the present study showed for the first time the association between acute @ChemicalSrc$ haloperidol-induced @/ChemicalSrc$ EPSs and SLC6A3 VNTR and @GeneTgt$ COMT @/GeneTgt$ Val158Met polymorphisms . Although the precise biological mechanisms underlying these findings are not yet understood , the results suggest that the dopaminergic gene variations could predict the vulnerability to the development of the acute EPSs in @ChemicalSrc$ haloperidol-treated @/ChemicalSrc$ schizophrenic patients .	3 3 3 5 3 7 5 7 7 7 7 11|7 7 11|7 7 5 19 19 19 5 23 23 23 19 23 26 24 24 24 3 32 39 34 32 34 39 39 39 39 41 39 39 44 49 47 47 44 49 49 52 52 49 55 55 52 52 59 59 52 49 62 66 65 65 62 66 68 66 70 68 80 80 80 75 80 77 80 77 80 70 82 80 82 80 84|80 80 84|80 88 85|86 85 85|86 88 92 80 80 95 80 100 100 100 100 70 100 103 100|101 101 100|101 106 103 106 110 110 101 113 113 110 66 119 121 121 121 124 124 121 121 129 129 129 146 129 133 133 129 133 137 137 133 133 133 141 143|140 143 143|140 133 129 146 146 146 150 151 151 153 151 156 156 153 156 159 153 151 163 163 165 165 165 168 168 165 168 169|172 172 169|172 173 168 168 176 168 165 184 183 183 183 179 184 186 188 188 184 190 188 190 194 194 184 199 199 199 199 194 202 202 194 202 202 202 207 209 209 194 209 213 213 209 213 209 194 223 222 218|222 222 218|222 222 217 184 225 226 227 223 229 227 229 232 229 238 238 238 234|238 238 234|238 232 241 241 232 241 241 241 246 248 248 241 248 252 252 248 241 223 258 258 262 261 262 258 264 262 264 264 264 269 267 269 269 269 269 273|269 269 273|269 269 264 279 264 282 282 279 258 286 294 294 289 294 293 293 293 289 294 298 298 298 294 300 294 305 305 302|305 305 302|305 300 305 308 305 305 308|313 313 308|313 313 305 294 328 321 321 321 328 321 324 322 328 328 328 332 332 331 332 332 339 337 337 337 339 339 332 341 339 344 344 341 348 348 348 344 353 349|353 353 349|353 353 344 332	Association
